1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34
row_id,t,OMIM no.,Disease Name,Disease Name comments,Gene Affected,Enzyme/protein Defected,EC number/ Protein Entry,Drug name comments,Drug name,Drug ID,Study Type (Evidence code),Mutations improved by treatment,Mutations improved by treatment comments,Mutation that didn't get benefits out the treatment,Mutation that didn't get benefits out the treatment comments,Treatment mechanism of action,Abbreviation for treatment mechanism,new ontology category,Comments(This column will be retired),phenotypes  improved,phenotypes  improved comments,Phenotypes  IDS,Reference,Reference,Reference,Reference,Reference,Reference,Reference,Reference,Reference,Reference,Reference
1,1,202110,17-alpha-hydroxylase deficiency ,,CYP17A1,Steroid 17-alpha-hydroxylase,1.14.14.19,,Hydrocortisone,DB00741,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,Abnormal plasma aldosterone,,HP:0040085,https://www.ncbi.nlm.nih.gov/pubmed/26161337,,https://www.ncbi.nlm.nih.gov/pubmed/18458702,,,,,,,,
2,,,,,,,,,,,,,,,,,,,,Abnormality of potassium homeostasis,,HP:0011042,,,,,,,,,,,
3,,,,,,,,,,,,,,,,,,,,Abnormal circulating renin,,HP:0040084,,,,,,,,,,,
4,,,,,,,,,,,,,,,,,,,,Hypertension,,HP:0000822,,,,,,,,,,,
5,,,,,,,,,Dexamethasone,DB01234,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,Abnormal plasma aldosterone,,HP:0040085,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,,,,,,,,,,
6,,,,,,,,,,,,,,,,,,,,Hypokalemia,,HP:0002900,https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,,,,,,,,,
7,,,,,,,,,,,,,,,,,,,,Abnormal circulating renin,,HP:0040084,,,,,,,,,,,
8,,,,,,,,,,,,,,,,,,,,Hypertension,,HP:0000822,https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,,,,,,,,,
9,,,,,,,,,,,,,,,,,,,,Bone mass loss,,NA,,,,,,,,,,,
10,,,,,,,,,Testosterone,DB00624,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,Puberty and gonadal disorders,,HP:0008373,https://www.ncbi.nlm.nih.gov/pubmed/26161337#,,,,,,,,,,
11,,,,,,,,,"Estrogen replacement (                                                             
Estradiol)",DB00783,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,Puberty and gonadal disorders,,HP:0008373,https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/26161337#,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,,,,,,,,
12,,,,,,,,,Cyclic medroxyprogesterone,DB00603,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,Puberty and gonadal disorders,,HP:0008373,https://www.ncbi.nlm.nih.gov/pubmed/26161337#,,,,,,,,,,
13,,,,,,,,,,,,,,,,,,,,Amenorrhea,,HP:0000141,,,,,,,,,,,
14,,,,,,,,,Pioglitazone,DB01132,ECO:0007121 /ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure,,Insulin resistance,,HP:0000855,https://www.orpha.net/consor/cgi-bin/ResearchTrials_ClinicalTrials.php?lng=EN&data_id=38680&ClinicalTrialName=Effecten-van-Pioglitazone-bij-Congenitale-Bijnierhyperplasie&title=Effecten-van-Pioglitazone-bij-Congenitale-Bijnierhyperplasie&search=ResearchTrials_ClinicalTrials_Simple,https://www.ncbi.nlm.nih.gov/pubmed/19755409,https://clinicaltrials.gov/ct2/show/NCT00151710,,,,,,,,
15,,,,,,,,,,,,,,,,,,,,Hypertension,,HP:0000822,,,,,,,,,,,
16,2,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,,Riboflavin,DB00140 ,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,activity modification of a genetically defective protein,,Cognitive impairment,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/22391998,,,,,,,,,,
17,,,,,,,,,,,,,,,,,,,,L-2-hydroxyglutaric aciduria,,HP:0040144,https://www.ncbi.nlm.nih.gov/pubmed/24321868,,,,,,,,,,
18,,,,,,,,,,,,,,,,,,,,Poor motor coordination,,HP:0002275,https://www.ncbi.nlm.nih.gov/pubmed/24321868,,,,,,,,,,
19,,,,,,,,,Flavin adenine dinucleotide + levocarnitine chloride.,DB03147 +DB00583,ECO:0000352,,,,,Direct interaction (Mechanistic A)+Functional interaction (Mechanistic B),A+B,activity modification of a genetically defective protein+functional complementation of a genetically defective protein,,defected  L-2-HGDH enzyme activity,,NA,https://www.ncbi.nlm.nih.gov/pubmed/18362286,https://www.ncbi.nlm.nih.gov/pubmed/22391998,,,,,,,,,
20,,,,,,,,,,,,,,,,,,,,L-2-hydroxyglutaric aciduria,,HP:0040144,https://www.ncbi.nlm.nih.gov/pubmed/18362286,https://www.ncbi.nlm.nih.gov/pubmed/22391998,,,,,,,,,
21,,,,,,,,,,,,,,,,,,,,Leukodystrophy,,HP:0002415,,,,,,,,,,,
22,,,,,,,,,,,,,,,,,,,,dystonia,,HP:0001332,,,,,,,,,,,
23,,,,,,,,,,,,,,,,,,,,Neurological impairment,,HP:0000707,https://n.neurology.org/content/70/13/1051,,,,,,,,,,
24,,,,,,,,,FAD+Riboflavin,DB03147+DB00140,ECO:0000352,,,,,Direct interaction (Mechanistic A)+Functional interaction (Mechanistic B),A+B,activity modification of a genetically defective protein+functional complementation of a genetically defective protein,,Neurological impairment,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/26208971,https://www.sciencedirect.com/science/article/pii/S109037980800010X,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025,,,,,,,
25,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26,,# 203700,ALPERS SYNDROME,,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,Magnesium,DB14513,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Status epilepticus,,,https://www.ncbi.nlm.nih.gov/pubmed/20803213?dopt=Abstract,,,,,,,,,,
27,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
28,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
30,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
31,,#615182,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,"Tricarboxylate transport protein, mitochondrial",P53007,,Citrate treatment,DB09125,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/24687295,,,,,,,,,,
32,,,,,,,,,,,,,,,,,,,,D-2-hydroxyglutaric aciduria,,HP:0012321,,,,,,,,,,,
33,,,,,,,,,,,,,,,,,,,,L-2-hydroxyglutaric aciduria,,HP:0040144,,,,,,,,,,,
34,,,,,,,,,,,,,,,,,,,,low urinary excretion of TCA cycle intermediates malate and succinate,,,,,,,,,,,,,
35,,,,,,,,,,,,,,,,,,,,Hypocitraturia,,HP:0012405,,,,,,,,,,,
36,3,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,Treatment attempts with isoleucine and protein restriction did not clearly alter or improve the course of the disease despite reduction in the excretion of 2-methyl-3-hydroxybutyrate and tiglylglycine. https://www.ncbi.nlm.nih.gov/pubmed/22132097. https://www.ncbi.nlm.nih.gov/pubmed/11102558,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,,Benzhexol,DB00376,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,tremor,,HP:0001337,https://www.ncbi.nlm.nih.gov/pubmed/?term=2-Methyl-3-hydroxybutyryl-CoA+dehydrogenase+deficiency+in+a+23-year-old+man,,,,,,,,,,
37,,,,,,,,,,,,,,,,,,,,dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/?term=2-Methyl-3-hydroxybutyryl-CoA+dehydrogenase+deficiency+in+a+23-year-old+man,,,,,,,,,,
38,,,,,,,,,Vigabatrin,DB01080 ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,seizures,,HP:0001250,http://www.medlink.com/scripts/mpdf/print_friendly.php?title=2-methyl-3-hydroxybutyryl-coa_dehydrogenase_deficiency&action=download&channel=public_content&entryid=19985,https://www.ncbi.nlm.nih.gov/pubmed/11102558,,,,,,,,,
39,,,,,,,,,levodopa ,DB01235,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/30013934,,,,,,,,,,
40,,,,,,,,,carbidopa,DB00190,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,tremor,,HP:0001337,https://www.ncbi.nlm.nih.gov/pubmed/30013934,,,,,,,,,,
41,,,,,,,,,cefoperazone sodium,DB01329,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Abnormal inflammatory response,,HP:0012647,https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37,,,,,,,,,,
42,,,,,,,,,tazobactam sodium,DB01606,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Abnormal inflammatory response,,HP:0012647,https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37,,,,,,,,,,
43,,,,,,,,,B vitamins,A11E,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Abnormality of the nervous system,,HP:0000707,https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37,,,,,,,,,,
44,,,,,,,,,creatine phosphate sodium,DB13191,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Abnormality of cardiovascular system physiology,,HP:0011025,,,,,,,,,,,
45,,,,,,,,,Carbamazepine,DB00564,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/22132097,,,,,,,,,,
46,,,,,,,,The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day),Carnitine ,DB00583,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Abnormal muscle physiology,,HP:0011804,https://www.ncbi.nlm.nih.gov/pubmed/22132097,,,,,,,,,,
47,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
49,4,# 610006,2-methylbutyryl-CoA dehydrogenase deficiency,,ACADSB,3-hydroxy-2-methylbutyryl-CoA dehydrogenase,1.1.1.178,,L-Carnitine+ low-protein diet,DB00583,ECO:0000352,,,,,Symptomatic (C)+Functional interaction (Mechanistic B),C+B,symptomatic treatment procedure+dietary exclusion,,Abnormality of muscle physiology,,HP:0011804,https://www.ncbi.nlm.nih.gov/pubmed/12837870,,,,,,,,,,
50,,,,,,,,,,,,,,,,,,,,Elevated serum toxic intermediates in isoleucine pathway,,HP:0001939,,,,,,,,,,,
51,5,210200,3-methylcrotonyl-CoA carboxylase deficiency ,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,"Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630",Biotin,DB00121,ECO:0000352,MCCA-R385S(heterozygote mutation),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108/,MCCB-(IVS16þ1G>A)/ MCCB-missense mutation E99Q Homozygous mutation,,Functional interaction (Mechanistic B),B,activity modification of a genetically defective protein,,seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108/,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948/,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf,,,,
52,,,,,,,,,,,,"heterozygote missense mutation, MCCA-R385S",https://www.ncbi.nlm.nih.gov/pubmed/16773504,,,,,,,Organic aciduria,,HP:0001992,,,,,,,,,,,
53,,,,,,,,,,,,,,,,,,,,EEG abnormality,,HP:0002353,,,,,,,,,,,
54,,,,,,,,,,,,,,,,,,,,Hypsarrhythmia,,HP:0002521,https://www.ncbi.nlm.nih.gov/pubmed/16773504,,,,,,,,,,
55,,,,,,,,,vigabatrin,DB01080 ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,seizures,,HP:0001250,,,,,,,,,,,
56,,,,,,,,,,,,,,,,,,,,Increased 3-hydroxyisovaleric acid excretion,,NA,,,,,,,,,,,
57,,,,,,,,,,,,,,,,,,,,Increased 3-methylcrotonylglycine excretion,,NA,,,,,,,,,,,
58,,,,,,,,,,,,,,,,,,,,abnormal Biotinidase activity in plasma,,NA,,,,,,,,,,,
59,,,,,,,,,,,,,,,,,,,,EEG abnormality,,HP:0002353,,,,,,,,,,,
60,,,,,,,,,L-Carnitine,DB00583,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Abnormality of muscle physiology,,HP:0011804,https://www.ncbi.nlm.nih.gov/pubmed/10485305,https://www.ncbi.nlm.nih.gov/pubmed/18155631,https://www.ncbi.nlm.nih.gov/pubmed/17968484,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,,,,,
61,,,,,,,,,,,,,,,,,,,,secondary carnitine deficiency,,HP:0003234*,https://www.ncbi.nlm.nih.gov/pubmed/8831079,,,,,,,,,,
62,,,,,,,,,,,,,,,,,,,,elevated serum toxic intermediates (,,HP:0001939,,,,,,,,,,,
63,,,,,,,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",Glycine,DB00145 ,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,Drug name: controversial results,defected excertion of 3- MCG,,NA,https://www.ncbi.nlm.nih.gov/pubmed/7474896,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/8831079,,,,,,,,
64,,,,,,,,,,,,,,,,,,,,Accumulation of 3-methylcrotonyl-CoA metabolite level ( Metabolism abnormality)*,,HP:0001939 *,,,,,,,,,,,
65,,,,,,,,,Glycine +L-Carnitine,DB00145 +DB00583,ECO:0000352,,,,,Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B),B+B,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Acute metabolic crisis ( Metabolism abnormality)*,,HP:0001939 *,https://link.springer.com/article/10.1007/BF00710419,,,,,,,,,,
66,,,,,,,,,,,,,,,,,,,,Accumulation of 3-methylcrotonyl-CoA metabolite level ( Metabolism abnormality)*,,HP:0001939 *,https://link.springer.com/article/10.1007/BF00710419,https://www.orpha.net/data/patho/GB/uk-MCC.pdf,https://www.jci.org/articles/view/11948,,,,,,,,
67,6,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency ,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,L-carnitine,DB00583,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein, Drug name: Use is controverial. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644/?otool=igbcambulib,secondary carnitine deficiency,,HP:0003119,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644/,,,,,,,,,,
68,,,,,,,,,,,,,,,,,,,,high  short chain acyl-carnitine metabolite level,,HP:0001939,,,,,,,,,,,
69,,,,,,,,,,,,,,,,,,,,Muscle weakness,,HP:0001324,https://link.springer.com/article/10.1023%2FA%3A1024031714659?LI=true,,,,,,,,,,
70,,,,,,,,,vitamin E supplements,DB00163 ,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Abnormality of peripheral nerves,,HP:0045010,https://clinicaltrials.gov/ct2/show/study/NCT00840112?show_desc=Y#desc,,,,,,,,,,
71,,,,,,,,,,,,,,,,,,,,Neuropathy,,HP:0009830,,,,,,,,,,,
72,,,,,,,,,Triheptanoin,DB11677,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Myalgia,,HP:0003326,https://clinicaltrials.gov/ct2/show/study/NCT01379625,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644/,,,,,,,,,
73,,,,,,,,,,,,,,,,,,,,Abnormal cardiac function,,HP:0011025,,,,,,,,,,,
74,,,,,,,,,,,,,,,,,,,,Fatigue,,HP:0011025,,,,,,,,,,,
75,,,,,,,,,Prednisone,DB00635,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Fatigue,,HP:0011025,https://www.ncbi.nlm.nih.gov/pubmed/7748366,https://www.sciencedirect.com/science/article/pii/088789949400109F,,,,,,,,,
76,,,,,,,,,,,,,,,,,,,,Impaired nerve conduction,,HP:0040129,,,,,,,,,,,
77,,,,,,,,,,,,,,,,,,,,Defected mucle plasma membrane,,,,,,,,,,,,,
78,,,,,,,,,,,,,,,,,,,,Defected neuronal plasma membrane,,,,,,,,,,,,,
79,7,% 236795,3-Hydroxyisobutyric aciduria ,,ALDH6A1,3-hydroxyisobutyrate dehydrogenase,1.1.1.31,,Carnitine,DB00583 ,ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure,,acidemia,,HP:0001941,http://eknygos.lsmuni.lt/springer/365/81-92.pdf,,,,,,,,,,
80,8,250950,3-methylglutaconyl-CoA hydratase deficiency (AUH defect) ,,AUH,Methylglutaconyl-CoA hydratase,4.2.1.18,,L-carnitine,DB00583 ,ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358122/,https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new,,,,,,,,,
81,,,,,,,,,,,,,,,,,,,,Abnormality of movement,,HP:0100022,,,,,,,,,,,
82,,,,,,,,,,,,,,,,,,,,Metabolic Decompensation,,HP:0001939,https://www.ncbi.nlm.nih.gov/pubmed/11400757/,,,,,,,,,,
83,,,,,,,,,,,,,,,,,,,,Delayed Growth,,HP:0001510,,,,,,,,,,,
84,9,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,Sapropterin,DB00360,ECO:0007121/ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,Behavioral abnormality,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/19323589,https://www.ncbi.nlm.nih.gov/pubmed/22832064,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,,,,,,,
85,,,,,,,,,,,,,,,,functional complementation of a defective protein by stimulation',,,,Personality disorder,,HP:0012075,,,,,,,,,,,
86,,,,,,,,,,,,,,,,,,,,Hyperphenylalaninemia,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/22832064,,,,,,,,,,
87,,,,,,,,,Antisense morpholino oligonucleotides (AMOs),NA,ECO:0001565,"c.84−322A>T, c.163 + 695_163 + 751del57, or c.164−712A>T",,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein,,pseudoexon activation ,,NA,https://www.ncbi.nlm.nih.gov/pubmed/21542064,,,,,,,,,,
88,,,,,,,,,BH4+L-Dopa+5HTP,DB00360+DB01235+DB02959,ECO:0000352,,,,,Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B),B+B+B,metabolite replacement+metabolite replacement+metabolite replacement,,Hyperphenylalaninemia,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/,,,,,,,,,
89,,,,,,,,,,,,,,,,,,,,Abnormality of neurotransmitter metabolism,,HP:0012535,https://www.ncbi.nlm.nih.gov/pubmed/25304915,,,,,,,,,,
90,,,,,,,,,,,,,,,,,,,,Neurological abnormality,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/25304915,,,,,,,,,,
91,,,,,,,,,,,,,,,,,,,,Neurodevelopmental abnormality,,HP:0012759,https://www.ncbi.nlm.nih.gov/pubmed/25304915,,,,,,,,,,
92,,,,,,,,,,,,,,,,,,,,Intellectual disability,,HP:0001249,https://www.ncbi.nlm.nih.gov/pubmed/25304915,,,,,,,,,,
93,,,,,,,,,,,,,,,,,,,,Delayed CNS mylinaton,"The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879",HP:0002188,https://www.ncbi.nlm.nih.gov/pubmed/16601879,,,,,,,,,,
94,,,,,,,,The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration https://www.ncbi.nlm.nih.gov/pubmed/16601879,Oxitriptan,DB02959,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,Abnormality of neurotransmitter metabolism,,HP:0012535,https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879,,,,,,,,,
95,,,,,,,,,,,,,,,,,,,,Abnormality in serotonin turnover (Abnormality of circulating hormone level),,HP:0003117,,,,,,,,,,,
96,,,,,,,,"The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effects. 
Clinicians should be cautious, because Levodopa-Induced Dyskinesia "" LIDs can occur commonly in patients with DRD‐plus, especially because of SR, TH, and PTPS deficiencies. The current study showed that LIDs were reported in  44.4% of patients who had PTPS deficiencies. In such patients, a very low starting dose of l‐dopa with from 0.5 to 1 mg/kg daily divided into 4 to 6 doses is recommended https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/",levodopa (L-dopa),DB01235,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,Abnormality of neurotransmitter metabolism,,HP:0012535,https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879,,,,,,,,,
97,,,,,,,,,,,,,,,,,,,,Paroxysmal movements,,HP:0007166,,,,,,,,,,,
98,,,,,,,,,,,,,,,,,,,,Movement disorder,,HP:0100022,,,,,,,,,,,
99,,,,,,,,"The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effectshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/",carbidopa,DB00190,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a defective protein by inhibition,,Abnormality of neurotransmitter metabolism,,HP:0012535,https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879,,,,,,,,,
100,,,,,,,,"The addition of pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy.https://www.ncbi.nlm.nih.gov/pubmed/19704083",pramipexole + L- dopa,DB00413+DB01235,ECO:0007121,,,,,Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B),B+B,functional complementation of a defective protein by stimulation+metabolite replacement," Drug name: The addition of  pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy. Similar benefits may be expected in other forms of inherited tetrahydrobiopterin deficiency. https://www.ncbi.nlm.nih.gov/pubmed/19704083",Movement Disability ,,HP:0100022,https://www.ncbi.nlm.nih.gov/pubmed/19704083,,,,,,,,,,
101,,,,,,,,,,,,,,,,,,,,High prolactin level,,HP:0000870,,,,,,,,,,,
102,,,,,,,,,,,,,,,,,,,,Behavioural Disability,,HP:0000708,,,,,,,,,,,
103,,,,,,,,,,,,,,,,,,,,Abnormal Unified Parkinson's Disease Rating Scale (UPDRS )score(Abnormality of neurotransmitter metabolism)*,,NA,,,,,,,,,,,
104,,,,,,,,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",selective monoamine oxidase (MAO) B inhibitor,DB01247 ,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Low dopamine level,,HP:0012656,https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf,https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency,https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/,,,,,,,,
105,,,,,,,,,Retrovirus-mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase,NA,ECO:0001565,,,,,Direct interaction(A),A,direct complementation of a genetically defective protein by gene therapy,,Low tetrahydrobiopterin level,,HP:0040210,https://www.ncbi.nlm.nih.gov/pubmed/8864759,,,,,,,,,,
106,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
107,,,,,,,,,folinic acid,DB03256,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,Abnormal serum folate,,HP:0040087,,,,,,,,,,,
108,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,BH4,DB00360,,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,Elevated Phe level in blood,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/7110811/,https://www.ncbi.nlm.nih.gov/pubmed/8433887/,,,,,,,,,
109,,,,,,,,,,,,,,,,,,,,Neurological abnormality,,HP:0000707,,,,,,,,,,,
110,,,,,,,,,BH4+L-dopa+5-hydroxytryptophan,DB00360+DB01235+DB02959,ECO:0000352,,,,,Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B),B+B+B,metabolite replacement+metabolite replacement+metabolite replacement,,Elevated blood phenylalanine concentration,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/7110811/,https://www.ncbi.nlm.nih.gov/pubmed/23138986,,,,,,,,
111,,,,,,,,,,,,,,,,,,,,Abnormality of neurotransmitter metabolism,,HP:0012535,,,,,,,,,,,
112,,,,,,,,,,,,,,,,,,,,Neurological abnormality,,HP:0000707,,,,,,,,,,,
113,,,,,,,,,BH4+L-dopa/carbidopa+5-hydroxytryptophan+Folinic acid,DB00360+DB01235+DB02959+DB03256,ECO:0000352,,,,,Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B),B+B+B+B,metabolite replacement+metabolite replacement+metabolite replacement+functional complementation of a genetically defective protein,,Developmental delay,,HP:0001263,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580/,,,,,,,,,,
114,,,,,,,,,,,,,,,,,,,,Delayed receptive language,,HP:0010863,,,,,,,,,,,
115,,,,,,,,,,,,,,,,,,,,Neurological impairment,,HP:0000707,,,,,,,,,,,
116,,,,,,,,,,,,,,,,,,,,Hyperphenylalaninemia,,HP:0004923,,,,,,,,,,,
117,,,,,,,,,folinic acid,DB03256,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,compensatory complementation of a genetically defective protein,,Progressive basal ganglia calcification,,HP:0002135,https://www.ncbi.nlm.nih.gov/pubmed/2785251,https://www.ncbi.nlm.nih.gov/pubmed/12003346,,,,,,,,,
118,,,,,,,,,,,,,,,,,,,,Subcortical calcification,,HP:0007346,,,,,,,,,,,
119,,,,,,,,,,,,,,,,,,,,Seizure,,HP:0001250,,,,,,,,,,,
120,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
121,10,# 200100,Abetalipoproteinemia,"The mainstays of treatment include adherence to a low-fat diet, and supplementation with essential fatty acids and high oral doses of fat soluble vitamins. https://www.ncbi.nlm.nih.gov/pubmed/24288038",MTTP,microsomal triglyceride transfer protein,P55157,,vitamin E therapy,DB00163 ,ECO:0000352,,,,,Functional interaction (B),B,metabolite replacement,,nervous system abnormalities,,HP:0002011,https://www.ncbi.nlm.nih.gov/pubmed/30358967,https://www.ncbi.nlm.nih.gov/pubmed/26086616,https://www.ncbi.nlm.nih.gov/pubmed/25488886,https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,
122,,,,,,,,,,,,,,,,,,,,neurologic dysfunction ,,HP:0000707,,,,,,,,,,,
123,,,,,,,,,,,,,,,,,,,,Retinopathy,,HP:0000488,https://www.ncbi.nlm.nih.gov/pubmed/3954973/,,,,,,,,,,
124,,,,,,,,,medium-chain fatty acid supplements,DB13959,ECO:0000352,,,,,Functional interaction (B),B,metabolite replacement,,Growth impairment,,HP:0008897,,,,,,,,,,,
125,,,,,,,,,Vitamin K,CHEBI:28384,ECO:0000352,,,,,Functional interaction (B),B,metabolite replacement,,Malabsorption of lipid-soluble vitamins (Fat malabsorption)*,,HP:0002630,https://www.ncbi.nlm.nih.gov/pubmed/26396722,,,,,,,,,,
126,,,,,,,,,Vitamin D,DB11094,ECO:0000352,,,,,Functional interaction (B),B,metabolite replacement,,Malabsorption of lipid-soluble vitamins (Fat malabsorption)*,,HP:0002630,,,,,,,,,,,
127,,,,,,,,"Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031",vitamin A+ Vitamin E,DB00162+DB00163 ,ECO:0000352,,,,,Functional interaction (B)+Functional interaction (B),B+B,metabolite replacement+metabolite replacement,,Retinal degeneration,,HP:0000546,https://www.ncbi.nlm.nih.gov/pubmed/11767031,https://www.ncbi.nlm.nih.gov/pubmed/30731125,,,,,,,,,
128,,,,,,,,,,,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/14749227,,,,,,,,,,
129,,,,,,,,,Medium-chain fatty acid supplements+Vitamin A+Vitamin D+Vitamin E+Vitamin K,DB13959+DB00162+DB11094+DB00163+CHEBI:28384,ECO:0000352,,,,,Functional interaction (B)+Functional interaction (B)+Functional interaction (B)+Functional interaction (B)+Functional interaction (B)+Functional interaction (B),B+B+B+B+B,metabolite replacement+metabolite replacement+metabolite replacement+metabolite replacement+metabolite replacement,,Neurological abnormalities,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,,
130,,,,,,,,,,,,,,,,,,,,Disease progression (Progressive),,HP:0003676,,,,,,,,,,,
131,,,,,,,,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",Progesteron,DB00396,ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure,,Female infertility,,HP:0008222,,,,,,,,,,,
132,,,,,,,,,Vitamin B12+iron,DB00115+DB01592,ECO:0000352,,,,,Symptomatic (C)+Symptomatic (C),C+C,symptomatic treatment procedure+symptomatic treatment procedure,,Anemia,,HP:0001903,,,,,,,,,,,
133,,,,,,,,,levothyroxine,DB00451,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,subclinical hypothyroidism,,HP:0000821,https://www.ncbi.nlm.nih.gov/pubmed/26396722,https://www.ncbi.nlm.nih.gov/pubmed/17132287/,,,,,,,,,
134,11,# 604290,Aceruloplasminemia,,CP,Ferroxidase,1.16.3.1,,Deferasirox,DB01609,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a defective protein by inhibition,,high serum ferritin concentration,,HP:0003281,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/books/NBK1493/,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,,,,,,,
135,,,,,,,,,,,,,,,,,,,,high brain and liver iron stores,,HP:0003281*,,,,,,,,,,,
136,,,,,,,,,vitamin E+ Zinc ,DB00163 +DB01593,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,tissue damage,,NA,,,,,,,,,,,
137,,,,,,,,,,,,,,,,,,,,Liver dysfunction,,HP:0001410,,,,,,,,,,,
138,,,,,,,,,,,,,,,,,,,,pancreatic dysfunction,,HP:0001738,,,,,,,,,,,
139,12,606175,Acetyl-carnitine deficiency,,CRAT,Carnitine acetyltransferase,2.3.1.7,,L-Carnitine,DB00583 ,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,fasting ketogenesis,,HP:0001946/HP:0025212,,,,,,,,,,,
140,,,,,,,,,,,,,,,,,,,,cardiac dysfunction,,HP:0011025,,,,,,,,,,,
141,,,,,,,,,,,,,,,,,,,,Delayed growth,,HP:0001510,,,,,,,,,,,
142,,,,,,,,,,,,,,,,,,,,cognitive impairment,,HP:0100543,,,,,,,,,,,
143,13,# 201100,Acrodermatitis enteropathica ,,SLC39A4,zinc/iron-regulated transporter-like protein ,Q6P5W5,,zinc ,DB01593,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,skin inflammation,,HP:0011123,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399/,https://www.ncbi.nlm.nih.gov/pubmed/24718477,,,,,,,,,
144,,,,,,,,,,,,,,,,,,,,Alopecia,,HP:0001596,,,,,,,,,,,
145,,,,,,,,,,,,,,,,,,,,Agitation,,HP:0000713,,,,,,,,,,,
146,,,,,,,,,,,,,,,,,,,,irritability,,HP:0000737,,,,,,,,,,,
147,,,,,,,,,,,,,,,,,,,,diarrhea,,HP:0002014,,,,,,,,,,,
148,,,,,,,,,,,,,,,,,,,,emotional disturbances,,HP:0000712,,,,,,,,,,,
149,,,,,,,,,Zinc+ linoleic acid,DB01593+DB14104,ECO:0000352,,,,,Functional interaction (Mechanistic B)+Symptomatic (C),B+C,metabolite replacement+symptomatic treatment procedure,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779298/,,,,,,,,,,
150,,,,,,,,"Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070",Diiodoquinoline,DB09115,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Acrodermatitis (Dermatitis)*,,HP:0011123,https://www.ncbi.nlm.nih.gov/pubmed/14354277,https://www.ncbi.nlm.nih.gov/pubmed/13044560,https://www.ncbi.nlm.nih.gov/pubmed/4929571,https://www.ncbi.nlm.nih.gov/pubmed/1275520,,,,,,,
151,,,,,,,,,,,,,,,,,,,,Diarrhea,,HP:0002014,,,,,,,,,,,
152,,,,,,,,,,,,,,,,,,,,Alopecia,,HP:0001596,,,,,,,,,,,
153,,,,,,,,,,,,,,,,,,,,Perioral dermatitis,,HP:0040181,,,,,,,,,,,
154,,,,,,,,,Clioquinol,DB04815,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Dermatitis,,HP:0011123,https://www.ncbi.nlm.nih.gov/pubmed/375935,,,,,,,,,,
155,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
156,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
157,,,,,,,,"A potential therapeutic options for the long-term treatment of AE.  This compound had little overall effect on zinc content in various tissues that were assessed, although further characterisation is required to more fully explore the cellular changes underlying the physiological benefit of this compound. https://www.ncbi.nlm.nih.gov/pubmed/30669644",Zn-DTSM (zinc ionophore),,ECO:0001565/ ECO:0005542,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,,,,https://www.ncbi.nlm.nih.gov/pubmed/30669644,,,,,,,,,,
158,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
159,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
160,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
161,14,# 176000,Acute intermittent porphyria ,,HMBS,Hydroxymethylbilane synthase.,2.5.1.61,"Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787",Glucose,DB09341,ECO:0000352,,,,,Supportive (C),C,functional complementation of a genetically defective protein,,Excretion of heme precursors(Abnormality of the heme biosynthetic pathway)*,,HP:0010472,https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,,,,,,,,
162,,,,,,,,,,,,,,,,,,,,"(abdominal pain, nausea, vomiting)",,HP:0002027/ HP:0002017,,,,,,,,,,,
163,,,,,,,,,,,,,,,,,,,,Mild attack,,HP:0012825,https://www.ncbi.nlm.nih.gov/pubmed/23605132/,,,,,,,,,,
164,,,,,,,,,Panhematin,DB03404,ECO:0000352/ECO:0007121,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,pain,,HP:0012531,https://clinicaltrials.gov/ct2/show/NCT02922413,https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,,,,,
165,,,,,,,,,,,,,,,,,,,,hypertension,,HP:0000822,,,,,,,,,,,
166,,,,,,,,,,,,,,,,,,,,tachycardia,,HP:0001649,,,,,,,,,,,
167,,,,,,,,,,,,,,,,,,,,abnormal mental status,,HP:0100543,,,,,,,,,,,
168,,,,,,,,,,,,,,,,,,,,Acute attack,,HP:0011009,,,,,,,,,,,
169,,,,,,,,"The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/",rh-HMBS,NA,ECO:0007121,,,,,Direct intercation (Mechanistic A),,direct complementation of a genetically defective protein,,Accumulated  plasma porphobilinogen,,,https://www.ncbi.nlm.nih.gov/pubmed/17375984/,,,,,,,,,,
170,,,,,,,,,,,,,,,,,,,,Accumulated  urine porphobilinogen,,HP:0012217,,,,,,,,,,,
171,,,,,,,,,rhPBGD,NA,ECO:0005542,,,,,Direct intercation (Mechanistic A),,direct complementation of a genetically defective protein,,Eevated porphyrin precursors porphobilinogen,,HP:0012217,https://www.ncbi.nlm.nih.gov/pubmed/15208740/,,,,,,,,,,
172,,,,,,,,,rAAV8-mediated gene therapy expressing murine HMB-synthase ,NA,ECO:0005542,,,,,Direct intercation (Mechanistic A),,direct complementation of a genetically defective protein by gene therapy,,Hepatic metabolic abnormalities ( Metabolism abnormality)*,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/19861948,,,,,,,,,,
173,,,,,,,,,,,,,,,,,,,,Abnormal neuromotor function,,HP:0002333,,,,,,,,,,,
174,,,,,,,," There is a study for ""Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317",AAV2/5-PBGD,NA,ECO:0007121,,,,,Direct intercation (Mechanistic A),,direct complementation of a genetically defective protein by gene therapy,,Low PBGD expression in liver,,NA,https://www.ncbi.nlm.nih.gov/pubmed/24933563,https://www.ncbi.nlm.nih.gov/pubmed/24933563,,,,,,,,,
175,,,,,,,,,Givosiran,DB15066,ECO:0007121/ECO:0005542,,,,,,,functional complementation of a defective protein by inhibition,,Abnormal circulating porphyrin concentration,,HP:0010472,https://www.ncbi.nlm.nih.gov/pubmed/30766957,https://www.ncbi.nlm.nih.gov/pubmed/30726693,https://www.ncbi.nlm.nih.gov/pubmed/24821812,https://clinicaltrials.gov/ct2/show/NCT02452372,,,,,,,
176,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
177,15,# 614723,Adenine phosphoribosyltransferase deficiency ,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,allopurinol,DB00437 ,ECO:0007121,,,,,Functional intearction (Mechanistic B),B,functional complementation of a genetically defective protein,,urolithiasis,,HP:0000787,https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://academic.oup.com/ckj/article/9/6/800/2709623,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,
178,,,,,,,,,,,,,,,,,,,,crystalline nephropathy,,HP:0000112,,,,,,,,,,,
179,,,,,,,,,,,,,,,,,,,,Hematuria,,HP:0000790,,,,,,,,,,,
180,,,,,,,,,,,,,,,,,,,,Dysuria,,HP:0100518,,,,,,,,,,,
181,,,,,,,,,,,,,,,,,,,,Recurrent urinary tract infections,,HP:0000010,,,,,,,,,,,
182,,,,,,,,,,,,,,,,,,,,Chronic kidney disease,,HP:0012622,,,,,,,,,,,
183,,,,,,,,,,,,,,,,,,,,Elevated Urinary DHA excretion,,,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,,,,
184,,,,,,,,,,,,,,,,,,,,Kidney stones ,,,,,,,,,,,,,
185,,,,,,,,"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/",febuxostat,DB04854,ECO:0007121,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,urolithiasis,,HP:0000787,https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,,
186,,,,,,,,,,,,,,,,,,,,crystalline nephropathy,,HP:0000112,,,,,,,,,,,
187,,,,,,,,,,,,,,,,,,,,Hematuria,,HP:0000790,,,,,,,,,,,
188,,,,,,,,,,,,,,,,,,,,Dysuria,,HP:0100518,,,,,,,,,,,
189,,,,,,,,,,,,,,,,,,,,Recurrent urinary tract infections,,HP:0000010,,,,,,,,,,,
190,,,,,,,,,,,,,,,,,,,,Chronic kidney disease,,HP:0012622,,,,,,,,,,,
191,,,,,,,,,,,,,,,,,,,,Elevated Urinary DHA excretion,,,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,,,,
192,16,# 102700,Adenosine deaminase deficiency ,,ADA,Adenosine deaminase,3.5.4.4,,Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),DB14712,ECO:0000352,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein,,lymphopenia,,HP:0001888,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://www.asgct.org/education/disease-treatments/inherited-immunodeficiencies,,,,,,,,
193,,,,,,,,,,,,,,,,,,,,hepatosplenomegaly,,HP:0001433,,,,,,,,,,,
194,,,,,,,,,,,,,,,,,,,,Elevated liver enzyme levels,,HP:0002910,,,,,,,,,,,
195,,,,,,,,,,,,,,,,,,,,Low weight,,HP:0004325,,,,,,,,,,,
196,,,,,,,,,,,,,,,,,,,,Abnormal eosinophil counts,,HP:0001879,,,,,,,,,,,
197,,,,,,,,,,,,,,,,,,,,Hemolysis,,HP:0001878,,,,,,,,,,,
198,,,,,,,,,,,,,,,,,,,,Thyroid antibodies (autoimmunity)*,,HP:0002960,,,,,,,,,,,
199,,,,,,,,,,,,,,,,,,,,Abnormal immune function,,HP:0010978,https://adisinsight.springer.com/trials/700243447,,https://clinicaltrials.gov/ct2/show/NCT01420627,,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,,,,,,
200,,,,,,,,,,,,,,,,,,,,dermatitis,,HP:0011123,,,,,,,,,,,
201,,,,,,,,"Further data gathering is necessary to determine overall outcome of patients on long-term therapy ""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/",Pegademase bovine ((PEG-ADA)),DB00061  ,ECO:0000352,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein,,Abnormal immune function,,HP:0010978,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/,,,,,,,,,,
202,,,,,,,,,,,,,,,,,,,,Recurrent infection ,,HP:0002719,,,,,,,,,,,
203,,,,,,,,,,,,,,,,,,,,"Frequent, severe infections ",,HP:0002719,,,,,,,,,,,
204,,,,,,,,,,,,,,,,,,,,Abnormal lymphocyte counts,,HP:0040088,,,,,,,,,,,
205,,,,,,,,,,,,,,,,,,,,Abnormal number of b cells,,HP:0010975,,,,,,,,,,,
206,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
207,,,,,,,,IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/,Immune Globulin Human,DB00028,ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure,,Recurrent infection,,HP:0002719,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/,,,,,,,,,,
208,17,# 615511,Adenosine monophosphate deaminase 1 deficiency ,, AMPD1,AMP deaminase,3.5.4.6,,D- Ribose,DB02053 ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Exercise-induced muscle fatigue,,HP:0009020,https://pdfs.semanticscholar.org/99dc/08fa85d5728e08f29b8c13177aac3206f4ec.pdf,,,,,,,,,,
209,,,,,,,,,,,,,,,,,,,,Exercise-induced myalgia,,HP:0003738,,,,,,,,,,,
210,,,,,,,,,,,,,,,,,,,,Limb muscle weakness,,HP:0003690,,,,,,,,,,,
211,,,,,,,,,,,,,,,,,,,,Muscle cramps,,HP:0003394,,,,,,,,,,,
212,18,# 300100,Adrenomyeloneuropathy ,,ABCD1,adrenoleukodystrophy protein,,"It is used as an investigational treatment for asymptomatic patients, however, there are other controversial studies about the significance of this treatment 1: https://www.ncbi.nlm.nih.gov/pubmed/8350883. 2: https://www.ncbi.nlm.nih.gov/pubmed/10078732",Lorenzo's oil(Terminated),DB12528,ECO:0007121,,,,,Supportive (C),C,symptomatic treatment procedure,,Disease progression,,HP:0003678,https://clinicaltrials.gov/ct2/show/NCT00545597,https://www.ncbi.nlm.nih.gov/pubmed/16009761,https://www.ncbi.nlm.nih.gov/pubmed/7666063,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,,,,,,,
213,,,,,,,,,,,,,,,,,,,,Abnormal elevated level of VLCFA in plasma,,HP:0003455,,,,,,,,,,,
214,,,,,,,,,Lenti-D gene therapy(advanced self-inactivating lentiviral vector TYF-ABCD1),,ECO:0007121,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein by gene therapy,,Functional disability(Constitutional symptom)*,,HP:0025142,https://clinicaltrials.gov/ct2/show/NCT03727555?cond=Adrenoleukodystrophy&rank=4,https://www.myelin.org/tag/lenti-d/,https://www.ncbi.nlm.nih.gov/pubmed/28976817,,,,,,,,
215,,,,,,,,The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/,Sobetirome (NV1205),DB07425,ECO:0007121/ECO:0005542,,,,,Functional interaction (Mechanistic B),B,functional complementatoin of a defective protein by stimulation,,Elevated long chain fatty acids,,HP:0003455,https://www.ncbi.nlm.nih.gov/pubmed/28200172,https://clinicaltrials.gov/ct2/show/NCT03196765?cond=Adrenoleukodystrophy&rank=3,,,,,,,,,
216,,,,,,,,,Lovastatin,DB00227,ECO:0000352/ECO:0001565/ECO:0007121,,,,,Symptomatic (C),C,functional complementatoin of a defective protein,,High plasma level of very-long-chain fatty acids  ,,HP:0003455,https://www.ncbi.nlm.nih.gov/pubmed/16949688,https://www.ncbi.nlm.nih.gov/pubmed/10870849,https://www.ncbi.nlm.nih.gov/pubmed/20089986,,,,,,,,
217,,,,,,,,,,,,,,,,,,,,High plasma levels of hexacosanoic acid ,,NA,https://www.ncbi.nlm.nih.gov/pubmed/10870849,,,,,,,,,,
218,,,,,,,,"All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub",interferon beta + thalidomide,DB00060+DB01041,ECO:0007121,,,,,Supportive (C),C+C,symptomatic treatment procedure+symptomatic treatment procedure,,NO revealed clinical benefit,,,https://clinicaltrials.gov/ct2/show/NCT00004450?cond=Adrenoleukodystrophy&rank=20,,https://www.ncbi.nlm.nih.gov/pubmed/?term=X-linked+adrenoleukodystrophy%3A+Clinical%2C+biochemical+and+pathogenetic+aspects,,,,,,,,
219,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
220,19,# 263570,Adult polyglucosan body disease ,,GBE1,"Limit dextrin alpha-1,6-maltotetraose-hydrolase",3.2.1.196,,Triheptanoin,DB11677,ECO:0007121,,,,,Symptomatic (C)+Supportive (C),C,symptomatic treatment procedure,,muscle pain,,HP:0003326,https://clinicaltrials.gov/ct2/show/NCT00947960?cond=Adult+Polyglucosan+Body+Disease&rank=1,,,,,,,,,,
221,,,,,,,,,,,,,,,,,,,,defective heart function,,HP:0011025,,,,,,,,,,,
222,,,,,,,,,,,,,,,,,,,,Lack of energy,,HP:0012378,,,,,,,,,,,
223,20,# 603471,adult-onset type II citrullinemia,Liver transplantation is the only radical treatment for CTLN2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/, SLC25A13,citrin ( protein),Q9UJS0,Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749,Medium-chain triglycerides,DB13959,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of genetically defective protein,,High blood ammonia level,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/29651749,,https://www.ncbi.nlm.nih.gov/pubmed/26427088,,,,,,,,
224,,,,,,,,,,,,,,,,,,,,Relapse of hyperammonemic encephalopathy,,HP:0001298*,,,,,,,,,,,
225,,,,,,,,,,,,,,,,,,,,High plasma citrulline levels,,HP:0011966,,,,,,,,,,,
226,,,,,,,,,,,,,,,,,,,,low plasma glutamine levels,,HP:0010903,,,,,,,,,,,
227,,,,,,,,,L-Arginine,DB00125 ,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of genetically defective protein,,hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/18958581,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315,,,,,,,,
228,,,,,,,,,,,,,,,,,,,,Disease progression (Rapidly progressive)*,,HP:0003678*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,,,,,,,,,,
229,,,,,,,,,,,,,,,,,,,,Encephalopathy,,HP:0001298,https://www.jstage.jst.go.jp/article/kanzo1960/43/11/43_11_492/_article,,,,,,,,,,
230,,,,,,,,,Pyruvic acid,DB00119,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,https://www.ncbi.nlm.nih.gov/books/NBK1181/,,,,,,,,,
231,,,,,,,,It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/,L-Arginine+Pyruvic acid,DB00125+DB00119,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,anorexia,,HP:0002039,https://www.ncbi.nlm.nih.gov/pubmed/18958581,,,,,,,,,,
232,,,,,,,,,,,,,,,,,,,,lethargy,,HP:0001254,,,,,,,,,,,
233,,,,,,,,,,,,,,,,,,,,fatigue,,HP:0012378,,,,,,,,,,,
234,,,,,,,,,,,,,,,,,,,,Poor growth,,HP:0001510,,,,,,,,,,,
235,,,,,,,,,,,,,,,,,,,,hyperammonemia,,HP:0001987,,,,,,,,,,,
236,,,,,,,,,,,,,,,,,,,,Elevated plasma citrulline level,,HP:0011966,,,,,,,,,,,
237,,,,,,,,,,,,,,,,,,,,Elevated threonine-to-serine ratio ( Abnormality of amino acid metabolism)*,,HP:0004337*,,,,,,,,,,,
238,,,,,,,,,,,,,,,,,,,,Elevated serum pancreatic secretory trypsin inhibitor,,NA,,,,,,,,,,,
239,,,,,,,,"According to a retrospective study, 11 of 12 patients who received Glyceol died, whereas both of 2 patients who received D-mannitol survived.https://www.ncbi.nlm.nih.gov/pubmed/15050970 
D-mannitol is unlikely to affect cytosolic NADH production even in citrin de ciency. Therefore, it is highly recommended to administer D-mannitol but not Glyceol to treat brain edema in patients with CTLN2. https://www.ncbi.nlm.nih.gov/pubmed/16449956",D-mannitol,DB00742,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Brain oedema,,HP:0002181,https://www.ncbi.nlm.nih.gov/pubmed/16449956,,,,,,,,,,
240,21,# 612953,Adult-onset dystonia-parkinsonism ,,PLA2G6,Phospholipase A(2),3.1.1.4,It was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.,Pergolide,DB01186,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,Drug name: It was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.,parkinsonism,,HP:0001300,https://www.ncbi.nlm.nih.gov/pubmed/24613933,,,,,,,,,,
241,,,,,,,,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",L- dopa,DB01235,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,parkinsonism,,HP:0001300,https://www.ncbi.nlm.nih.gov/pubmed/25660576/,https://www.ncbi.nlm.nih.gov/pubmed/20938027,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,,,,,
242,22,# 615395,Combined oxidative phosphorylation deficiency 16,,MRPL44,MITOCHONDRIAL RIBOSOMAL PROTEIN L44,Q9H9J2,,creatine,DB00148,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Low physical capacity (Constitutional symptom)*,,HP:0025142,https://www.ncbi.nlm.nih.gov/pubmed/25797485,,,,,,,,,,
243,23,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,cholic acid,DB02659 ,ECO:0007121,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,Hepatic Biochemical abnormalities (Laboratory abnormality)*,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/11067870,,,,,,,,,,
244,,,,,,,,,,,,,,,,,,,,Histologic abnormalities in liver (Abnormal test result)*,,HP:0500014,,,,,,,,,,,
245,,,,,,,,,,,,,,,,,,,,progression of the disease (Rapidly progressive)*,,HP:0003678*,,,,,,,,,,,
246,,,,,,,,,,,,,,,,,,,,Bile flow defect,,HP:0001396,,,,,,,,,,,
247,,,,,,,,,,,,,,,,,,,,synthesis of atypical bile acids,,NA,,,,,,,,,,,
248,,,,,,,,,,,,,,,,,,,,production of toxic intermediates,,HP:0001939*,,,,,,,,,,,
249,,,,,,,,,,,,,,,,,,,,fat soluble vitamin malabsorption(Fat malabsorption)*,,HP:0002630*,,,,,,,,,,,
250,,,,,,,,,chenodeoxycholic acid,DB06777,ECO:0007121,,,,,Functional interaction (Mechanistic B),B,functional complementation of genetically defective protein,,Abnormal liver function tests,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/2072042,https://www.ncbi.nlm.nih.gov/pubmed/11067870,,,,,,,,,
251,,,,,,,,,,,,,,,,,,,,Pruritus,,HP:0000989,https://www.ncbi.nlm.nih.gov/pubmed/11067870,,,,,,,,,,
252,,,,,,,,,,,,,,,,,,,,Abnormal urinary steroids levels(Abnormality of urine hormone level)*,,HP:0012029,,,,,,,,,,,
253,,,,,,,,,ursodeoxycholic acid,DB01586,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Abnormal liver function tests,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/7915305,,,,,,,,,,
254,,,,,,,,,Glycocholic Acid,DB02691,ECO:0007121,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280294/,,,,,,,,,,
255,,,,,,,,,,,,,,,,,,,,fat soluble vitamin malabsorption(Fat malabsorption)*,,HP:0002630*,,,,,,,,,,,
256,,,,,,,,,Vitamin A+Vitamin D+Vitamin K+Vitamin E+ursodeoxycholic acid+chenodeoxycholic acid,DB00162+DB11094+DB01022+DB00163+DB01586+DB06777,ECO:0000352,,,,,Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B),B+B+B+B+B+B,metabolite replacement+metabolite replacement+metabolite replacement+metabolite replacement+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,fat soluble vitamin malabsorption(Fat malabsorption)*,,HP:0002630*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296980/,,,,,,,,,,
257,,,,,,,,,,,,,,,,,,,,Abnormal gait,,HP:0001288,,,,,,,,,,,
258,,,,,,,,,,,,,,,,,,,,Muscle weakness,,HP:0001324,,,,,,,,,,,
259,24,# 235555,"Congenital bile acid synthesis defect, type 2 ",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,cholic acid,DB02659 ,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,biochemical abnormalities,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/8225213,,,,,,,,,,
260,,,,,,,,,,,,,,,,,,,,Histologic abnormalities in liver(Abnormal test result)*,,HP:0500014,,,,,,,,,,,
261,,,,,,,,,,,,,,,,,,,,Disease progression (Rapidly progressive)*,,HP:0003678*,,,,,,,,,,,
262,,,,,,,,,,,,,,,,,,,,Bile flow defect,,HP:0001396,,,,,,,,,,,
263,,,,,,,,,,,,,,,,,,,,synthesis of atypical bile acids,,NA,,,,,,,,,,,
264,,,,,,,,,,,,,,,,,,,,production of bile acid toxic intermediates,,HP:0001939*,,,,,,,,,,,
265,,,,,,,,,,,,,,,,,,,,fat soluble vitamin malabsorption (Fat malabsorption)*,,HP:0002630*,,,,,,,,,,,
266,,,,,,,,"While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100",Chenodeoxycholic acid + cholic acid,DB06777+DB02659 ,ECO:0000352,,,,,Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B),,functional complementation of a genetically defective protein+metabolite replacement,,Abnormal liver function tests,,,https://www.ncbi.nlm.nih.gov/pubmed/8707100,,,,,,,,,,
267,,,,,,,,,,,,,,,,,,,,Liver biopsy abnormalities,,,,,,,,,,,,,
268,,,,,,,,,,,,,,,,,,,,Abnormal bilirubin level,,,,,,,,,,,,,
269,,,,,,,,,Chenodeoxycholic acid,DB06777,ECO:0000352,,,,,Functional interaction (Mechanistic B),,functional complementation of a genetically defective protein,,Abnormal liver function ,,,https://www.ncbi.nlm.nih.gov/pubmed/28697823,,,,,,,,,,
270,,,,,,,,,,,,,,,,,,,,Hepatomegaly ,,,,,,,,,,,,,
271,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
272,25,# 203500,Alkaptonuria ,,HGD,"Homogentisate 1,2-dioxygenase.",1.13.11.5,"Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria ""for more information please check http://www.developakure.eu/index.html",Nitisinone,DB00348  ,ECO:0007121,,,,,Functional interaction (Mechanistic B),B,functional complementation of a defective protein by inhibition,,Disease progression (Rapidly progressive)*,,HP:0003678*,https://clinicaltrials.gov/ct2/show/NCT00107783?cond=Alkaptonuria&rank=4,https://clinicaltrials.gov/ct2/show/NCT01828463?cond=Alkaptonuria&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/28813744,https://www.ncbi.nlm.nih.gov/pubmed/30477028,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,,,,,
273,,,,,,,,,,,,,,,,,,,,ochronosis,,HP:0030764,https://www.ncbi.nlm.nih.gov/pubmed/26891864,,,,,,,,,,
274,,,,,,,,,,,,,,,,,,,,High circulating HGA (homogentisic acid)level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/26891864,,,,,,,,,,
275,,,,,,,,,,,,,,,,,,,,Joint disesae,,HP:0001367,,,,,,,,,,,
276,,,,,,,,,N-ACETYL-CYSTEINE,DB06151,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,apoptosis induced in chondrocytes,,NA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alkaptonuria,,,,,,,,,,
277,,,,,,,,"Controversial effectivness of AA  in an old study they have demonesterated that AA didn't have much effect in treating patients https://link.springer.com/content/pdf/10.1007%2Fs004310050956.pdf, In a more recent Study , It was noted that AA 's  mild antioxidant nature , helps retard the process of conversion of homogentisate to the polymeric material that is deposited in cartilaginous tissues. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/",ASCORBIC ACID,DB00126,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Abnormal chondrocyte growth ,,NA,https://www.ncbi.nlm.nih.gov/pubmed/9718357/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,,,,,,,,,
278,,,,,,,,,,,,,,,,,,,,Disease progression (Rapidly progressive)*,,HP:0003678*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,,,,,,,,,,
279,,,,,,,,,,,,,,,,,,,,abnormality of proteoglycan metabolism,,HP:0004355,,,,,,,,,,,
280,26,# 613490,Alpha-1 antitrypsin deficiency ,,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),P01009," The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.",ARC-AAT,NA,ECO:0007121,,,,,Direct interaction (Mechanistic A),A,activity modification of a genetically defective protein,,,,,https://clinicaltrials.gov/ct2/show/NCT02363946?cond=Alpha-1+antitrypsin+deficiency&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23527792,https://clinicaltrials.gov/ct2/show/NCT02900183,,,,,,,,
281,,,,,,,,,Recombinant alpha 1-antitrypsin (rAAT),DB05481,ECO:0007121,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein,,Progressive emphysema,,HP:0002097,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361470/,https://www.ncbi.nlm.nih.gov/pubmed/15978931/,,,,,,,,,
282,,,,,,,,,,,,,,,,,,,,Decreased lung function ,,HP:0005952,,,,,,,,,,,
283,,,,,,,,,,,,,,,,,,,,Recurrent infection,,HP:0002719,,,,,,,,,,,
284,,,,,,,,,Retinoic acid,DB00755,ECO:0005542,,,,,Symptomatic(C),,symptomatic treatment procedure,,Alveoli damage ( interstitial pulmonary abnormality)*,,HP:0006530,https://www.ncbi.nlm.nih.gov/pubmed/22282548/,,,,,,,,,,
285,,,,,,,,,Beta2-agonists +corticosteroids + anti-cholinergics,,ECO:0000352,,,,,Symptomatic(C),,symptomatic treatment procedure,,Difficulty breathing,,HP:0002098,,,,,,,,,,,
286,,,,,,,,,,,,,,,,,,,, Lung inflammation (Abnormality of respiratory system),,HP:0002086,,,,,,,,,,,
287,27,* 609458,Alpha-mannosidosis ,,MAN2B1,Alpha-mannosidase, 3.2.1.24,,Lamazym(rhLAMAN),DB12374,ECO:0007121,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein,,Reduced pulmonary function,,HP:0005952,https://clinicaltrials.gov/ct2/show/NCT01681940?cond=Alpha-mannosidosis&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/26827607,https://clinicaltrials.gov/ct2/show/NCT02998879?cond=Alpha-mannosidosis&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/,,,
288,,,,,,,,,,,,,,,,,,,,Low FVC%,,HP:0030878*,,,,,,,,,,,
289,,,,,,,,,,,,,,,,,,,,High NFL (neurofilament light signature ) in CSF,,NA,,,,,,,,,,,
290,,,,,,,,,,,,,,,,,,,,Elevated GFAP(Glial fibrillary acidic protein) level in CSF,,NA,,,,,,,,,,,
291,,,,,,,,,,,,,,,,,,,,Elevated Tau-p level in CSF,,NA,,,,,,,,,,,
292,,,,,,,,,,,,,,,,,,,,High CSF MAN2-oligosaccharides,,,,,,,,,,,,,
293,,,,,,,,,,,,,,,,,,,,cognitive deficits,,HP:0100543,,,,,,,,,,,
294,,,,,,,,,AAV1vector expressing α-Mannosidase,NA,ECO:0005542,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein by gene therapy,,Neurological abnormalities,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Effective+gene+therapy+for+an+inherited+CNS+disease+in+a+large+animal+mode,,,,,,,,,,
295,28,# 207800,Arginase deficiency ,,ARG1,Arginase,3.5.3.1,The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807,Glycerol phenylbutyrate,DB08909,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,low quality of life(Constitutional symptom )*,,HP:0025142*,https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017326/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922/,,,,,,,,
296,,,,,,,,,AEB1102(Pegzilarginase) – Co-ArgI-PEG modified human Arginase I,NA,ECO:0007121,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein,,Elevated blood arginine levels( Abnorality in arginie metabolism)*,,HP:0010909*,https://clinicaltrials.gov/ct2/show/NCT03378531?cond=Arginase+deficiency&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/26358771,,,,,,,,,
297,,,,,,,,,,,,,,,,,,,,Unstable neurological function (Abnormality of the nervous system)*,,HP:0000707*,,,,,,,,,,,
298,,,,,,,,,,,,,,,,,,,,Disease progression (Rapidly progressive)*,,HP:0003678*,,,,,,,,,,,
299,,,,,,,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,sodium benzoate,DB03793,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/11148549,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title,,,,,,,,,
300,,,,,,,,,sodium phenylbutyrate,DB06819,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/11148549,,,,,,,,,,
301,,,,,,,,,AAV-based gene therapy,NA,ECO:0005542,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein by gene therapy,,neurotoxicity,,NA,https://www.ncbi.nlm.nih.gov/pubmed/25474440,,https://www.ncbi.nlm.nih.gov/pubmed/23388701,,,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,,,,,
302,,,,,,,,,,,,,,,,,,,,neurological abnormalities,,HP:0000707,,,,,,,,,,,
303,,,,,,,,,,,,,,,,,,,,cognitive dysfunction,,HP:0100543,,,,,,,,,,,
304,29,# 207900,Argininosuccinic aciduria ,,ASL,argininosuccinate lyase,4.3.2.1,,Nitric oxide supplement,DB00435,ECO:0005542,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,hypertension,,HP:0000822,https://www.ncbi.nlm.nih.gov/pubmed/22541557,,https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub,,,,,,,,
305,,,,,,,,,,,,,,,,,,,,absence of flow-mediated dilatation of brachial artery,,NA,,,,,,,,,,,
306,,,,,,,,,,,,,,,,,,,,endothelial dysfunction,,NA,,,,,,,,,,,
307,,,,,,,,,,,,,,,,,,,,Cardiac hypertrophy ,,,,,,,,,,,,,
308,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
309,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
310,,,,,,,,,Sodium citrate ,DB09154 ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Abnormal renal nitrogen elimination,,HP:0004364,https://www.ncbi.nlm.nih.gov/pubmed/8582405,,,,,,,,,,
311,,,,,,,,,keto-analogues of essential amino acids,NA,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,seizure,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/668730,,,,,,,,,,
312,,,,,,,,,,,,,,,,,,,,High blood ammonia levels,,HP:0001987,,,,,,,,,,,
313,,,,,,,,,,,,,,,,,,,,Defective argininosuccinic acid excretion,,HP:0001939*,,,,,,,,,,,
314,,,,,,,,,Sodium Phenylbutyrate +Arginin,DB06819+DB00125 ,ECO:0007121,,,,,Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Hyperammonemia,,HP:0001987,https://clinicaltrials.gov/ct2/show/NCT00345605,https://www.ncbi.nlm.nih.gov/pubmed/8582405,,,,,,,,,
315,,,,,,,,,Arginine,DB00125 ,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,abnormal hepatic function tests,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/19585269,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://www.ncbi.nlm.nih.gov/pubmed/23040521,,,,,,,,
316,,,,,,,,,,,,,,,,,,,,Low plasma arginine levels,,HP:0005961,,,,,,,,,,,
317,,,,,,,,,,,,,,,,,,,,Acute hyperammonemia,,HP:0008281,,,,,,,,,,,
318,30,# 608643,Aromatic L-amino acid decarboxylase deficiency ,, DDC,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,AAV2-hAADC ( Gene therapy),NA,ECO:0007121,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein by gene therapy,,motor malperformance,,HP:0002275,https://clinicaltrials.gov/ct2/show/NCT02926066?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=2,,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,,,,,,
319,,,,,,,,,,,,,,,,,,,,increased dopamine and serotonin levels (neurotransmitter levels),,HP:0012654,,,,,,,,,,,
320,,,,,,,,,Bromocriptine ,DB01200,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,hypokinesia,,HP:0002375,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
321,,,,,,,,,,,,,,,,,,,,axial hypotonia,,HP:0008936,,,,,,,,,,,
322,,,,,,,,,,,,,,,,,,,,limb hypertonia,,HP:0002509,,,,,,,,,,,
323,,,,,,,,,,,,,,,,,,,,dystonia,,HP:0001332,,,,,,,,,,,
324,,,,,,,,,,,,,,,,,,,,choreoathetosis,,HP:0001266,,,,,,,,,,,
325,,,,,,,,,,,,,,,,,,,,Poor head control,,HP:0002421,,,,,,,,,,,
326,,,,,,,,,,,,,,,,,,,,Oculogyric crises,,HP:0010553,,,,,,,,,,,
327,,,,,,,,,,,,,,,,,,,,Abnormalitilty in voluntary movements(Abnormality of movement)*,,HP:0100022*,,,,,,,,,,,
328,,,,,,,,,,,,,,,,,,,,Autonomic dysfunction,,HP:0002459,,,,,,,,,,,
329,,,,,,,,,Pyridoxine,DB00165 ,ECO:0000352,,,,,Direct interaction (Mechanistic A),A,activity modification of a genetically defective protein,,boost residual AADC activity with a cofactor excess,,NA,,,,,,,,,,,
330,,,,,,,,Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/,Pyrodixal 5 phosphate,DB00114,ECO:0000352,,,,,Direct interaction (Mechanistic A),A,activity modification of a genetically defective protein,,boost residual AADC activity with a cofactor excess,,,https://www.ncbi.nlm.nih.gov/pubmed/25001633/,,,,,,,,,,
331,,,,,,,,,pramipexole,DB12890,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,Consider PLP trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/,Hypotonia,,HP:0001290,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
332,,,,,,,,,,,,,,,,,,,,Oculogyric crisis,,HP:0010553,,,,,,,,,,,
333,,,,,,,,,,,,,,,,,,,,Poor head control,,HP:0002421,,,,,,,,,,,
334,,,,,,,,,,,,,,,,,,,,Voluntary movement abnormalities(Abnormality of movement)*,,HP:0100022*,,,,,,,,,,,
335,,,,,,,,,,,,,,,,,,,,Autonomic dysfunction,,HP:0002459,,,,,,,,,,,
336,,,,,,,,"In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.",Rotigotine,DB05271,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Hypotonia,,HP:0001290,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pubmed/23390030/,,,,,,,,,
337,,,,,,,,,,,,,,,,,,,,Oculogyric crisis,,HP:0010553,,,,,,,,,,,
338,,,,,,,,,,,,,,,,,,,,Poor head control,,HP:0002421,,,,,,,,,,,
339,,,,,,,,,,,,,,,,,,,,Voluntary movement abnormalities (Abnormality of movement)*,,HP:0100022*,,,,,,,,,,,
340,,,,,,,,,,,,,,,,,,,,Autonomic dysfunction,,HP:0002459,,,,,,,,,,,
341,,,,,,,,,Pergolide,DB01186,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Hypotonia,,HP:0001290,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
342,,,,,,,,,,,,,,,,,,,,Oculogyric crisis,,HP:0010553,,,,,,,,,,,
343,,,,,,,,,,,,,,,,,,,,Poor head control,,HP:0002421,,,,,,,,,,,
344,,,,,,,,,,,,,,,,,,,,Voluntary movement abnormalities (Abnormality of movement)*,,HP:0100022*,,,,,,,,,,,
345,,,,,,,,,,,,,,,,,,,,Autonomic dysfunction,,HP:0002459,,,,,,,,,,,
346,,,,,,,,,Folinic acid,DB00650,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,cerebral folate depletion,,HP:0012446,https://www.ncbi.nlm.nih.gov/pubmed/25001633/,,,,,,,,,,
347,,,,,,,,"From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/",Pargyline,DB01626,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Hypotonia,,HP:0001290,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
348,31,# 301835,Arts Syndrome,,PRPS1,Ribose-phosphate diphosphokinase,2.7.6.1,,S-adenosylmethionine,DB00118,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,low levels of purines,,HP:0004369,https://www.sciencedirect.com/science/article/pii/S0002929707613470,https://www.ncbi.nlm.nih.gov/pubmed/20380929,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/17701896,,,,,,
349,,,,,,,,,,,,,,,,,,,,Progression of retinal degeneration ( Rapidly Progressive)*,,HP:0003678*,,,,,,,,,,,
350,,,,,,,,,,,,,,,,,,,,Ataxia Progression(Rapid progression),,HP:0002719,https://www.ncbi.nlm.nih.gov/pubmed/23190330,,,,,,,,,,
351,,,,,,,,,,,,,,,,,,,,Recurrent infection,,HP:0002719,,,,,,,,,,,
352,,,,,,,,,,,,,,,,,,,,frequent hospital admission,,NA,,,,,,,,,,,
353,,,,,,,,,,,,,,,,,,,,Hearing impairment progression(Rapid progression)*,,HP:0003678*,,,,,,,,,,,
354,,,,,,,,,,,,,,,,,,,,Noctornal difficulty breathing,,HP:0002098,,,,,,,,,,,
355,32,208400,Aspartylglycosaminuria ,"As by 2016 Banning et al. mentioned ""Currently, no treatment for AGU is available, although several preclinical studies aiming at enzyme replacement (ERT) or gene therapy have been published. Neither of these treatment options is expected to be available within the next few years", AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,"Amlexanox, which inhibits NMD and causes a translational read-through, facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. A potential therapy based on results of a study conducted by Banning et al. 2016 https://www.ncbi.nlm.nih.gov/pubmed/29247835 Consistently, AMX is currently under strong clinical development for rare metabolic diseases by the company Apteeus (Terence Beghyn, Apteeus, personal communication). The drug as released in Banning et al. study works by inhibiting NMD and causing a translational read-through, it facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. ""This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. "" It posses the ability to cross the BBB. ""Our data show for the first time that Amlexanox might provide a valid therapy for AGU."" https://www.ncbi.nlm.nih.gov/pubmed/29247835 ",Amlexanox,DB01025,ECO:0001565,Ser72Pro/Trp168X,,,,Direct interaction (Mechanistic A),A,activity modification of a genetically defective protein,,Low AGA activity ,,NA,https://www.semanticscholar.org/topic/amlexanox/510418,https://www.ncbi.nlm.nih.gov/pubmed/29247835,,,https://www.ncbi.nlm.nih.gov/pubmed/29247835,,,,,,
356,,,,,,,,"The trial was done on cell culture not model animals, authors of this paper "" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/"" have mentioned that "" Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system"".",betaine,DB06756,ECO:0001565,T122K,"Our data show that both T122K and AGU-Fin AGA enzyme variants most likely exhibit a relatively local folding defect that neither completely impairs the structure, nor results in severe destabilization and degradation of the mutant enzyme. These findings are somewhat contradictory to what has been proposed for the AGU-Fin mutated AGA, which has been suggested to become rapidly degraded after synthesis in the ER19,28. However, these previous studies have been based on overexpression of the mutated enzyme mainly in chinese hamster ovarian cells, which may result in ER overload and unfolded protein response, facilitating the degradation of the AGU-Fin mutant precursors. We here show that endogenous T122K and AGU-Fin AGA in patient fibroblasts do not colocalize with the ER marker calnexin, whereas a high degree of colocalization was observed with lysosomal markers. However, it is likely that the misfolding induced by T122K mutation is milder than that of AGU-Fin which impairs the formation of an intramolecular disulfide bond20. This would also be consistent with the data that the PC-like compounds used here showed a higher increase of enzyme activity in the case of T122K than AGU-Fin https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/",,,Direct interaction (Mechanistic A),A,activity modification of a genetically defective protein,,Low AGA activity ,,NA,https://www.nature.com/articles/srep37583/figures/5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/,,,,,,,,,
357,,,,,,,,,,,,,,,,,,,,Unstable AGA enzyme,,NA,,,,,,,,,,,
358,,,,,,,,,,,,,,,,,,,,Misfolded AGA ,,NA,,,,,,,,,,,
359,,,,,,,,,,,,,,,,,,,,Abnormal AGA processing,,NA,,,,,,,,,,,
360,,,,,,,,,Glycine,DB00145,,,,,,Direct interaction (Mechanistic A),A,activity modification of a genetically defective protein,,Low AGA activity ,,NA,https://www.nature.com/articles/srep37583/figures/5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/,https://www.ncbi.nlm.nih.gov/pubmed/23601642,,,,,,,,
361,,,,,,,,"There is a combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease. https://www.ncbi.nlm.nih.gov/pubmed/20607610",Recombinant human Aspartylglucosamidase,NA,ECO:0005542,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein,,pathology in many somatic tissues,,HP:0000924*,https://www.ncbi.nlm.nih.gov/pubmed/10657992,https://www.ncbi.nlm.nih.gov/pubmed/20607610/,https://www.ncbi.nlm.nih.gov/pubmed/15342551/,,https://www.ncbi.nlm.nih.gov/pubmed/27906067,,,,,,
362,,,,,,,,,,,,,,,,,,,,accumulating substance aspartylglucosamine from ( Metaboic abnormality)*,,HP:0001939*,,,,,,,,,,,
363,,,,,,,,,,,,,,,,,,,,High amount of Man2GlcNAc2-Asn in in nonneuronal tissues ( Metabolism abnormality)*,,HP:0001939*,,,,,,,,,,,
364,,,,,,,,,,,,,,,,,,,,High amount of aspartylglucosamine in brain tissue (( Metabolism abnormality)*),,HP:0001939*,,,,,,,,,,,
365,,,,,,,,"The  injections  of  recombinant  viruses in vivo into  theAGU  mouse  brain  showed  no  inflammation  peak  orgliosis related to the viral injection, but mild periventricu-lar  microglial  activation  persisted  throughout  the  wholefollow-up  time.  The  AGA  immunostaining  prevailed  inthe  ependymal  cells  lining  the  ventricles  and  expressedAGA  was  also  found  in  the  surrounding  brain  areas.
Other reports of adenovirus-mediated gene expression inthe brain have indicated inflammation during the first 2weeks   after  injection 

https://www.sciencedirect.com/science/article/pii/030645229500068T 
https://www.ncbi.nlm.nih.gov/pubmed/9930336",Gene therapy (wild-type Ad-AGA),NA,ECO:0005542,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein by gene therapy,,Low expression of AGA enzyme,,,https://www.ncbi.nlm.nih.gov/pubmed/9930336/,,,,,,,,,,
366,,,,,,,,,,,,,,,,,,,,Liver lysosomal storage abnormality,,,,,,,,,,,,,
367,,,,,,,,,,,,,,,,,,,,Brain lysosomal storage disease,,,,,,,,,,,,,
368,,,,,,,,,,,,,,,,,,,,ipsilateral brain neuronal storage abnormalities,,,https://www.ncbi.nlm.nih.gov/pubmed/16518877/,,,,,,,,,,
369,33,# 277460,Ataxia with vitamin E deficiency ,,TTPA,α-tocopherol transfer protein ,P49638,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",vitamin E,DB00163,ECO:0000352,,,,,Functional interaction (B),B,metabolite replacement,,Disease progression (Rapidly progressive)*,,HP:0003678*,https://clinicaltrials.gov/ct2/show/NCT01797055?cond=Atransferrinemia&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/20301419,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,,,,,,,
370,,,,,,,,,,,,,,,,,,,,Abnormal vitamin E level(Vitamin E deficiency)*,,HP:0100513*,,,,,,,,,,,
371,,,,,,,,,,,,,,,,,,,,Ataxia,,HP:0001251,https://www.ncbi.nlm.nih.gov/pubmed/9931538,https://www.ncbi.nlm.nih.gov/pubmed/11554913,,,,,,,,,
372,,,,,,,,,,,,,,,,,,,,Neurological abnormalitis,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/11554913,https://www.ncbi.nlm.nih.gov/pubmed/15300460,,,,,,,,,
373,,,,,,,,,RRR-α-tocopherol,DB14002,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,,High urinary LTE4 excretion (Abnormality of leukotriene metabolism)*,,HP:0030390*,https://www.sciencedirect.com/science/article/pii/S0022347699704245?via%3Dihub,,,,,,,,,,
374,,,,,,,,,,,,,,,,,,,,Abnormal H50 (The erythrocyte resistance to oxidative stress),,NA,,,,,,,,,,,
375,34,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,myo-inositol,DB13178,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,neurological malfunction,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/17586848,,,,,,,,,,
376,,,,,,,,,,,,,,,,,,,,immune dysfunctions,,HP:0002715,,,,,,,,,,,
377,,,,,,,,,Alpha lipoic acid ,DB00166,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Neuronal death,,HP:0002529,https://www.ncbi.nlm.nih.gov/pubmed/17586848,,,,,,,,,,
378,,,,,,,,,,,,,,,,,,,,Oxidative stress ,,HP:0025464,,,,,,,,,,,
379,,,,,,,,,nicotinamide,DB02701,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Abnormal levels of urine total alkanes,,NA,https://www.ncbi.nlm.nih.gov/pubmed/17586848,,,,,,,,,,
380,,,,,,,,,,,,,,,,,,,,Oxidative stress ,,HP:0025464,,,,,,,,,,,
381,,,,,,,,,Alpha-lipoic acid + nicotinamide,DB00166+DB02701,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Abnormal serum fast ORAC(oxygen reduced absorbance capacity),,NA,,,,,,,,,,,
382,,,,,,,,,,,,,,,,,,,,Abnormal lymphocyte counts,,HP:0040088,https://www.ncbi.nlm.nih.gov/pubmed/17586848,,,,,,,,,,
383,,,,,,,,,Immunoglobulin replacement therap,DB00028,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Recurrent infection,,HP:0002719,https://www.ncbi.nlm.nih.gov/pubmed/28318010,,,,,,,,,,
384,,,,,,,,,amantadine,DB00915,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Ataxia,,HP:0001251,https://www.ncbi.nlm.nih.gov/pubmed/22550086/,,,,,,,,,,
385,,,,,,,,,,,,,,,,,,,,involuntary movements,,HP:0004305,,,,,,,,,,,
386,,,,,,,,,,,,,,,,,,,,parkinsonism,,HP:0001300,,,,,,,,,,,
387,,,,,,,,,clonazepam,DB01068,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,myoclonuic Jerk,,HP:0001336,https://www.ncbi.nlm.nih.gov/pubmed/26232052/,,,,,,,,,,
388,,,,,,,,,,,,,,,,,,,,Poor fine motor skills,,HP:0007010,,,,,,,,,,,
389,,,,,,,,,,,,,,,,,,,,Voice tremor,,HP:0012477,,,,,,,,,,,
390,,,,,,,,,,,,,,,,,,,,Poor intelligibility,,HP:0001249,,,,,,,,,,,
391,35,# 208920,Ataxia-oculomotor apraxia type 1 ,,APTX,Aprataxin,3.1.12.2,,CoQ10 ,DB09270,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,lack of strenght,,HP:0003750,https://www.ncbi.nlm.nih.gov/pubmed/28277561,,,,,,,,,,
392,,,,,,,,,,,,,,,,,,,,seizures,,HP:0001250,,,,,,,,,,,
393,36,# 209300,Atransferrinemia ,,TF,transferrin,P02787,,Human apotransferrin,CHEBI:2786,ECO:0007121,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein,,hypochromic anemia ,,HP:0001931,https://clinicaltrials.gov/ct2/show/NCT01797055?cond=Atransferrinemia&rank=1,,,,https://www.ncbi.nlm.nih.gov/pubmed/8317485,,,,,,
394,,,,,,,,,Deferoxamine,DB00746,ECO:0000352,,,,,Supportive (C),C,functional complementation of a genetically defective protein,,hypochromic anemia ,,HP:0001931,https://www.ncbi.nlm.nih.gov/pubmed/8187613,,,,,,,,,,
395,,,,,,,,"Oral iron is given as a supplementary treatment to improve the outcome of Plasma transufsion. ""Plasma transfusion, as a natural source of transferrin, leads to Hb synthesis. Since the excess iron is unavailable for erythropoiesis in this disease, and transferrin‐bound iron uptake by TfR1 is the only known means of iron delivery for erythropoiesis,3 iron supply during the period in which serum transferrin molecules are present may increase the amount of iron transported to marrow and augment Hb synthesis. https://www.ncbi.nlm.nih.gov/pubmed/28895280",Ferrous sulfate,DB13257,ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure,,Decreased hemoglobin,,HP:0001903,https://www.ncbi.nlm.nih.gov/pubmed/28895280,,,,,,,,,,
396,,,,,,,,,,,,,,,,,,,,High ferritin level,,HP:0003281,,,,,,,,,,,
397,37,162350,Autosomal dominant neuronal ceroid lipofuscinosis 4B ,,DNAJC5,DnaJ homolog subfamily C member 5(cysteine string PROTEIN),Q9H3Z4,"Symptomatic treatment can be successful in mitigating the manifestations of NCL. Seizures, sleep-related problems, malnutrition, gastroesophageal reflux, pneumonia, sialorrhea, hyperactivity and behavior problems, psychosis, anxiety, spasticity, Parkinsonian symptoms, and dystonia can be palliated. https://www.ncbi.nlm.nih.gov/books/NBK1428/#ncl.Management",No treatment is available in DDIEM,,,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,,,,,,,,,,,,,
398,38,256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,Overall no significant clinical positive effect of Cystagon was seen in the current study involving four patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/,Cystagon,DB00847,ECO:0007121,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,progression of neurodegeneration,,HP:0002344,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/,,https://clinicaltrials.gov/ct2/show/NCT00028262?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=13,,,,,,,,
399,,,,,,,,"A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880",N-Acetylcysteine+cysteamine bitartrate,DB06151+DB00847 ,ECO:0007121,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,granular osmiophilic deposits (GROD),,HP:0003657,https://www.ncbi.nlm.nih.gov/pubmed/24997880,,,,,,,,,,
400,,,,,,,,,,,,,,,,,,,,irritability,,HP:0000737,,,,,,,,,,,
401,,,,,,,,,,,,,,,,,,,,Defected alertness,,HP:0004372,,,,,,,,,,,
402,,,,,,,,,,,,,,,,,,,,Isoelectric electroencephalogram,,HP:0002353,,,,,,,,,,,
403,,,,,,,,,δ-tocopherol (DT),DB11251,ECO:0001565,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,cognitive deficits ,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/29631617,,,,,,,,,,
404,,,,,,,,,hydroxypropyl-β-cyclodextrin (HPBCD),NA,ECO:0001565,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,brain atrophy,,HP:0012444,,,,,,,,,,,
405,,,,,,,,A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,δ-tocopherol (DT) + hydroxypropyl-β-cyclodextrin (HPBCD),DB11251,ECO:0001565,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Lipid accumulation( Abnorality in lipid meabolism)*,,HP:0003119*,,,,,,,,,,,
406,,,,,,,,,,,,,,,,,,,,Lysosomal enlargment (Abnormality of lysosomal metabolism)*,,HP:0004356*,,,,,,,,,,,
407,,,,,,,,,Recombinant human palmitoyl-protein thioesterase 1 ( PPT1),NA,ECO:0001565,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein,,Enlarged lysosomes in NCL NSCs and fibroblasts (Abnormality of lysosomal metabolism)*,,HP:0004356*,,,,,,,,,,,
408,39,# 204200,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,battenin,Q13286,,Mycophenolate mofetil,DB00688 ,ECO:0007121/ECO:0005542,,,,,Symptomatic (C),C,symptomatic treatment procedure,"Drug name: The primary outcome of the study was to check tolaribilty to treatment. The drug was well tolarated https://link.springer.com/chapter/10.1007%2F8904_2018_113. 

However, there were no definite effects on measured autoimmunity or clinical outcomes in the setting of short-term use of CellCept(Mycophenolate mofetil).

The brief exposure to treatment was useful to study short-term safety risks and support future long-term studies, but it “did not allow clinical insights into potential efficacy,” researchers stated in https://battendiseasenews.com/2018/06/27/cellcept-safe-but-ineffective-phase-2-clinical-trial-cln3-disease/",The primary outcome of the study was to check tolaribilty to treatment. The drug was well tolarated,,,,,https://clinicaltrials.gov/ct2/show/results/NCT01399047?cond=neuronal+ceroid+lipofuscinosis&rank=1&sect=X70156#outcome1,https://clinicaltrials.gov/ct2/show/NCT01399047?cond=Batten+Disease&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/29923092,,,,,,
409,,,,,,,,,carbenoxolone,DB02329,ECO:0005542,,,,,Symptomatic (C),C,symptomatic treatment procedure,Drug name: Study has been conducted invivo and invitro in mice. https://www.ncbi.nlm.nih.gov/pubmed/29660499,Blood-brain barrier (BBB) impairment ,,NA,,,https://www.ncbi.nlm.nih.gov/pubmed/29660499,,,,,,,,
410,,,,,,,,,,,,,,,,,,,,Low cell autofluorescence,,NA,,,,,,,,,,,
411,,,,,,,,,,,,,,,,,,,,membrane fluidity alterations,,NA,,,,,,,,,,,
412,,,,,,,,,,,,,,,,,,,,extended G1 interval,,HP:0011018,,,,,,,,,,,
413,40,# 601780,Late infantile neuronal ceroid lipofuscinoses CLN6,,CLN6,"CLN6, transmembrane ER protein",NO Human id,,scAVV9.CB.CLN6,NA,ECO:0007121,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein by gene therapy, Drug name: under investgation/ aim is to slow the neurodegeneration progression HP:0002344,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/31331814,,https://clinicaltrials.gov/ct2/show/NCT02725580?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=14,,,,,,
414,41,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,cerliponase alfa,DB13173,ECO:0007121/ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,neurologic deficits,,HP:0000707,https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://www.ncbi.nlm.nih.gov/pubmed/29688815/,https://emedicine.medscape.com/article/1178391-treatment,https://www.ncbi.nlm.nih.gov/pubmed/24938720,,,,,,
415,,,,,,,,,,,,,,,,,,,,cognitive dysfunction,,HP:0100543,,,,,,,,,,,
416,,,,,,,,,,,,,,,,,,,,brain atrophy,,HP:0012444,,,,,,,,,,,
417,,,,,,,,,,,,,,,,,,,,loss of ambulation,,HP:0002540,,,,,,,,,,,
418,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
419,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
420,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
421,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
422,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
423,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
424,,,,,,,,,AAVrh.10CUhCLN2,NA,ECO:0007121,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein by gene therapy, Drug name: under investgation/ aim is to slow the neurodegeneration progression,,,,,,https://clinicaltrials.gov/ct2/show/NCT01161576?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=8,,,,,,,,
425,,,,,,,,,AAV2CUhCLN2,NA,ECO:0007121,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein by gene therapy, Drug name: under investgation/ aim is to slow the neurodegeneration progression,,,,,,https://clinicaltrials.gov/ct2/show/NCT00151216?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=9,https://emedicine.medscape.com/article/1178391-treatment,,,,,,,
426,,,,,,,,,δ-tocopherol (DT),DB11251,ECO:0001565,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,cognitive deficits ,,HP:0100543,,,https://www.ncbi.nlm.nih.gov/pubmed/29631617,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/,,,,,,
427,,,,,,,,,hydroxypropyl-β-cyclodextrin (HPBCD),NA,ECO:0001565,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,brain atrophy,,HP:0012444,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891977/,,,,,,,,
428,,,,,,,,,BMN 190 (cerliponase alfa),DB13173,ECO:0001565/ECO:0007121,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein,,neurological disease ,,HP:0000707,,,https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/24938720,,,,,,,
429,,,,,,,,,,,,,,,,,,,,neurologic deficits,,HP:0000707,,,https://clinicaltrials.gov/ct2/show/NCT01907087,,,,,,,,
430,,,,,,,,,,,,,,,,,,,,cognitive dysfunction,,HP:0100543,,,,,,,,,,,
431,,,,,,,,,,,,,,,,,,,,brain atrophy,,HP:0012444,,,,,,,,,,,
432,,,,,,,,,,,,,,,,,,,,loss of ambulation,,HP:0002540,,,,,,,,,,,
433,42,# 612016,Autosomal recessive spinocerebellar ataxia 9 ,,ADCK3,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,CoQ10(ubiquinone),DB09270,ECO:0007121,comp. htz c.[895C > T] + [1358delT] exons 7 and 11 p.[Arg299Trp] + [ Leu453Argfs*24],,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,"Drug name:                                 Mutation that didn't benefit the treatment:  E551K  in one patient & A compound heterozygotes for( R213W,  G272V) in another.  https://www.ncbi.nlm.nih.gov/pubmed/18319072                                                                                                                                                                                                       ; Duplication mutation on ADCK3/CABC1 https://www.ncbi.nlm.nih.gov/pubmed/27793482",tremor,,HP:0001298,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427193/,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,
434,,,,,,,,,,,,,,,,,,,,Drawing inabiliity,,MP:0004144,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/,,,,,,,,,,
435,,,,,,,,,,,,comp. htz c.1523 T > C exon13 + del exons 3 to 15 p.Phe508Ser,,,,,,,,Myoclonus,,HP:0002180,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,,,
436,,,,,,,,,,,,comp. htz c.1523 T > C exon13 + del exons 3 to 15 p.Phe508Ser,,,,,,,,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,,,
437,,,,,,,,,,,,Hetero c.[1541A→G] + [1750_1752 delACC],,,,,,,,exercise intolerance,,HP:0012211,https://www.ncbi.nlm.nih.gov/pubmed/18319074,,,,,,,,,,
438,,,,,,,,,,,,G272D https://www.ncbi.nlm.nih.gov/pubmed/18319072 ,,,,,,,"Phenotypes improved: Although there was a slight improvement of patient 4 on COQ10 , but a progressive cerebellar ataxia appeared 2 years later. https://www.ncbi.nlm.nih.gov/pubmed/18319072 https://www.ncbi.nlm.nih.gov/pubmed/15326254/",,,,https://www.ncbi.nlm.nih.gov/pubmed/15326254/,,,,,,,,,,
439,,,,,,,,,,,,,,,,,,,"Phenotypes improved: Although there was a slight improvement of patient 4 on COQ10 , but a progressive cerebellar ataxia appeared 2 years later. https://www.ncbi.nlm.nih.gov/pubmed/18319072 https://www.ncbi.nlm.nih.gov/pubmed/15326254/",hyperlactatemia,,HP:0003128,https://www.ncbi.nlm.nih.gov/pubmed/15326254/,,,,,,,,,,
440,,,,,,,,,,,,Homozygous deletion (c.504del_CT) ,,,,,,,,Speech problem,,HP:0002167,https://www.ncbi.nlm.nih.gov/pubmed/26818466,,,,,,,,,,
441,,,,,,,,,,,,,,,,,,,,Gait abnormality,,HP:0001288,,,,,,,,,,,
442,,,,,,,,,,,,,,,,,,,,Neurological abormalities,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/26818466,,,,,,,,,,
443,,,,,,,,,,,,Homozygous deletion (c.1511_1512delCT) that leads to a premature truncation of the protein (p. Ala504fs),,,,,,,,Fatigue,,HP:0012378,https://www.ncbi.nlm.nih.gov/pubmed/29159460,,,,,,,,,,
444,,,,,,,,,,,,,,,,,,,,High ataxia score ( Ataxia)*,,HP:0001251*,,,,,,,,,,,
445,,,,,,,,,,,,homozygous frameshift mutation (c.1844_1845insG) in the C-terminus of mitochondrial atypical kinase COQ8A,,,,,,,,Myoclonic abnormalities(Myoclouns)*,,HP:0001336*,https://www.ncbi.nlm.nih.gov/pubmed/29159460,https://www.ncbi.nlm.nih.gov/pubmed/24218524,,,,,,,,,
446,,,,,,,,,,,,,,,,,,,,ataxic gait,,HP:0002066,,,,,,,,,,,
447,,,,,,,,,,,,,,,,,,,,dysarthric speech,,HP:0001260,,,,,,,,,,,
448,,,,,,,,"Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873",idebenone,DB09081,ECO:0000352,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15326254/,,,,,,,,,,
449,,,,,,,,,Sodium Valproate,DB00313,,,,,,Symptomatic (C),,symptomatic treatment procedure,,seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298/,,,,,,,,,,
450,42,# 607091,B4GALT1-CDG (CDG-IId) ,,GALT1,"beta-1,4-galactosyl transferase.", 2.4.1.274,Drug name: Treatment is under trial.,galactose supplementation,DB11735,ECO:0007121,,,,,Symptomatic (C),C,dietary supplementation,,,,,,,https://clinicaltrials.gov/ct2/show/NCT02955264,,,,,,,,
451,43,# 602579,CDG-Ib,,MPI,Mannose-6-phosphate isomerase,5.3.1.8,,mannose supply,DB12907,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Metabolism abnormality,,HP:0001939,,,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,,,,,,,
452,,,,,,,,,,,,,,,,,,,,hypoproteinemia,,MP:0005567,,,,,,,,,,,
453,,,,,,,,,,,,,,,,,,,,blood coagulation,,HP:0001928,,,,,,,,,,,
454,,,,,,,,,,,,,,,,,,,,protein-losing enteropathy,,HP:0002243,,,,,,,,,,,
455,,,,,,,,,,,,,,,,,,,,hypoglycaemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/10484808,,,,,,,,,,
456,,,,,,,,,,,,,,,,,,,,Hypoglycosylation of serum glycoproteins,,NA,https://www.ncbi.nlm.nih.gov/pubmed/9525984,,,,,,,,,,
457,,,,,,,,,,,,,,,,,,,,urinary tract infection,,HP:0000010,,,,,,,,,,,
458,,#614921,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,Phosphoglucomutase-1,5.4.2.2,,D- Galactose,DB11735,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Abnormal aPTT level ,,HP:0003645,https://www.ncbi.nlm.nih.gov/pubmed/28617415,,,,,,,,,,
459,,,,,,,,,,,,,,,,,,,,Abnormal AST level (Abnormal liver enzymes)*,,HP:0002910,,,,,,,,,,,
460,,,,,,,,,,,,,,,,,,,, Abnormal ALT level(Abnormal liver enzymes)*,,HP:0002910,,,,,,,,,,,
461,,,,,,,,,,,,,,,,,,,,Abnormal Antithrombin-III levels,,HP:0001976,,,,,,,,,,,
462,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
463,44,# 266265,CDG IIc,,SLC35C1,GDP-fucose transporter 1,Q96A29,,fucose therapy,DB03485,ECO:0001565,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,,Abnormal Golgi located fucosylation,,NA,http://www.jbc.org/content/282/14/10762.long#ref-14,,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,,,,"espite the successful correction of immunodeficiency-related defects in CDG IIc (LAD II), correction of the delayed psychomotor development was expected to be more difficult to achieve. However, the patient showed significant psychomotor improvement while on fucose therapy.",,,,
464,,,,,,,,,,,,,,,,,,,,Abnormal fucosylation state of glycoconjugates.,,NA,,,,,,,,,,,
465,,,,,,,,,,,ECO:0005542,,,,,,,,,Abnormal selectin ligand function,,NA,http://www.bloodjournal.org/content/94/12/3976.abstract?ijkey=201ceaaf5f2f21a180c7df639f863d067551bca5&keytype2=tf_ipsecsha,,,,,,,,,,
466,,,,,,,,,,,ECO:0005542,,,,,,,,,Neutropenia,,HP:0001875,http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,,,,,,,,,,
467,45,# 241510,Childhood hypophosphatasia ,,ALPL,Alkaline phosphatase,3.1.3.1,,Asfotase Alfa,DB09105,ECO:0000352,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein,,Abnormal developmental milestones,,HP:0012759,,,https://www.ncbi.nlm.nih.gov/pubmed/22397652/,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800/,,"ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number, NCT00744042.).",,"Bone-targeted enzyme replacement therapy (asfotase alfa, now Strensiq™) was approved for HPP in Japan (July, 2015), and for pediatric-onset HPP in Canada (August, 2015), Europe (August, 2015), and the USA (October, 2015). Supportive treatment includes hydration and restriction of dietary calcium and perhaps administration of calciuretics for infants with hypercalcemia and hypercalciuria [35, 36]. Management of the respiratory complications of perinatal and infantile HPP may be complex as multiple factors compromise their pulmonary function [108]. Vitamin B6-dependent seizures can respond temporarily to pyridoxine administration.",,
468,,,,,,,,,,,,,,,,,,,,deteriorating pulmonary function,,HP:0005952,,,,,,,,,,,
469,,,,,,,,,,,,,,,,,,,, Decreased physical function,,HP:0025142,,,,,,,,,,,
470,,,,,,,,,,,,,,,,,,,,failure-to-thrive,,HP:0001508,,,,,,,,,,,
471,,,,,,,,,,,,,,,,,,,,Dental Defects,,HP:0000164,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144124/,,,,,,,,
472,,,,,,,,,pyridoxal,DB00147,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,epilepsy ,,HP:0001250,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316461/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,,,,,
473,46,# 308050,CHILD syndrome ,,NSDHL,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,simvastatin,DB00641,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a defective protein by inhibition,,Accumulation of toxic metabolites in cholesterol biosynthetic pathway,,HP:0001939*,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,,,,,,,,
474,,,,,,,,,,,,,,,,,,,,ichthyosiform erythematous plaques,,HP:0008064,,,,,,,,,,,
475,,,,,,,,,,,,,,,,,,,,waxy scaling plaques,,HP:0040189*,,,,,,,,,,,
476,,,,,,,,,,,,,,,,,,,,inflammation,,MP:0001845,,,,,,,,,,,
477,,,,,,,,,,,,,,,,,,,,skin thickening,,HP:0100725,,,,,,,,,,,
478,,,,,,,,,lovastatin+cholesterol ,DB00227+DB04540,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a defective protein by inhibition,,Cutaneous abnormalities,,MP:00011911,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,,,,,,,,
479,,,,,,,,,, ,,,,,,,,,,Ichthyosiform erythroderma,,HP:0007431,,,,,,,,,,,
480,,,,,,,,,ketoconazole,DB01026,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,,Cutaneous abnormalities,,MP:0001191,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,,,,,,,,
481,,,,,,,,,simvastatin+cholesterol,DB00641+ DB04540 ,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a defective protein by inhibition,,Ichthyosiform erythroderma,,HP:0007431,,,,,,,,,,,
482,,,,,,,,,,,,,,,,,,,,Itchy skin,,HP:0000989,,,,,,,,,,,
483,,,,,,,,,,,,,,,,,,,,Scaling Skin ,,HP:0040189,,,,,,,,,,,
484,,,,,,,,,,,,,,,,,,,,Erythema,,HP:0010783,,,,,,,,,,,
485,,,,,,,,,,,,,,,,,,,,Verruciform plaques(verruciform xanthomas)*,,HP:0031517*,,,https://www.ncbi.nlm.nih.gov/pubmed/29341259,,,,,,,,
486,,,,,,,,,,,,,,,,,,,,VX‐like lesions,,NA,,,,,,,,,,,
487,,,,,,,,,Retinoids,CHEBI:26537,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Scaling Skin ,,HP:0040189,,,https://www.ncbi.nlm.nih.gov/pubmed/29392821,,,,,,,,
488,,,,,,,,,Glycolic acid+lovastatin+cholesterol ,DB03085+DB00227+DB04540,ECO:0000352,,,,,,,,,verruciform xanthomas,,HP:0031517,,,,,,,,,,,
489,47,# 275630,Chanarin-Dorfman syndrome ,,ABHD5,adipose triglyceride lipase (ATGL),3.1.1.3,, Emollients +acitretin, A06AA+DB00459,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Ichthyosis,,HP:0008064,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Acitretin%E2%80%90Responsive+Ichthyosis+in+Chanarin–Dorfman+Syndrome+with+a+Novel+Mutation+in+the+ABHD5%2FCGI%E2%80%9058+Gene,https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170,,,,,,,
490,,,,,,,,,,,,,,,,,,,,Erythroderma,,HP:0001019,,,https://www.ncbi.nlm.nih.gov/pubmed/21981352/,,,,,,,,
491,,,,,,,,,,,,,,,,,,,,Diffuse scaling(Skin Scaling)*,,HP:0040189*,,,https://www.ncbi.nlm.nih.gov/pubmed/21981352/,,,,,,,,
492,,,,,,,,,,,,,,,,,,,,Collodion membrane(Nonbullous congenital ichthyosiform erythroderma)*,,HP:0007479*,,,https://www.ncbi.nlm.nih.gov/pubmed/21981352/,,,,,,,,
493,,,,,,,,,,,,,,,,,,,,Erythema,,HP:0010783,,,https://www.ncbi.nlm.nih.gov/pubmed/28979034,,,,,,,,
494,,,,,,,,,,,,,,,,,,,,Scaling,,HP:0040189,,,https://www.ncbi.nlm.nih.gov/pubmed/28979034,,,,,,,,
495,,,,,,,,,Emollients,A06AA,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,erythema,,HP:0010783,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Dorfman-Chanarin+syndrome+in+two+female+siblings%3A+A+case+report+and+discussion+on+approach+%26+management,,,,,,,,
496,,,,,,,,,,,,,,,,,,,,Ichthyosis,,HP:0008064,,,https://www.ncbi.nlm.nih.gov/pubmed/28636073,,,,,,,,
497,,,,,,,,,,,,,,,,,,,,Pruritis,,HP:0000989,,,https://www.ncbi.nlm.nih.gov/pubmed/28636073,,,,,,,,
498,,,,,,,,,,,,,,,,,,,,scaling,,HP:0040189,,,,,,,,,,,
499,,,,,,,,,Ursodeoxycholic acid ,DB01586,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,steatohepatitis,,HP:0001397,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Dorfman-Chanarin+syndrome+in+two+female+siblings%3A+A+case+report+and+discussion+on+approach+%26+management,,,,,,,,
500,,,,,,,,,vitamin E,DB00163,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,steatohepatitis,,HP:0001397,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Dorfman-Chanarin+syndrome+in+two+female+siblings%3A+A+case+report+and+discussion+on+approach+%26+management,,,,,,,,
501,49,# 213700,Cerebrotendinous xanthomatosis ,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,chenodeoxycholic acid,DB06777,ECO:0000352,,,,,Functional interaction (B),B,metabolite replacement,,neurological dysfunctions ,,HP:0000707,,,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/25424010,https://www.ncbi.nlm.nih.gov/pubmed/28980151,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518,,,
502,,,,,,,,,,,,,,,,,,,,cataracts ,,HP:0000518,,,,,,,,,,,
503,,,,,,,,,,,,,,,,,,,,chronic diarrhoea,,MP:0001665,,,,,,,,,,,
504,,,,,,,,,,,,,,,,,,,,Elevated serum cholesterol,,HP:0003124,,,,https://www.ncbi.nlm.nih.gov/pubmed/31115677,,,,,,,
505,,,,,,,,,,,,,,,,,,,,EEG abnormalities,,HP:0002353,,,,,,,,,,,
506,,,,,,,,,,,,,,,,,,,,abnormal gait,,HP:0001288,,,,,https://www.ncbi.nlm.nih.gov/pubmed/28590052,,,,,,
507,,,,,,,,,,,,,,,,,,,,Xanthoma,,HP:0001114,,,,,https://www.ncbi.nlm.nih.gov/pubmed/28590052,,,,,,
508,,,,,,,,,,,,,,,,,,,,Incoordination ,,HP:0002311,,,,,https://www.ncbi.nlm.nih.gov/pubmed/28590052,,,,,,
509,,,,,,,,,,,,,,,,,,,,Movement disorder,,HP:0100022,,,,,https://www.ncbi.nlm.nih.gov/pubmed/28590052,,,,,,
510,,,,,,,,,,,,,,,,,,,,Cognitive impairment,,HP:0100543,,,,,https://www.ncbi.nlm.nih.gov/pubmed/28590052,,,,,,
511,,,,,,,,,,,,,,,,,,,,Abnormal nerve conduction velocity,,HP:0040129,,,,https://www.ncbi.nlm.nih.gov/pubmed/1316120,,,,,,,
512,,,,,,,,,,,,,,,,,,,,seizure,,HP:0001250,,,,,,,,,,,
513,,,,,,,,,Pravastatin+Chenodeoxycholic acid,DB00175 +DB06777,ECO:0000352,,,,,Functional interaction (B)+Functional interaction (B),B+B,functional complementation of a genetically defective protein+metabolite replacement,,Xanthoma,,HP:0001114,,,https://www.ncbi.nlm.nih.gov/pubmed/7964884,,https://www.ncbi.nlm.nih.gov/pubmed/28590052,,,,,,
514,,,,,,,,,,,,,,,,,,,,Elevated serum cholesterol,,HP:0003124,,,,,,,,,,,
515,,,,,,,,,,,,,,,,,,,,Disease progression,,,,,,,,,,,,,
516,,,,,,,,,coenzyme Q10,DB09270,ECO:0000352,,,,,Symptomatic (C),C,functional complementation of a genetically defective protein,,muscle weakness,,HP:0001324,,,https://www.ncbi.nlm.nih.gov/pubmed/20301583,,,,,,,,
517,50,# 613068,Cerebral folate deficiency ,,FOLR1,Folate receptor alpha,P15328,,folinic acid,DB00650,ECO:0000352,,,,,Symptomatic (C),C,functional complementation of a genetically defective protein,,Impaired social interaction,,HP:0000735,,,,,,,,,,,
518,,,,,,,,,,,,,,,,,,,,Movement disorder,,HP:0100022,,,,,,,,,,,
519,,,,,MTHFR,Methylenetetrahydrofolate reductase,1.5.1.20,,,,,,,,,,,,,seizure,,HP:0001250,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727671/,,,,,,,,
520,,,,,,,,,,,,,,,,,,,,Myoclonic seizures,,HP:0002123,,,https://www.ncbi.nlm.nih.gov/pubmed/22734130,,,,,,,,
521,,,,,,,,,,,,,,,,,,,,astatic seizures,,HP:0010819,,,,,,,,,,,
522,51,# 125700,Central diabetes insipidus ,,AVP,Hormone ( Arginine vasopressin),,,Desmopressin,DB00035,ECO:0007121,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein,,polyuria,,HP:0000103,,,https://clinicaltrials.gov/ct2/show/NCT01280188?cond=Central+diabetes+insipidus&rank=1,,,,,,,,
523,,,,,,,,,Vasopressin,DB00067,,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein,,polydipsia,,MP:0001426,,,https://academic.oup.com/jcem/article/98/10/3958/2833930,,,,,,,,
524,,,,,,,,,,,,,,,,,,,,thirst,,HP:0001959,,,,,,,,,,,
525,,,,,,,,,chlorpropamide,DB00672 ,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Polyurea,,HP:0000103,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1517999/,,,,,,,,
526,,,,,,,,This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254,Chlorpropamide + carbamazepine,DB00672+DB00564,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,Drug name: This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254,chlorpropamide-induced hypoglycaemia (Hypoglycemia)*,,HP:0001943*,,,https://www.ncbi.nlm.nih.gov/pubmed/1220254,,,,,,,,
527,,,,,,,,,,,,,,,,,,,,Polyuria,,HP:0000103,,,,,,,,,,,
528,,,,,,,,Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.,chlorpropamide+Hydrochlorothiazide ,DB00672+DB00999,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,Drug name: Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.,Ployuria,,HP:0000103,,,,,,,,,,,
529,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
530,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
531,,,,,,,,,Pitressin tannate in oil,NA,ECO:0000352,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein, Drug name: The study was withdrawn.,Ployuria,,HP:0000103,,,https://www.ncbi.nlm.nih.gov/pubmed/3940717,,,,,,,,
532,,,,,,,,,Clofibrate,DB00636,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Ployuria,,HP:0000103,,,https://www.ncbi.nlm.nih.gov/pubmed/23884783,,,,,,,,
533,,,,,,,,,,,,,,,,,,,,Hyposthenuria,,HP:0003158,,,,,,,,,,,
534,,,,,,,,,Indapamide,DB00808,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,High serum osmolality,,NA,,,https://www.ncbi.nlm.nih.gov/pubmed/10510995,https://www.ncbi.nlm.nih.gov/pubmed/12016800,,,,,,,
535,,,,,,,,,,,,,,,,,,,,Ployuria,,HP:0000103,,,,,,,,,,,
536,,,,,,,,,,,,,,,,,,,,Reduced urinary osmolality,,HP:0003158,,,,,,,,,,,
537,,,,,,,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",dDAVP (1-Desamino-8-D Arginine Vasopressin),DB00035,ECO:0000352,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",Increased urine output,,HP:0000103,,,https://www.ncbi.nlm.nih.gov/pubmed/626447,,,,,,,,
538,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
539,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
540,52,# 212138,Carnitine-acylcarnitine translocase deficiency ,,SLC25A20 ,carnitine-acylcarnitine translocase,,,Medium-chain triglycerides,DB13959,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,,developmental delay,,HP:0001263,,,https://www.ncbi.nlm.nih.gov/pubmed/25614308,https://www.ncbi.nlm.nih.gov/pubmed/19452263/,,,,,,,
541,,,,,,,,,carnitine,DB00583,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,,Hypocarnitinemia,,HP:0003234,,,https://www.ncbi.nlm.nih.gov/pubmed/25614308,,,,,,,,
542,,,,,,,,,carnitine+Medium-chain triglycerides,DB00583+DB13959,ECO:0000352,,,,,Functional interaction (B)+Functional interaction (B),B+B,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,developmental delay,,HP:0001263,,,https://www.ncbi.nlm.nih.gov/pubmed/17508264,,,,,,,,
543,,,,,,,,,,,,,,,,,,,,Hypocarnitinemia,,HP:0003234,,,,,,,,,,,
544,,,,,,,,,,,,,,,,,,,,High plasma long-chain acylcarnitines,,HP:0045045,,,,,,,,,,,
545,53,* 601987,"Carnitine palmitoyltransferase I deficiency , muscle ",,CPT1B,"carnitine O-palmitoyltransferase 1, muscle isoform",2.3.1.21,,Medium-chain triglycerides,DB13959,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,,neurological damage,,HP:0000707,,,https://rarediseases.info.nih.gov/diseases/10325/carnitine-palmitoyltransferase-i-deficiency-muscle,,,,,,,,
546,,,,,,,,,,,,,,,,,,,,hypoglycemia,,HP:0001943,,,,,,,,,,,
547,54,# 255120,Carnitine palmitoyl transferase 1 deficiency ,,CPT1A,carnitine palmitoyltransferase 1A,2.3.1.21,,Triheptanoin,DB11677,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,,muscle pain,,HP:0003326,,,https://www.ncbi.nlm.nih.gov/pubmed/18645163,https://www.ncbi.nlm.nih.gov/pubmed/18645163,,,,,,,
548,,,,,,,,,,,,,,,,,,,,rhabdomyolysis,,HP:0003201,,,https://www.ncbi.nlm.nih.gov/pubmed/18645163,PMC2676979,,,,,,,
549,,,,,,,,,,,,,,,,,,,,abnormal SF-36 physical composite scores,,NA,,,,,,,,,,,
550,,,,,,,,,cornstarch,DB11599,ECO:0000352,,,,,Functional interaction (B),B,dietary supplementation,,Hypoglycemia,,HP:0001943,,,https://www.ncbi.nlm.nih.gov/pubmed/15669684,,,,,,,,
551,,,,,,,,,,,,,,,,,,,,Low growth rate (Abnormal growth)*,,HP:0001507*,,,,,,,,,,,
552,55,# 237300,Carbamoyl phosphate synthetase 1 deficiency ,,CPS1,Carbamoyl-phosphate synthase (ammonia,6.3.4.16,,N-Carbamylglutamate ,DB06775,ECO:0001565/ECO:0000352,,,,,Direct Interaction (A),A,activity modification of a genetically defective protein,Active,Hyperammonemia,,HP:0001987,,,https://www.ncbi.nlm.nih.gov/pubmed/28281899,https://www.ncbi.nlm.nih.gov/pubmed/31392111,https://www.ncbi.nlm.nih.gov/pubmed/23649895/,https://www.ncbi.nlm.nih.gov/pubmed/14213380/,https://www.ncbi.nlm.nih.gov/pubmed/13992367/,https://www.ncbi.nlm.nih.gov/pubmed/30034506,,,
553,,,,,,,,,N-acetyl-l-glutamate ,DB04075 ,ECO:0001565,,,,,Direct Interaction (A),A,activity modification of a genetically defective protein,,Acidemia,,HP:0001941,,,https://www.ncbi.nlm.nih.gov/pubmed/23649895,,,,,,,,
554,,,,,,,,,Gene Therapy ??,NA,ECO:0007121/ECO:0000352,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,Under trial,Hyperammonemia,,HP:0001987,,,https://www.semanticscholar.org/paper/Cell-and-Gene-Therapy-for-Carbamoyl-Phosphate-1-Zhang-Li/2099b4f31e1fe5e8825f03deff088f7702694f02,,,,,,,,
555,56,# 253260,Biotinidase deficiency ,,BTD,biotinidase,3.5.1.12,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Biotin,DB00121,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,Active,seizure,,HP:0001250,,,https://clinicaltrials.gov/ct2/show/NCT03269045,https://www.ncbi.nlm.nih.gov/pubmed/28649539,https://www.ncbi.nlm.nih.gov/pubmed/26577040,https://www.ncbi.nlm.nih.gov/pubmed/25638506/,https://www.ncbi.nlm.nih.gov/pubmed/28220409,,,,
556,,,,,,,,,baclofen,DB00181,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,Active,dystonia,,HP:0001332,,,https://emedicine.medscape.com/article/942055-treatment,,,,,,,,
557,,,,,,,,,,,,,,,,,,,,Spasticity,,HP:0001257,,,,,,,,,,,
558,57,# 607483,Biotin-thiamine-responsive basal ganglia disease ,,SLC19A3,thiamine transporter,not available,,Biotin+thiamine,DB00121+DB00152,ECO:0000352,,,,,Functional interaction (B)+Functional interaction (B),B+B,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,Active,seizures ,,HP:0001250,,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,https://www.ncbi.nlm.nih.gov/pubmed/31061755,,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,,,,,
559,,,,,,,,,,,,,,,,Symptomatic (C),C,,,encephalopathy,,HP:0001298,,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,https://www.ncbi.nlm.nih.gov/pubmed/31061755,https://www.ncbi.nlm.nih.gov/pubmed/24260777,,,,,,
560,,,,,,,,,,,,,,,,,,,,signal abnormality of the cortex ,,HP:0030178,,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,,,,,,,,
561,,,,,,,,,,,,,,,,,,,,Abnormal movement,,HP:0100022,,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,,,,,,,,
562,,,,,,,,,,,,,,,,,,,,Dystonia,,HP:0001332,,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,,,,,,,,
563,,,,,,,,,,,,,,,,,,,,Abnormal reflexes,,HP:0001347,,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,,,,,,,,
564,,,,,,,,,L-dopa,DB01235,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,dystonia,,HP:0001332,,,https://www.ncbi.nlm.nih.gov/pubmed/24260777,Abstract,,,,,,,
565,58,# 203750,Beta ketothiolase deficiency ,,ACAT1,Acetyl-CoA C-acetyltransferase.,2.3.1.9,,glucose,DB09341,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,Active,Ketosis,,HP:0001946,,,https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1552-6569.2012.00772.x,,,,,,,,
566,,,,,,,,,carnitine,DB00583 ,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,,Organic aciduria,,HP:0001992,,,https://www.sciencedirect.com/science/article/pii/S1110863016300763,,,,,,,,
567,,,,,,,,,Bicitra,DB09154 ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Acidosis,,HP:0001941,,,http://www.babysfirsttest.org/newborn-screening/conditions/beta-ketothiolase-deficiency,,,,,,,,
568,59,# 601678,Bartter Syndrome 1,,SLC12A1,Solute carrier family 12 member 1,Q13621,,spironolactone+potassium+ACE-inhibitor,DB00421+DB14500+C09A,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,Active,electrolyte disturbances,,HP:0003111,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233707/,,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,,,,,,,
569,,,,,,,,,Acetazolamide,DB00819,EC:0007121,,,,,Symptomatic (C),,symptomatic treatment procedure,,Metabolic alkalosis,,HP:0200114,https://clinicaltrials.gov/ct2/results?cond=%22Bartter+syndrome%22,,,,,,,,,,
570,,,,,,,,,,,,,,,,,,,,Hypokalemia Metabolic Alkalosis,,HP:0002900,,,,,,,,,,,
571,60,# 241200,Bartter Syndrome 2,,KCNJ1,ATP-sensitive inward rectifier potassium channel 1,P48048,,,,,,,,,,,,,hypomagnesemia,,HP:0002917,https://www.ncbi.nlm.nih.gov/pubmed/2646391,,,,,,,,,,
572,61,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,,Tanespimycin ,DB05134,ECO:0005542,,,,,Functional interaction (Mechanistic B),B,activity modification of a genetically defective protein,,Low plasma membrane expression of R8Lin kidney,,NA,https://www.ncbi.nlm.nih.gov/pubmed/24189473,,,,,,,,,,
573,,,,,,,,,,,,,,,,,,,,Hypokalemia,,HP:0002900,,,,,,,,,,,
574,,,,,,,,,,,,,,,,,,,,Metabolic alkalosis,,HP:0200114,,,,,,,,,,,
575,,,,,,,,,,,,,,,,,,,,Sensorineural hearing impairment,,HP:0000407,,,,,,,,,,,
576,,,,,,,,,,,,,,,,,,,,ER-associated degradation of R8L,,NA,,,,,,,,,,,
577,,,,,,,,,,,,,,,,,,,,Mislocalization of R8L,,NA,,,,,,,,,,,
578,,,,,,,,,Potassium Chloride,DB00761,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,hypokalemia,,HP:0002900,https://www.ncbi.nlm.nih.gov/books/NBK442019/,,,,,,,,,,
579,,,,,,,,,Naproxen,DB00788,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,hypokalemia,,HP:0002900,https://www.nejm.org/doi/full/10.1056/NEJM197807132990214,,,,,,,,,,
580,,,,,,,,,Niflumic acid,DB04552,ECO:0001565,L155/ G345/ A349,"Those three mutants are localized in two different protein regions that, based on the crystal structure of bacterial CLC homologs, are expected to be exposed to the extracellular side of the channel, relatively close to each other, and are thus good candidates for being part of the potentiating NFA binding site",G167A / F213A,These two. mutations drastically altered general gating properties and are unlikely to be involved in NFA binding,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Abnormal ClC-Ka function,,NA,https://www.ncbi.nlm.nih.gov/pubmed/20649569/,,,,,,,,,,
581,,,,,,,,,,,,"L155A, G345S and A349E",,,,,,,,,,,,,,,,,,,,,
582,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
583,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
584,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,POTASSIUM-SPARING AGENTS,C03D,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Deleterious prognosis,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30387909,,,,,,,,,,
585,,,,,,,,,,,,,,,,,,,,Decreased life expectancy,,NA,,,,,,,,,,,
586,,,,,,,,,,,,,,,,,,,,Salt wasting,,HP:0000127,,,,,,,,,,,
587,,,,,,,,,,,,,,,,,,,,Growth retardation,,HP:0001510,,,,,,,,,,,
588,,,,,,,,,Indomethacin,DB00328,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Deleterious prognosis,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract,,,,,,,,,
589,,,,,,,,,,,,,,,,,,,,Decreased life expectancy (Mortality)*,,HP:0040006*,,,,,,,,,,,
590,,,,,,,,,,,,,,,,,,,,Salt wasting,,HP:0000127,,,,,,,,,,,
591,,,,,,,,,Growth hormone,DB00052,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Short stature,,HP:0004322,https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/?term=Classic+Bartter+syndrome+complicated+with+profound+growth+hormone+deficiency%3A+a+case+report,,,,,,,,,
592,,,,,,,,,,,,,,,,,,,,Decreased serum IGF‐1,,HP:0030353,,,,,,,,,,,
593,,,,,,,,,,,,,,,,,,,,Failure to thrive,,HP:0001508,,,,,,,,,,,
594,,,,,,,,,Potassium,DB14500,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Hypokalemia,,HP:0002900,https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract,,,,,,,,,,
595,,,,,,,,,Magnesium,DB14513,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Hypomagnesemia,,HP:0002917,https://www.sciencedirect.com/science/article/abs/pii/S0002962915356895?via%3Dihub,,,,,,,,,,
596,,,,,,,,,Sodium,DB09395,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Hyponatremia,,HP:0002902,https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract,,,,,,,,,,
597,,,,,,,,,Aminoglycoside (Geneticin),DB04263,ECO:0001565,W610X,,,,Direct Interaction,A,direct complementation of a genetically defective protein,,Defected ClC-Kb expression,,NA,https://www.ncbi.nlm.nih.gov/pubmed/23772144?dopt=Abstract,,,,,,,,,,
598,,,,,,,,,Potassium+Indomethacin±Spironolactone,DB14500+DB00328+ DB00421,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Short stature,,HP:0004322,https://www.ncbi.nlm.nih.gov/pubmed/28288174,,,,,,,,,,
599,,,,,,,,,Nonsteroidal anti-inflammatory drugs,M01AX,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Elevated prostaglandin E2,,HP:0003566,https://www.ncbi.nlm.nih.gov/pubmed/24189473/,,,,,,,,,,
600,,,,,,,,,,,,,,,,,,,,Hypokalemia,,HP:0002900,,,,,,,,,,,
601,,,,,,,,,,,,,,,,,,,,High calcium excretion in urine,,HP:0002150,,,,,,,,,,,
602,,# 300971,"BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5","Among antenatal Bartter syndrome, the transient form was defined as a regression of clinical symptoms and normalization of biologic parameters allowing the arrest of treatment. https://www.ncbi.nlm.nih.gov/pubmed/29146702
This condition can be successfully treated with close monitoring and fluid and electrolyte replacement, avoiding the potential harmful effects of indomethacin. This diagnosis is important for clinical management and parental counseling regarding overall patient prognosis. https://www.ncbi.nlm.nih.gov/pubmed/29594084",MAGED2,Melanoma-associated antigen D2,Q9UNF1,,Electrolytes,B05BB01,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Renal salt wasting,,HP:0000127,https://www.ncbi.nlm.nih.gov/pubmed/27120771,,,,,,,,,,
603,,,,,,,,,Indomethacin,DB00328,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,,,,,,,,,,,,,,
604,62,302060,Barth syndrome ,,TAZ,tafazzin ( Protein),Not available,,Elamipretide,DB11981,ECO:0007121,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,oxidative stress,,HP:0025464,https://mitochondrialdiseasenews.com/2018/03/09/stealth-biotherapeutics-completes-enrollment-elamipretide-trial-barth-syndrome/,https://clinicaltrials.gov/ct2/show/NCT03098797?cond=Elamipretide+in+Barth+syndrome&rank=1,,,,,,,,,
605,,,,,,,,,,,,,,,,,,,,abnormal energy production in damaged mitochondria,,HP:0003287,https://clinicaltrials.gov/ct2/show/NCT03098797?cond=Barth+syndrome&rank=1,,,,,,,,,,
606,,,,,,,,,,,,,,,,,,,,Fatigue,,HP:0012378,,,,,,,,,,,
607,,,,,,,,,Granulocyte colony stimulating factor (G‐CSF),DB00020,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Neutropenia,,HP:0001875,https://www.ncbi.nlm.nih.gov/pubmed/15098233/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,,,,,
608,,,,,,,,,,,,,,,,,,,,Recurrent infection,,HP:0002719,https://www.ncbi.nlm.nih.gov/pubmed/23432031,,,,,,,,,,
609,,,,,,,,,Digoxin,DB00390,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,Drug name: Temporary improvemnet ,Low ejection fraction,,HP:0012664,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025545/,,,,,,,,,,
610,,,,,,,,,,,,,,,,,,,,Tricusped incompetence,,HP:0005180,,,,,,,,,,,
611,,,,,,,,,,,,,,,,,,,,Mitral incomptence,,HP:0001653,,,,,,,,,,,
612,,,,,,,,,Pantothenic acid,DB01783,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Low myocardial function,,HP:0001638,https://www.ncbi.nlm.nih.gov/pubmed/7833193,,,,,,,,,,
613,,,,,,,,,,,,,,,,,,,,T wave abnormalities,,HP:0005135,,,,,,,,,,,
614,,,,,,,,,,,,,,,,,,,,Delayed Growth ,,HP:0001510,,,,,,,,,,,
615,,,,,,,,,,,,,,,,,,,,hypocholesterolaemia,,HP:0003146,,,,,,,,,,,
616,,,,,,,,,,,,,,,,,,,,hyperuricaemia,,HP:0002149,,,,,,,,,,,
617,,,,,,,,,,,,,,,,,,,,Neutropenia,,HP:0001875,,,,,,,,,,,
618,,,,,,,,,Angiotensin-converting enzyme inhibitors / angiotensin II receptor blockers/ beta-blockers/ diuretics,C09A/C09CA/C07/C03,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Heart failure,,HP:0001635,https://www.ncbi.nlm.nih.gov/pubmed/31239752,,,,,,,,,,
619,,,,,,,,,Angiotensin-converting enzyme inhibitors / angiotensin II receptor blockers/ beta-blockers/ diuretics + anticoagulate,C09A/C09CA/C07/C04+B01A,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Atrial fibrillation,,HP:0005110,https://www.ncbi.nlm.nih.gov/pubmed/31239752,,,,,,,,,,
620,,,,,,,,,Bezafibrate ,DB01393,ECO:0005542,,,,,,,symptomatic treatment procedure,,Cardiac dysfunction,,HP:0001635,https://www.ncbi.nlm.nih.gov/pubmed/29695963/,https://www.ncbi.nlm.nih.gov/pubmed/28279226/,,,,,,,,,
621,,,,,,,,,,,,,,,,,,,,Exercise intolerance,,HP:0003546,https://www.ncbi.nlm.nih.gov/pubmed/29695963/,,,,,,,,,,
622,,,,,,,,,AAV9-TAZ,NA,ECO:0005542,,,,,Direct interaction (Mechanistic A),A,direct complementatoin of a genetically defective protein by gene therapy,,Abnormal cardiac protein (TAZ) expression ,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30788385/,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,,,,,,,,,
623,,,,,,,,,,,,,,,,,,,,Mitochondrial dysfunction ,,HP:0003287,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,,,,,,,,,,
624,,,,,,,,,,,,,,,,,,,,Mueculoskeletal dysfunction,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,,,,,,,,,,
625,,,,,,,,,Digoxin+furosemide+captopril,DB00390+DB00695+DB01197,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Cardiomegaly,,HP:0001640,https://www.ncbi.nlm.nih.gov/pubmed/20981509,,,,,,,,,,
626,,,,,,,,,,,,,,,,,,,,Reduced ejection fraction,,HP:0012664,https://www.ncbi.nlm.nih.gov/pubmed/20981509,,,,,,,,,,
627,,,,,,,,,,,,,,,,,,,,Developmetal delay,,HP:0001263,https://www.ncbi.nlm.nih.gov/pubmed/20981509,,,,,,,,,,
628,,,,,,,,,,,,,,,,,,,,Abormal liver size,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/20981509,,,,,,,,,,
629,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
630,63,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,lysosomal acid lipase ,P38571,,sebelipase alfa,DB11563,ECO:0000352/ECO:0005542,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein,,High plasma cholesterol level*,,HP:0003107,https://www.ncbi.nlm.nih.gov/pubmed/29773783,https://www.ncbi.nlm.nih.gov/pubmed/27878737,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,,,,,,,
631,,,,,,,,,,,,,,,,,,,,hypertriglycemia,,HP:0002155,https://clinicaltrials.gov/ct2/show/NCT02376751?cond=Cholesteryl+ester+storage+disease&rank=4,https://clinicaltrials.gov/ct2/show/NCT01371825,,,,,,,,,
632,,,,,,,,,,,,,,,,,,,,Abnormal liver function,,HP:0002910,,,,,,,,,,,
633,,,,,,,,,,,,,,,,,,,,Dyslipidemia,,HP:0003119,,,,,,,,,,,
634,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
635,,,,,,,,,fenofibrate,DB01039,ECO:0005542,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Increased plasma triglycerides,,HP:0002155,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930475/,,,,,,,,,,
636,,,,,,,,,Simvastatin,DB00641,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Hyperlipidemia,,HP:0003077,https://www.ncbi.nlm.nih.gov/pubmed/16848116,,,,,,,,,,
637,,,,,,,,Treatment success with statins has been mixed. ,Lovastatin,DB00227,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Increased LDL cholesterol,,HP:0003141,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441/,,,,,,,,,,
638,,,,,,,,,,,,,,,,,,,,Increased plasma triglycerides,,HP:0002155,,,,,,,,,,,
639,,,,,,,,,,,,,,,,,,,,Increased total cholesterol,,HP:0003124,,,,,,,,,,,
640,,,,,,,,,,,,,,,,,,,,Elevated urine mevalonate levels,,NA,,,,,,,,,,,
641,,,,,,,,,Colestyramine+Simivastatin,DB01432+DB00641,ECO:0000352,,,,,Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Dyslipidemia,,HP:0003119,https://www.ncbi.nlm.nih.gov/pubmed/1801793,https://www.sciencedirect.com/science/article/pii/S1521691810001101,,,,,,,,,
642,,,,,,,,,,,,,,,,,,,,Abnormal liver function,,HP:0002910,,,,,,,,,,,
643,,,,,,,,,Ezetimibe ,DB00973,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Dyslipidemia,,HP:0003119,https://www.ncbi.nlm.nih.gov/pubmed/29374495,,,,,,,,,,
644,,,,,,,,,,,,,,,,,,,,Abnormal liver function,,HP:0002910,,,,,,,,,,,
645,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
646,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
647,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
648,64,# 118600,Chondrocalcinosis 2 ,,ANKH,Progressive ankylosis protein homolog,Q9HCJ1,"Effective in flares when used in combination with NSAIDs. It is also beneficial as prophylaxis for preventing recurrent flares. Oral COL should be preferred over the intravenous form. If contraindications present to use oral COL, then intravenous COL solution should be pre-diluted with 0.9% NaCl prior to infusion.",Colchicine(COL),DB01394,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Arthritis,,HP:0001369,https://clinicaltrials.gov/ct2/show/NCT03128905?cond=Chondrocalcinosis&draw=2&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,,,,,,,,,
649,,,,,,,,,,,,,,,,,,,,Arthralgia,,HP:0002829,,,,,,,,,,,
650,,,,,,,,Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,prednisone,DB00635,ECO:0000352/ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Arthritis,,HP:0001369,https://clinicaltrials.gov/ct2/show/NCT03128905?cond=Chondrocalcinosis&draw=2&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/27790033/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study/,,,,,,,
651,,,,,,,,,naproxen sodium,DB00788,,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Arthralgia,,HP:0002829,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,,,,,,,,,
652,,,,,,,,,,,,,,,,,,,,Recurrent repisode of flares (Recurrent)*,,HP:0025303,,,,,,,,,,,
653,,,,,,,,"Anakinra was administered as preventive therapy in one study"" https://www.ncbi.nlm.nih.gov/pubmed/19289295"". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/",Anakinra/canakinuma,DB00026/DB06168,ECO:0007121/ ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Recurrent repisode of flares (Recurrent)*,,HP:0025303,https://www.ncbi.nlm.nih.gov/pubmed/29675606,https://www.ncbi.nlm.nih.gov/pubmed/19289295,https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924/,https://www.ncbi.nlm.nih.gov/pubmed/23022422?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,,,,
654,,,,,,,,,,,,,,,,,,,,Arthritis,,HP:0001369,https://www.ncbi.nlm.nih.gov/pubmed/23022422,https://www.ncbi.nlm.nih.gov/pubmed/25922564?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18240249?dopt=Abstract,,,,,,,,
655,,,,,,,,,,,,,,,,,,,,Refractory Arthritis,,HP:0031375,https://www.ncbi.nlm.nih.gov/pubmed/22658375,,,,,,,,,,
656,,,,,,,,,,,,,,,,,,,,Synovitis,,HP:0100769,https://www.ncbi.nlm.nih.gov/pubmed/22341584?dopt=Abstract,,,,,,,,,,
657,,,,,,,,,rilonacept,DB06372,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Recurrent repisode of flares (Recurrent)*,,HP:0025303,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,,,,,,,,,,
658,,,,,,,,"There is a contraversy about effectivness of methotrexate in treating ""Condrocalcinosis 2"" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/
  ",methotrexate,DB00563,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,swollen joint,,HP:0001386,https://www.ncbi.nlm.nih.gov/pubmed/29675606,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379613/,https://www.ncbi.nlm.nih.gov/pubmed/25315665,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,,,,,,
659,,,,,,,,,,,,,,,,,,,,Arthralgia,,HP:0002829,,,,,,,,,,,
660,,,,,,,,,Hydroxychloroquine,DB01611,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,swollen joint,,HP:0001386,https://www.ncbi.nlm.nih.gov/pubmed/9195122/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,,,,,,,,
661,,,,,,,,,,,,,,,,,,,,Arthralgia,,HP:0002829,,,,,,,,,,,
662,,,,,,,,,,,,,,,,,,,,Arthropathy,,HP:0003040,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,,,,,,,,
663,,,,,,,,,Probenecid,DB01032,ECO:0001565,,,,,Functional interaction (Mechanistic B),,functional complementation of a genetically defective protein,,Abnormality of phosphate homeostasis,,HP:0100529,https://www.ncbi.nlm.nih.gov/pubmed/7520501,,,,,,,,,,
664,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
665,65,118610,Chondrocalcinosis due to apatite crystal deposition ,,,,,,NSAIDs,DB00788,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,acute arthritis,,HP:0001369,https://www.ncbi.nlm.nih.gov/pubmed/17541659,,,,,,,,,,
666,67,# 246700,Chylomicron retention disease ,,SAR1B,Sar1b protein,,,vitamin E,DB00163,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,neurological abnormalities,,HP:0012638,https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691/,https://www.ncbi.nlm.nih.gov/pubmed/23329770,,,,,,,,
667,,,,,,,,,Alpha-tocopherol,DB11251,,,,,,Symptomatic (C),C,symptomatic treatment procedure,,neurological abnormalities,,HP:0012638,,,,,,,,,,,
668,,,,,,,,,,,,,,,,,,,,Abnormal Adipose tissue tocopherol level.,,NA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982212/,,,,,,,,,,
669,,,,,,,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",Tocofersolan,DB11635,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,No Studies were done on this drug.,,,https://www.ncbi.nlm.nih.gov/pubmed/27520363,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,
670,,,,,,,,,Vitamin A+ Vitamin E,DB00162+DB00163,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Minor visual abnormalities,,HP:0000505,https://www.ncbi.nlm.nih.gov/pubmed/19285442/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,
671,,,,,,,,,,,,,,,,,,,,Neurological abnormality,,HP:0012638,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,,
672,,,,,,,,,,,,,,,,,,,,Muscular abnormality,,HP:0012638,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,,
673,,,,,,,,,vitamin D ,DB11094,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,osteopenia,,HP:0000938,,,,,,,,,,,
674,,,,,,,,,,,,,,,,,,,,Vitamin D insufficiency,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,,
675,,,,,,,,,vitamin K,DB01022,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Bleeding tendency,,HP:0001892,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,,
676,,,,,,,,,,,,,,,,,,,,Vitamin K insufficiency,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,,
677,,,,,,,,,medium-chain triglycerides,DB13959,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Low weight/growth,,HP:0004325,https://www.sciencedirect.com/science/article/pii/S0929693X16302044?via%3Dihub,,,,,,,,,,
678,,,,,,,,,,,,,,,,,,,,Diarrhea,,HP:0002014,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,,
679,,,,,,,,,,,,,,,,,,,,Malnutrition,,HP:0004395,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,,
680,,,,,,,,,fat emulsion,DB09422,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Fat malabsorption,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/2596948/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,
681,68,#215720,Citrulline transport defect ,,,,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
682,69,# 611209,COG1-CDG (CDG-IIg) ,,COG1,component of oligomeric golgi complex 1,,,No treatment is available in DDIEM,,,,,,,,,,,,,,https://nyaspubs.onlinelibrary.wiley.com/doi/full/10.1111/j.1749-6632.2010.05840.x,,,,,,,,,,
683,70,# 615395,Combined oxidative phosphorylation deficiency 16 ,,MRPL44,mitochondrial ribosomal protein L44,Q9H9J2,,l-carnitine +propranolol,DB00583+DB00571,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,low physical capacity,,HP:0012378,https://link.springer.com/article/10.1007%2Fs10048-015-0444-2,https://www.ncbi.nlm.nih.gov/pubmed/25797485,,,,,,,,,
684,71,# 607765,"Congenital bile acid synthesis defect, type 1 ",,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase ,,,Cholic acid ,DB02659,ECO:0000352,,,,,Functional interaction (B),B,metabolite replacement,,Atypical bile acids ,,NA,https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-1,https://www.ncbi.nlm.nih.gov/pubmed/16819396?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360,,,,,
685,,,,,,,,,,,,,,,,,,,,Defected bile flow,,HP:0001396,https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-2,,,,,,,,,,
686,,,,,,,,,,,,,,,,,,,,Cirrhosis,,HP:0001394,https://www.ncbi.nlm.nih.gov/pubmed/30373615,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,,,,,,,,,
687,,,,,,,,,chenodeoxycholic acid,DB06777,ECO:0000352,,,,,Functional interaction (B),B,metabolite replacement,,Pruritus,,HP:0000989,https://www.ncbi.nlm.nih.gov/pubmed/2072042,,,,,,,,,,
688,,,,,,,,,,,,,,,,,,,,Abnormal urinary steroid level,,HP:0012030,https://www.ncbi.nlm.nih.gov/pubmed/2072042,,,,,,,,,,
689,,,,,,,,,,,,,,,,,,,,Ill-being (Constitutional symptoms)*,,HP:0025142*,,,,,,,,,,,
690,,,,,,,,,Ursodeoxycholic acid,DB01586,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,,,,,,,,,,,,,,,
691,72,# 235555,"Congenital bile acid synthesis defect, type 2 ",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,Cholic acid ,DB02659,ECO:0000352,,,,,Functional interaction (B),B,metabolite replacement,,Liver biochemical abnormalities (Laboratory abnormalities)*,,HP:0001939,https://rarediseases.info.nih.gov/diseases/10045/congenital-bile-acid-synthesis-defect-type-2,,,,,,,,,,
692,,,,,,,,,,,,,,,,,,,,Histological abnormalities (Abnormal test result)*,,HP:0500014,,,,,,,,,,,
693,,,,,,,,,,,,,,,,,,,,Disease progression (Rapidly progressive)*,,HP:0003678*,,,,,,,,,,,
694,,,,,,,,,,,,,,,,,,,,Defected bile flow(Cholestasis)*,,HP:0001396,,,,,,,,,,,
695,,,,,,,,,,,,,,,,,,,,fat soluble vitamin malabsorption*,,HP:0002630,,,,,,,,,,,
696,,,,,,,,,,,,,,,,,,,,Atypical bile acid synthesis ,,NA,,,,,,,,,,,
697,,,,,,,,,,,,,,,,,,,,production of toxic bile acid metabolic intermediates,,NA,,,,,,,,,,,
698,,,,,,,,,chenodeoxycholic acid ,DB06777,ECO:0000352,,,,,Functional interaction (B),B,metabolite replacement,,abnormal liver function,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/28697823,,,,,,,,,,
699,,,,,,,,,,,,,,,,,,,,hepatomegaly,,HP:0002240,,,,,,,,,,,
700,73,# 224120,Congenital dyserythropoietic anemia type 1,,CDAN1,codanin 1,,,interferon α-2a,DB00034,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,controversial,low hemoglobin concentration,,HP:0001931,https://www.ncbi.nlm.nih.gov/pubmed/16141353,https://www.ncbi.nlm.nih.gov/pubmed/16141353?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/15804998?dopt=Abstract,,,,,,,,
701,,,,,,,,,,,,,,,,,,,,Abnormal upregulated enteral iron uptake (Abnormality of iron homeostasis)*,,HP:0011031*,,,,,,,,,,,
702,,,,,,,,,deferoxamine,DB00746,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,high plasma ferritin,,HP:0003281,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531/,,,,,,,,,
703,,,,,,,,,deferiprone,DB08826,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Elevated serum ferritin concentrations,,HP:0003281,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531/,https://www.ncbi.nlm.nih.gov/pubmed/16141353,,,,,,,,,
704,74,# 220120,D-glycericacidemia ,,GLYCTK,d-glycerate kinase ,2.7.1.31 ,,Sodium bicarbonate,DB01390,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,Active,Metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/26247153,http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652015005050021&lng=en&nrm=iso&tlng=en,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,,,,,,,,
705,75,# 261515,D-bifunctional protein deficiency ,"No proven treatments exist to address the underlying biochemical defect in this disorder, although dietary phytanic acid restriction and/or bile acid supplementation may warrant further study.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/",HSD17B4 ,17β-hydroxysteroid dehydrogenase type 4,,,chenodeoxycholic acid+cholic acid,DB06777+DB02659 ,ECO:0007121,,,,,Supportive (C),C,functional complementation of a genetically defective protein,,The study was terminated,,,https://clinicaltrials.gov/ct2/show/NCT00004442?cond=D-bifunctional+protein+deficiency&rank=1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,,,,,,,,,
706,,,,,,,,,cholic acid+ursodiol,DB02659 +DB14555,ECO:0007121,,,,,Supportive (C),C,functional complementation of a genetically defective protein,,The study was terminated,,,,,,,,,,,,,
707,76,# 600721,D-2-hydroxyglutaric aciduria ,,D2HGDH,D-2-hydroxyglutarate dehydrogenase,,,L- carnitine,DB00583,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,DNA damage (Abnormality of DNA repair)*,,HP:0003254*,https://www.ncbi.nlm.nih.gov/pubmed/28396261?dopt=Abstract,,,,,,,,,,
708,,,,,,,,,,,,,,,,,,,,oxidative injury*,,HP:0025463,,,,,,,,,,,
709,,,,,,,,,,,,,,,,,,,,Protein oxidation,,NA,,,,,,,,,,,
710,,,,,,,,,,,,,,,,,,,,lipid peroxidation ,,NA,,,,,,,,,,,
711,77,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,,cytochrome c oxidase assembly factor ,1.9.3.1 ,,Valproic acid,DB00313,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,better to be avoided,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/22149023,,,,,,,,,,
712,,,,,,,,,carbamazepine,DB00593,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Seizures,,HP:0001250,,,,,,,,,,,
713,,,,,,,,,phenobarbital,DB01174 ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Seizures,,HP:0001250,,,,,,,,,,,
714,,,,,,,,,phenytoin,DB00252,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Seizures,,HP:0001250,,,,,,,,,,,
715,,,,,,,,,oxcarbazepine,DB00776,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Seizures,,HP:0001250,,,,,,,,,,,
716,,,,,,,,,vigabatrin,DB01080,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Seizures,,HP:0001250,,,,,,,,,,,
717,,,,,,,,,gabapentin,DB00996,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Seizures,,HP:0001250,,,,,,,,,,,
718,,,,,,,,,topiramate,DB00273  ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Seizures,,HP:0001250,,,,,,,,,,,
719,,,,,,,,,zonisamide,DB00909,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Seizures,,HP:0001250,,,,,,,,,,,
720,,,,,,,,,ethosuximide,DB00593,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Seizures,,HP:0001250,,,,,,,,,,,
721,78,# 219750,"Cystinosis, ocular nonnephropathic ",,CTNS,cystinosin,O60931,,cysteamine ,DB00847,ECO:0005542/ECO:0007121,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,corneal crystals,,HP:0000531,https://www.ncbi.nlm.nih.gov/pubmed/12370309/,,http://www.ncbi.nlm.nih.gov/pubmed/21897743?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12488257/,https://www.ncbi.nlm.nih.gov/pubmed/1929112/,,,,,,
722,79,# 219800,Cystinosis,,CTNS,cystinosin,O60931,"Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/",cysteamine ,DB00847,ECO:0000352/ECO:0005542,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,"Drug name: Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients.    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/                                                                                                                                                                                                                                                                                                                                          Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/",corneal crystals,,HP:0000531,https://www.ncbi.nlm.nih.gov/pubmed/11001803,https://www.ncbi.nlm.nih.gov/pubmed/9758713,http://www.ncbi.nlm.nih.gov/pubmed/21897743?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,,,,,,
723,,,,,,,,,,,,,,,,,,,,Photophobia,,HP:0000613,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,,,,,,,,,,
724,,,,,,,,,,,,,,,,,,,,Kidney disease progression ( Progressive disorder)*,,HP:0003678*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,,,,,,,,,
725,,,,,,,,,,,,,,,,,,,"Phenotypes improved : lifelong and diligent cysteamine therapy prevents 
hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, 
and prevents a host of nonrenal complications ",development of extra-renal pathologies ( Progressive disorder)*,"lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications",HP:0003678*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,,,,,,,,,
726,,,,,,,,,,,,,,,,,,,"Phenotypes improved : lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications ",hypothyroidism,"lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications",HP:0000821,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,,,,,,,,,,
727,,,,,,,,,,,,,,,,,,,"Phenotypes improved : lifelong and diligent cysteamine therapy prevents 
hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, 
and prevents a host of nonrenal complications ",Delayed growth,"lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications",HP:0001510,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,,,,,,,,
728,,,,,,,,,,,,,,,,,,,"Phenotypes improved : lifelong and diligent cysteamine therapy prevents 
hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, 
and prevents a host of nonrenal complications ",cystine accumulation in muscle parenchyma,"lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications",HP:0003358,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,,,,,,,,,,
729,,,,,,,,,,,,,,,,,,,,shorter life expectancy ,,NA,,,,,,,,,,,
730,,,,,,,,,,,,,,,,,,,,Reduction of WBC cystine levels,,NA,,,,,,,,,,,
731,,,,,,,,,,,,,,,,,,,,renal function declines ,,HP:0012622,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,,,,,,,,,,
732,,,,,,,,,,,,,,,,,,,,Elevated intralysosomal cystine accumulation( abnormality of cysteine metabolism),,HP:0010918*,https://www.ncbi.nlm.nih.gov/pubmed/23416144,,,,,,,,,,
733,,,,,,,,,,,,,,,,,,,,glomerular damage,,HP:0000095*,,,,,,,,,,,
734,,,,,,,,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,indomethacin,DB00328,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,Drug name: Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,polyuria,,HP:0000103,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,,,,,,,,,,
735,,,,,,,,,,,,,,,,,,,,weight gain,,HP:0004324,,,,,,,,,,,
736,,,,,,,,,,,,,,,,,,,,proximal tubule salt losses (Proximal tubular defect),,HP:0000114,,,,,,,,,,,
737,,,,,,,,,,,,,,,,,,,,renal salt wasting,,HP:0000127,,,,,,,,,,,
738,,,,,,,,,Bicarbonate+potassium supplements,DB01390+DB01345,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,acidosis,,HP:0001941,,,,,,,,,,,
739,,,,,,,,,neutral phosphate+Vitamin D,DB14502 orDB09449 +DB11094,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,Drug name: Substitution with sodium or potassium phosphate and 1–25-(OH)2 cholecalciferol should be initiated from early childhood to compensate for the phosphate imbal- ance and to prevent rickets in patients with preserved GFR https://www.ncbi.nlm.nih.gov/pubmed/27102039,Phosphate imbalance (Abnormality of phosphate homeostasis),,HP:0100529,https://www.ncbi.nlm.nih.gov/pubmed/27102039,,,,,,,,,,
740,,,,,,,,,Thiazide,DB01324,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,"Drug name: Usage of Diutics like thiazide to avoid volume expansion, could aggrevate Potassium loss and augments the need for potassium supplements https://emedicine.medscape.com/article/981774-treatment not benefical",low proximal tubular reabsorption of bicarbonates ,,HP:0004910*,,,,,,,,,,,
741,,,,,,,,,growth hormone,DB00052,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,retarded growth,,HP:0001510,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061/,,,,,,,,,
742,,,,,,,,,,,,,,,,,,,,low phosphate reabsorption,,HP:0000117,,,,,,,,,,,
743,,,,,,,,,Thyroxine,DB00451,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,hypothyroidism,,HP:0000821,,,,,,,,,,,
744,,,,,,,,,ACE inhibitors,DB01348,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,Drug name: Effectivness of the drug is controversial.                                                                                                                                                                                                                     ACE inhibitors must be used with caution in patients with extracellular volume and sodium depletion https://www.ncbi.nlm.nih.gov/pubmed/14690254/,glomerular proteinuria,,HP:0000100,,,,,,,,,,,
745,,,,,,,,,,,,,,,,,,,,Albuminuria,,HP:0012592,https://www.ncbi.nlm.nih.gov/pubmed/14690254/,,,,,,,,,,
746,,,,,,,,,Testosterone,DB00624,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,"Drug name:  Currently, insufficient data is available on the pathophysiology of the azoospermia observed in male cystinosis patients. Testosterone supplementation is indicated in patients with a primary testicular failure and low plasma testosterone levels https://www.ncbi.nlm.nih.gov/pubmed/19217094/",Low serum testosterone levels,,HP:004017,https://www.ncbi.nlm.nih.gov/pubmed/19217094/,,,,,,,,,,
747,80,# 606785,"Crigler Najjar syndrome, type 2 ","Treatment of CNS type 2 is usually conservative with avoidance of drugs that displace bilirubin from albumin like penicillin, sulphonamides, salicylates, ceftriaxone and furosemide. https://www.ncbi.nlm.nih.gov/pubmed/23162302/
Affected patients should also avoid drugs that displace bilirubin from albumin such as penicillines, sulphonamides, salicylates, ceftriaxone and furosemide.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",UGT1A1 ,UDP glucuronosyltransferase family 1 member A1 ,,,phenobarbital ,DB01174,ECO:0000352,,,,,Direct Interaction (A),A,activity modification of a genetically defective protein,,high serum bilirubin level,,HP:0002904,https://www.ncbi.nlm.nih.gov/pubmed/23162302/,,https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=27264814&dopt=abstractplus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/,,,,
748,,,,,,,,,orlistat,DB01083,ECO:0007121,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,high plasma level of unconjugated bilirubin concentration,,HP:0008282,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/,,https://clinicaltrials.gov/ct2/show/NCT00461799?cond=Crigler+Najjar+syndrome&rank=4,,,,,,,,
749,,,,,,,,,,,,,,,,,,,,increased fecal fat excretion,,HP:0002570,,,,,,,,,,,
750,,,,,,,,,,,,,,,,,,,,low fecal excretion of unconjugated bilirubin (Unconjugated hyperbilirubinemia)*,,HP:0008282*,,,,,,,,,,,
751,,,,,,,,,AT342,NA,ECO:0007121,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,,High serum  bilirubin concentration,,HP:0002904,,,https://clinicaltrials.gov/ct2/show/NCT03223194?cond=Crigler+Najjar+syndrome&rank=3,,,,,,,,
752,,,,,,,,,GNT0003 ,NA,ECO:0007121,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,,High serum  bilirubin concentration,,HP:0002904,,,https://clinicaltrials.gov/ct2/show/NCT03466463?cond=Crigler+Najjar+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099/,,,,,,,
753,,,,,,,,,hypericum extract,DB01323,ECO:0000352,,,,,Direct Interaction (A),A,activity modification of a genetically defective protein,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/26692114?dopt=Abstract,,,,,,,,
754,,,,,,,,Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases,AAV-mediated gene therapy,NA,ECO:0005542,,,,,Direct Interaction (A),,direct complementation of a genetically defective protein by gene therapy,,Abnormal liver function,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/15753292,https://www.ncbi.nlm.nih.gov/pubmed/10603107/,,,,,,,,,
755,,,,,,,,,,,,,,,,,,,,High serum  bilirubin concentration,,HP:0002904,,,,,,,,,,,
756,,,,,,,,,,,,,,,,,,,,Increased inflammatory response,,HP:0012649,,,,,,,,,,,
757,,,,,,,,,,,,,,,,,,,,Abnormality of metabolism,,HP:0001939,,,,,,,,,,,
758,,,,,,,,,Chlofibrate,DB00636,ECO:0000352,,,,,Symptomatic (C),,activity modification of a genetically defective protein,,High serum  bilirubin concentration,,HP:0002904,https://www.ncbi.nlm.nih.gov/pubmed/7483726,https://www.ncbi.nlm.nih.gov/pubmed/19752526/,,,,,,,,,
759,,,,,,,,,Fenofibrate,DB01039,ECO:0000352,,,,,Symptomatic (C),,activity modification of a genetically defective protein,,Drug wasn't effective (Insignificant effect),,,https://www.ncbi.nlm.nih.gov/pubmed/16830281,,,,,,,,,,
760,,,,,,,,,Calcium ,DB01373,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Calcium makes phototherapy more efficient ,,,https://www.ncbi.nlm.nih.gov/pubmed/10603107/,,,,,,,,,,
761,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
762,81,# 218800,"Crigler Najjar syndrome, type 1",,UGT1A1 ,uridine diphosphate–glucuronyl transferase ,,The drug is effective in conjuction with phototherapy,Tin-protoporphyrin,DB02285,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,,High serum bilirubin level,,HP:0002904,https://www.nature.com/articles/pr1989488,,http://pediatrics.aappublications.org/content/86/1/152,https://www.sciencedirect.com/topics/medicine-and-dentistry/crigler-najjar-syndrome,,,,,,,
763,,,,,,,,"Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.",orlistat,DB01083,ECO:0007121/ECO:0005542,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,high plasma level of unconjugated bilirubin concentration,,HP:0008282,https://www.ncbi.nlm.nih.gov/pubmed/17957158,https://clinicaltrials.gov/ct2/show/NCT00461799,https://www.ncbi.nlm.nih.gov/pubmed/14517515?dopt=Abstract&holding=npg,https://www.ncbi.nlm.nih.gov/pubmed/15726662,,,,,,,
764,,,,,,,,,AT342,NA,ECO:0007121,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,,Study was suspended based on Sponsor Decision.,,HP:0002904,https://clinicaltrials.gov/ct2/show/NCT03223194,,,,,,,,,,
765,,,,,,,,Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf,GNT0003,NA,ECO:0007121,,,,,Direct Interaction (A),,direct complementation of a genetically defective protein by gene therapy,,Study is still recruiting,,,https://clinicaltrials.gov/ct2/show/NCT03466463,,,,,,,,,,
766,,,,,,,,,Ad5/CMV/hUG-Br1,NA,ECO:0005542,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,,Hyperbilirubinemia,,HP:0002904,https://www.ncbi.nlm.nih.gov/pubmed/9525311/,https://www.ncbi.nlm.nih.gov/pubmed/9156798/,https://www.ncbi.nlm.nih.gov/pubmed/15753292,,,,,,,,
767,,,,,,,,,Chimeric oligonucleotide(oligonucleotide-based gene therapy),NA,ECO:0005542,,,,,Direct Interaction (A),,direct complementation of a genetically defective protein by gene therapy,,UDP-glucuronosyltransferase gene defect,,NA,https://www.ncbi.nlm.nih.gov/pubmed/10468611/,,,,,,,,,,
768,,,,,,,,,Retrovirus ,NA,ECO:0005542,,,,,Direct Interaction (A),,direct complementation of a genetically defective protein by gene therapy,,Hyperbilirubinemia,,HP:0002904,https://www.ncbi.nlm.nih.gov/pubmed/9457971/,,,,,,,,,,
769,,,,,,,,,Ad-hBUGT1,NA,ECO:0005542,,,,,Direct Interaction (A),,direct complementation of a genetically defective protein by gene therapy,,Hyperbilirubinemia,,HP:0002904,https://www.ncbi.nlm.nih.gov/pubmed/8900123/,,,,,,,,,,
770,82,% 608158,CoQ-responsive OXPHOS deficiency ,,,,,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",sodium benzoate,DB03793,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,Not Active,hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/12948744,,https://www.sciencedirect.com/science/article/pii/S1096719215300895?via%3Dihub,,,,,,,,
771,,,,,,,,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",sodium phenylacetate,DB09269,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,Not Active,hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/12948744,,,,,,,,,,
772,,,,,,,,,CoQ ,DB09270,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,,Abnormal liver function,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/12948744,,,,,,,,,,
773,83,121270,"Copper deficiency, familial benign ",,,,,,copper,DB09130,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,,hypocupraemia,,HP:0010836,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1627787/,,,,,,,,,,
774,,,,,,,,,,,,,,,,,,,,seizures,,HP:0001250,,,,,,,,,,,
775,84,# 263700,Congenital erythropoietic porphyria ,,UROS ,uroporphyrinogen III synthase,4.2.1.75,,bortezomib,DB00188 ,ECO:0005542/ECO:0001565,,,,,Functional interaction (B),B,activity modification of a genetically defective protein,,high porphyrin accumulation in circulating RBCs,,HP:0012187,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831495/,https://www.ncbi.nlm.nih.gov/pubmed/24145442,,,,,,,,,
776,,,,,,,,,,,,,,,,,,,,skin photosensitivity,,HP:0000992,,,,,,,,,,,
777,,,,,,,,,,,,,,,,,,,,premature degradation of misfolded UROS mutants,,NA,https://www.ncbi.nlm.nih.gov/pubmed/28334762,,,,,,,,,,
778,,,,,,,,,,,,,,,,,,,,abnormal porphyrin accumulation in urine,,HP:0010473,,,,,,,,,,,
779,85,# 610198,"DCMA syndrome (3-methylglutaconic aciduria, type V)",,DNAJC19,DnaJ heat shock protein family (Hsp40) member C19 ,Q96DA6,,Angiotensin-converting enzyme (ACE) inhibitors+digoxin+furosemide,C09C+DB00390+DB00695,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Low ejection fraction,,,https://www.ncbi.nlm.nih.gov/pubmed/27928778,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,,,,,,,,
780,86,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,Phosphorylase b kinase regulatory subunit beta,Q93100,,Dextrothyroxine,DB00509,ECO:0007121,,,,,,,symptomatic treatment procedure,,Hepatomegaly,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/280544,,,,,,,,,,
781,,,,,,,,,,,,,,,,,,,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/280544,,,,,,,,,,
782,,,,,,,,,,,,,,,,,,,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/280544,,,,,,,,,,
783,,,,,,,,,,,,,,,,,,,,Mild asymptomatic hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/280544,,,,,,,,,,
784,,,,,,,,,Complex Carbohydrates,NA,ECO:0000352,,,,,,,dietary supplementation,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
785,,,,,,,,,,,,,,,,,,,,Short Stature,,HP:0004322,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
786,,,,,,,,,Complex carbohydrates+Beneprotein+Low fats,NA,ECO:0000352,,,,,,,dietary supplementation,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
787,,306000,GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8 ),,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",P46019,,Uncooked cornstarch+ Beneprotein+Low fats diet,DB11599+NA,ECO:0000352,,,,,,,dietary supplementation,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
788,,,,,,,,,Uncooked cornstarch+ Beneprotein,DB11599+NA,ECO:0000352,,,,,,,dietary supplementation,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
789,,,,,,,,,,,,,,,,,,,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
790,,,,,,,,,Uncooked cornstarch,DB11599+NA,ECO:0000352,,,,,,,dietary supplementation,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
791,,,,,,,,,,,,,,,,,,,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
792,,,,,,,,,Uncooked cornstarch+ Beneprotein+CoCarbs(Complex carbohydrate),DB11599+NA+NA,ECO:0000352,,,,,,,dietary supplementation,,Elevated hepatic transaminases,"On this regimen, one patient had the enlevated liver enxymes stabilized while the other had mild improvement.",HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
793,,,,,,,,,CoCarbs + HPro,NA,ECO:0000352,,,,,,,dietary supplementation,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
794,,# 613027,GLYCOGEN STORAGE DISEASE IXc; GSD9C,,PHKG2,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",P15735,,Uncooked cornstarch+ Beneprotein,,ECO:0000352,,,,,,,dietary supplementation,,Elevated hepatic transaminases,Patient transaminases  slowly decreased with time in https://www.ncbi.nlm.nih.gov/pubmed/12930917,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/12930917,,,,,,,,,
795,,,,,,,,,,,,,,,,,,,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/12930917,,,,,,,,,,
796,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
797,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
798,87,# 240600,"Glycogen storage disease type 0, liver ","GS deficiency has a good long term prognosis: it is usually associated with a normal intellectual outcome, symptoms can be prevented if the condition is recognized and treated by avoidance of prolonged fasting and tolerance to fasting improves with age. https://www.ncbi.nlm.nih.gov/pubmed/12794686
Patients are treated with a diet high in protein with complex, low glycemic index carbohydrates. Since gluconeogenesis is intact, protein supplementation provides gluconeogenic precursors that can be used for endogenous glucose production. In turn, there is also less dependence upon fatty acid oxidation, and accumulation of free fatty acids and ketones is prevented. This not only reduces systemic acidosis, but prevention of hyperketonemia also enhances gluconeogenesis since more alanine can be released from skeletal muscle. https://www.ncbi.nlm.nih.gov/pubmed/106027
Simple carbohydrates should be limited since they can increase blood lactate concentrations. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",GYS2,glycogen synthase 2,2.4.1.11,,Glycosade,NA,ECO:0007121,,,,,Functional interaction (B),B,dietary supplementation,,Nocturnal Hypoglycemia(Hypoglycemia)*,,HP:0001943*,https://clinicaltrials.gov/ct2/show/NCT02054832?cond=Glycogen+Storage+Disease+Type+0&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/29223626,,,,,,,,,
799,,,,,,,,,,,,,,,,,,,,Poor sleep quality(Sleep disturbance)*,,HP:0002360*,https://www.ncbi.nlm.nih.gov/pubmed/29223626,,,,,,,,,,
800,,,,,,,,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",Cornstarch,DB11599,ECO:0000352,,,,,Functional interaction (B),B,dietary supplementation,,MorningHypoglycemia (Hypoglycemia)*,,HP:0012051,https://www.ncbi.nlm.nih.gov/pubmed/12794686,,,,,,,,,,
801,,,,,,,,,,,,,,,,,,,,Ketosis,,HP:0001946,,,,,,,,,,,
802,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
803,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
804,88,#611881,Glycogen storage disease type 12 ,,ALDOA,"aldolase, fructose-bisphosphate A",4.1.2.13,,No treatment is available in DDIEM,,,,,,,,,,,,,done,https://link.springer.com/article/10.1007%2Fs11940-017-0473-2,,,,,,,,,,
805,89,#612932,Glycogen storage disease type 13 ,,ENO3,enolase 3,4.2.1.11,,No treatment is available in DDIEM,,,,,,,,,,,,,done,https://link.springer.com/article/10.1007%2Fs11940-017-0473-2,,,,,,,,,,
806,90,# 232200,Glycogen storage disease type 1A ,,G6PC,Glucose 6-phophatase,3.1.3.9,,DTX401,NA,ECO:0007121,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,,"The study is still recruting. The primary objective of the study is to determine the safety of single doses of DTX401, including the incidence of dose-limiting toxicities (DLTs) at each dose level. ",,done,https://clinicaltrials.gov/ct2/show/NCT03517085?cond=von+Gierke&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/20163245,,,,,,,,,
807,,,,,,,,,FIV-hAAT-G6Pase,NA,ECO:0005542,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,,Hypoglycemia,,done,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916/,,,,,,,,,,
808,,,,,,,,,Ad-mG6Pase,NA,ECO:0005542,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,,Growth retardation,,,https://www.ncbi.nlm.nih.gov/pubmed/10625614,,,,,,,,,,
809,,,,,,,,,,,,,,,,,,,,Hypoglycemia,,,https://www.ncbi.nlm.nih.gov/pubmed/10625614,,,,,,,,,,
810,,,,,,,,,,,,,,,,,,,,Hyperuricemia,,,https://www.ncbi.nlm.nih.gov/pubmed/10625614,,,,,,,,,,
811,,,,,,,,,,,,,,,,,,,,Hyperlipidemia,,,https://www.ncbi.nlm.nih.gov/pubmed/10625614,,,,,,,,,,
812,,,,,,,,,,,,,,,,,,,,Enlarged kidney,,HP:0000105,https://www.ncbi.nlm.nih.gov/pubmed/10625614,,,,,,,,,,
813,,,,,,,,,,,,,,,,,,,,Hepatomegaly,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/10625614,,,,,,,,,,
814,,,,,,,,,AAV-cG6PGH,NA,ECO:0005542,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,,Growth Failure,,,https://www.ncbi.nlm.nih.gov/pubmed/16672983,,,,,,,,,,
815,,,,,,,,,,,,,,,,,,,,Hyperlipidemia,,,https://www.ncbi.nlm.nih.gov/pubmed/16672983,https://www.ncbi.nlm.nih.gov/pubmed/17430128,,,,,,,,,
816,,,,,,,,,,,,,,,,,,,,Hypoglycemia,,,https://www.ncbi.nlm.nih.gov/pubmed/16672983,https://www.ncbi.nlm.nih.gov/pubmed/17430128,,,,,,,,,
817,,,,,,,,"Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292",HDAd-G6Pase,NA,ECO:0005542,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,,Hypoglycemia,,,https://www.ncbi.nlm.nih.gov/pubmed/17505475,,,,,,,,,,
818,,,,,,,,,Glycosade,NA,ECO:0007121,,,,,Functional interaction (B),B,dietary supplementation,,Fasting hypoglycemia,,HP:0003162,https://clinicaltrials.gov/ct2/show/NCT02054832?cond=von+Gierke&rank=6,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432,,,,,,,
819,,,,,,,,,,,,,,,,,,,,Sleep disturbance/Poor sleep quality,The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862,HP:0002360,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,,,,,,,,,
820,,,,,,,,,,,,,,,,,,,,Low quality of life(Constitutional symptoms)*,,HP:0025142*,,,,,,,,,,,
821,,,,,,,,,l-carnitine,DB00583,ECO:0007764,,,,,Symptomatic (C),C,symptomatic treatment procedure,,mitochondrial dysfunction,,HP:0003287,http://www.ncbi.nlm.nih.gov/pubmed/28317891?dopt=Abstract,https://www.nature.com/articles/srep44408,,,,,,,,,
822,,,,,,,,,Tempol,DB12449,ECO:0005242,,,,,Symptomatic (C),,symptomatic treatment procedure,,Abnormal renal function,,HP:0012211,https://www.ncbi.nlm.nih.gov/pubmed/20195241,,,,,,,,,,
823,,,,,,,,,,,,,,,,,,,,Renal disease progression( Progressive disorder)*,,HP:0003676*,https://www.ncbi.nlm.nih.gov/pubmed/20195241,,,,,,,,,,
824,,,,,,,,,,,,,,,,,,,,Nephropathy,,HP:0000112,https://www.ncbi.nlm.nih.gov/pubmed/20195241,,,,,,,,,,
825,,,,,,,,,ACE‐inhibitors,C09C,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Glomerular hyperfilteration (Abnormal glomerular filtration rate),,HP:0012212,https://www.ncbi.nlm.nih.gov/pubmed/15963056,https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580,,,,,,,,,
826,,,,,,,,,Antioxidant + ACE inhibitors ,DB12449+C09C,ECO:0007764,,,,,Symptomatic (C),,symptomatic treatment procedure,,Nephropathy,,HP:0000112,,,,,,,,,,,
827,,,,,,,,,Glucose,DB01914,ECO:0000352,,,,,Functional interaction (B),B,metabolite replacement,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/26835382,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916/,,,,,,,,,
828,,,,,,,,,Uncooked cornstarch,DB11599+NA,ECO:0000352,,,,,Functional interaction (B),,dietary supplementation,,Hypoglycemia,,HP:0001943,https://www.researchgate.net/publication/307584174_Glycogen_storage_diseases_Diagnosis_treatment_and_outcome,https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580,https://www.ncbi.nlm.nih.gov/pubmed/20975743/,,,,,,,,
829,,,,,,,,,Allopurinol,DB00437,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,High plasma uric acid levels,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/26835382,,,,,,,,,,
830,,,,,,,,Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.,Calcium+ vitamin D3,DB01373+DB00169,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Osteoporosis,Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.,HP:0000939,https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580,,,,,,,,,,
831,,,,,,,,,medium chain triglycerides,DB13959,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Hyperuricemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/20357432,,,,,,,,,,
832,,,,,,,,,,,,,,,,,,,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/20357432,,,,,,,,,,
833,,,,,,,,,,,,,,,,,,,,Growth failure,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/20357432,,,,,,,,,,
834,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
835,91,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,Long-term use of GCSF is associated with complications such as hypersplenism and malignancy. https://www.ncbi.nlm.nih.gov/pubmed/26835382,Human granulocyte-colony-stimulating-factor,DB00099,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Neutropenia,,HP:0001875,https://www.ncbi.nlm.nih.gov/pubmed/26835382,https://www.ncbi.nlm.nih.gov/pubmed/25288127,https://www.ncbi.nlm.nih.gov/pubmed/8447561,https://www.ncbi.nlm.nih.gov/pubmed/19066956,,,,,,,
836,,,,,,,,,,,,,,,,,,,,Recurrent bacterial infection,,HP:0002718,https://www.ncbi.nlm.nih.gov/pubmed/1709246,https://www.ncbi.nlm.nih.gov/pubmed/1719175,,,,,,,,,
837,,,,,,,,,,,,,,,,,,,,"Frequent, severe infections",,HP:0002719,https://www.ncbi.nlm.nih.gov/pubmed/1709246,https://www.ncbi.nlm.nih.gov/pubmed/1719175,,,,,,,,,
838,,,,,,,,"Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585",G‐CSF + 5‐aminosalicylic acid ,DB00099+DB00244,ECO:0000352,,,,,,,symptomatic treatment procedure,,Neutropenia with IBD,,HP:0001875+HP:0002037,https://www.ncbi.nlm.nih.gov/pubmed/12373585,https://www.ncbi.nlm.nih.gov/pubmed/25288127,https://www.ncbi.nlm.nih.gov/pubmed/19541498,,,,,,,,
839,,,,,,,,,Adalimumab,DB00051,ECO:0000352,,,,,,,symptomatic treatment procedure,,GSD-associated enterocolitis(enterocolitis),,HP:0004387,https://www.ncbi.nlm.nih.gov/pubmed/18172743,,,,,,,,,,
840,,,,,,,,,Glycosade,NA,ECO:0007121,,,,,Functional interaction (B),B,dietary supplementation,,Fasting hypoglycemia,,HP:0003162,https://clinicaltrials.gov/ct2/show/NCT02054832?cond=von+Gierke&rank=6,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432,,,,,,,
841,,,,,,,,,,,,,,,,,,,,Sleep disturbance/Poor sleep qaulity,The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862,HP:0002360,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,,,,,,,,,
842,,,,,,,,,,,,,,,,,,,,Low quality of life(Constitutional symptoms)*,,HP:0025142*,,,,,,,,,,,
843,,,,,,,,,rAAV-GPE-G6PT ,NA,ECO:0007121,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,,hyperlipidemia,,HP:0003077,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,,,,,,,,,,
844,,,,,,,,,,,,,,,,,,,,hypoglycemia,,HP:0001943,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,,,,,,,,,,
845,,,,,,,,,,,,,,,,,,,,hyperuricemia,,HP:0002149,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,,,,,,,,,,
846,,,,,,,,,,,,,,,,,,,,lactic acidemia,,HP:0003128,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,,,,,,,,,,
847,,,,,,,,,,,,,,,,,,,,age-related insulin resistance(Insulin resistance)*,,HP:0000855*,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,,,,,,,,,,
848,,,,,,,,,,,,,,,,,,,,obesity,,HP:0001513,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,,,,,,,,,,
849,,,,,,,,"To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.",galactose+Uridine,DB11735+DB02745,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Partial correction of neutrophil dysfunction,"In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract",HP:0011990,http://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract,,,,,,,,,,
850,,,,,,,,,vitamin E,DB00163,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,neutropenia,,HP:0001875,https://www.ncbi.nlm.nih.gov/pubmed/19066956,,,,,,,,,,
851,,,,,,,,,,,,,,,,,,,,"Frequent, severe infections",,HP:0002719,https://www.ncbi.nlm.nih.gov/pubmed/19066956,,,,,,,,,,
852,,,,,,,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.",testosterone,DB00624,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,decreased male libido,,HP:0040306,https://www.ncbi.nlm.nih.gov/pubmed/28160246,,,,,,,,,,
853,,,,,,,,,,,,,,,,,,,,low physical activity,,HP:0025142,,,,,,,,,,,
854,,,,,,,,,,,,,,,,,,,,decrease muscle strenght,,HP:0001324,,,,,,,,,,,
855,,,,,,,,,medium chain triglycerides,DB13959,ECO:0000352,,,,,Functional interaction (B),B,dietary supplementation,,Hyperurecemia,,done,https://www.ncbi.nlm.nih.gov/pubmed/20357432,,,,,,,,,,
856,,,,,,,,,,,,,,,,,,,,Hypertriglyceridemia,,,,,,,,,,,,,
857,,,,,,,,,,,,,,,,,,,,Growth failure,,,,,,,,,,,,,
858,92,# 232400,Glycogen storage disease type 3,Managment guidelines for treating GSD3 can be accessed through https://www.ncbi.nlm.nih.gov/pubmed/20631546,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,Cornstarch ,DB11599,ECO:0000352,,,,,Symptomatic (C),C,dietary supplementation,,linear growth velocity(Abnormality of body height)*,,HP:0000002*,https://www.nature.com/articles/gim201069,https://www.ncbi.nlm.nih.gov/pubmed/20631546,https://www.ncbi.nlm.nih.gov/pubmed/25153581,https://www.ncbi.nlm.nih.gov/pubmed/24613482,,,,,,,
859,,,,,,,,,,,,,,,,,,,,hypoglycemic seizures,,HP:0002173,,,,,,,,,,,
860,,,,,,,,,,,,,,,,,,,,Enlarged size of the liver,,HP:0002240,,,,,,,,,,,
861,,,,,,,,,calcium and vitamin D,DB01373 + DB11094,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Osteoporosis,,HP:0000939,,,,,,,,,,,
862,,,,,,,,,Glycosade,NA,ECO:0007121,,,,,Functional interaction (B),B,dietary supplementation,,Fasting hypoglycemia,,HP:0003162,https://clinicaltrials.gov/ct2/show/NCT02054832?cond=von+Gierke&rank=6,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/17514432,,,,,,,,
863,,,,,,,,,,,,,,,,,,,,Sleep disturbance,,HP:0002360,https://www.ncbi.nlm.nih.gov/pubmed/29223626,,,,,,,,,,
864,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,Rapamycin,DB00877 ,ECO:0005542,,,,,functional complementation of a defective protein by inhibition,B,functional complementation of a defective protein by inhibition,Drug name:   Study was done in a canine model.,high glycogen levels in muscles,,HP:0009051,https://www.ncbi.nlm.nih.gov/pubmed/24509886,,,,,,,,,,
865,,,,,,,,,,,,,,,,,,,,liver fibrosis progression,,HP:0001395,https://www.ncbi.nlm.nih.gov/pubmed/24509886,,,,,,,,,,
866,,,,,,,,,fructose,DB04173,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,exercise intolerance,,HP:0003546,https://www.ncbi.nlm.nih.gov/pubmed/25832663,,,,,,,,,,
867,,,,,,,,,high protein diet,NA,,,,,,Symptomatic (C),C,dietary regime modification,Drug name: A dietary tretament,delayed growth,,HP:0001510,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/8245377,,,,,,,,,
868,,,,,,,,,,,,,,,,,,,,myopathy,,HP:0003198,,,,,,,,,,,
869,,,,,,,,,,,,,,,,,,,,cardiomyopathy,,HP:0001638,,,,,,,,,,,
870,,,,,,,,,Modified Atkins diet,NA,ECO:0000352,,,,,Symptomatic (C),C,dietary regime modification,Drug name: A dietary tretament,abnormal blood levels of ketone bodies,,HP:0001939,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/20631546/,,,,,,,,,
871,,,,,,,,,,,,,,,,,,,,Abnormal blood levels of  fatty acids,,HP:0004359,,,,,,,,,,,
872,,,,,,,,,,,,,,,,,,,,high creatine kinase,,HP:0003236,,,,,,,,,,,
873,,,,,,,,,,,,,,,,,,,,cardiomyopathy,,HP:0001638,,,,,,,,,,,
874,,,,,,,,,,,,,,,,,,,,low energetic state of heart(Abnormality of cardiovascular system physiology)*,,HP:0011025*,,,,,,,,,,,
875,,,,,,,,,,,,,,,,,,,,low energetic state of skeletal muscle,,HP:0011804,,,,,,,,,,,
876,,,,,,,,,,,,,,,,,,,,Increased creatine kinase activity,,HP:0003236,,,,,,,,,,,
877,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
878,93,# 232600,Glycogen storage disease type 5 ,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,,Sodium Valproate,DB00313,ECO:0007121/ECO:0001565,,,,,Functional interaction (Mechanistic B),B,functional complementation of a defective protein by stimulation,Drug name:,Difficulty walking,,HP:0002355,,https://clinicaltrials.gov/ct2/show/NCT03112889?cond=McArdle+Disease&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/25455802?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/25762569,,,,,,,
879,,,,,,,,,Triheptanoin,DB11677,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,abnormal fat metabolism,,HP:0004359,https://link.springer.com/article/10.1007%2Fs11940-017-0473-2,https://clinicaltrials.gov/ct2/show/NCT02432768?cond=Glycogen+Storage+Disease+Type+V&rank=1,,,,,,,,,
880,,,,,,,,,,,,,,,,,,,,abnormal carbohydrate metabolism*,,HP:0011013,,,,,,,,,,,
881,,,,,,,,,creatine,DB00148,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,exercise intolerance,,HP:0003546,https://www.ncbi.nlm.nih.gov/pubmed/25391139,http://www.ncbi.nlm.nih.gov/pubmed/28932990?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/17490880,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://link.springer.com/content/pdf/10.1016%2Fj.nurt.2008.08.006.pdf,,,,,,
882,,,,,,,,,sucrose,DB02772,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,exercise intolerance,,HP:0003547,http://www.ncbi.nlm.nih.gov/pubmed/28932990?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/25391139,https://www.ncbi.nlm.nih.gov/pubmed/17490880,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,,,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract,,,
883,,,,,,,,,vitamin B6,DB00165 ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,insufficient anaerobic glycolysis of skeletal muscle,,,https://www.ncbi.nlm.nih.gov/pubmed/22334182,https://www.ncbi.nlm.nih.gov/pubmed/17490880,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://www.ncbi.nlm.nih.gov/pubmed/19019309,,,,,,,
884,,,,,,,,,,,,,,,,,,,,exercise intolerance,,HP:0003546,,,,,,,,,,,
885,,,,,,,,,,,,,,,,,,,,abnormal muscle phosphorylase activity,,NA,,,,,,,,,,,
886,,,,,,,,,ramipril ,DB00178,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,disability(Functional motor problems)*,,HP:0004302*,https://www.ncbi.nlm.nih.gov/pubmed/18098237,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,,,,,,,,
887,,,,,,,,,,,,,,,,,,,,Abnormal exercise physiology,,HP:0009020,,,,,,,,,,,
888,,,,,,,,,GENTAMICIN ,DB04729,ECO:0000352,,,,,Symptomatic (C),C,activity modification of a genetically defective protein,Drug name: ineffective/ further study is needed,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pubmed/16434679?dopt=Abstract,,,,,,,,
889,94,# 232700,Glycogen storage disease type 6 ,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,Cornstarch(Uncooked),DB11599,ECO:0000352,,,,,Functional interaction (B),B,dietary supplementation,"Drug name: Uncooked cornstarch administartion can result in avoidance of ketosis, hypoglycemia and hepatomegaly. https://www.ncbi.nlm.nih.gov/pubmed/20301760",short stature,,HP:0004322,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,
890,,,,,,,,,,,,,,,,,,,,Abnormal blood glucose concentration,,HP:0011015,https://www.ncbi.nlm.nih.gov/pubmed/20301760,,,,,,,,,,
891,,,,,,,,,,,,,,,,,,,,Low energy level(Tiredness)*,,HP:0012378,https://www.ncbi.nlm.nih.gov/pubmed/20301760,,,,,,,,,,
892,,,,,,,,,,,,,,,,,,,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
893,,,,,,,,,,,,,,,,,,,,Elevated Hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
894,,,,,,,,,Beneprotein,NA,ECO:0000352,,,,,Functional interaction (B),B,dietary supplementation,,short stature,,HP:0004322,,,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,
895,,,,,,,,,Uncooked cornstarch+Beneprotein,DB11599+NA,ECO:0000352,,,,,Functional interaction (B),,dietary supplementation,,Elevated Hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
896,,,,,,,,,D-Thyroxine,DB00509,ECO:0000352,,,,,Functional interaction (B),,functional complementation of a genetically defective protein,,Hepatomeglay,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/3483883,https://www.nature.com/articles/pr19842087,,,,,,,,,
897,,,,,,,,,,,,,,,,,,,,Elevated Hepatic transaminases,,HP:0002910,,,,,,,,,,,
898,,,,,,,,,,,,,,,,,,,,Failure to thrive,,HP:0001508,,,,,,,,,,,
899,,,,,,,,,,,,,,,,,,,,Increased erythrocyte glycogen content,,HP:0001939,,,,,,,,,,,
900,,,,,,,,,,,,,,,,,,,,Hypertriglyceridemia,,HP:0002155,,,,,,,,,,,
901,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
902,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
903,95,# 232800,Glycogen storage disease type 7 ,"The infantile form of PFK deficiency is characterized by the early onset of muscle weakness and multisystem involvement, which often leads to death in infancy or early childhood. Early diagnosis and improved understanding would enable clinicians to provide better clinical care. https://www.ncbi.nlm.nih.gov/pubmed/26108272",PFKM,"ATP-dependent 6-phosphofructokinase, muscle type",2.7.1.11,"A clinical trail studying the effect of Triheptanoin on excersise intolerance and fat metabolism, is currently under process. https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&rank=1",Triheptanoin,DB11677,ECO:0007121,,,,,,,symptomatic treatment procedure,,Trial is still in the Recruiting stage. ,,,https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&rank=1,,,,,,,,,,
904,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
905,96,# 606664,Glycine N-methyltransferase deficiency ,"Treatment recommendations could be regular monitoring and low-methionine diet if symptoms appear or if methionine is very high. https://www.ncbi.nlm.nih.gov/pubmed/27207470.                                                                                                                                                                                                                                                                                            The necessity for treatment of this asymptomatic seemingly benign disorder is presently questionable, careful follow-up being the main parameter for optimal care. https://www.ncbi.nlm.nih.gov/pubmed/27671891. No treatment needed in most cases.",GNMT ,glycine N-methyltransferase,2.1.1.20,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,Nicotinamide,DB02701 ,ECO:0005542,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,"Disease name: Treatment recommendations could be regular monitoring and low-methionine diet if symptoms appear or if methionine is very high.

https://www.ncbi.nlm.nih.gov/pubmed/27207470.                                                                                                                                                                                                                                                                                            The necessity for treatment of this asymptomatic seemingly benign disorder is presently questionable, careful follow-up being the main parameter for optimal care. https://www.ncbi.nlm.nih.gov/pubmed/27671891. No treatment needed in most cases.  Drug name: An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/",Liver steatosis,,HP:0001397,https://www.ncbi.nlm.nih.gov/pubmed/20578266/,https://www.ncbi.nlm.nih.gov/pubmed/27207470,https://www.ncbi.nlm.nih.gov/pubmed/19585268,,,,,,,,
906,,,,,,,,,,,,,,,,,,,,Fatty liver,,HP:0001397,,,,,,,,,,,
907,,,,,,,,,,,,,,,,,,,,Liver fibrosis,,HP:0001395,,,,,,,,,,,
908,,,,,,,,,,,,,,,,,,,,DNA hypermethylation,,NA,,,,,,,,,,,
909,96,# 231950,Glutathionuria ,,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,3.4.19.13/2.3.2.2,,OTZ (L-2-oxothiazoline-4-carboxylic acid,NA,ECO:0005542,,,,,Functional interaction (B),B,metabolite replacement,Disease name : In 2007 Ristoff et al.   mentioned in their paper  that there is no treatment that has been recommended. https://www.ncbi.nlm.nih.gov/pubmed/17397529?dopt=Abstract. Drug name: These drugs have been tested on mice. ,low intracellular cysteine*,,HP:0010918,,,http://www.ncbi.nlm.nih.gov/pubmed/12757858?dopt=Abstract,,,,,,,,
910,,,,,,,,,,,,,,,,,,,,behavioral abnormalities ,,HP:0000708,,,,,,,,,,,
911,,,,,,,,,,,,,,,,,,,,GSH deficiency,,HP:0003343,,,,,,,,,,,
912,,,,,,,,,N-acetylcysteine,DB06151,ECO:0005542,,,,,Functional interaction (B),B,metabolite replacement,Drug name: These drugs have been tested on mice.,Delayed growth,,HP:0001510,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC38850/,,https://www.ncbi.nlm.nih.gov/pubmed/20868666,,,,,,,,
913,,,,,,,,,,,,,,,,,,,,Cataract,,HP:0000518,https://www.ncbi.nlm.nih.gov/pubmed/11095909,,,,,,,,,,
914,,,,,,,,,,,,,,,,,,,,low reproductive capacity (infertility),,HP:0000144,https://www.ncbi.nlm.nih.gov/pubmed/11089562,,,,,,,,,,
915,97,# 266130,Glutathione synthetase deficiency ,,GSS,glutathione synthetase,6.3.2.3,,ascorbic acid,DB00126,ECO:0000352,,,,,Symptomatic (C),C,functional complementation of a genetically defective protein,,oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/8301428/,,https://www.ncbi.nlm.nih.gov/pubmed/17397529,,,,,,,,
916,,,,,,,,,Ascorbate + N-acetylcysteine,DB00126+DB06151 ,ECO:0000352,,,,,,,functional complementation of a genetically defective protein,,High erythrocyte turnover(Abnormality of erythrocytes)*,,HP:0001877*,https://www.ncbi.nlm.nih.gov/pubmed/8301428/,,,,,,,,,,
917,,,,,,,,,Polycitra (citric acid +potassium citrate + sodium citrate)+vitamin C+vitamin E+selenium,DB11135,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,oxidative stress,,HP:0025464,http://www.ncbi.nlm.nih.gov/pubmed/26984560?dopt=Abstract,,,,,,,,,,
918,,,,,,,,,alpha-tocopherol,DB00163,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,abnormal microtubule assembly ,,NA,https://www.ncbi.nlm.nih.gov/pubmed/29340523,https://www.ncbi.nlm.nih.gov/pubmed/7375069,,,,,,,,,
919,,,,,,,,,,,,,,,,,,,,Short erythrocyte survival (Abnormality of erythrocytes)*,,HP:0001877*,https://www.ncbi.nlm.nih.gov/pubmed/29340523,,,,,,,,,,
920,,,,,,,,,,,,,,,,,,,,abnormal polymorphonuclear leukocyte function,,HP:0001874,,,,,,,,,,,
921,,,,,,,,,,,,,,,,,,,,Neutropenia,,HP:0001875,,,,,,,,,,,
922,,,,,,,,,,,,,,,,,,,,Susceptibility to Bacterial infection,,HP:0002718,,,,,,,,,,,
923,,,,,,,,,,,,,,,,,,,,retinal dystrophy,,HP:0000556,https://www.ncbi.nlm.nih.gov/pubmed/17206463?dopt=Abstract,,,,,,,,,,
924,,,,,,,,,,,,,,,,,,,,CNS damage progression,,HP:0007367,,,,,,,,,,,
925,,,,,,,,,L-carnitine+vitamin E+vitamin B1+ cobalamin,DB00583+DB00163+DB00152+DB14098+DB01390,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Hypersomnia,,HP:0100786,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
926,,,,,,,,,,,,,,,,,,,,Jaundice,,HP:0000952,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
927,,,,,,,,,,,,,,,,,,,,Carnitine deficiency,,HP:0003234,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
928,,,,,,,,,,,,,,,,,,,,Hypotonia,,HP:0001290,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
929,,,,,,,,,L-carnitine+vitamin B1+B2+ B12+ C+E + sodium bicarbonate,DB00583+DB00163+DB00152+DB00140 +DB01390+DB00126+DB00115,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
930,,,,,,,,,,,,,,,,,,,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
931,,,,,,,,,,,,,,,,,,,,Elevated urine 5-oxoproline,,NA,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
932,,,,,,,,,,,,,,,,,,,,Decreased blood free carnitine,,HP:0008315,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
933,,,,,,,,,L-carnitine+ vitamin B1+B12+C + E,DB00583+DB00152+DB00115+DB00126+DB00163,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Elevated urine 5-oxoproline,,NA,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
934,,,,,,,,,,,,,,,,,,,,Decreased blood free carnitine,,HP:0008315,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
935,,,,,,,,,Sodium Bicarbonate,DB01390,ECO:0000352,,,,,,,symptomatic treatment procedure,,Metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/29340523,https://www.ncbi.nlm.nih.gov/pubmed/26669244/,,,,,,,,,
936,,,,,,,,,coenzyme Q10,DB09270,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,high-anion gap acidosis ,,HP:0001941*,http://www.ncbi.nlm.nih.gov/pubmed/26669244?dopt=Abstract,,,,,,,,,,
937,,,,,,,,,dorzolamide+acetazolamide,DB00869+DB00819,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,cystoid macular edema,,HP:0011505,https://www.ncbi.nlm.nih.gov/pubmed/29395598?dopt=Abstract,,,,,,,,,,
938,,,,,,,,,erythropoietin + iron+folic acid + vitamin B12,DB00016+DB01592+DB00158+DB00165,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,anaemia,,HP:0001903,http://www.ncbi.nlm.nih.gov/pubmed/16435214?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16435214,,,,,,,,,
939,98,# 231670,Glutaric acidemia type I ,"It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. https://www.ncbi.nlm.nih.gov/pubmed/21431622",GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",1.3.8.6,"This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918",Carnitine +anti-catabolic drugs(eg.Glutamine)+ Amino Acid supplements,DB00583+DB00130+DB09393,ECO:0000352,,,,,Symptomatic (C),C,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+dietary supplementation,,Brain damage,Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. The combination is suggested to given in presymptomatic patients to prevent brain damage.https://www.ncbi.nlm.nih.gov/pubmed/21431622,HP:0001298,https://www.ncbi.nlm.nih.gov/pubmed/23326493,,,,,,,,,,
940,,,,,,,,,,,,,,,,,,,,Cerebral palsy,"Early diagnosis can prevent the phenotype, Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. https://www.ncbi.nlm.nih.gov/pubmed/21431622. https://www.ncbi.nlm.nih.gov/pubmed/10630918",HP:0100021,https://www.ncbi.nlm.nih.gov/pubmed/10630918,,,,,,,,,,
941,,,,,,,,,,,,,,,,,,,,Secondary Carnitine deficiency( Carnitine deficiency)*,,HP:0003234*,,,,,,,,,,,
942,,,,,,,,,Carnitine+ Riboflavin+baclofen,DB00583+DB00130+DB00181,ECO:0000352,,,,,Symptomatic (C),C,functional complementation of a genetically defective protein+activity modification of a genetically defective protein+functional complementation of a genetically defective protein,,Disease progression,,HP:0003676,https://www.ncbi.nlm.nih.gov/pubmed/3335963,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,,,,,,,,,
943,,,,,,,,,,,,,,,,Symptomatic (C),C,,,Secondary Carnitine deficiency( Carnitine deficiency)*,,HP:0003234*,,,,https://www.ncbi.nlm.nih.gov/pubmed/16368216,,,,,,,
944,,,,,,,,,,,,,,,,,,,,Metabolic acidosis,,HP:0001942,,,,,,,,,,,
945,,,,,,,,,Carnitine+Thioridazine Hcl+Chloral hydrate+Baclofen,DB00583+DB00679+DB01563+DB00181,ECO:0000352,,,,,Symptomatic (C),,functional complementation of a genetically defective protein+symptomatic treatment procedure+symptomatic treatment procedure+functional complementation of a genetically defective protein,,Dystonia,The phenotype has been reported in association to treatment with baclofen as ,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/8881997,,,,,,,,,,
946,,,,,,,,,chlorpromazine,DB00477,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,hyperpyrexia in case of acute encephalopathic crises(Fever)*,,HP:0001945*,https://www.ncbi.nlm.nih.gov/pubmed/10222465,,,,,,,,,,
947,,,,,,,,The combination was accompanied by Low L-lysine diet,Carnitine+Riboflavin+L-Arginine+clofibrate,DB00583+DB00130+DB00125+DB00636,ECO:0005542,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein+activity modification of a genetically defective protein+functional complementation of a genetically defective protein+symptomatic treatment procedure,,Glutaric acidemia,Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787 ,HP:0003530,https://www.ncbi.nlm.nih.gov/pubmed/20923787,,,,,,,,,,
948,99,# 231680,Glutaric acidemia type II ,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",,Synergism inmproves results,Carnitine+ riboflavin,DB00583+DB00140,ECO:0000352,,,,,Functional interaction (B)+Direct Interaction (A),B,functional complementation of a genetically defective protein+activity modification of a genetically defective protein,,High serum creatine kinase,,HP:0003236,https://www.ncbi.nlm.nih.gov/pubmed/10723193,https://www.ncbi.nlm.nih.gov/pubmed/19249206,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,,,,,,,,
949,,,,,,,,,,,,,,,,,,,synergism inmproves results,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/10723193,,,,,,,,,,
950,,,,,,,,,,,,,,,,,,,,Secondary Carnitine deficiency( Carnitine deficiency)*,,HP:0003234,https://www.ncbi.nlm.nih.gov/pubmed/10723193,,,,,,,,,,
951,,,,,,,,,Carnitine+ riboflavin+Coenzyme Q,DB00583+DB00140+DB09270,ECO:0000352,,,,,Functional interaction (B)+Direct Interaction (A)+symptomatic,A,functional complementation of a genetically defective protein+activity modification of a genetically defective protein+functional complementation of a genetically defective protein,,Dysphagia,,HP:0002015,https://www.ncbi.nlm.nih.gov/pubmed/26236614,,,,,,,,,,
952,,,,,,,,,,,,,,,,,,,,Difficulty walking,,HP:0002355,,,,,,,,,,,
953,,,,,,,,,,,,,,,,,,,,Secondary Carnitine deficiency( Carnitine deficiency)*,,HP:0003234,https://www.ncbi.nlm.nih.gov/pubmed/10723193,,,,,,,,,,
954,,,,,,,,,Glycine+Riboflavin+Carnitine,DB00145+DB00140+DB00583,ECO:0000352,,,,,Symptomatic (C)+Direct Interaction (A)+Functional interaction (B),C,functional complementation of a genetically defective protein+activity modification of a genetically defective protein+functional complementation of a genetically defective protein,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/3229565,,,,,,,,,,
955,,,,,,,,,"sodium-d,l-3-hydroxybutyrate ",CHEBI:113373,ECO:0000352,,,,,Symptomatic (C),C,functional complementation of a genetically defective protein,,progressive leukodystrophy,,HP:0002415,https://www.ncbi.nlm.nih.gov/pubmed/12727399,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,,,,,,,,,
956,,,,,,,,,,,,,,,,,,,,paralysis,,HP:0003470,https://www.ncbi.nlm.nih.gov/pubmed/12727399,,,,,,,,,,
957,,,,,,,,,,,,,,,,,,,,cardiomyopathy ,,HP:0001638,https://www.ncbi.nlm.nih.gov/pubmed/12727399,,,,,,,,,,
958,,,,,,,,,,,,,,,,,,,,Impaired myocardial contractility,,HP:0006670,https://www.ncbi.nlm.nih.gov/pubmed/12727399,,,,,,,,,,
959,,,,,,,,,Riboflavin,DB00140,ECO:0000352,,,,,Direct Interaction (activity modification)*,,activity modification of a genetically defective protein,,,,,https://www.ncbi.nlm.nih.gov/pubmed/10581232,,,,,,,,,,
960,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
961,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
962,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
963,100,# 231690,Glutaric acidemia type III ,,SUGCT,succinate-hydroxymethylglutarate coA-transferase,2.8.3.13,,Metronidazole,DB00140,ECO:00007121,,,,,Functional intercation (Mechanistic B),C,functional complementation of a genetically defective protein,,Cyclic vomiting (Vomiting)*,,HP:0002013,https://www.ncbi.nlm.nih.gov/pubmed/28766179,,,,,,,,,,
964,,,,,,,,,,,,,,,,,,,,Bacterial glutric acid production,,NA,,,,,,,,,,,
965,101,# 266130,Glutathione synthetase deficiency ,,GLUL,Glutamine synthetase,6.3.1.2,,l-glutamine,DB00130,ECO:0007121,,,,,Functional intercation (Mechanistic B),B,metabolite replacement,,Abnormal plasma glutamine levels,,HP:0010903,https://www.ncbi.nlm.nih.gov/pubmed/22830360,,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/22830360,,,,,,,
966,,,,,,,,,,,,,,,,,,,,Low CSF glutamine level,,HP:0030980*,,,,,,,,,,,
967,,,,,,,,,,,,,,,,,,,,unalertness,,HP:0002329,,,,,,,,,,,
968,,,,,,,,,,,,,,,,,,,,Lack of emotional expressions,,HP:0030213,,,,,,,,,,,
969,,,,,,,,,,,,,,,,,,,,Abnormal EEG results,,HP:0002353,,,,,,,,,,,
970,,,,,,,,,,,,,,,,,,,,Low brain glutamine concentration,,HP:0030980,,,,,,,,,,,
971,,,,,,,,,,,,,,,,Symptomatic (C),,,,Secondary NAD+ deficiency in leucocytes,,NA,https://www.ncbi.nlm.nih.gov/pubmed/22830360,https://www.ncbi.nlm.nih.gov/pubmed/25896882/,,,,,,,,,
972,,,,,,,,,Nicotinamide ,DB02701,ECO:0001565,,,,,Symptomatic (C),C,functional complementation of a genetically defective protein,,Secondary NAD+ deficiency in leucocytes,,NA,https://www.ncbi.nlm.nih.gov/pubmed/25896882/,,,,,,,,,,
973,,,,,,,,,Vitamin C+Vitamin E+Selenium,DB00126+DB00163+DB11135,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/26984560,,,,,,,,,,
974,,,,,,,,,Citric acid+Sodium citrate+ Potassium citrate,DB04272+DB09154+DB09125,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/26984560,,,,,,,,,,
975,102,# 229100,Glutamate formiminotransferase deficiency ,The majority of individuals with FTCD deficiency detected by newborn screening are asymptomatic. https://www.ncbi.nlm.nih.gov/pubmed/30740726,FTCD,formiminotransferase cyclodeaminase,,,pyridoxine +folic acid,DB00165+DB00158,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein+metabolite replacement,,Megaloblastic anemia,,HP:0001889,https://www.ncbi.nlm.nih.gov/pubmed/5301410,,,,,,,,,,
976,103,# 606824,Glucose-galactose malabsorption ,Treatment rests with the avoidance of Glucse and galactose dietary sugars.https://www.ncbi.nlm.nih.gov/pubmed/28283348.  https://www.ncbi.nlm.nih.gov/pubmed/28753187,SLC5A1,sodium/glucose cotransporter protein called SGLT1,,The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940,Fructose +Carbohydrate free formula,DB04173+NA,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Watery Diarrhea,,HP:0002014,https://www.ncbi.nlm.nih.gov/pubmed/10404446,https://www.ncbi.nlm.nih.gov/pubmed/20486940,,https://www.ncbi.nlm.nih.gov/pubmed/28283348,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808885/,,,,,,
977,,,,,,,,,,,,,,,,,,,,Dehydration,,HP:0001944,,,,,,,,,,,
978,104,# 606777,Glucose transporter type 1 deficiency syndrome ,"The currently established or investigated precision medicine treatments include the ketogenic diet in patients with GLUT1 deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27781560/ https://www.ncbi.nlm.nih.gov/pubmed/22812641/ https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract
Clinical exacerbation in Glut 1 DS could happen with certain AEDs based on their mechanism of action or effects on the Glut 1 transporter. Common AEDs known to inhibit the Glut 1 transporter in vitro, for example, 1) phenobarbital https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract , 2) Valporate https://www.ncbi.nlm.nih.gov/pubmed/16149077?dopt=Abstract 3) Benzodiazepines https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract are relatively contraindicated in Glut 1 DS. https://www.ncbi.nlm.nih.gov/pubmed/22812641/
In addition, combination therapy of KD and carbonic anhydrase inhibitors—for example, topiramate, zonisamide, and acetazolamide—may increase risk of non–anion gap metabolic acidosis and urolithiasis, and should be avoided if possible https://www.ncbi.nlm.nih.gov/pubmed/20466520?dopt=Abstract ",SLC2A1,glucose transporter protein type 1 (GLUT1),,,UX007 (triheptanoin),DB11677,ECO:0007121/ECO:0005542,,,,,Symptomatic (C),C,symptomatic treatment procedure,,seizures,,HP:0001250,https://clinicaltrials.gov/ct2/show/NCT01993186?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=1,https://clinicaltrials.gov/ct2/show/NCT02960217?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=2,https://clinicaltrials.gov/ct2/show/NCT02036853?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=3,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/29303961,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,,,,
979,,,,,,,,,,,,,,,,,,,,EEG with focal spike waves,,HP:0011197,,,,,,,,,,,
980,,,,,,,,,,,,,,,,,,,,Nonepileptic paroxysmal abnormalities,,NA,,,,,,,,,,,
981,,,,,,,,,,,,,,,,,C,,,Seizures ,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/22812641/,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/22812641/,,,,,,,,
982,,,,,,,,,,,,,,,,,C,,,movement disorders,,HP:0100022,,,,,,,,,,,
983,,,,,,,,,,,,,,,,,,,,Dyskinesia,,HP:0100660,,,https://www.ncbi.nlm.nih.gov/pubmed/26982753,,,,,,,,
984,,,,,,,,,AAV-GLUT1,NA,ECO:0005542,,,,,Direct interaction (Mechanistic A) ,A,direct complementation of a genetically defective protein by gene therapy,, Abnormal CSF glucose levels ,,HP:0031884,,,https://www.ncbi.nlm.nih.gov/pubmed/29624790,,,,,,,,
985,,,,,,,,,,,,,,,,,,,,Abnormal motor function,,HP:0004302,,,,,,,,,,,
986,,,,,,,,,,,,,,,,,,,,Paroxysmal exertion-induced dyskinesia (Paroxysmal dyskinesia),,HP:0007166,,,,,,,,,,,
987,105,# 263800,Gitelman syndrome ,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,The use of the drug is limited by its long-term cardiovascular adverse effects. https://www.ncbi.nlm.nih.gov/pubmed/12141411,Rofecoxib,DB00533,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Refractory hypokalemia,,HP:0002900*,https://www.ncbi.nlm.nih.gov/pubmed/12141411,,,,https://www.sciencedirect.com/science/article/pii/S0085253816306020?via%3Dihub,,,,,,
988,,,,,,,,,,,,,,,,,,,,Abnormally reduced levels of aldosterone ,,HP:0004319,,,,,,,,,,,
989,,,,,,,,,,,,,,,,,,,,Abnormal serum renin level,,HP:0040084,,,,,,,,,,,
990,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
991,,,,,,,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083

",Indometacin/Amiloride/Eplerenone+Potassium,(DB00328/DB00594/DB00700)+DB00761,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Refractory hypokalemia,,HP:0002900*,https://www.ncbi.nlm.nih.gov/pubmed/25012174,,https://clinicaltrials.gov/ct2/show/NCT01146197?cond=Gitelman+syndrome&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/25012174,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,,,,
992,,,,,,,,,Indometacin,DB00328,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,developmental delay,,HP:0001263,https://www.ncbi.nlm.nih.gov/pubmed/25852896/,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,,,,,,,,
993,,,,,,,,,,,,,,,,,,,,high plasma RAAS activity,,HP:0000847*,,,,,,,,,,,
994,,,,,,,,,,,,,,,,Symptomatic (C),C,,,Abnormally reduced levels of aldosterone ,,HP:0004319,https://www.ncbi.nlm.nih.gov/pubmed/25012174,,,,,,,,,,
995,,,,,,,,,,,,,,,,Symptomatic (C),C,,,Abnormal serum renin level,,HP:0040084,https://www.ncbi.nlm.nih.gov/pubmed/25012174,,,,,,,,,,
996,,,,,,,,,Magnesium,DB14513,ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure,,hypomagnesemia,"In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications",HP:0002917,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128/,,,,,,,,,,
997,,,,,,,,,,,,,,,,,,,,chondrocalcinosis,,HP:0000934,,,,,,,,,,,
998,,,,,,,,,Potassium chloride,DB00761,ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure,,hypokalemia,,HP:0002900,,,,,,,,,,,
999,106,# 230800,Gaucher disease ,,GBA ,beta-glucocerebrosidase,3.2.1.45,,Taliglucerase alfa,DB08876,ECO:0007121,,,,,Direct interaction (Mechanistic A) ,A,direct complementation of a genetically defective protein,,Hepatomegaly,,HP:0002240,https://clinicaltrials.gov/ct2/show/results/NCT01422187?cond=Gaucher+disease&draw=3&rank=23&sect=X01256#all,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://www.ncbi.nlm.nih.gov/pubmed/29388611,https://www.ncbi.nlm.nih.gov/pubmed/27839981,,,,,,,
1000,,,,,,,,,,,,,,,,,,,,Splenomegaly,,HP:0001744,https://www.ncbi.nlm.nih.gov/pubmed/28131618,,,https://www.ncbi.nlm.nih.gov/pubmed/27102949,https://www.ncbi.nlm.nih.gov/pubmed/27499018,,,,,,
1001,,,,,,,,,,,,,,,,,,,,thrombocytopenia,,HP:0001873,,,,,,,,,,,
1002,,,,,,,,,,,,,,,,,,,,low mean hemoglobin concentration ,,HP:0025547,,,,,,,,,,,
1003,,,,,,,,,,,,,,,,,,,,low bone marrow fat fraction value,,NA,,,https://www.ncbi.nlm.nih.gov/pubmed/30066229,,,,,,,,
1004,,,,,,,,,Imiglucérase (ISU302),DB00053,ECO:0007121,,,,,Direct interaction (Mechanistic A) ,A,direct complementation of a genetically defective protein,,primary low heamoglobin level,,HP:0001903*,https://clinicaltrials.gov/ct2/show/results/NCT02770625?cond=Gaucher+disease&draw=3&rank=24&sect=X4301256#othr,,,,,,,,,,
1005,,,,,,,,,,,,,,,,,,,,thrombocytopenia,,HP:0001873,,,,,,,,,,,
1006,,,,,,,,,,,,,,,,,,,,splenomegaly,,HP:0001744,,,,,,,,,,,
1007,,,,,,,,,,,,,,,,,,,,Hepatomegaly,,HP:0002240,,,,,,,,,,,
1008,,,,,,,,,,,,,,,,,,,,high angiotensin- converting enzyme,,HP:0000841,,,,,,,,,,,
1009,,,,,,,,,,,,,,,,,,,,high  Chitotriosidase Level(Abnormality of lysosomal metabolism)*,,HP:0004356,,,,,,,,,,,
1010,,,,,,,,,,,,,,,,,,,,elevated Chemokine Ligand (CCL-18) Level [ng/mL],,NA,,,,,,,,,,,
1011,,,,,,,,,prGCD,DB06667,ECO:0007121,,,,,Direct interaction (Mechanistic A) ,A,direct complementation of a genetically defective protein,Study is no longer available,Trial is no longer available ,,,https://clinicaltrials.gov/ct2/show/NCT00705939,,https://clinicaltrials.gov/ct2/show/NCT00962260?cond=Gaucher+disease&draw=4&rank=25,https://clinicaltrials.gov/ct2/show/results/NCT00376168?cond=Gaucher+disease&draw=5&rank=39&sect=X30156#evnt,,,,,,,
1012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1013,,,,,,,,,Eliglustat tartrate,DB09039,ECO:0007121,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Low mean hemoglobin level ,,HP:0001903,https://clinicaltrials.gov/ct2/show/NCT01074944?cond=Gaucher+disease&draw=4&rank=26,https://www.ncbi.nlm.nih.gov/pubmed/20439622,,,,,,,,,
1014,107,# 608013,Gaucher disease perinatal lethal ,,GBA ,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,Thrombocytopenia,,HP:0001873,,,,,,,,,,,
1015,,,,,,,,,,,,,,,,,,,,Hepatomegaly,,HP:0002240,,,,,,,,,,,
1016,,,,,,,,,,,,,,,,,,,,Splenomegaly,,HP:0001744,,,,,,,,,,,
1017,,,,,,,,,,,,,,,,,,,,Low lumbar spine bone mineral density(bnormality of bone mineral density)*,,HP:0004348,,,,,,,,,,,
1018,108,# 230800,Gaucher disease type 1,,GBA ,beta-glucocerebrosidase,3.2.1.45,,N-acetylcysteine,DB06151 ,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Oxidative stress,,HP:0025464,https://clinicaltrials.gov/ct2/show/NCT01427517,https://clinicaltrials.gov/ct2/show/NCT02583672?cond=Gaucher+disease&rank=9,,https://www.ncbi.nlm.nih.gov/pubmed/23860343,,,,,,,
1019,,,,,,,,,,,,,,,,,,,,Low blood glutathione redox ratios,,MP:0012604*,,,,,,,,,,,
1020,,,,,,,,,,,,,,,,,,,,Inflammation,,HP:0012649,https://www.ncbi.nlm.nih.gov/pubmed/23860343,,,,,,,,,,
1021,,,,,,,,,,,,,,,,,,,,concentration of myo-inositol in brain,,HP:0025460,,,,,,,,,,,
1022,,,,,,,,,,,,,,,,,,,,concentration of TNF-alpha in plasma ,,HP:0011118*,,,,,,,,,,,
1023,,,,,,,,,Elelyso ,DB08876,ECO:0000352/ ECO:0007121,,,,,Direct interaction (Mechanistic A) ,A,direct complementation of a genetically defective protein,,Hepatomegaly,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/22916340,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT03021941?cond=Gaucher+disease&rank=7,,,,,,,,
1024,,,,,,,,,,,,,,,,,,,,Splenomegaly,,HP:0001744,,,,,,,,,,,
1025,,,,,,,,,,,,,,,,,,,,thrombocytopenia,,HP:0001873,,,,,,,,,,,
1026,,,,,,,,,,,,,,,,,,,,anaemia,,HP:0001903,,,,,,,,,,,
1027,,,,,,,,,Velaglucerase alfa,DB06720,ECO:0007121,,,,,Direct interaction (Mechanistic A) ,A,direct complementation of a genetically defective protein,,changes in lumbar spine (LS),,HP:0100712,https://www.ncbi.nlm.nih.gov/pubmed/29503270,,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,,,,,,
1028,,,,,,,,,,,,,,,,,,,,abnormality in bone mineral density ,,HP:0004348,,,,,,,,,,,
1029,,,,,,,,,,,,,,,,,,,,anaemia,,HP:0001903,,,,,,,,,,,
1030,,,,,,,,,,,,,,,,,,,,thrombocytopenia,,HP:0001873,,,,,,,,,,,
1031,,,,,,,,,,,,,,,,,,,,hepatosplenomegaly,,HP:0001433,,,,,,,,,,,
1032,,,,,,,,,,,,,,,,,,,,growth faliure,,HP:0001510,,,,,,,,,,,
1033,,,,,,,,,,,,,,,,,,,,avascular osteonecrosis,,HP:0010885,https://www.ncbi.nlm.nih.gov/pubmed/29503270,,,,,,,,,,
1034,,,,,,,,,,,,,,,,,,,,Bone pain,,HP:0002653,https://www.ncbi.nlm.nih.gov/pubmed/29503270,,,,,,,,,,
1035,,,,,,,,The drug was used in a pilot study.,Ambroxol,DB06742,ECO:0007121,,,,,Direct interaction (A) ,A,activity modification of a genetically defective protein,Suspended study,Anemia,,done,https://clinicaltrials.gov/ct2/show/NCT01463215?cond=Gaucher+disease&draw=2&rank=17,https://www.ncbi.nlm.nih.gov/pubmed/23085429,,,,,,,,,
1036,,,,,,,,,,,,,,,,,,,,Splenomegaly,,HP:0001744,https://www.ncbi.nlm.nih.gov/pubmed/23085429,,,,,,,,,,
1037,,,,,,,,,,,,,,,,,,,,Thrombocytpenia,,HP:0001873,https://www.ncbi.nlm.nih.gov/pubmed/23085429,,,,,,,,,,
1038,,,,,,,,,,,,,,,,,,,,Hepatomegaly,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/23085429,,,,,,,,,,
1039,,,,,,,,,Miglustat (NB-DNJ)(OGT 918),,ECO:0007121/ECO:0005542,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Splenomegly,,HP:0001744,,,https://www.ncbi.nlm.nih.gov/pubmed/11227045,https://www.ncbi.nlm.nih.gov/pubmed/12064906,,https://www.ncbi.nlm.nih.gov/pubmed/15505381,https://www.ncbi.nlm.nih.gov/pubmed/15895716,,,,
1040,,,,,,,,,,,,,,,,,,,,hepatomegly,,HP:0002240,,,https://www.ncbi.nlm.nih.gov/pubmed/16199246,https://www.ncbi.nlm.nih.gov/pubmed/16285070,,,,,,,
1041,,,,,,,,,,,,,,,,,,,,High chitotriosidase level,,NA,,,,,,,,,,,
1042,109,# 230900,Gaucher disease type 2," By Knocking out RIPK3, we show that modulating the receptor-interacting protein kinase-3 (Ripk3) pathway markedly improves neurological and systemic disease in a mouse model of GD. https://www.ncbi.nlm.nih.gov/pubmed/24441827
Notably, Ripk3 deficiency substantially improved the clinical course of GD mice, with increased survival and motor coordination and salutary effects on cerebral as well as hepatic injury.",GBA ,beta-glucocerebrosidase,,The treatment was done via convection-enhanced delivery ,Glucocerebrosidase+ gadolinium-diethylenetriamine penta-acetic acid ,DB06667,ECO:0007121/ ECO:0000352,,,,,Direct interaction (Mechanistic A) ERT,A,direct complementation of a genetically defective protein+symptomatic treatment procedure,,No result is  added,,,https://www.ncbi.nlm.nih.gov/pubmed/18952590,,https://clinicaltrials.gov/ct2/show/NCT00244582?cond=Gaucher+disease+type+II&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/24441827,https://www.ncbi.nlm.nih.gov/pubmed/18952590,https://www.ncbi.nlm.nih.gov/pubmed/7814809,,,,,
1043,,,,,,,,,,,,,,,,,,,,,,done,,,https://link.springer.com/article/10.1007%2Fs11011-018-0236-1,,,,,,,,
1044,110,# 231005,Gaucher disease type 3 ,,GBA ,beta-glucocerebrosidase,,,Miglustat (Substrate reduction therapy)+imiglucerase,DB00419+DB00053,ECO:0007121,,,,,Functional interaction (Mechanistic B)+Direct interaction (Mechanistic A),B,functional complementation of a genetically defective protein+direct complementation of a genetically defective protein,,neuropathy,,HP:0009830,https://www.ncbi.nlm.nih.gov/pubmed/17433057,https://clinicaltrials.gov/ct2/show/NCT02520934?cond=Gaucher+disease&rank=2,,,,,,,,,
1045,,,,,,,,,,,,,,,,,,,,generalized tonic-clonic seizures,,HP:0002069,,,,,,,,,,,
1046,,,,,,,,,,,,,,,,,,,,speech impairment,,HP:0002167,,,,,,,,,,,
1047,,,,,,,,,Eliglustat(Substrate reduction therapy),DB09039,ECO:0007121,CYP2D6,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,abnormal glucocerebroside level,,HP:0003656,https://www.ncbi.nlm.nih.gov/pubmed/29680197,https://www.ncbi.nlm.nih.gov/pubmed/30264864,http://clinicaltrials.gov/show/NCT00358150,https://www.ncbi.nlm.nih.gov/pubmed/30247105,https://www.ncbi.nlm.nih.gov/pubmed/29358012,,,,,,
1048,,,,,,,,,,,,,,,,,,,,Hepatosplenomegaly ,,HP:0001433,https://www.ncbi.nlm.nih.gov/pubmed/28935503,,,,,,,,,,
1049,,,,,,,,,,,,,,,,,,,,thrombocytopenia,,HP:0001873,,,,,,,,,,,
1050,,,,,,,,,,,,,,,,,,,,low mean hemoglobin concentration ,,HP:0025547,,,,,,,,,,,
1051,,,,,,,,,velaglucerase alfa,DB06720,ECO:0007121,,,,,Direct interaction (Mechanistic A) ,A,direct complementation of a genetically defective protein,,Decreased hemoglobin,,HP:0001903,https://clinicaltrials.gov/ct2/show/NCT03519646?cond=Gaucher+disease&draw=2&rank=18,https://clinicaltrials.gov/ct2/show/results/NCT01685216?cond=Gaucher+disease&draw=5&rank=35&sect=X01256#all,,,,,,,,,
1052,,,,,,,,,,,,,,,,,,,,thrombocytopenia,,HP:0001873,,,,,,,,,,,
1053,,,,,,,,,,,,,,,,,,,,High spleen volume,,HP:0001744,,,,,,,,,,,
1054,,,,,,,,,,,,,,,,,,,,high liver volume,,HP:0002240,,,,,,,,,,,
1055,111,# 219500,Gamma-cystathionase deficiency ,Cystathioninuria not associated with vitamin B6 dependency is an evidence of genetic heterogeneity in primary cystathioninuria. https://www.ncbi.nlm.nih.gov/pubmed/417288        https://www.ncbi.nlm.nih.gov/pubmed/5707897,CTH,cystathionine gamma-lyase,4.4.1.1,,pyridoxine,DB00165,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,activity modification of a genetically defective protein,,Cystathioninuria,,HP:0003153,http://www.ncbi.nlm.nih.gov/pubmed/20584029?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/417288,https://www.ncbi.nlm.nih.gov/pubmed/5707897,,,,,,,
1056,,,,,,,,,,,,,,,,,,,,Tremor ,,HP:0001337,,,,,,,,,,,
1057,,,,,,,,,,,,,,,,,,,,Impaired fine motor skillls,,HP:0007010,,,,,,,,,,,
1058,,,,,,,,,,,,,,,,,,,,EEG abnormality,,HP:0002353,,,,,,,,,,,
1059,,,,,,,,,,,,,,,,,,,,High total homocysteine level,,HP:0010919,,,,,,,,,,,
1060,112,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,,flumazenil,DB01205,ECO:0007121/ECO:0000352,,,,,Symptomatic (C),C,functional complementation of a defective protein by inhibition,,unalertness,,HP:0002329,http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pubmed/29480352,,,,,,,,
1061,,,,,,,,,,,,,,,,,,,,EEG abnormality,,HP:0002353,http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,,,,,,,,,,
1062,,,,,,,,,,,,,,,,,,,,Functional motor deficit,,HP:0004302,http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,,,,,,,,,,
1063,,,,,,,,,,,,,,,,,,,,excessive adventitious movements,,HP:0100022*,http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,,,,,,,,,,
1064,,,,,,,,,,,,,,,,,,,,hypersomnolence ,,HP:0100786,http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,,,,,,,,,,
1065,,,,,,,,,,,,,,,,,,,,Oculomotor apraxia,,HP:0000657,https://www.ncbi.nlm.nih.gov/pubmed/29480352,,,,,,,,,,
1066,,,,,,,,,,,,,,,,,,,,Developmental delay,,HP:0012758,https://www.ncbi.nlm.nih.gov/pubmed/29480352,,,,,,,,,,
1067,,,,,,,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",Phenobarbital/clonazepam/valproate/ midazolam,DB01174/DB01068/DB00313/DB00683,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure,,Seizures,,HP:0001250,,,,,,,,,,,
1068,,,,,,,,,rapamycin,DB00877,ECO:0007764/ECO:0005542,,,,,Symptomatic (C),C,symptomatic treatment procedure,,elevated CSF GHB levels,,NA,https://www.ncbi.nlm.nih.gov/pubmed/25485164,https://www.ncbi.nlm.nih.gov/pubmed/24578415/,,,,,,,,,
1069,,,,,,,,,,,,,,,,,,,,oxidative stress,,HP:0025464,,,,,,,,,,,
1070,113,# 256540,Galactosialidosis ,,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase,3.4.16.5,, rAAV-PPCR ,NA,ECO:0005542,,,,,Direct interaction (Mechanistic A) ,A,direct complementation of a genetically defective protein,,edematous,,HP:0000969,,https://www.ncbi.nlm.nih.gov/pubmed/22008912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780/,https://www.ncbi.nlm.nih.gov/pubmed/15084520/,,,,,,,
1071,,,,,,,,,,,,,,,,,,,,infertility,,HP:0000789,,,,,,,,,,,
1072,,,,,,,,,,,,,,,,,,,,incoordination,,HP:0002311,,,,,,,,,,,
1073,,,,,,,,,,,,,,,,,,,,gait abnormality,,HP:0001288,,,,,,,,,,,
1074,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1075,,,,,,,,,N-octyl-4-epi-β-valienamine (NOEV),NA,ECO:0001565,"SpDEx7];/p.[Q49R;Y395C]/c.[478_480delTTC];[?]* no mutation was in the second all
",,,,Functional interaction (Mechanistic B),B,functional complementation of a defective protein by stimulation,,Low β-gal activity (Abnormal enzyme/coenzyme activity )*,,,,,https://www.ncbi.nlm.nih.gov/pubmed/26259553,,,,,,,,
1076,114,# 230200,Galactokinase deficiency ,,GALK1,galactokinase 1,2.7.1.6,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1077,115,# 606812,Fumarase deficiency ,"The high fat, low carbohydrate diet may has a possible disease modifying effect. https://www.ncbi.nlm.nih.gov/pubmed/29052812",FH,"Fumarate hydratase, mitochondrial",4.2.1.2,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1078,116,253800,Fukuyama type muscular dystrophy ,,FKTN,fukutin,O75072,,antisense oligonucleotide (VMO AED cocktail),NA,ECO:0005542/ECO:0001565,,,,,Direct interaction (Mechanistic A) ,A,activity modification of a genetically defective protein by transcriptional or translational modification,,Abnormal fukutin mRNA expression,,HP:0030098,https://www.nature.com/articles/nature10456,https://www.ncbi.nlm.nih.gov/pubmed/27421908,,,,,,,,,
1079,,,,,,,,,,,,,,,,,,,,pathogenic exon trapping ,,NA,,,,,,,,,,,
1080,,,,,,,,,AAV9-MCK-fukutin,NA,ECO:0005542,,,,,Direct interaction (Mechanistic A) ,A,direct complementation of a genetically defective protein by gene therapy,,Imapired muscle function,,HP:0011804,https://www.ncbi.nlm.nih.gov/pubmed/21102543,,,,,,,,,,
1081,,,,,,,,,Corticosteroid,DB00288,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Muscle weakness ,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/21726969,,,,,,,,,,
1082,,,,,,,,,,,,,,,,,,,,Muscle necrosis ,,HP:0003713,,,,,,,,,,,
1083,,,,,,,,,,,,,,,,,,,,Muscle inflammation,,HP:0100614,,,,,,,,,,,
1084,117,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,recombinant canine α-l-fucosidase enzyme,NA,ECO:0005542,,,,,Direct interaction (Mechanistic A) ,A,direct complementation of a genetically defective protein,,High level of fucosyl-linked oligosaccharide accumulation,,,https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923,,,,,,,,
1085,,,,,,,,,,,,,,,,,,,,Neuronal vacuolation,,NA,,,,,,,,,,,
1086,,,,,,,,,,,,,,,,,,,,Pyramidal neuron loss,,HP:0002062*,,,,,,,,,,,
1087,,,,,,,,,,,,,,,,,,,,Astrocytosis,,MP:0003354,,,,,,,,,,,
1088,,,,,,,,,,,,,,,,,,,,Microgliosis,,HP:0100708,,,,,,,,,,,
1089,,,,,,,,,,,,,,,,,,,,Purkinji cells apoptosis,,MP:0000880,,,,,,,,,,,
1090,,,,,,,,,,,,,,,,,,,,Oligodendrocyte loss,,HP:0100709,,,,,,,,,,,
1091,,,,,,,,,,,,,,,,,,,,Hypomyelination,,MP:0013438,,,,,,,,,,,
1092,,,,,,,,,,,,,,,,,,,,Lysosomal expansion in neurons of deep cortex,,HP:0004356*,,,,,,,,,,,
1093,,,,,,,,,,,,,,,,,,,,Astrocytosis in cerebral cortex,,HP:0002446,,,,,,,,,,,
1094,,,,,,,,,,,,,,,,,,,,Abnormal lysosomal membrane associated protein-1 (LAMP-1) gene expression,,NA,,,,,,,,,,,
1095,,,,,,,,,,,,,,,,,,,,Abnormal neurololgical function,,HP:0000707,,,,,,,,,,,
1096,,,,,,,,,Tocilizumab,DB06273,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Arthritis,,HP:0001369,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649943/,,,,,,,,,,
1097,118,# 229700,"Fructose-1,6-bisphosphatase deficiency ","The therapy is based on avoiding prolonged fasts, glucose infusion, and a specific diet, rich in glucose without fructose intake. https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=29390242&dopt=abstractplus
Fructose, glycerol and oral medicines that may contain sucrose and sorbitol should not be given during acute illness. https://link.springer.com/chapter/10.1007/978-3-642-15720-2_9",FBP1,"Fructose-1,6-bisphosphatase 1",3.1.3.11,"Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains <7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193",Glucose,DB01914,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/29203193,,https://www.ncbi.nlm.nih.gov/pubmed/29390242,,,,,,,,
1098,119,# 136120,Fish-eye disease ,"Fat restriction is recommended as it leads to progressive mesangial and glomerular sclerosis.https://www.ncbi.nlm.nih.gov/pubmed/2068059. 
and as well another author have suggested that low fat/calorie diet mainly consisting of vegetables may inhibit the progression of the renal disease.https://www.ncbi.nlm.nih.gov/pubmed/2634146",LCAT,lecithin-cholesterol acyltransferase ,2.3.1.43,,statin,DB00175,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a defective protein,,decreased cholesterol absorption,,MP:0002647,https://www.ncbi.nlm.nih.gov/pubmed/24636183,,,,,,,,,,
1099,,,,,,,,The drug was accomapined with fat-restricted diet ,ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs),C09C,ECO:0000352,,,,,,,symptomatic treatment procedure,,Abnormal lipoprotein profile,,HP:0010979,https://www.ncbi.nlm.nih.gov/pubmed/23522979,,,,,,,,,,
1100,,,,,,,,,,,,,,,,,,,,Abnormal renal function,,HP:0012211,https://www.ncbi.nlm.nih.gov/pubmed/23522979,,,,,,,,,,
1101,,,,,,,,,,,,,,,,,,,,Proteinuria,,HP:0000093,https://www.ncbi.nlm.nih.gov/pubmed/23522979,,,,,,,,,,
1102,,,,,,,,,,,,,,,,,,,,Low serum HDL-cholesterol,,HP:0003233,https://www.ncbi.nlm.nih.gov/pubmed/23522979,,,,,,,,,,
1103,,,,,,,,rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512,r LCAT,NA,ECO:0005542,,,,,,,direct complementation of a genetically defective protein,,Abnormal lipoprotein profile,,HP:0010979,https://www.ncbi.nlm.nih.gov/pubmed/20605907,,,,,,,,,,
1104,,,,,,,,,,,,,,,,,,,,Low HDL-C  level,,HP:0003233,https://www.ncbi.nlm.nih.gov/pubmed/20605907,,,,,,,,,,
1105,120,# 612319,Fatty acid hydroxylase-associated neurodegeneration ,,FA2H,fatty acid 2-hydroxylase,,,baclofen/tizanidine/trihexyphenidyl/benzodiazepine/dantrolene,DB00182/DB00697/DB00376/DB12537/DB01219,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/21735565,,,,,,,,,,
1106,,,,,,,,,,,,,,,,,,,,spasticity,,HP:0001257,https://www.ncbi.nlm.nih.gov/pubmed/21735565,,,,,,,,,,
1107,,,,,,,,,botulinum toxin ,DB00083,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,abnormal muscular co-contraction,,HP:0001257,https://www.ncbi.nlm.nih.gov/pubmed/21735565,,,,,,,,,,
1108,,,,,,,,,Nimodipine,DB00393,ECO:0000305/ECO:0001565,,,,,Direct interaction (Mechanistic A) ,,activity modification of a genetically defective protein,,Abnormality of circulating enzyme level,,HP:0011021,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454877/,,,,,,,,,,
1109,121,# 616896,Fatal infantile encephalomyopathy ,,OPA1,mitochondrial dynamin like GTPase ,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1110,122,# 228000,Farber's disease ,,ASAH1,acid ceramidase,3.5.1.23,,human recombinant acid ceramidase/human ACDase-encoding lentivector,NA,ECO:0005542/ECO:0001565,,,,,Direct interaction (Mechanistic A) ERT,A,direct complementation of a genetically defective protein,,Delayed growth,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,,,,,,,,
1111,,,,,,,,,,,,,,,,,,,,High cermaide level,,MP:0020582,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/,,,,,,,
1112,,,,,,,,,,,,,,,,,,,,High intracellular cermaid level,,MP:0020582*,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,,,,,,,,
1113,,,,,,,,,,,,,,,,,,,,Abnormal spleen size,,HP:0001744,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,,,,,,,,
1114,,,,,,,,,,,,,,,,,,,,abnormal sphingosine level(Abnormality of lipid metabolism)*,,MP:0009587,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,,,,,,,,
1115,,,,,,,,,,,,,,,,,,,,high plasma MCP-1,,NA,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,,,,,,,,
1116,,,,,,,,,,,,,,,,,,,,High macrophage infiltration into tissues(Abnormal inflammatory response)*,,HP:0012647*,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,,,,,,,,
1117,,,,,,,,,,,,,,,,,,,,Abnormal tissue lipid profiles(Abnormality of lipid metabolism)*,,HP:0003119,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,,,,,,,,
1118,,,,,,,,,,,,,,,,,,,,Joint inflammation,,HP:0001369,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,,,,,,,,
1119,,,,,,,,"The drug wasn't tried in animal model of Farber's disease, however, it seems to have an effect on ceraminde level in lungs. ",Amitriptyline,DB00321,ECO:0000305/ECO:0005542,,,,,,,functional complementation of a defective protein by inhibition,,Abnormal pulmonary ceramide level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/18376404,,,,,,,,,,
1120,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1121,123,# 227810,Fanconi Bickel syndrome ,,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",P11168, Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,Uncooked Cornstarch,DB11599,ECO:0000352,,,,,Symptomatic (C),C,Dietary supplementation,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353876/,https://www.ncbi.nlm.nih.gov/pubmed/7564233/,,,,,,,,,
1122,,,,,,,,,Vitamin D,DB11094,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Short stature,,HP:0004322,https://www.ncbi.nlm.nih.gov/pubmed/24912437,,,,,,,,,,
1123,,,,,,,,,phosphorus,DB14151,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Rickets,,HP:0002748,https://www.ncbi.nlm.nih.gov/pubmed/24912437,,,,,,,,,,
1124,,,,,,,,,bicarbonate,DB01390,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Renal tubular acidosis,,HP:0001947,https://www.ncbi.nlm.nih.gov/pubmed/24912437,,,,,,,,,,
1125,,,,,,,,,Insulin,DB00030 ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Diabetes mellitus,,HP:0000819,http://www.ncbi.nlm.nih.gov/pubmed/29116606?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/23456528,,,,,,,,,
1126,124,151660,Familial partial lipodystrophy type 2 ,Data regarding TZD therapy and the restoration of adipose tissue in lipoatrophic areas has been conflicting; it appears as though TZDs do not improve lipoatrophy in patients with FPLD2. https://www.ncbi.nlm.nih.gov/pubmed/19040647/ ,LMNA,lamins ( Lamins A and C),P02545,,ISIS 703802 (AKCEA-ANGPTL3-LRx),NA,ECO:0007121,,,,,Symptomatic(C),C,symptomatic treatment procedure,,high fasting triglycerides,,HP:0002155*,https://clinicaltrials.gov/ct2/show/NCT03514420?cond=Familial+partial+lipodystrophy+type+2&rank=1,,,,,,,,,,
1127,,,,,,,,,Metreleptin(A-100),DB09046,ECO:0007121/ECO:0000352,,,,,Symptomatic(C),C,symptomatic treatment procedure,,abnormal free fatty acid levels,,HP:0040300,https://clinicaltrials.gov/ct2/show/NCT00025883?cond=Familial+partial+lipodystrophy+type+2&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/25734254,,,,,,,,,
1128,,,,,,,,,,,,,,,,,,,,high facial soft tissue volume,,HP:0000287,https://www.ncbi.nlm.nih.gov/pubmed/28993984,,,,,,,,,,
1129,,,,,,,,,,,,,,,,,,,,abnormal fasting glucose,,MP:0013277,https://www.ncbi.nlm.nih.gov/pubmed/29044799,https://www.ncbi.nlm.nih.gov/pubmed/26584826,,,,,,,,,
1130,,,,,,,,,,,,,,,,,,,,high  HbA1c levels,,HP:0040217,,,,,,,,,,,
1131,,,,,,,,,Albiglutide (glucagon-like peptide-1 receptor agonist),DB09043,,,,,,Symptomatic (C),C,symptomatic treatment procedure,,abnormal fasting glucose,,MP:0013277,,,,,,,,,,,
1132,,,,,,,,,,,,,,,,,,,,high  HbA1c levels,,HP:0040217,,,,,,,,,,,
1133,,,,,,,,,volanesorsen (IONIS-APOCIIIRx),NA,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Abnormal fasting triglycerides,,HP:0002155*,https://clinicaltrials.gov/ct2/show/NCT02300233,https://clinicaltrials.gov/ct2/show/NCT02211209,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,,,,,,,,
1134,,,,,,,,,Obeticholic Acid,DB05990,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Hepatic steatosis,,HP:0001397,https://clinicaltrials.gov/ct2/show/NCT02430077?cond=%22familial+partial+lipodystrophy%22&rank=3,,,,,,,,,,
1135,,,,,,,,,,,,,,,,,,,,High liver triglyceride level(hyperlipidemia)*,,HP:0003077*,,,,,,,,,,,
1136,,,,,,,,,Gemcabene,DB05123,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Hypertriglyceridemia,,HP:0002155,https://clinicaltrials.gov/ct2/show/NCT03508687?cond=%22familial+partial+lipodystrophy%22&rank=6,,,,,,,,,,
1137,,,,,,,,,,,,,,,,,,,,Hepatic steatosis,,HP:0001397,,,,,,,,,,,
1138,,,,,,,,Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616,fibrates + omega-3 fatty acids (OMG-3) ,DB00636 +DB11133,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/27710244,,,,,,,,,,
1139,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1140,125,# 245900,Familial LCAT deficiency ,,LCAT,lecithin-cholesterol acyltransferase ,2.3.1.43,,recombinant human LCAT (ACP-501),NA,ECO:0007121,,,,,Direct interaction (Mechanistic A) ,A,direct complementation of a genetically defective protein,,anemia,,HP:0001903,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,,,,,,,,,
1141,,,,,,,,,,,,,,,,,,,,Abnormal lecithin:cholesterol acyltransferase activity,,MP:0011598,,,,,,,,,,,
1142,,,,,,,,,,,,,,,,,,,,abnormal plasma lipids levels,,HP:0003119,,,,,,,,,,,
1143,,,,,,,,,,,,,,,,,,,,low HDL level,,HP:0003233,,,,,,,,,,,
1144,,,,,,,,,,,,,,,,,,,,low HDL-C level,,HP:0003233,,,,,,,,,,,
1145,,,,,,,,,,,,,,,,,,,,Abnormal cholesterol efflux from cells,,MP:0003193,,,,,,,,,,,
1146,,,,,,,,,,,,,,,,,,,,dyslipidemia,,MP:0003949,,,,,,,,,,,
1147,,,,,,,,,,,,,,,,,,,,low APO A level,,HP:0025201*,,,,,,,,,,,
1148,,,,,,,,,,,,,,,,,,,,Low Apo B protein level,,HP:0025201*,,,,,,,,,,,
1149,,,,,,,,,,,,,,,,,,,,proteinuria,,HP:0000093,,,,,,,,,,,
1150,,,,,,,,,Captopril,DB01197,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Hypertension,,HP:0000822,https://www.ncbi.nlm.nih.gov/pubmed/23391322,,,,,,,,,,
1151,,,,,,,,,Thiazide,DB01324,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Oedema,,HP:0000969,,,,,,,,,,,
1152,126,# 162000,Familial juvenile hyperuricaemic nephropathy ,,UMOD,uromodulin,P07911,,Probenecid,DB01032,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Hyperurecemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/20301530,https://www.ncbi.nlm.nih.gov/pubmed/8842764,,,,,,,,,
1153,,,,,,,,,Probenecid+Allopurinol,DB01032+DB00437,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Hyperurecemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/8842764,,,,,,,,,,
1154,,,,,,,,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",Allopurinol,DB00437,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Hyperurecemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/12205338,https://www.ncbi.nlm.nih.gov/pubmed/11068651,,,,,,,,,
1155,,,,,,,,,,,,,,,,,,,,Mortality,,HP:0040006,https://www.ncbi.nlm.nih.gov/pubmed/12205338,,,,,,,,,,
1156,,,,,,,,,,,,,,,,,,,,Disaess progression(Progressive)*,,HP:0003676,https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=20301530&dopt=abstractplus,,,,,,,,,,
1157,,,,,,,,,Allopurinal+Benzbromarone,DB00437+DB12319,ECO:0000352,,,,,,,symptomatic treatment procedure,,Hyperurecemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/9678437,,,,,,,,,,
1158,127,# 145980,Familial hypocalciuric hypercalcemia type 1 ,"In majority of cases, there is no need for treatment until thecalcium level is very high, it becomes necessary to treat FHH.https://www.ncbi.nlm.nih.gov/pubmed/21986511",CASR,calcium-sensing receptor ,P41180,,Cinacalcet,DB01012,ECO:0000352,,,,,,,activity modification of a genetically defective protein,,Hypercalcemia,,HP:0003072,https://www.ncbi.nlm.nih.gov/pubmed/28459040,https://www.ncbi.nlm.nih.gov/pubmed/16882283/,https://www.ncbi.nlm.nih.gov/pubmed/17803689/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/,,,,,
1159,,,,,,,,,,,,,,,,,,,,Elevated circulating parathyroid hormone level,,HP:0003165,https://www.ncbi.nlm.nih.gov/pubmed/20495831/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,,,,,,,,,
1160,,,,,,,,,,,,,,,,,,,,Impaired renal uric acid clearance,,HP:0004732,https://www.ncbi.nlm.nih.gov/pubmed/28459040,,,,,,,,,,
1161,,,,,,,,,,,,,,,,,,,,Polydipsia,,HP:0001959,https://www.ncbi.nlm.nih.gov/pubmed/28459040,,,,,,,,,,
1162,128,# 145981,Familial hypocalciuric hypercalcemia type 2 ,,GNA11,guanine nucleotide-binding protein (Gα11),P21278,,Cinacalcet,DB01012,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,activity modification of a genetically defective protein,,high serum ionized calcium concentrations,,HP:0003072*,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,,https://www.ncbi.nlm.nih.gov/pubmed/28833550,,,,,,,,
1163,,,,,,,,,,,,,,,,,,,,abnormal parathyroid hormone level,,HP:0003165,,,,,,,,,,,
1164,129,# 600740,Familial hypocalciuric hypercalcemia type 3 ,,AP2S1,adaptor protein-2 σ-subunit , P53680,,Cinacalcet,DB01012 ,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,activity modification of a genetically defective protein,,high serum ionized calcium concentrations,,HP:0003072*,https://www.ncbi.nlm.nih.gov/pubmed/27050234/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/25993639,,,,,,,,
1165,,,,,,,,,,,,,,,,,,,,abnormal parathyroid hormone level,,HP:0003165,,,,,,,,,,,
1166,,,,,,,,,,,,,,,,,,,,low calcium urine excretion,,HP:0003127,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367245/,,,,,,,,,,
1167,,# 145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,Apolipoprotein A-V,Q6Q788,,Gemfibrozil+dietary fat restriction ,DB01241,ECO:0000352,,,,,,,symptomatic treatment procedure+Dietary exclusion,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/15251700/,,,,,,,,,,
1168,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1169,,,,,,,,,fenofibrate +niacin+omega‐3 fatty acids,DB01039,ECO:0000352,,,,,,,activity modification of a genetically defective protein,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/24524914,,,,,,,,,,
1170,,,,,,,,,Omega 3 FA,DB11133,ECO:0000352,,,,,,,symptomatic treatment procedure,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/10925336?dopt=Abstract,,,,,,,,,,
1171,,,,,,,,,Omega-3-acid ethyl esters,DB09539,ECO:0000352,,,,,,,symptomatic treatment procedure,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/16390715?dopt=Abstract,,,,,,,,,,
1172,,,,,,,,,Insulin,DB01306,ECO:0000352,,,,,,,functional complementation of a defective protein by stimulation,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/19770656?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28225998,,,,,,,,,
1173,,,,,,,,"Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965",Heparin,DB01109,ECO:0000352,,,,,,,functional complementation of a genetically defective protein,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/1800965,https://www.ncbi.nlm.nih.gov/pubmed/12114919,https://www.ncbi.nlm.nih.gov/pubmed/19770656?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28225998,,,,,,,
1174,,,,,,,,,,,,,,,,,,,,Acute pancreatitis,,HP:0001735,,,,,,,,,,,
1175,,,,,,,,,Chenodeoxycholic acid,DB06777,ECO:0007121,,,,,,,functional complementation of a defective protein by inhibition,,Hypertriglyceridemia,,HP:0002155,https://clinicaltrials.gov/ct2/show/NCT00465751?cond=Familial+hypertriglyceridemia&draw=3&rank=2,,,,,,,,,,
1176,,,,,,,,,Rosuvastatin,DB01098,ECO:0007121,,,,,,,symptomatic treatment procedure,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/23323877,,,,,,,,,,
1177,,,,,,,,,,,,,,,,,,,, High LDL level,,HP:0003141,,,,,,,,,,,
1178,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1179,130,# 604091,Familial HDL deficiency (Tangier Disease),,ABCA1,Phospholipid-transporting ATPase ABCA1,7.6.2.1,,Niacin,DB00627,ECO:0007121,,,,,Direct interaction (Mechanistic A) ,A,activity modification of a genetically defective protein,,hypoalphalipoproteinemia ,,HP:0003233,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988622/,https://www.clinicaltrials.gov/ct2/show/NCT01942291?cond=%22Hypolipoproteinemia%22&rank=10,,,,,,,,,
1180,,,,,,,,,,,,,,,,,,,,Low HDL cholesterol concentration,,HP:0003233,https://www.ncbi.nlm.nih.gov/pubmed/18993152,,,,,,,,,,
1181,,,,,,,,,Gemfibrozil,DB01241,ECO:0005542,,,,,Direct interaction (Mechanistic A) ,A,activity modification of a genetically defective protein,,Low HDL cholesterol concentration,,HP:0003233,https://www.ncbi.nlm.nih.gov/pubmed/9493705,,,,,,,,,,
1182,,,,,,,,,Pravastatin,DB00175,ECO:0007121,R219K,,,,,,activity modification of a genetically defective protein,,Increased low-density lipoprotein cholesterol concentration,,HP:0003141,https://www.ncbi.nlm.nih.gov/pubmed/24854628/,,,,,,,,,,
1183,,,,,,,,"Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152",Atorvastatin/ Fenofibrate/ Niacin,,ECO:0007121,,,,,,A,activity modification of a genetically defective protein/,,hypoalphalipoproteinemia ,,HP:0003233,https://www.clinicaltrials.gov/ct2/show/NCT00458055?cond=%22Hypolipoproteinemia%22&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/18993152,,,,,,,,,
1184,,,,,,,,,,,,,,,,,A,,,Low HDL cholesterol concentration,Niacin was the only effective drug to increase HDL cholesterol.,HP:0003233,,,,,,,,,,,
1185,,,,,,,,,"CER 001, a recombinant high-density lipoprotein (HDL)",NA,ECO:0007121/ECO:00055442/ECO:0001565,,,,,Direct interaction (Mechanistic A) ,A,functional complementation of a genetically defective protein,,Decreased apolipoprotein AI level,,HP:0031799,https://www.ncbi.nlm.nih.gov/pubmed/25561459/,,https://www.ncbi.nlm.nih.gov/pubmed/28213743,https://www.clinicaltrials.gov/ct2/show/NCT02697136?cond=%22Hypolipoproteinemia%22&draw=2&rank=8,,,,,,,
1186,,,,,,,,,,,,,,,,,,,,Vasculitis,,HP:0002633,,,,,,,,,,,
1187,,,,,,,,,,,,,,,,,,,,Decreased plasma HDL-c levels,,HP:0003233,,,,,,,,,,,
1188,,,,,,,,,,,,,,,,,,,,Arterial pluque,,HP:0002621,,,,,,,,,,,
1189,131,# 301500,Fabry disease ,,GLA,alpha-galactosidase A,,,Fabrazyme ( agalsidase beta) + pegunigalsidase alfa ( PRX-102),DB00103+DB14992,ECO:0007121,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein,,Abnormal kidney function,,HP:0012211,,https://clinicaltrials.gov/ct2/show/study/NCT02795676?term=PRX-102&cond=Fabry+Disease&show_locs=Y#locn,https://www.ncbi.nlm.nih.gov/pubmed/25885911,,,,https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8,,,,
1190,,,,,,,,,REPLAGAL (Agalsidase Alfa),DB00103,ECO:0007121,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein,,cardiomegaly,,HP:0001640,https://clinicaltrials.gov/ct2/show/NCT03018730?cond=fabry+disease&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/25885911,,,,,,,,,
1191,,,,,,,,,,,,,,,,,,,,low renal glomerular filtration rate,,HP:0012213,,,,,,,,,,,
1192,,,,,,,,,,,,,,,,,,,,pain,,HP:0012531,,,,,,,,,,,
1193,,,,,,,,"Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy",Pegunigalsidase alfa ( PRX-102),DB14992,ECO:0007121,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein,,Abnormal kidney function,,HP:0012211,https://clinicaltrials.gov/ct2/show/NCT03180840?term=PRX-102&cond=Fabry+Disease,https://clinicaltrials.gov/ct2/show/NCT01678898?term=PRX-102&cond=Fabry+Disease,https://clinicaltrials.gov/ct2/show/NCT01769001?term=PRX-102&cond=Fabry+Disease,https://clinicaltrials.gov/ct2/show/NCT01981720?term=PRX-102&cond=Fabry+Disease,,,,,,,
1194,,,,,,,,,Lucerastat,DB14872,ECO:0007121/ECO:0001565,,,,,,,functional complementation of a defective protein by inhibition,,High Gb3(globotriaosylceramide) accumulation.,,NA,https://clinicaltrials.gov/ct2/show/NCT02930655?cond=fabry+disease&rank=2,https://clinicaltrials.gov/ct2/show/NCT03425539,https://clinicaltrials.gov/ct2/show/NCT03737214,https://www.ncbi.nlm.nih.gov/pubmed/28088251,https://www.ncbi.nlm.nih.gov/pubmed/29982630,,,,,,
1195,,,,,,,,"The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/",migalastat hydrochloride (AT1001),DB05018,ECO:0007121/ECO:0001565,"p.D33G/p.L36W (n=2)/p.D55V/p.Q57L /p.G85D/p.R112H/G144V/p.I253T (n=4)/p.G258R (n=2) ,.A156T (n=3)                             p.P293T (n=2) /p.C174R                                                                                                           p.F295C                                                                  p.G183D (n=2)                                    p.L300P                                                                      p.M187I                                                                             p.R301Q   (n=3)                                                                           p.P205T (n=2)                                p.I317T                                                                  p.Y216C (n=3) /                             p.D322E (n=2)                                                    33p.L243F                                                                              p.G325R (n=2)/p.G373S / p.D244N/ p.R356W  ",,"E48K, R49P, S65I, I117S, G183V, G261D, G271S, S276G, R342Q (n=8), L414S",,Direct interaction (Mechanistic A),A,activity modification of a genetically defective protein,,High plasma lyso-globotriaosylsphingosine level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30875019,https://www.ncbi.nlm.nih.gov/pubmed/30765910,https://www.ncbi.nlm.nih.gov/pubmed/27509102/,https://clinicaltrials.gov/ct2/show/NCT00925301,https://clinicaltrials.gov/ct2/show/NCT01458119,https://www.ncbi.nlm.nih.gov/pubmed/30723321,,,,,
1196,,,,,,,,,,,,,,,,,,,,High mean number of GL-3 inclusions/kidney interstitial capillary(KIC) ,,NA,,,,,,,,,,,
1197,,,,,,,,,,,,,,,,,,,,Left ventricular hypertrophy,,HP:0001712,https://www.ncbi.nlm.nih.gov/pubmed/27834756/,https://www.nature.com/articles/s41436-019-0451-z,,,,,,,,,
1198,132,# 612073,MITOCHONDRIAL DNA DEPLETION SYNDROME 5,,SUCLA2,Succinyl-CoA synthetase ( beta subunit),,,Carbamazepine,DB00564 ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,seizures,,HP:0001250,,,https://www.ncbi.nlm.nih.gov/books/NBK6803/,,,,,,,,
1199,,,,,,,,,Riboflavin and thiamine,DB00140+DB00152  ,ECO:0000352,,,,,,,symptomatic treatment procedure,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/19666145,,,,,,,,,,
1200,,,,,,,,"The drug has been used in two patients; in one patient it resulted in a tempoary improvment for 6 months, in the other it resulted in adverse effects and irritability with involuntary movements, and the treatment was discontinued.",L-DOPA ,DB01235,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Abnormal facial expression,,HP:0005346,https://www.ncbi.nlm.nih.gov/pubmed/19666145,,,,,,,,,,
1201,,,,,,,,,,,,,,,,,,,,Functional motor deficit,,HP:0004302,,,,,,,,,,,
1202,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1203,133,# 249900,Encephalopathy due to prosaposin deficiency,,PSAP ,prosaposin,,https://www.ncbi.nlm.nih.gov/pubmed/8370580,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1204,134,# 177000,Erythropoietic protoporphyria ,,FECH,ferrochelatase,,,vitamin D,DB11094,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,concommitant low vit D level,,HP:0100512*,,,https://www.ncbi.nlm.nih.gov/pubmed/24137761,,,,,,,,
1205,,,,,,,,,Afamelanotide (Scenesse),DB04931,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Erythema,,HP:0010783,https://www.ncbi.nlm.nih.gov/pubmed/28003770,https://www.ncbi.nlm.nih.gov/pubmed/25402764,https://www.ncbi.nlm.nih.gov/pubmed/19656325/,https://www.ncbi.nlm.nih.gov/pubmed/25402764,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/,,,,,
1206,,,,,,,,,,,,,,,,,,,,Cutaneous photosensitivity,,HP:0000992,,,,,,,,,,,
1207,,,,,,,,,corticosteroids,DB00288 ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Pain,,HP:0012531,https://www.ncbi.nlm.nih.gov/pubmed/27139922,https://www.ncbi.nlm.nih.gov/pubmed/19744342,,,,,,,,,
1208,,,,,,,,,,,,,,,,,,,,Pruritus,,HP:0000989,,,,,,,,,,,
1209,,,,,,,,,zinc ,DB01593,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Increased ROS formation,,HP:0025464,http://www.ncbi.nlm.nih.gov/pubmed/22092997?dopt=Abstract,,,https://www.ncbi.nlm.nih.gov/pubmed/22092997,,,,,,,
1210,,,,,,,,"Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/",β-carotene,DB06755,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,No significant difference was found in the controlled trial. https://www.ncbi.nlm.nih.gov/pubmed/341955/,intolerance to sunlight,,HP:0000992,https://www.ncbi.nlm.nih.gov/pubmed/341955/,https://www.ncbi.nlm.nih.gov/pubmed/22791288,,,,,,,,,
1211,,,,,,,,,,,,,,,,,,,,Pain in the skin,,HP:0025280*,,,,,,,,,,,
1212,,,,,,,,,Cholestyramine,DB01432,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Abnormal  protoporphyrin enterhepatic circulation,,HP:0012187,https://www.ncbi.nlm.nih.gov/pubmed/7758200?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10189233?dopt=Abstract,,,,,,,,,
1213,,,,,,,,Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract,activated charcoal,DB09278,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Abnormal liver function test,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/3335288?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10189233?dopt=Abstract,,,,,,,,,
1214,,,,,,,,,,,,,,,,,,,,Abdominal pain,,HP:0002027,https://www.ncbi.nlm.nih.gov/pubmed/20375647,,,,,,,,,,
1215,,,,,,,,,,,,,,,,,,,,Photosenstivity,,HP:0000992,https://www.ncbi.nlm.nih.gov/pubmed/20375647,https://www.ncbi.nlm.nih.gov/pubmed/3335288?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7758200?dopt=Abstract,,,,,,,,
1216,,,,,,,,,,,,,,,,,,,,Pruritis,,HP:0000989,https://www.ncbi.nlm.nih.gov/pubmed/10189233?dopt=Abstract,,,,,,,,,,
1217,,,,,,,,,,,,,,,,,,,,Hepatotoxicity,,,https://www.ncbi.nlm.nih.gov/pubmed/3335288?dopt=Abstract,,,,,,,,,,
1218,,,,,,,,,,,,,,,,,,,,Fluid retention,,HP:0000969,https://www.ncbi.nlm.nih.gov/pubmed/10189233?dopt=Abstract,,,,,,,,,,
1219,,,,,,,,,hemin,DB03404,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a defective protein by inhibition,,Hepatic prophyria(Abnormality of the heme biosynthetic pathway)*,,HP:0010472*,https://www.ncbi.nlm.nih.gov/pubmed/23016163,,,,,,,,,,
1220,,,,,,,,,cysteine hydrochloride,DB00151 ,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,photosensitivity,,HP:0000992,https://www.ncbi.nlm.nih.gov/pubmed/12535027,https://clinicaltrials.gov/ct2/show/NCT00004940,https://clinicaltrials.gov/ct2/show/NCT00004831,,,,,,,,
1221,,,,,,,,"The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332",Isoniazid,DB00951,ECO:0005542/ECO:0007121,,,,,Symptomatic (C),C,functional complementation of a defective protein by inhibition,Terminated,Study was Terminated (Interim analysis demonstrated the treatment was not effective),,,https://www.ncbi.nlm.nih.gov/pubmed/31395332,,https://clinicaltrials.gov/ct2/show/NCT01550705,,,,,,,,
1222,,,,,,,,,Iron,DB01592,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,high erythrocyte protoporphyrin levels,,HP:0012187,,,https://clinicaltrials.gov/ct2/show/NCT02979249?cond=Erythropoietic+protoporphyria&draw=1&rank=10,,,,,,,,
1223,135,,Erythropoietic uroporphyria associated with myeloid malignancy ,,,,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,https://www.sciencedirect.com/science/article/pii/S0022202X15352507?via%3Dihub,,,,,,,,
1224,136,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,,,Acetylcysteine,DB06151,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein/functional complementation of a defective protein by inhibition,,high Lactic acid,,HP:0003648,https://www.ncbi.nlm.nih.gov/pubmed/16376514,https://www.ncbi.nlm.nih.gov/pubmed/27830356,,https://www.ncbi.nlm.nih.gov/pubmed/29526615,,,,,,,
1225,,,,,,,,Drug used as an aternate therapy with (Metronidazole+Acetylcysteine),neomycin+Acetylcysteine,DB00994+DB06151,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein/functional complementation of a defective protein by inhibition,,abnormal thiosulfates level,,HP:0011943,https://www.ncbi.nlm.nih.gov/pubmed/29526615,,,,,,,,,,
1226,,,,,,,,,(Metronidazole+Acetylcysteine)+Dietary restricting sulfur containing amino acids treatment,DB00916+DB06151,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein/functional complementation of a defective protein by inhibition,,Hypotonia,,MP:0004144,https://www.ncbi.nlm.nih.gov/pubmed/29526615,https://www.ncbi.nlm.nih.gov/pubmed/20657580?dopt=Abstract,,,,,,,,,
1227,,,,,,,,,,,,,,,,,,,,diarrhea,,HP:0002014,,,,,,,,,,,
1228,,,,,,,,,,,,,,,,,,,,high EMA levels,,HP:0003219,,,,,,,,,,,
1229,,,,,,,,,Ascorbic acid,DB00126,ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure,,Decreased activity of cytochrome C oxidase in muscle tissue,,HP:0003688,https://www.ncbi.nlm.nih.gov/pubmed/29526615,,,,,,,,,,
1230,,,,,,,,A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.,carnitine+metronidazole,DB00583+DB00916,ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure+functional complementation of a genetically defective protein,,,,,https://www.ncbi.nlm.nih.gov/pubmed/26917598,,,,,,,,,,
1231,,,,,,,,,Riboflavin and/or coenzyme Q10,DB00140+DB09270,ECO:0000352,,,,,,,functional complementation of a genetically defective protein,,Functional motor deficit,,HP:0004302,https://www.ncbi.nlm.nih.gov/pubmed/11916321,https://www.ncbi.nlm.nih.gov/pubmed/17712735,,,,,,,,,
1232,,,,,,,,,,,,,,,,,,,,Cognitive impairment,, HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/17712735,,,,,,,,,,
1233,,,,,,,,,,,,,,,,,,,,Elevated plasma acylcarnitine levels,,HP:0045045,https://www.ncbi.nlm.nih.gov/pubmed/17712735,,,,,,,,,,
1234,,,,,,,,,,,,,,,,,,,,Chronic mucoid diarrhea,,HP:0002028,https://www.ncbi.nlm.nih.gov/pubmed/17712735,https://www.ncbi.nlm.nih.gov/pubmed/17712735,,,,,,,,,
1235,,,,,,,,,,,,,,,,,,,,Petechiae ,,HP:0000967,https://www.ncbi.nlm.nih.gov/pubmed/17712735,,,,,,,,,,
1236,,,,,,,,,,,,,,,,,,,,Psychomotor retardation,,HP:0025356,https://www.ncbi.nlm.nih.gov/pubmed/17712735,,,,,,,,,,
1237,,,,,,,,"It significantly reduces the inhibitory effect of sulfide on cytochrome c oxidase, resulting in higher rates of respiration and sulfide oxidation in rat mitochondria. ",Dehydroascorbic acid,DB08830,ECO:0005542,,,,,,,symptomatic treatment procedure,,Sulfide toxicity,,NA,https://www.sciencedirect.com/science/article/pii/S0005272811001447#bb0230,,,,,,,,,,
1238,137,# 237500,Dubin-Johnson syndrome,,ABCC2 ,Multidrug resistance protein-2,,"Rifampicin and ursodeoxycholic acid (UDCA) therapy have beneficial effects in chronic cholestatic diseases. These may result, in part, from the induction of MRP2 expression in the liver and kidney. However, neither an indication nor a general role for these agents in Dubin-Johnson syndrome has been defined.https://www.ncbi.nlm.nih.gov/pubmed/12012642
These drugs, in fact, should be used with caution in patients with Dubin-Johnson syndrome. Reporting on a patient with the disease who had a novel 974C→G nonsense mutation of the MRP2gene, Corpechot et al found a rise in conjugated bilirubinemia following the chronic administration of rifampicin, as well as a sharp increase in serum bile acid concentration following the concomitant chronic administration of rifampicin and UDCA. These adverse effects may result from an increased expression of MRP3at the basolateral membrane of hepatocytes as a direct consequence of drug induction.https://www.ncbi.nlm.nih.gov/pubmed/16952291 https://emedicine.medscape.com/article/173517-treatment",rifampicin+UDCA,DB01045+DB01586,,,,,,Symptomatic (C),C,??? activity modification of a genetically defective protein,,pruritus,,HP:0000989,https://www.ncbi.nlm.nih.gov/pubmed/16952291/,https://www.ncbi.nlm.nih.gov/pubmed/16083704/,https://www.ncbi.nlm.nih.gov/pubmed/26264947,https://www.ncbi.nlm.nih.gov/pubmed/12012642,,,,,,,
1239,,,,,,,,,,,,,,,,,,,,hyperbilirunbinemia,,HP:0002904,,,,,,,,,,,
1240,,,,,,,,,,,,,,,,,,,,elevated serum concentrations of bile acids,,HP:0012202,,,,,,,,,,,
1241,,,,,,,,,,,,,,,,,,,,high serum alkaline phosphatase,,HP:0003155,,,,,,,,,,,
1242,,,,,,,,,,,,,,,,,,,,hyperbilirunbinemia,,HP:0002904,,,,,,,,,,,
1243,,,,,,,,,,,,,,,,,,,,elevated serum concentrations of bile acids,,HP:0012202,,,,,,,,,,,
1244,,,,,,,,,,,,,,,,,,,,High biliary cholesterol saturation index,,NA,,,,,,,,,,,
1245,138,# 608799,DPM1-CDG (CDG-Ie) ,,DPM1,dolichol-P-mannose synthase 1,,https://rarediseases.org/rare-diseases/congenital-disorders-of-glycosylation/,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1246,139,# 615042,DPM2-CDG ,,DPM2,dolichyl-phosphate mannosyltransferase subunit 2,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1247,140,# 612937,DPM3-CDG (CDG-Io) ,,DPM3,dolichyl-phosphate mannosyltransferase subunit 3,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1248,141,# 179850,Dowling-Degos disease ,,KRT5/POGLUT1,keratin 5/protein O-glucosyltransferase,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1249,142,# 223360,Dopamine beta hydroxylase deficiency ,,DBH,dopamine beta (β)-hydroxylase,,,droxidopa,DB06262,ECO:0007121,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,orthostatic hypotension,,HP:0001278,https://www.ncbi.nlm.nih.gov/pubmed/20301647,https://www.sciencedirect.com/topics/medicine-and-dentistry/dopamine-beta-hydroxylase-deficiency,https://clinicaltrials.gov/ct2/show/NCT00889135?cond=Dopamine+beta+hydroxylase+deficiency&rank=10,,,,,,,,
1250,143,# 128230,Dopa-responsive dystonia,,GCH1/TH/SPR,GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,,,levedopa/carbidopa,DB01235/DB00190,ECO:0007121,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/9886460/,https://www.ncbi.nlm.nih.gov/pubmed/11346370/,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887,,,
1251,,,,,,,,,,,,,,,,,,,,Parkinsonism,,,,,,,,,,,,,
1252,,,,,,,,,,,,,,,,,,,,Fatigue,,,,,,,,,,,,,
1253,,,,,,,,,,,,,,,,,,,,Cerebellar dysfunction,,,https://www.ncbi.nlm.nih.gov/pubmed/16908750,,,,,,,,,,
1254,,,,,,,,,Serotonin reuptake inhibitors,N06AB,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a defective protein by inhibition,,Depression,,HP:0000716,https://www.ncbi.nlm.nih.gov/pubmed/16361586,,,,,,,,,,
1255,,,,,,,,,,,,,,,,,,,,Obsessive-compulsive behavior ,,HP:0000722,,,,,,,,,,,
1256,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1257,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1258,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1259,,,,,,,,,5‐hydroxytryptophan,DB02959 ,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a defective protein by inhibition,,Depression,,HP:0000716,https://www.ncbi.nlm.nih.gov/pubmed/16361586,,,,,,,,,,
1260,,,,,,,,,,,,,,,,,,,,Serotonin deficiency,,HP:0003117*,,,,,,,,,,,
1261,,# 605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,Tyrosine hydroxylase,1.14.16.2,,selegiline+L-dopa,DB01037+DB01235,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/20399390,https://www.ncbi.nlm.nih.gov/pubmed/11241071,https://www.ncbi.nlm.nih.gov/pubmed/10753262,,,,,,,,
1262,,,,,,,,,,,,,,,,,,,,lack of eye contact,,HP:0000817,,,,,,,,,,,
1263,,,,,,,,,,,,,,,,,,,,Delayed motor skills,,HP:0002194,,,,,,,,,,,
1264,,,,,,,,,,,,,,,,,,,,Poor head control,, HP:0002421,,,,,,,,,,,
1265,,,,,,,,,,,,,,,,,,,,Delayed mental development,,HP:0001263,,,,,,,,,,,
1266,,,,,,,,,,,,,,,,,,,,lack of gross motor function,,HP:0002194,,,,,,,,,,,
1267,,,,,,,,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,L- dopa,,ECO:0000352,,,(926T>C,,,,metabolite replacement,,Decreased CSF homovanillic acid,,HP:0003785,https://www.ncbi.nlm.nih.gov/pubmed/8817341,https://www.ncbi.nlm.nih.gov/pubmed/10585338,https://www.ncbi.nlm.nih.gov/pubmed/10407773,https://www.ncbi.nlm.nih.gov/pubmed/9732974,,,,,,,
1268,,,,,,,,,,,,,,,,,,,,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/22815559,,,,,,,,,,
1269,,,,,,,,,,,,,,,,,,,,Myoclonus jerk,,HP:0001336,https://www.ncbi.nlm.nih.gov/pubmed/22815559,,,,,,,,,,
1270,,,,,,,,,,,,,,,,,,,,Abnormal epinephrine/norepinephrin ratio,,NA,https://www.ncbi.nlm.nih.gov/pubmed/10585338,,,,,,,,,,
1271,,,,,,,,,,,,,,,,,,,,Hypokinesia,,HP:0002375,,,,,,,,,,,
1272,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1273,144,# 614921,PGM1-CDG ,,PGM1,Phosphoglucomutase-1,5.4.2.2,,D-galactose,DB11735,ECO:0007121/ECO:0001565,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,"abnormal alanine transaminase,",,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/28617415,https://clinicaltrials.gov/ct2/show/NCT02955264,https://www.ncbi.nlm.nih.gov/pubmed/24499211/,,,,,,,,
1274,,,,,,,,,,,,,,,,,,,,abnormal aspartate transaminase,,HP:0002910,,,,,,,,,,,
1275,,,,,,,,,,,,,,,,,,,,abnormal activated partial thromboplastin time,,HP:0003645,,,,,,,,,,,
1276,,,,,,,,,,,,,,,,,,,,abnormal Antithrombin-III levels,,HP:0001976,,,,,,,,,,,
1277,,,,,,,,,,,,,,,,,,,,abnormal nucleotide sugars,,NA,,,,,,,,,,,
1278,145,# 266265,SLC35C1-CDG (CDG-IIc) ,,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,Q96A29,,Fucose,DB03485,ECO:0001565/ECO:0005542,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,defected phagocytic function,,HP:0010977,https://www.ncbi.nlm.nih.gov/pubmed/29702557,https://www.ncbi.nlm.nih.gov/pubmed/17276979,https://www.ncbi.nlm.nih.gov/pubmed/10590041,,,,,,,,
1279,,,,,,,,,,,,,,,,,,,,low neutrophil count,,HP:0001875,,,,,,,,,,,
1280,,,,,,,,,,,,,,,,,,,,recurrent infection,,HP:0002719,,,,,,,,,,,
1281,,,,,,,,,,,,,,,,,,,,abnormal expression of E- and P-selectin ligands,,NA,,,,,,,,,,,
1282,,,,,,,,,,,,,,,,,,,,atypical psychomotor development,,HP:0001263*,,,,,,,,,,,
1283,146,# 610768,DOLK-CDG,,DOLK,dolichol kinase,2.7.1.108,,vigabatrin,DB01080,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/23890587,https://www.ncbi.nlm.nih.gov/pubmed/23890587,,,,,,,,,
1284,,,,,,,,,Carbamazepine,,ECO:0000352,,,,,,,symptomatic treatment procedure,,Generalized tonic–clonic seizure,,HP:0002069,,,,,,,,,,,
1285,,,,,,,,,,,,,,,,,,,,Focal seizures,,HP:0007359,,,,,,,,,,,
1286,,,,,,,,,clonazepam+vigabatrin,DB01068+DB01080,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,seizures,,HP:0001250,,,,,,,,,,,
1287,147,,Dipsogenic diabetes insipidus,Behavioural therapy was a successful treatmemnt for primary polydipsia.https://www.ncbi.nlm.nih.gov/pubmed/2373769?dopt=Abstract https://www.ncbi.nlm.nih.gov/pubmed/12102585?dopt=Abstract https://www.ncbi.nlm.nih.gov/pubmed/3392224?dopt=Abstract,,,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",desmopressin ,DB00035 ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,polyuria,,HP:0000103,https://www.ncbi.nlm.nih.gov/pubmed/16544179,,https://www.ncbi.nlm.nih.gov/pubmed/16544179,,,,,,,,
1288,,,,,,,,,,,,,,,,,,,,affected functional activity,,HP:0025142*,,,,,,,,,,,
1289,148,# 274270,Dihydropyrimidine dehydrogenase (DPD) deficiency,,DPYD ,dihydropyrimidine dehydrogenase,1.3.1.2,,uridine triacetate,DB09144 ,ECO:0005542/ECO:0000305,,,,,Functional interaction (Mechanistic B),B,functional complementation of a defective protein by inhibition,,mortality,,HP:0040006,https://www.ncbi.nlm.nih.gov/pubmed/29908244,https://www.ncbi.nlm.nih.gov/pubmed/27622829,,,,,,,,,
1290,,,,,,,,,,,,,,,,,,,,Weight loss,,HP:0001824,,,https://link.springer.com/chapter/10.1007%2F8904_2017_14,https://link.springer.com/chapter/10.1007%2F8904_2017_14,,,,,,,
1291,,,,,,,,,Valproic acid ,DB00313,ECO:0000352,,,,,,,symptomatic treatment procedure,,Generalized muscular hypotonia,, HP:0001290,https://www.ncbi.nlm.nih.gov/pubmed/28275972,,,,,,,,,,
1292,,,,,,,,,,,,,,,,,,,,EEG with parito-occipital spike waves,,HP:0012011,,,,,,,,,,,
1293,,,,,,,,,,,,,,,,,,,,Developmental impairment,,HP:0001270,,,,,,,,,,,
1294,,,,,,,,,,,,,,,,,,,,Speech and languague delay,,,HP:0000750,,,,,,,,,,
1295,,,,,,,,,Valpric acid + carbamazepine,DB00313+DB00564,ECO:0000352,,,,,,,symptomatic treatment procedure,,seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/30349988,,,,,,,,,,
1296,149,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,1.5.1.34,,BH4+L-dopa/carbidopa +5-hydroxytryptophan+ folinic acid,DB00360+DB01235/DB00190+DB02959+DB00650 ,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,High plasma phenylalanine level,,HP:0004923,,,https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292,,,,,,,
1297,,,,,,,,,,,,,,,,,,,,developmental delay,,HP:0001263,,,,,,,,,,,
1298,,,,,,,,,,,,,,,,,,,,unalertencess,,HP:0002329*,,,,,,,,,,,
1299,,,,,,,,,,,,,,,,,,,,Receptive language delay,,HP:0010863,,,,,,,,,,,
1300,,,,,,,,,Phe-restricted diet +folinic acid+L-dopa+5-hydroxytryptophan,DB00650 +DB01235+DB02959 ,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,dietary exclusion+metabolite replacement,,high plasma phenylalanine level,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/7760062,https://www.ncbi.nlm.nih.gov/pubmed/18425437,,,,,,,,
1301,,,,,,,,,,,,,,,,,,,,High serum  prolactin,,HP:0040086,,,,,,,,,,,
1302,,,,,,,,,,,,,,,,,,,,Neurological abnormalities,,HP:0000707,,,,,,,,,,,
1303,,,,,,,,,,,,,,,,,,,,abnormal blood Phe levels,,HP:0010893,,,,,,,,,,,
1304,,,,,,,,,l‐dopa+5-hydroxytryptophan+BH4+entacapone,DB01235+DB02959+DB00360+DB00494,ECO:0000352,,,,,Supportive (C),C,metabolite replacement+symptomatic treatment procedure,,high plasma phenylalanine level,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/25667865,,,,,,,,,,
1305,,,,,,,,,Levetiracetam ,DB01202,ECO:0000352,,,,,,,symptomatic treatment procedure,,seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/25667865,,,,,,,,,,
1306,,,,,,,,,Phenobarbital + Valproate ,DB01174+DB00313,ECO:0000352,,,,,,,symptomatic treatment procedure,,Spastic tetraparesis,,HP:0001285,https://www.ncbi.nlm.nih.gov/pubmed/18060820,,,,,,,,,,
1307,,,,,,,,,,,,,,,,,,,,Epilepsy,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/18060820,,,,,,,,,,
1308,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1309,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1310,,,,,,,,,l‐dopa+carbidop+5-hydroxytryptophan+selegiline,DB01235+DB00190+DB02959+DB01037,ECO:0000352,,,,,l‐dopa+carbidop+5-hydroxytryptophan+selegiline,C,metabolite replacement+symptomatic treatment procedure,,high plasma phenylalanine level,,done,https://www.ncbi.nlm.nih.gov/pubmed/18425437,,,,,,,,,,
1311,,,,,,,,,pramipexole,DB00413,ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure,,dopamine deficiency,,HP:0012656,https://www.ncbi.nlm.nih.gov/pubmed/22325981,https://www.ncbi.nlm.nih.gov/pubmed/25707872,https://www.ncbi.nlm.nih.gov/pubmed/27423595,,,,,,,,
1312,,,,,,,,,,,,,,,,,,,,movement disability,,HP:0100022,,,,,,,,,,,
1313,,,,,,,,,,,,,,,,,,,,behavioral disability,,HP:0000708,,,,,,,,,,,
1314,,,,,,,,,,,,,,,,,,,,hyperprolactinemia,,HP:0000870,,,,,,,,,,,
1315,,,,,,,,"Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.",Rotigotine+L-dopa+carbidopa,DB05271+DB01235+DB00190,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a defective protein by stimulation,,parkinsonian symptoms,,HP:0001300,https://www.ncbi.nlm.nih.gov/pubmed/27423595,,,,,,,,,,
1316,,,,,,,,,,,,,,,,,,,,Postural tremor,,HP:0002174,,,,,,,,,,,
1317,,,,,,,,,,,,,,,,,,,,Kinetic tremor ,,HP:0030186,,,,,,,,,,,
1318,,,,,,,,,,,,,,,,,,,,Bradykinesia,,HP:0002067,,,,,,,,,,,
1319,,,,,,,,,,,,,,,,,,,,Dystonia,,HP:0001332,,,,,,,,,,,
1320,150,# 222748,Dihydropyrimidinase deficiency ,,DPYS,dihydropyrimidinase,3.5.2.2,,No treatment is available in DDIEM,,,,,,,,,,,dyskinesias,,HP:0100660,,,,,,,,,,,
1321,151,# 246900,Dihydrolipoamide dehydrogenase deficiency ,,DLD,dihydrolipoamide dehydrogenase,1.8.1.4,,Riboflavin,DB00140,ECO:0000352/ECO:0001565,,,,,Direct interaction (Mechanistic A),A,activity modification of a genetically defective protein,,Exercise intolerance,,HP:0003546,,,https://www.ncbi.nlm.nih.gov/pubmed/25251739,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/10970889,,,,,,
1322,,,,,,,,,,,,,,,,,,,,Myopathy,,HP:0003198,,,,,,,,,,,
1323,,,,,,,,,,,,,,,,,,,,Fatiguability,,HP:0003750,,,,,,,,,,,
1324,,,,,,,,,biotin+coenzyme Q+carnitine+Riboflavin,DB00121+DB09270+DB00148+DB00140,ECO:0000352,,,,,Supportive (C),C,activity modification of a genetically defective protein+symptomatic treatment procedure,,Repeated vomiting,,HP:0002572,https://www.ncbi.nlm.nih.gov/pubmed/14765544,,,,,,,,,,
1325,,,,,,,,,,,,,,,,Supportive (C),C,,,Encephalopathy,,HP:0001298,,,,,,,,,,,
1326,,,,,,,,,,,,,,,,Supportive (C),C,,,Lactic acidosis,,HP:0003128,,,,,,,,,,,
1327,,,,,,,,,Sodium bicarbonate+Dichloroacetate+ Carnitine+ Thiamin+ Coenzyme Q+ Riboflavin,,ECO:0000352,,,,,,,symptomatic treatment procedure+activity modification,,Metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/10448086,,,,,,,,,,
1328,,,,,,,,,Thiamine,DB00152,ECO:0000352,p.I480M,,,,Supportive (C),C,activity modification of a genetically defective protein,,Recurrent vomiting,,HP:0002572,,,https://www.ncbi.nlm.nih.gov/pubmed/25032271,https://www.ncbi.nlm.nih.gov/pubmed/10448086,,,,,,,
1329,,,,,,,,,,,,,,,,,,,,Ptosis,,HP:0000508,https://www.ncbi.nlm.nih.gov/pubmed/20652410,,,,,,,,,,
1330,,,,,,,,,,,,,,,,,,,,Increased muscle fatiguability,,HP:0003750,https://www.ncbi.nlm.nih.gov/pubmed/20652410,,,,,,,,,,
1331,,,,,,,,"Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022",sodium dichloroacetate,DB08809,ECO:0000352,,,,,Supportive (C),C,activity modification of a genetically defective protein,,lactic acidemia ,,HP:0003128,https://www.ncbi.nlm.nih.gov/pubmed/8652022,https://www.ncbi.nlm.nih.gov/pubmed/11687750,https://www.ncbi.nlm.nih.gov/pubmed/23478190,https://www.ncbi.nlm.nih.gov/pubmed/25032271,,,,,,,
1332,,,,,,,,,Lipoic acid,DB00166 ,ECO:0000352,,,,,Functional interaction (B),B,metabolite replacement,,lactic acidemia ,,HP:0003128,https://www.ncbi.nlm.nih.gov/pubmed/6418873,,,,,,,,,,
1333,,,,,,,,,,,,,,,,,,,,pyruvic acidemia,,HP:0001941,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040/,,,,,,
1334,152,# 222730,Dicarboxylic aminoaciduria,,SLC1A1,Excitatory amino acid transporter 3,P43005 ,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1335,154,# 125370,Dentatorubral-pallidoluysian atrophy ,,ATN1 ,atrophin 1,P54259,,levetiracetam,DB01202 ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Tonic-clonic seizures,,HP:0002069,,,https://www.ncbi.nlm.nih.gov/pubmed/25558587,https://www.ncbi.nlm.nih.gov/pubmed/24816443,,,,,,,
1336,,,,,,,,,,,,,,,,,,,,Myoclonus,,HP:0001336,,,,,,,,,,,
1337,,,,,,,,,,,,,,,,,,,,EEG abnormality,,HP:0002353,,,,,,,,,,,
1338,,,,,,,,,,,,,,,,,,,,Poor appetite,,HP:0004396,,,,,,,,,,,
1339,,,,,,,,,,,,,,,,,,,,Low quality of life,,HP:0025142,,,,,,,,,,,
1340,,,,,,,,,,,,,,,,,,,The drug reduces the frequency of the epileptic seizures.,Epileptic seizures,,HP:0001250,,,,,,,,,,,
1341,,,,,,,,"""A limitation of this study is that we did not use quantative measures, such as the Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale, to evaluate severity of psychosis. This issue warrants further investigations for the benefit of SGAs to treat psychosis with DRPLA."" https://www.ncbi.nlm.nih.gov/pubmed/29739138",olanzapine,DB00334 ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Psychosis,,HP:0000709,,,https://www.ncbi.nlm.nih.gov/pubmed/29739138,,,,,,,,
1342,,,,,,,,,,,,,,,,,,,,Hallucinatory-paranoid state,,HP:0011999*,,,,,,,,,,,
1343,,,,,,,,,,,,,,,,,,,,Auditory hallucinations,,HP:0008765,,,,,,,,,,,
1344,,,,,,,,The treatment regimen resulted in neuroleptic malignant syndrome.,Haloperidol +Levomepromazine,DB00502+DB01403,ECO:0000352,,,,,,,symptomatic treatment procedure,,Psychosis,,HP:0000709,https://www.ncbi.nlm.nih.gov/pubmed/11449034/,,,,,,,,,,
1345,,,,,,,,,Perampanel,DB08883,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Diminished intellectual abilities,,HP:0001249,https://www.ncbi.nlm.nih.gov/pubmed/28856097,,,,,,,,,,
1346,,,,,,,,,,,,,,,,,,,,myoclonic seizures,,HP:0002123,,,,,,,,,,,
1347,,,,,,,,,,,,,,,,,,,,inability to walk,,HP:0002540,,,,,,,,,,,
1348,155,# 602398,Desmosterolosis ,,DHCR24,3-beta-hydroxysterol delta-24-reductase,1.3.1.72,,Riboflavin+Nicotinamide+Thiamine,DB00140+DB02701+DB00152,ECO:0007764/ECO:0007121,,,,,Functional interaction (Mechanistic B),B,activity modification of a genetically defective protein,,High desmosterol levels (Abnormality of cholesterol metabolism)*,The change was not statistically significant.,HP:0003107*,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031/,,,,,,,,
1349,,,,,,,,,,,,,,,,,,,,High desmosterol/cholesterol ratio,The change was not statistically significant.,HP:0003107*,,,,,,,,,,,
1350,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1351,,,,,,,,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",cholesterol,DB04540 ,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a defective protein by inhibition,,High desmosterol levels (Abnormality of cholesterol metabolism)*,,HP:0003107*,https://www.ncbi.nlm.nih.gov/pubmed/10959439,,https://jhu.pure.elsevier.com/en/publications/inborn-errors-of-cholesterol-biosynthesis-6,,,,,,,,
1352,156,# 105650,Diamond-Blackfan anemia ,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,L-leucine,DB00149,ECO:0007121/ECO:0005542/ECO:0000352,,,,,Functional interaction (Mechanistic B),B,activity modification of a genetically defective protein by transcriptional or translational modification,,low heamoglobin leval,,HP:0001903,,,https://clinicaltrials.gov/ct2/show/NCT02386267?cond=Diamond-Blackfan+anemia&draw=2&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/22734070,https://www.ncbi.nlm.nih.gov/pubmed/25098371,https://www.ncbi.nlm.nih.gov/pubmed/17562599,https://www.ncbi.nlm.nih.gov/pubmed/22791294,,,,
1353,,,,,,,,,,,,,,,,,,,,Defect in protein synthesis (Abnormality of circulating protein level)*,,HP:0010876*,,,,,,,,,,,
1354,,,,,,,,,,,,,,,,,,,,Decreased red blood cell production ,,HP:0012133*,,,https://clinicaltrials.gov/ct2/show/NCT01362595?cond=Diamond-Blackfan+anemia&rank=4,,,,,,,,
1355,,,,,,,,,Antithymocyte globulin+Cyclosporine,DB00098+DB00091,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,In other blood/bone marrow disorders of immune etiology these drugs have synergistic effects. We propose a Phase II study to explore the combined use of ATG and cyclosporine as a rational approach to the treatment of Diamond Blackfan anemia. No results were posted in the website to tell what was the actual responce to the treatment. https://clinicaltrials.gov/ct2/show/NCT00001749,Pure red bllod cell aplasia,,HP:0012410,https://www.ncbi.nlm.nih.gov/pubmed/15813920,,https://clinicaltrials.gov/ct2/show/NCT00001749,,,,,,,,
1356,,,,,,,,,Rituximab,DB00073,ECO:0007121/ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,low RBC count,,HP:0001877,,,https://clinicaltrials.gov/ct2/show/study/NCT00229619?cond=Diamond-Blackfan+anemia&rank=7&sect=X70156,,,,,,,,
1357,,,,,,,,,Daclizumab,DB00111 ,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,low RBC count,,HP:0001877,,,https://clinicaltrials.gov/ct2/show/results/NCT00001962?cond=Diamond-Blackfan+anemia&rank=8&sect=X70156#outcome1,,,,,,,,
1358,,,,,,,,,lenalidomide,DB00480,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,low RBC count,,HP:0001877,,,https://clinicaltrials.gov/ct2/show/NCT01034592?cond=Diamond-Blackfan+anemia&rank=9,,,,,,,,
1359,,,,,,,,,prednisolone,DB00635,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,low hb level,,HP:0001903,https://www.ncbi.nlm.nih.gov/pubmed/27329125,,http://www.ncbi.nlm.nih.gov/pubmed/26758319?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/26305041?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26305041,https://www.ncbi.nlm.nih.gov/pubmed/28883274,,,,,
1360,,,,,,,,,,,,,,,,,,,,low quality of ife,,HP:0025142*,,,,,,,,,,,
1361,,,,,,,,,,,,,,,,,,,,Pathological apoptosis,,NA,,,,,,,,,,,
1362,,,,,,,,,,,,,,,,,,,,erythroid progenitor depletion,,HP:0025034*,,,,,,,,,,,
1363,,,,,,,,,,,,,,,,,,,,premature differentiation of erythroid cells,,HP:0012130*,,,,,,,,,,,
1364,,,,,,,,,Prednisone +Cyclosporine,DB00635+DB00091 ,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein+functional complementation of a defective protein by inhibition,,low Hb level,,HP:0001903,https://www.ncbi.nlm.nih.gov/pubmed/27329125,https://www.ncbi.nlm.nih.gov/pubmed/3389144?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/2503027?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/1546717?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10779036?dopt=Abstract,,,,,,
1365,,,,,,,,,,,,,,,,,,,,Reticulocytopenia,,HP:0001896,,,,,,,,,,,
1366,,,,,,,,,Metoclopramide,DB01233,ECO:0000352,,,,,Functional interaction (Mechanistic B),,functional complementation of a defective protein by stimulation,,low Hb level,,HP:0001903,https://www.ncbi.nlm.nih.gov/pubmed/15795909,https://www.ncbi.nlm.nih.gov/pubmed/12351372/,https://www.ncbi.nlm.nih.gov/pubmed/17921858/,https://www.ncbi.nlm.nih.gov/pubmed/24744655,,,,,,,
1367,,,,,,,,,,,,,,,,,,,,Reduced hematocrit,,HP:0031851,,,,,,,,,,,
1368,,,,,,,,,Metoclopramide+prednisolone,DB01233+DB00635,ECO:0000352,,,,,,,functional complementation of a defective protein by stimulation+functional complementation of a genetically defective protein,,low Hb level,,HP:0001903,https://www.ncbi.nlm.nih.gov/pubmed/24744655,,,,,,,,,,
1369,,,,,,,,,Eltrombopag,DB06210,ECO:0007121/ECO:0000352,(c.356+3>C),,,,Functional interaction (Mechanistic B),,functional complementation of a defective protein by stimulation,,low Hb level,,HP:0001903,http://www.bloodjournal.org/content/128/22/2682,https://clinicaltrials.gov/ct2/show/NCT01328587,https://www.ncbi.nlm.nih.gov/pubmed/29684566,,,,,,,,
1370,,,,,,,,,,,,,,,,,,,,Thrombocytopenia,,HP:0001873,,,,,,,,,,,
1371,157,# 258870,Gyrate atrophy of the choroid and retina ,,OAT,ornithine aminotransferase,2.6.1.13,,vitamin B6 ,DB00165,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,activity modification of a genetically defective protein,,high ornithine level,,HP:0012026,https://www.ncbi.nlm.nih.gov/pubmed/29757052,https://www.ncbi.nlm.nih.gov/pubmed/17565677/,https://www.ncbi.nlm.nih.gov/pubmed/7028650/,https://www.ncbi.nlm.nih.gov/pubmed/24082780,https://www.ncbi.nlm.nih.gov/pubmed/29654911,,,,,,
1372,,,,,,,,,lysine supplementation,DB00123 ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,, high ornithine level		HP:0012026,,,https://link.springer.com/content/pdf/10.1023%2FA%3A1010545811361.pdf,https://www.ncbi.nlm.nih.gov/pubmed/11486915,https://www.ncbi.nlm.nih.gov/pubmed/10896280,,,,,,,,
1373,,,,,,,,,Low protein intake(arginine-restricted diet) + pyridoxine,NA+DB00165,ECO:0000352,,,,,,,dietary exclusion+activity modification of a genetically defective protein,,cystoid macular edema ,,HP:0011505,https://www.ncbi.nlm.nih.gov/pubmed/28388263?dopt=Abstract,,,,,,,,,,
1374,,,,,,,,,,,,,,,,,,,,low visual acuity,,HP:0007663,,,,,,,,,,,
1375,,,,,,,,,Arginine-restricted diet,NA,ECO:0000352,,,,,,,dietary exclusion,,Disease progresssion,,HP:0003676,https://www.ncbi.nlm.nih.gov/pubmed/16601905,https://www.ncbi.nlm.nih.gov/pubmed/15159649,https://www.ncbi.nlm.nih.gov/pubmed/1755734,https://www.ncbi.nlm.nih.gov/pubmed/7356686,https://www.ncbi.nlm.nih.gov/pubmed/7254778/,,,,,,
1376,,,,,,,,,,,,,,,,,,,,High ornithine plasma level,,HP:0012026,,,,,,,,,,,
1377,,,,,,,,,,,,,,,,,,,,low visual acuity,,HP:0007663,,,,,,,,,,,
1378,,,,,,,,,topical NSAIDs +systemic CAI,DB00586+DB00311,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,cystoid macular edema ,,HP:0011505,https://www.ncbi.nlm.nih.gov/pubmed/28708224?dopt=Abstract,,,,,,,,,,
1379,,,,,,,,,Intravitreal bevacizumab,DB00112,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,choroidal neovascularization,,HP:0011506,https://www.ncbi.nlm.nih.gov/pubmed/28560651?dopt=Abstract,,,,,,,,,,
1380,,,,,,,,,,,,,,,,,,,,decreased visual acuity ,,HP:0007663,,,,,,,,,,,
1381,,,,,,,,,,,,,,,,,,,,abnormal central vision,,HP:0000504,,,,,,,,,,,
1382,,,,,,,,,Alpha-aminoisobutyric acid,DB02952,ECO:0000352,,,,,,,symptomatic treatment procedure,,High ornithine plasma level,,HP:0012026,https://www.ncbi.nlm.nih.gov/pubmed/7356686,https://www.ncbi.nlm.nih.gov/pubmed/7254778/,,,,,,,,,
1383,,,,,,,,,Gene therapy *,NA,ECO:0007121/ECO:0001565,,,,,Direct interaction (Mechanistic A) ,A,direct complementation of a genetically defective protein by gene therapy,,Abnormal enzyme/coenzyme activity,, HP:0012379,https://clinicaltrials.gov/ct2/show/NCT00001735?cond=Ornithine+aminotransferase+deficiency&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/9414260,https://clinicaltrials.gov/ct2/show/NCT00001735?cond=Ornithine+aminotransferase+deficiency&rank=1,,,,,,,,
1384,158,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase, 2.1.1.2,,creatine-monohydrate,DB00148,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,Extrapyramidal movement disorders,,HP:0002071,https://www.ncbi.nlm.nih.gov/pubmed/24268530,https://www.ncbi.nlm.nih.gov/pubmed/18652077,https://www.sciencedirect.com/science/article/pii/S1096719213003107,https://www.sciencedirect.com/science/article/pii/S1096719213003661,https://www.ncbi.nlm.nih.gov/pubmed/29506905,https://www.sciencedirect.com/science/article/pii/S1096719212002971,https://www.ncbi.nlm.nih.gov/pubmed/8813986,,,,
1385,,,,,,,,A competitive inhibition of AGAT activity via high-dose l-ornithine supplementation,l-ornithine+Arginine restriction,DB00129,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a defective protein by inhibition+dietary exclusion,,Epileptic seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/11749046,https://www.ncbi.nlm.nih.gov/pubmed/9686828,,,,,,,,,
1386,,,,,,,,,,,,,,,,,,,,Slow background activity in the EEG(EEG abnormality)*,,HP:0002353*,,,,,,,,,,,
1387,,,,,,,,,,,,,,,,,,,,Bilateral abnormal signal intensities in the globus pallidus (Abnormality of the globus pallidus)*,,HP:0002453*,,,,,,,,,,,
1388,,,,,,,,"The treatment reduces glycine levels, which reduces production of guanidinoacetate by conjugation and renal excretion however in one study it was mentioned that sodium benzoate did not improve moderate intellectual disability or normalize guanidinoacetate accumulation in the central nervous system.https://www.ncbi.nlm.nih.gov/pubmed/24766785
Sodium benzoate has been proposed as an additional approach to reduce the production of GAA via conjugation with glycine to form hippuric acid which is rapidly excreted by the kidneys",Sodium benzoate+ornithin +carnitine,DB03793+DB00129+DB00148,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a defective protein by inhibition,,High CSF guanidinoacetate levels,,NA,https://www.ncbi.nlm.nih.gov/pubmed/24071436,https://www.ncbi.nlm.nih.gov/pubmed/12557293,,,,,,,,,
1389,,,,,,,,,,,,,,,,,,,,High plasma guanidinoacetate levels,,NA,https://www.ncbi.nlm.nih.gov/pubmed/24071436,,,,,,,,,,
1390,,,,,,,,This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203,Creatine+l-ornithine+Arginine restriction,DB00148+DB00129,ECO:0000352,,,,,Functional interaction (Mechanistic B),,metabolite replacement+functional complementation of a defective protein by inhibition+dietary exclusion,,Epilepsy,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/24268530,https://www.ncbi.nlm.nih.gov/pubmed/12557293,,,,,,,,,
1391,,,,,,,,,,,,,,,,,,,,low urinary creatine excretion,,HP:0012113,https://www.ncbi.nlm.nih.gov/pubmed/16855203,,,,,,,,,,
1392,,,,,,,,,,,,,,,,,,,,low brain creatine phosphate,,NA,https://www.ncbi.nlm.nih.gov/pubmed/16855203,,,,,,,,,,
1393,,,,,,,,,,,,,,,,,,,,low cerebral creatine,,HP:0025051,https://www.ncbi.nlm.nih.gov/pubmed/16855203,,,,,,,,,,
1394,,,,,,,,,,,,,,,,,,,,High plasma guanidinoacetate levels,,NA,https://www.ncbi.nlm.nih.gov/pubmed/16855203,,,,,,,,,,
1395,,,,,,,,,,,,,,,,,,,,abnormal coordination of movements,,HP:0011443,https://www.ncbi.nlm.nih.gov/pubmed/24268530,https://www.ncbi.nlm.nih.gov/pubmed/16855203,https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency,,,,,,,,
1396,,,,,,,,,,,,,,,,,,,,behavioral abnormalities,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/24268530,https://www.ncbi.nlm.nih.gov/pubmed/16855203,,,,,,,,,
1397,,,,,,,,Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530,sodium phenylbutyrate+l-ornithine+Arginine restriction,DB06819+DB00129,ECO:0000352,,,,,,,functional complementation of a defective protein by inhibition+dietary exclusion,,High plasma guanidinoacetate levels,,NA,https://www.ncbi.nlm.nih.gov/pubmed/24268530,,,,,,,,,,
1398,159,# 233910,GTP cyclohydrolase I deficiency ,,GCH1,GTP cyclohydrolase 1,3.5.4.16,,Tetrahydrobiopterin,DB00360,ECO:0007121/ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,Mechanistic (A),high serum phenylalanine ,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/9667588,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005394-35/ES,https://www.sciencedirect.com/science/article/pii/S1096719205003057?via%3Dihub,,,,,,,
1399,,,,,,,,,L-dopa,DB01235,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,Symptomatic ©,dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/12391354,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.sciencedirect.com/science/article/pii/S1096719208000048,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729,https://www.ncbi.nlm.nih.gov/pubmed/20818608?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19234759?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10078749,,,,
1400,,,,,,,,,benserazide,DB12783,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,oromandibular dystonia ,,HP:0012048,https://www.ncbi.nlm.nih.gov/pubmed/10078749,https://www.ncbi.nlm.nih.gov/pubmed/12003346,,,,,,,,,
1401,,,,,,,,,5-hydroxytryptophane,DB04159 ,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,spasticity,,HP:0001257,,,,,,,,,,,
1402,,,,,,,,,,,,,,,,,,,,abnormal motor development,,HP:0001270,,,,,,,,,,,
1403,,,,,,,,,,,,,,,,,,,,Sleep disturbance,,HP:0002360,,,,,,,,,,,
1404,,,,,,,,,,,,,,,,,,,,Defected neurotransmitter homeostasis in the CNS,,HP:0012535,https://www.ncbi.nlm.nih.gov/pubmed/22729819,,,,,,,,,,
1405,,,,,,,,,folinic acid,DB00650,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,depletion of cerebral folate,,HP:0012446,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/18276179,,,,,,,,,
1406,,,,,,,,,,,,,,,,,,,,abnormal folate homeostasis in the CNS,,HP:0012335,,,,,,,,,,,
1407,,,,,,,,"The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.",Amantadine,DB00915,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,levodopa‐induced choreic dyskinesia(Dyskinesia)*,,HP:0100660*,https://www.ncbi.nlm.nih.gov/pubmed/15389992,,,,,,,,,,
1408,169,# 215140,Greenberg dysplasia ,,LBR,lamin B receptor,Q14739,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1409,170,# 603358,GRACILE syndrome ,,BCS1L,ubiquinol-cytochrome c reductase complex chaperone,Q9Y276,,Sodium bicarbonate,DB01390,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,Symptomatic ©,lactic acidosis,,HP:0003128,,,https://www.ncbi.nlm.nih.gov/pubmed/22970607,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422,,,,,,,
1410,171,# 609056,GM3 synthase deficiency ,,ST3GAL5,"GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase",2.4.99.9,,Gangliosides,DB12351,EC0:0007121,,,,,Direct action (Mechanistic A) Replacement,A,metabolite replacement,Mechanistic (A),Delayed Develoment,,HP:0001263,,,https://clinicaltrials.gov/ct2/show/NCT02234024?cond=GM3+synthase+deficiency&rank=1,,,,,,,,
1411,,,,,,,,,CoQ10,DB09270,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Poor eye contect,,HP:0000817,,,https://www.ncbi.nlm.nih.gov/pubmed/22990144,,,,,,,,
1412,,,,,,,,,,,,,,,,,,,,abnormal interactivity,,HP:0012433,,,,,,,,,,,
1413,172,# 230500,GM1 gangliosidosis type 1 ,,GLB1,beta-galactosidase,3.2.1.23,,(5aR)-5a-C-Pentyl-4-epi-isofagomine,NA,ECO:0001565,,,,,Direct interaction (Mechanistic A) ,A,activity modification of a genetically defective protein,Mechanistic (B),Neurologic abnormalities,,HP:0000707,,,https://www.ncbi.nlm.nih.gov/pubmed/27750150,,,,,,,,
1414,,,,,,,,,β-galactosidase:RTB lectin fusion,NA,ECO:0001565,,,,,,,direct complementation of a genetically defective protein,,Decreased beta-galactosidase activity,,HP:0008166,https://www.ncbi.nlm.nih.gov/pubmed/26766614,,,,,,,,,,
1415,173,# 230600,GM1 gangliosidosis type 2 ,,GLB1,beta-galactosidase,3.2.1.23,,6S-NBI-DGJ,PubChem:CID 76070514 ,ECO:0001565,,,,,Direct interaction (Mechanistic A) ,A,activity modification of a genetically defective protein,Mechanisitic (B),Brain pathology,,HP:0001298,,,https://www.ncbi.nlm.nih.gov/pubmed/23337983?dopt=Abstract,,,,,,,,
1416,174,# 230650,GM1 gangliosidosis type 3 ,,GLB1,beta-galactosidase,3.2.1.23,,Cyclodextrin,CHEBI:23456,ECO:0005542,,,,,Symptomativc (C),C,symptomatic treatment procedure,Mechanistic (,CD failed to ameliorate cholesterol or glycosphingolipid storage in GM1 gangliosidosis ,,NA,,,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,,,,,,,,
1417,,,,,,,,,,,,,,,,,,,,elevated intraneuronal cholesterol,,NA,,,,,,,,,,,
1418,,,,,,,,,AAV-treated βgal,NA,ECO:0005542,,,,,Direct action (Mechanistic A) Replacement,A,direct complementation of a genetically defective protein,Mechanisitic(A),Abnormally decreased rate of beta-galactosidase activity,,HP:0008166,,,https://www.ncbi.nlm.nih.gov/pubmed/17164772?dopt=Abstract,,,,,,,,
1419,,,,,,,,,miglustat,DB00419 ,ECO:0007121,,,,,Functional interaction (Mechanistic B),B,functional complementation of a defective protein by inhibition,Mechanisitic (B),High ganglioside accumulation ,,NA,,,https://clinicaltrials.gov/ct2/show/NCT02030015?cond=GM1+gangliosidosis&rank=1,,,,,,,,
1420,,,,,,,,,,,,,,,,,,,,ataxic gait,,HP:0002066,,,,,,,,,,,
1421,175,# 607625,Niemann-Pick disease type C2 ,,NPC2,NPC intracellular cholesterol transporter 2,P61916,,2-hydroxypropyl-beta-cyclodextrin,DB15146,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a defective protein by inhibition,Mechanistic (B),Elevated intraneuronal cholesterol (Abnormality of cholesterol metabolism)*,,HP:0003107*,,,https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease,,,,,,,,
1422,,,,,,,,,,,,,,,,,,,,High intraneuronal GSL storage,,NA,,,,,,,,,,,
1423,,,,,,,,,,,,,,,,,,,,Increased free sphingosine accumulation(Abnormality of lipid metabolism)*,,HP:0003119*,,,,,,,,,,,
1424,176,# 257220,Niemann-Pick disease type C1 ,,NPC1,NPC intracellular cholesterol transporter 1,O15118,,N-butyldeoxynojirimycin +allopregnanolone,DB00419 +DB11859,ECO:0005542,,,,,Functional interaction (B),B,functional complementation of a defective protein by inhibition+metabolite replacement,Mechanistic (B),elevated intraneuronal cholesterol(Abnormality of cholesterol metabolism)*,,HP:0003107*,https://www.ncbi.nlm.nih.gov/pubmed/11227045/,,,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,,,,,,,
1425,,,,,,,,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,ECO:0007121/ECO:0000352/ECO:0005542,,,,,functional complementation of a defective protein by inhibition+metabolite replacement,B,functional complementation of a defective protein by inhibition,,High intraneuronal GSL storage,,NA,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/29429782,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/,,,,
1426,,,,,,,,,,,,,,,,,,,,Increased free sphingosine accumulation(Abnormality of lipid metabolism)*,,HP:0003119*,,,,,,,,,,,
1427,,,,,,,,,,,,,,,,,,,,Neurodegeneration,,HP:0002180,,,,,,,,,,,
1428,,,,,,,,,,,,,,,,,,,,Poor swallowing,,HP:0002015,,,https://www.ncbi.nlm.nih.gov/pubmed/29429782,,,,,,,,
1429,,,,,,,,,,,,,,,,,,,,Cognitive impairment,,HP:0100543,,,https://www.ncbi.nlm.nih.gov/pubmed/29429782,,,,,,,,
1430,,,,,,,,,,,,,,,,,,,,Fine motor impairment,,HP:0007010,,,https://www.ncbi.nlm.nih.gov/pubmed/29429782,,,,,,,,
1431,,,,,,,,,,,,,,,,,,,,Liver injury,,HP:0001392,,,https://www.ncbi.nlm.nih.gov/pubmed/26027824,,,,,,,,
1432,,,,,,,,,,,,,,,,,,,,Cholesterol sequestration (Abnormality of cholesterol metabolism)*,,HP:0003107*,,,https://www.ncbi.nlm.nih.gov/pubmed/26027824,,,,,,,,
1433,,,,,,,,,,,,,,,,,,,,Reduced life span (Mortality)*,,HP:0040006*,,,https://www.ncbi.nlm.nih.gov/pubmed/26027824,,,,,,,,
1434,,,,,,,,,,,,,,,,,,,,Rapid progression,,HP:0003678,,,,,,,,,,,
1435,,,,,,,,,Miglustat + Allopregnanolone+Cyclodextrin,DB00419+DB11859+CHEBI:23456,ECO:0005542,,,,,Functional interaction (Mechanistic B),B,functional complementation of a defective protein by inhibition+metabolite replacement,,Motor function impairment,,HP:0002275,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pubmed/23948640,,,,,,,,
1436,,,,,,,,,,,,,,,,,,,,Cerebeller neurodegeneration( neurodegeneration)*,,HP:0002180*,,,https://www.ncbi.nlm.nih.gov/pubmed/25400034,,,,,,,,
1437,,,,,,,,,,,,,,,,,,,,Abnormality of lipid metabolism,,HP:0003119,,,https://www.ncbi.nlm.nih.gov/pubmed/31248418,,,,,,,,
1438,,,,,,,,,,,,,,,,,,,,Splenomegaly,,HP:0001744,,,https://www.ncbi.nlm.nih.gov/pubmed/31248418,,,,,,,,
1439,,,,,,,,,,,,,,,,,,,,Increased number of splenic myeloid cells ,,NA,,,https://www.ncbi.nlm.nih.gov/pubmed/31248418,,,,,,,,
1440,,,,,,,,,Allopregnanolone,DB11859,ECO:0005542,,,,,,,metabolite replacement,,Mortality ,,HP:0040006,,,https://www.ncbi.nlm.nih.gov/pubmed/15208706/,,,,,,,,
1441,,,,,,,,,,,,,,,,,,,,Disease progression,,HP:0003678,,,,,,,,,,,
1442,,,,,,,,,,,,,,,,,,,,cortical GM2 ganglioside accumulation ,,HP:0003495,,,,,,,,,,,
1443,,,,,,,,,,,,,,,,,,,,GM3 ganglioside accumulation (Ganglioside accumulation )*,,HP:0004345,,,,,,,,,,,
1444,177,# 245010,Haim-Munk syndrome,,CTSC,Dipeptidyl peptidase 1,3.4.14.1,,(Trimethoprim+Sulfamethoxazole)+Acitretin,(DB00440+DB01015)+DB00459,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,Symptomatic ©,Palmoplantar keratoderma,,HP:0000982,,,https://www.ncbi.nlm.nih.gov/pubmed/21393975?dopt=Abstract,,,,,,,,
1445,,,,,,,,,,,,,,,,,,,,Periodontitis,,HP:0000704,,,,,,,,,,,
1446,,,,,,,,,Acitretin,DB00459,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Periodontitis,,HP:0000704,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870/,,,,,,,,
1447,,,,,,,,,etretinate,DB00926,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Keratoderma ,,HP:0000982,,,https://www.ncbi.nlm.nih.gov/pubmed/10738634/,,,,,,,,
1448,,,,,,,,,,,,,,,,,,,,Aggressive periodontitis(Sever periodontitis),,HP:0000166,,,,,,,,,,,
1449,,,,,,,,,salicylic acid+urea,DB00936+DB03904,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Palmoplantar hyperkeratosis,,HP:0000972,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870/,,,,,,,,
1450,178,# 234500,Hartnup disease ,,SLC6A19,Sodium-dependent neutral amino acid transporter B(0)AT1,Q695T7,,Niacin,DB00627,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,Mechanistic (A),Chronic diarrhea,,HP:0002028,,,https://www.ncbi.nlm.nih.gov/pubmed/25526748?dopt=Abstract,,,,,,,,
1451,,,,,,,,,,,,,,,,,,,,Hypoalbuminemia,,HP:0003073,,,,,,,,,,,
1452,,,,,,,,,,,,,,,,,,,,Exfoliative erythema,,HP:0001019,,,,,,,,,,,
1453,179,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,1.13.11.27,,Ascorbic acid,DB00126,ECO:0000352,,,,,Direct interaction (Mechanistic A),A,activity modification of a genetically defective protein,,Low activity of the immature 4-HPPD enzyme,,NA,https://www.ncbi.nlm.nih.gov/pubmed/26226126,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://www.ncbi.nlm.nih.gov/pubmed/14206878,http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf,,,,,,,
1454,,,,,,,,,N-acetyl-L-cysteine,DB06151,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,secondary glutathione deficiency(Abnormality of metabolism/homeostasis)*,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/24683506?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pubmed/27488560,,,,,,,,
1455,,,,,,,,,,,,,,,,,,,,pyroglutamic aciduria(Organic aciduria)*,,HP:0001992*,,,,,,,,,,,
1456,,,,,,,,,,,,,,,,,,,,metabolic acidosis,,HP:0001942,,,,,,,,,,,
1457,,,,,,,,,,,,,,,,,,,,decreased appetite,,HP:0004396,,,,,,,,,,,
1458,,,,,,,,,Medium-chain triglyceride oil ,DB13959,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,Symptomatic ©,failure to thrive,,HP:0001508,,,https://www.ncbi.nlm.nih.gov/pubmed/27488560,,,,,,,,
1459,,,,,,,,,,,,,,,,,,,,growth delay,,HP:0001510,,,,,,,,,,,
1460,,,,,,,,,,,,,,,,,,,,hemolytic anemia,,HP:0001878,,,,,,,,,,,
1461,,,,,,,,,,,,,,,,,,,,low β2 microglobulin/creatinine ratio,,NA,,,,,,,,,,,
1462,,,,,,,,,phosphate,DB14573,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Hypophosphatemia,,HP:0002148,,,https://www.ncbi.nlm.nih.gov/pubmed/27488560,,,,,,,,
1463,,,,,,,,,sodium bicarbonate,DB01390,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,metabolic acidosis,,HP:0001942,,,,,,,,,,,
1464,,,,,,,,,Nitisinone (NTBC),DB00348,ECO:0005542,,,,,Direct interaction (A),A,procedure to mitigate dominant effects of a genetically abnormal protein,,Extreme frailty (Fatigue)*,,HP:0012378*,,,https://www.ncbi.nlm.nih.gov/pubmed/20677779,,,,,,,,
1465,,# 235200,"HEMOCHROMATOSIS, TYPE 1; HFE1",,HFE,Hereditary hemochromatosis protein,Q30201,,Pantoprazole,DB00213,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,High serum ferritin,,HP:0003281,,,https://clinicaltrials.gov/ct2/show/NCT01524757?cond=Hemochromatosis+type+3&draw=2&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/28624580,,,,,,,
1466,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1467,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1468,180,# 602390,Hemochromatosis type 2,,HJV/HAMP,hemojuvelin/hepcidin,,,Deferoxamine,DB00746  ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,iron overload(Abnormality of iron homeostasis)*,,HP:0011031*,https://www.ncbi.nlm.nih.gov/pubmed/14632789,,https://www.ncbi.nlm.nih.gov/pubmed/17124037,,,,,,,,
1469,,,,,,,,,hepcidin,NA,ECO:0007764 ,,,,,Direct interaction (Mechanistic A),A,metabolite replacement,,Increased plasma iron concentration(Increased serum iron),,HP:0003452,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089/,https://www.researchgate.net/publication/314493225_Clinical_management_of_hemochromatosis_current_perspectives,http://www.bloodjournal.org/content/107/7/2952.abstract?ijkey=8710a861648a7799043d81f5a481aa922c2bd6df&keytype2=tf_ipsecsha&sso-checked=true,,,,,,
1470,181,# 604250,Hemochromatosis type 3 ,,TFR2 ,transferrin receptor 2,,,Deferoxamine,DB00746  ,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,Symptomatic ©,iron overload(Abnormality of iron homeostasis)*,,HP:0011031*,,,https://www.ncbi.nlm.nih.gov/pubmed/29134618,https://clinicaltrials.gov/ct2/show/NCT00001203,https://www.ncbi.nlm.nih.gov/pubmed/14632789,,,,,,
1471,,,,,,,,,hepcidin,NA,ECO:0007764 ,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,Increased plasma iron concentration(Increased serum iron),,HP:0003452,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089/,,,,,,,,
1472,,,,,,,,,LJPC-401(Synthetic human hepcidin),NA,ECO:0007121,,,,,Functional interaction (B),B,metabolite replacement,,High serum iron,,HP:0003452,,,https://clinicaltrials.gov/ct2/show/NCT03395704?cond=Hemochromatosis+type+3&draw=2&rank=13,,,,,,,,
1473,,,,,,,,,Deferiprone (L1),DB08826,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,elevated liver iron concentration,,HP:0040134,,,https://clinicaltrials.gov/ct2/show/NCT00350662?cond=Hemochromatosis+type+3&draw=4&rank=23,https://clinicaltrials.gov/ct2/show/NCT00733811?cond=Hemochromatosis+type+3&draw=5&rank=39,,,,,,,
1474,,,,,,,,,Nifedipine,DB01115 ,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,iron overload(Abnormality of iron homeostasis)*,,HP:0011031*,,,https://clinicaltrials.gov/ct2/show/NCT00712738?cond=Hemochromatosis+type+3&draw=4&rank=30,,,,,,,,
1475,,,,,,,,"Quercetin which is one of the polyphenols can reduce hepatic iron deposition in mice that were exposed to either ethanol or excess iron. They found that quercetin increased BMP6, intranuclear SMAD4, SMAD4 binding to the HAMP promoter, and hepcidin expression, which led to decreased hepatic iron levels and reduced iron-related damage. https://www.ncbi.nlm.nih.gov/pubmed/27393927",flavanols,NA,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,iron overload(Abnormality of iron homeostasis)*,,HP:0011031*,,,https://clinicaltrials.gov/ct2/show/NCT03453918?cond=Hemochromatosis+type+3&draw=5&rank=34,,,,,,,,
1476,183,* 151670,Hepatic lipase deficiency,,LIPC,hepatic lipase,3.1.1.3,Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447,Rosuvastatin,DB01098,ECO:0000352,,,,,Symptomatic(C),C,symptomatic treatment procedure,Symptomatic ©,High atherogenic lipoprotein(Abnormality of lipid metabolism)*,,HP:0003119*,https://www.ncbi.nlm.nih.gov/pubmed/22798447,https://www.ncbi.nlm.nih.gov/pubmed/26194979,https://www.ncbi.nlm.nih.gov/pubmed/12547874,,,,,,,,
1477,,,,,,,,,,,,,,,,,,,,High low-density lipoprotein (LDL)-C(Abnormality of lipid metabolism)*,,HP:0003119*,,,,,,,,,,,
1478,,,,,,,,,,,,,,,,,,,,High Apolipoprotein B (ApoB)(Abnormality of lipid metabolism)*,,HP:0003119*,,,,,,,,,,,
1479,184, # 176100,PORPHYRIA CUTANEA TARDA,,UROD/HEF,uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein,4.1.1.37/Q30201,,Hemin,DB03404,ECO:0005542/ECO:0001565,,,,,Functional interaction (mechanistic B),B,metabolite replacement,,Acute episodic abdominal pain,,HP:0002574,https://www.ncbi.nlm.nih.gov/pubmed/24652768,https://www.ncbi.nlm.nih.gov/pubmed/24175354,,,,,,,,,
1480,,,,,,,,,,,,,,,,,,,,Low pancreatic zymogens,,NA,,,,,,,,,,,
1481,,,,,,,,"The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.",Chloroquine ,DB00608,ECO:0000352,,,C282Y/H63D  heterozygosity or compound heterozygosity /C282Y(Homozygous mutation),https://www.ncbi.nlm.nih.gov/pubmed/12622622. https://www.ncbi.nlm.nih.gov/pubmed/4739135,Functional interaction (mechanistic B),,symptomatic treatment procedure,,Increased liver protoporphyrin concentration (Abnormality of the heme biosynthetic pathway)*,,HP:0010472*,https://www.ncbi.nlm.nih.gov/pubmed/12622622,https://www.ncbi.nlm.nih.gov/pubmed/5080345,https://www.ncbi.nlm.nih.gov/pubmed/7324107,https://www.ncbi.nlm.nih.gov/pubmed/22985607,,,,,,,
1482,,,,,,,,,,,,,,,,,,,,Increased liver iron level,,HP:0012465,https://www.ncbi.nlm.nih.gov/pubmed/5080345,https://www.sciencedirect.com/science/article/pii/S0022202X15441491,https://www.ncbi.nlm.nih.gov/pubmed/4811840/,https://www.ncbi.nlm.nih.gov/pubmed/6173993/,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,,,,,,
1483,,,,,,,,,,,,,,,,,,,,Abnormal liver function,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/4739135,,,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,,,,,,,
1484,,,,,,,,,,,,,,,,,,,,Increased serum ferritin,,HP:0003281,https://www.ncbi.nlm.nih.gov/pubmed/4739135,,,,,,,,,,
1485,,,,,,,,,,,,,,,,,,,,Elevated transferrin saturation,,HP:0012463,https://www.ncbi.nlm.nih.gov/pubmed/4739135,,,,,,,,,,
1486,,,,,,,,,,,,,,,,,,,,"Increased serum iron
",,HP:0003452,,,,,,,,,,,
1487,,# 176100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1488,185,# 241500,"Hypophosphatasia, INFANTILE",, ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,asfotase alfa,DB09105,ECO:0007121,,,,,Direct interaction (Mechanistic A) ,A,direct complementation of a genetically defective protein,,Defect of bone mineralisation,,HP:0004348,https://www.ncbi.nlm.nih.gov/pubmed/29405935?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S0929693X18300174?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/30811537,,,,,,,,
1489,,,,,,,,,,,,,,,,,,,,growth delay,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/29405935?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S0929693X18300174?via%3Dihub,,,,,,,,,
1490,,,,,,,,,,,,,,,,,,,,poor skeletal mineralization,,HP:0006462,https://www.ncbi.nlm.nih.gov/pubmed/30083035,,,,,,,,,,
1491,,,,,,,,,,,,,,,,,,,, respiratory insufficiency,,HP:0002093,https://www.ncbi.nlm.nih.gov/pubmed/30083035,,,,,,,,,,
1492,,,,,,,,,,,,,,,,,,,,rickets ,,HP:0002748,https://cdn.intechopen.com/pdfs/56869.pdf,,,,,,,,,,
1493,,,,,,,,,,,,,,,,,,,,gross motor dysfunction,,HP:0007015,https://www.ncbi.nlm.nih.gov/pubmed/26744272?dopt=Abstract,,,,,,,,,,
1494,,,,,,,,,,,,,,,,,,,,fine motor dysfunction,,HP:0007010,,,,,,,,,,,
1495,,,,,,,,,,,,,,,,,,,,cognitive impairment,,HP:0100543,,,,,,,,,,,
1496,,,,,,,,,,,,,,,,,,,,muscle weakness,,HP:0001324,,,,,,,,,,,
1497,,,,,,,,,,,,,,,,,,,,fatigue,,HP:0012378,,,,,,,,,,,
1498,,,,,,,,,,,,,,,,,,,,delayed growth(stature),,HP:0000002,,,,,,,,,,,
1499,,,,,,,,Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).,Vitamin D ,DB11094,,,,,,Direct interaction (Mechanistic A) ,A,activity modification of a genetically defective protein,,secondary hyperparathyrodism,,HP:0000867,,https://www.semanticscholar.org/paper/Hypophosphatasia%3A-A-Systemic-Skeletal-Disorder-by-Orimo/5d135fbc68735a3e95d3b313fc0636f10215b300,,,,,,,,,
1500,,,,,,,,,NSAID,S01BC,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Lower limb pain,,HP:0012514,https://www.ncbi.nlm.nih.gov/pubmed/16803637,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,,,,,,,,
1501,,,,,,,,,,,,,,,,,,,,Abnormal prostaglandin level,,HP:0011023,https://www.ncbi.nlm.nih.gov/pubmed/10574582,,,,,,,,,,
1502,,,,,,,,,,,,,,,,,,,,Low quality of life(Constitutional symptoms)*,,HP:0025142*,https://www.ncbi.nlm.nih.gov/pubmed/10574582,,,,,,,,,,
1503,,,,,,,,,,,,,,,,,,,,Muscle weakness,,,https://www.ncbi.nlm.nih.gov/pubmed/10574582,,,,,,,,,,
1504,,,,,,,,,,,,,,,,,,,,Abnormal walking distance,,,https://www.ncbi.nlm.nih.gov/pubmed/10574582,,,,,,,,,,
1505,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1506,,,,,,,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_
",Teriparatide ,DB06285,,D378V /G339R/E191K/A176T/V423A,,N461L,,Functional interaction(Mechinistic B),B,activity modification of a genetically defective protein,,stress fractures(Pathologic fracture)*,,HP:0002756*,https://www.ncbi.nlm.nih.gov/pubmed/26245849,https://www.ncbi.nlm.nih.gov/pubmed/27042741,https://www.ncbi.nlm.nih.gov/pubmed/22218563,,,,,,,,
1507,,,,,,,,,,,,Ala176Thr/Val423Ala/Val522Ala,,,,,,,,metatarsal stress fractures,,HP:0001832,https://www.ncbi.nlm.nih.gov/pubmed/20089612,https://www.ncbi.nlm.nih.gov/pubmed/17213282?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,,,,,,,,
1508,,,,,,,,,,,,compound heterozygotes for a p.G339R and p.E191K ALPL mutation,,,,,,,,proximal femur pseudofractures,,HP:0100036,https://www.ncbi.nlm.nih.gov/pubmed/20739387,https://www.ncbi.nlm.nih.gov/pubmed/20739387,,,,,,,,,
1509,,,,,,,,,,,,,,,,,,,,High bone turnover markers,,HP:0003260*,,https://www.ncbi.nlm.nih.gov/pubmed/20739387?dopt=Abstract,,,,,,,,,
1510,,,,,,,,,,,,,,,,,,,,defect in skeletal mineralization,,HP:0006462,,,,,,,,,,,
1511,,,,,,,,,,,,,,,,,,,,Pain,,HP:0012531,,,,,,,,,,,
1512,,,,,,,,,,,,,,,,,,,,mobility problems,,HP:0001376,,,,,,,,,,,
1513,,,,,,,,,,,,,,,,,,,,High urine phosphoethanolamine,,HP:0003239,https://www.ncbi.nlm.nih.gov/pubmed/20089612,,,,,,,,,,
1514,,,,,,,,,,,,,,,,,,,,High serum pyridoxal 5'-phosphate ,,NA,https://www.ncbi.nlm.nih.gov/pubmed/20089612,,,,,,,,,,
1515,,,,,,,,,Vitamin B6,DB00165 ,,,,,,,,,,Seizure,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/17395561?dopt=Abstract,,,,,,,,,,
1516,,,,,,,,,BPS804 (setrusumab),DB14778,ECO:0007121,,,,,Functional interaction (B),B,functional complementation of a defective protein by inhibition,,bone weakness,,HP:0002749,https://clinicaltrials.gov/ct2/show/NCT01406977?cond=hypophosphatasia&rank=5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251/,,,,,,,,,
1517,,,,,,,,,,,,,,,,,,,,bone fructure,,HP:0002757,,,,,,,,,,,
1518,,,,,,,,,,,,,,,,,,,,low bone formation biomarkers,,HP:0031429 ,,,,,,,,,,,
1519,,,,,,,,,,,,,,,,,,,,low bone mineral density,,HP:0004349,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251/,,,,,,,,,,
1520,186,# 615558,Hypolipoproteinemia (Familial hypobetalipoproteinemia),, APOB,apolipoprotein B-48 + apolipoprotein B-100,,,Vitamin A,DB00162,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Fat soluble vitamin  Malabsorption,,HP:0002630,https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1521,,,,,,,,,,,,,,,,,,,,Progressive ataxic retinopathy,,HP:0000488,https://www.ncbi.nlm.nih.gov/pubmed/26086616,,,,,,,,,,
1522,,,,,,,,,Vitamin E,DB00163,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Central nervous degeneration,,HP:0007009,https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1523,,,,,,,,,,,,,,,,,,,,Retinal degeneration,,HP:0000546,,,,,,,,,,,
1524,,,,,,,,,,,,,,,,,,,,Neuromuscular degeneration,,HP:0002180,,,,,,,,,,,
1525,,,,,,,,,,,,,,,,,,,,Oxidative stress,,HP:0025464,,,,,,,,,,,
1526,,,,,,,,,,,,,,,,,,,,Progressive ataxic neuropathy ,,HP:0003434,https://www.ncbi.nlm.nih.gov/pubmed/26086616,,,,,,,,,,
1527,187,# 615558,Homozygous Hypolipoproteinemia,, APOB,apolipoprotein B-48 + apolipoprotein B-100,,,Vitamin A,DB00162,ECO:0000352,,,,,Symptomatic(C),C,symptomatic treatment procedure,,Fat soluble vitamin  Malabsorption (Fat malabsorption)*,,HP:0002630,https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1528,,,,,,,,,,,,,,,,,,,,Progressive ataxic retinopathy,,HP:0000488,https://www.ncbi.nlm.nih.gov/pubmed/26086616,,,,,,,,,,
1529,,,,,,,,,Vitamin E,DB00163,ECO:0000352,,,,,Symptomatic(C),C,symptomatic treatment procedure,,Central nervous degeneration,,HP:0007009,https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1530,,,,,,,,,,,,,,,,,,,,Retinal degeneration,,HP:0000546,,,,,,,,,,,
1531,,,,,,,,,,,,,,,,,,,,Neuromuscular degeneration,,HP:0002180,,,,,,,,,,,
1532,,,,,,,,,,,,,,,,,,,,Oxidative stress,,HP:0025464,,,,,,,,,,,
1533,,,,,,,,,,,,,,,,,,,,Progressive ataxic neuropathy ,,HP:0003434,https://www.ncbi.nlm.nih.gov/pubmed/26086616,,,,,,,,,,
1534,188,# 600627,Hypertryptophanemia ,Hypertryptophanemia should be regarded as a benign condition,TDO2,"tryptophan 2,3-dioxygenase ",1.13.11.11,,No treatment is available in DDIEM,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/22081291,https://www.ncbi.nlm.nih.gov/pubmed/28285122,,,,,,,,,
1535,,,,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12822831,,,,,,,,,,
1536,,,,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15036384,,,,,,,,,,
1537,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1538,189,# 239500,Hyperprolinemia ,,PRODH,proline dehydrogenase 1,1.5.5.2,,Vitamen B6,DB00165,ECO:0000352,,,,,Symptomatic(C),C,symptomatic treatment procedure,"However vitamin B6 and/or PP supplementation was not clinically effective in our patient group. In one patient it seemed to give a temporary improvement, in another patient however, it even seemed to result in a deterioration of the epilepsy
",Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/24173411,,,,,,,,,,
1539,,,,,,,,,Pyridoxine phosphate,DB02209,ECO:0000352,,,,,Symptomatic(C),C,symptomatic treatment procedure,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/24173411,,,,,,,,,,
1540,,,,,,,,,olanzapine,DB00334,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,behavioural disturbance,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/28202261,,,,,,,,,,
1541,,,,,,,,,lithium,DB14507 ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,psychotic  disorder,,HP:0000725,,,,,,,,,,,
1542,,,,,,,,,green tea extract,DB14307,ECO:0005542,,,,,Supportive (C),C,symptomatic treatment procedure,,Oxidative Stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/27589827,https://www.ncbi.nlm.nih.gov/pubmed/24980685,,,,,,,,,
1543,,,,,,,,,Vitamin D,DB11094,ECO:0000352,,,,,Direct interaction (Mechanistic A),A,activity modification of a genetically defective protein by transcriptional or translational modification,,schizophrenia,"The findings reported here support the possibility that supplementation might reduce symptoms or augment recovery of patients with schizophrenia, particularly targeting those with elevated proline, who may represent over one quarter of the schizophrenia population.",HP:0100753,https://www.ncbi.nlm.nih.gov/pubmed/24787057,,,,,,,,,,
1544,,,,,,,,"α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .
",α-Tocopherol+ascorbic acid,DB14476+DB00126,ECO:0005542,,,,,Symptomatic (C),C,symptomatic treatment procedure,,impairment of reference,,,https://www.ncbi.nlm.nih.gov/pubmed/16214240,,,,,,,,,,
1545,,,,,,,,,,,,,,,,,C,,,working spatial memory impairment*,, HP:0002354 ,https://www.ncbi.nlm.nih.gov/pubmed/16214240,,,,,,,,,,
1546,,,,,,,,,,,,,,,,,,,,Oxidative stress,,HP:0025464,,,,,,,,,,,
1547,,,,,,,,,,,,,,,,,,,,cerebral cortex acetylcholinesterase inhibition,,NA,,,,,,,,,,,
1548,,,,,,,,,,,,,,,,,,,,"hippocampal Na+, K+-ATPase reduced activity",,NA,,,,,,,,,,,
1549,190,# 239510,Hyperprolinemia type 2,,ALDH4A1,Δ1-pyrroline 5-carboxylate dehydrogenase ,1.2.1.88,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1550,191,# 264070,Hyperphenylalaninemia due to dehydratase deficiency ,Protein and phenylalanine restriction should be maintained in order to avoid disease progression.,PCBD1,pterin-4 alpha-carbinolamine dehydratase,4.2.1.96,,Tetrahydrobiopterin,DB00360,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,Muscular hypotonia,,HP:0001252,https://www.ncbi.nlm.nih.gov/pubmed/22729819,,,,,,,,,,
1551,,,,,,,,,,,,,,,,,,,,Dystonia ,,HP:0001332,,,,,,,,,,,
1552,,,,,,,,,,,,,,,,,,,,Hyperphenylalaninemia,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/9585615,https://www.ncbi.nlm.nih.gov/pubmed/24204001,,,,,,,,,
1553,,,,,,,,,,,,,,,,,,,,Growth failure,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/9760199,,,,,,,,,,
1554,,,,,,,,,,,,,,,,,,,,High urinary levels of primapterin (7-biopterin),,NA,https://www.ncbi.nlm.nih.gov/pubmed/24204001,,,,,,,,,,
1555,,,,,,,,,Salfonylureas,DB01124,ECO:0005542,,,,,Symptomatic (C),,symptomatic treatment procedure,,PCBD1-diabetes (Noninsulin-dependent diabetes)*,,HP:0005978*,https://www.ncbi.nlm.nih.gov/pubmed/24848070,,,,,,,,,,
1556,192,# 238700,Hyperlysinemia ,"Lysine-restricted diet achieved a mild improvement of some signs but did not reverse cognitive impairment. The moderate decrease of plasma lysine concentrations after dietary treatment in the patients supports the need of increase lysine restriction.https://www.ncbi.nlm.nih.gov/pubmed/23890588
",AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",1.5.1.8+1.5.1.9,,botulinum toxin,DB00083,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Delayed motor development,,HP:0001270,https://www.ncbi.nlm.nih.gov/pubmed/23570448,,,,,,,,,,
1557,,,,,,,,,valproate+carbamazepine,DB00313+DB00564,,,,,,Symptomatic (C),C,symptomatic treatment procedure,,seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/23570448,,,,,,,,,,
1558,,,,,,,,,,,,,,,,Symptomatic (C),C,,,Generalized tonic convulsions,, HP:0010818,https://www.ncbi.nlm.nih.gov/pubmed/23570448,,,,,,,,,,
1559,,,,,,,,The drug was accompanied with lysin restricted diet,Valproic acid+Lysin restricted diet,DB00313,ECO:0000352,,,,,Symptomatic (C)+Dietry restriction,,symptomatic treatment procedure+dietary exclusion,,seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/23570448,,,,,,,,,,
1560,,,,,,,,,pyridoxine,DB00165,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure+dietary exclusion,,"No remarkable clinical improvement was observed and therefore, treatment was discontinued",,,https://www.ncbi.nlm.nih.gov/pubmed/23890588,,,,,,,,,,
1561,193,# 144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,rosuvastatin,DB01098 ,ECO:00007121,,,,,Symptomatic (C),C,symptomatic treatment procedure+dietary exclusion,,hypertriglyceridemia ,,HP:0002155,https://clinicaltrials.gov/ct2/show/NCT00473655?cond=Hyperlipoproteinemia+type+V&rank=2,,,,,,,,,,
1562,,,,,,,,,,,,,,,,,,,, High LDL level,,HP:0003141,,,,,,,,,,,
1563,,,,,,,,,,,,,,,,,,,, High total cholesterol,,HP:0003124,,,,,,,,,,,
1564,,,,,,,,,,,,,,,,,,,,High Apoliporprotein B level(Abnormal abpolipoprotein level)*,,HP:0025201*,,,,,,,,,,,
1565,,,,,,,,,fenofibrates ,DB13873,ECO:00007121,,,,,Functional interaction (B),B,activity modification of a genetically defective protein by transcriptional or translational modification,,hypertriglyceridemia ,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/22129523,https://www.ncbi.nlm.nih.gov/pubmed/2653622,https://www.ncbi.nlm.nih.gov/pubmed/12709436,https://www.ncbi.nlm.nih.gov/pubmed/23633496,,,,,,,
1566,,,,,,,,,,,,,,,,,,,,High level of very low-density lipoprotein,,HP:0003362,,,,,,,,,,,
1567,,,,,,,,,,,,,,,,,,,,High total cholesterol,,HP:0003124,,,,,,,,,,,
1568,,,,,,,,,,,,,,,,,,,,Low HDL-cholesterol,,HP:0003233,,,,,,,,,,,
1569,,,,,,,,"Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523",nicotinic acid ,DB00627 ,ECO:0000352,,,,,Functional interaction (B),B,activity modification of a genetically defective protein,,hypertriglyceridemia ,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/1894760,https://www.ncbi.nlm.nih.gov/pubmed/18001312,https://www.ncbi.nlm.nih.gov/pubmed/5679950,https://www.ncbi.nlm.nih.gov/pubmed/4883477,,,,,,,
1570,,,,,,,,,,,,,,,,,,,,High total plasma cholesterol,,HP:0003124,,,,,,,,,,,
1571,,,,,,,,,,,,,,,,,,,,Elevated LDL-C level,,HP:0003141,,,,,,,,,,,
1572,,,,,,,,,,,,,,,,,,,,High VLDL-triglycerides ,,HP:0003362,,,,,,,,,,,
1573,,,,,,,,,,,,,,,,,,,,Low HDL-C ,,HP:0003233,,,,,,,,,,,
1574,,,,,,,,Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265,"strong statins (atorvastatin, pitavastatin, and rosuvastatin",DB01076 or DB08860 or DB01098,ECO:0000352,TT-1131,, C-1131,,Symptomatic (C),C,functional complementation of a genetically defective protein,Functional interaction,hypertriglyceridemia ,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/22129523,https://www.ncbi.nlm.nih.gov/pubmed/19530961/,https://www.ncbi.nlm.nih.gov/pubmed/29695967,,,,,,,,
1575,,,,,,,,,Gemfibrozil,DB01241,ECO:0000352/ ECO:0007121,,,,,Functional interaction (B),B,activity modification of a genetically defective protein by transcriptional or translational modification,,Tuberoeruptive xanthomas,"The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860",HP:0001013*,https://www.ncbi.nlm.nih.gov/pubmed/2702860,https://www.ncbi.nlm.nih.gov/pubmed/2681858,,,,,,,,,
1576,,,,,,,,,,,,,,,,,,,,Hyperchylomicronemia,,HP:0012238,https://www.ncbi.nlm.nih.gov/pubmed/2681858,,,,,,,,,,
1577,,,,,,,,,,,,,,,,,,,,High total plasma cholesterol leve,,,https://www.ncbi.nlm.nih.gov/pubmed/2681858,,,,,,,,,,
1578,,,,,,,,,,,,,,,,,,,,Elevated LDL-C level,,HP:0003141,https://www.ncbi.nlm.nih.gov/pubmed/2681858,,,,,,,,,,
1579,,,,,,,,,,,,,,,,,,,,High VLDL-triglycerides ,,HP:0003362,https://www.ncbi.nlm.nih.gov/pubmed/2681858,,,,,,,,,,
1580,,,,,,,,,,,,,,,,,,,,Low HDL-C ,,HP:0003233,https://www.ncbi.nlm.nih.gov/pubmed/2681858,,,,,,,,,,
1581,194,617347,"HYPERLIPOPROTEINEMIA, TYPE III",, APOE,apolipoprotein E,P02649,,Rosuvastatin+Pravastatin,DB01098 +DB00175,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,hypertriglycernemia,,HP:0002155,https://clinicaltrials.gov/ct2/show/NCT00214604?cond=Hyperlipidemia+type+3&rank=2,,,,,,,,,,
1582,,,,,,,,Study was terminated due to safety issues.,torcetrapib/atorvastatin,DB06281+ DB01076,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Study was terminated due to lack of safety,,,https://clinicaltrials.gov/ct2/show/NCT00145431?cond=Hyperlipidemia+type+3&rank=3,,,,,,,,,,
1583,,,,,,,,"In this study""https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract"" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.",simvastatin,DB00641,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,high non-HDL-C (Abnormality of lipid metabolism)*,,HP:0003119*,https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract,,,,,,,
1584,,,,,,,,,,,,,,,,,,,,High VLDL triglycerides ,,,,,,,,,,,,,
1585,,,,,,,,"In this study""https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract"" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.",gemfibrozil,DB01241,ECO:0000352,,,,,Functional interaction (B),B,activity modification of a genetically defective protein,,high non-HDL-C (Abnormality of lipid metabolism)*,,HP:0003119*,https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract,,,,,,,
1586,,,,,,,,,,,,,,,,,,,,High VLDL triglycerides ,,NA,,,,,,,,,,,
1587,,,,,,,,,lovastatin ,DB00227 ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,high non-HDL-C (Abnormality of lipid metabolism)*,,HP:0003119*,https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract,,,,,,,
1588,,,,,,,,,clofibrate,DB00636,ECO:0000352,,,,,Functional interaction (B),B,activity modification of a genetically defective protein,,high non-HDL-C (Abnormality of lipid metabolism)*,,HP:0003119*,https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,,,,,,,,
1589,,,,,,,,clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710,lovastatin and clofibrate,DB00227+DB00636,ECO:0000352,,,,,Functional interaction (B),B,symptomatic treatment procedure+activity modification of a genetically defective protein,,hypercholesterolemia,,HP:0003124,https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,,,,,,,,
1590,,,,,,,,,Fenofibrate,DB13873,ECO:0000352,,,,,Functional interaction (B),B,activity modification of a genetically defective protein,,Hypertriglyceridemia,,HP:0002155,https://link.springer.com/article/10.1007%2Fs11883-014-0440-2,https://www.ncbi.nlm.nih.gov/pubmed/25079293,,,,,,,,,
1591,,,,,,,,,Niacin,DB00627 ,ECO:0000352,,,,,Functional interaction (B),B,,,Hypertriglyceridemia,,HP:0002156,https://link.springer.com/article/10.1007%2Fs11883-014-0440-2,https://www.ncbi.nlm.nih.gov/pubmed/25079293,,,,,,,,,
1592,,,,,,,,,Fish oil,DB13961,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure+,,Hypertriglyceridemia,,HP:0002157,https://link.springer.com/article/10.1007%2Fs11883-014-0440-2,https://www.ncbi.nlm.nih.gov/pubmed/25079293,https://www.ncbi.nlm.nih.gov/pubmed/2065040?dopt=Abstract,,,,,,,,
1593,,,,,,,,,fenofibrate + atorvastatin,DB13873+ DB01076,ECO:0000352,,,,,Functional interaction (B),B,activity modification of a genetically defective protein+symptomatic treatment procedure,,xanthomas,,HP:0000991,https://link.springer.com/article/10.1007%2Fs11883-014-0440-2,https://www.ncbi.nlm.nih.gov/pubmed/25079293,,,,,,,,,
1594,,,,,,,,,,,,,,,,,,,,stenotic coronary atherosclerosis ,,HP:0001677,,,,,,,,,,,
1595,,,,,,,,,,,,,,,,,,,,angina pectoris,,HP:0001681,,,,,,,,,,,
1596,,,,,,,,,Atrovastatin,DB01076,ECO:0000352,,,,,,,symptomatic treatment procedure,,High serum total cholesterol,,HP:0003124,https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,,,,,,,,,
1597,,,,,,,,,,,,,,,,,,,,High serum triglyceride ,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,,,,,,,,,
1598,,,,,,,,,,,,,,,,,,,,High remnant-like particle (RLP)-cholesterol ,,NA,https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,,,,,,,,,,
1599,,,,,,,,,,,,,,,,,,,,High remnant-like particle (RLP)-TG ,,NA,https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,,,,,,,,,,
1600,,,,,,,,,,,,,,,,,,,,Elevated VLDL-cholesterol/serum TG ratio ,,HP:0003362,https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,,,,,,,,,,
1601,,,,,,,,,,,,,,,,,,,,Elevated apolipoprotein B level,,HP:0031798,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,,,,,,,,,,
1602,,,,,,,,Probucol is a non-Statin cholesterol-lowering drug and a potent inducer of apolipoprotein E (apoE) production in peripheral circulation. https://www.ncbi.nlm.nih.gov/pubmed/12946703,probucol,DB01599,ECO:0005542,,,,,,,activity modification of a genetically defective protein,,Atherosclerosis,,HP:0002621,https://www.ncbi.nlm.nih.gov/pubmed/9185508,,,,,,,,,,
1603,,,,,,,,"Based on their study auhors of""  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract""  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.",Bezafibrate/ atorvastatin,DB01393/DB01076,ECO:0000352,,,,,Functional interaction (B),,activity modification of a genetically defective protein+symptomatic treatment procedure,,Atherogenic dyslipidemia(Dyslipidemia)*,,HP:0003119*,https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract,,,,,,,,,,
1604,,,,,,,,,Recombinant apolipoprotein A-I,NA,ECO:0005542,,,,,,,functional complementation of a defective protein by stimulation,,Atherosclerosis,,HP:0002621,https://www.ncbi.nlm.nih.gov/pubmed/11425766/,,,,,,,,,,
1605,195,606762,Hyperinsulinism-hyperammonemia syndrome,"Treatments for hyperammonemia such as dietary protein limitation, arginine, benzoate, carbamoyl synthase activators (carglumic acid), and N-carbamoylglutamate have not been effective in reducing ammonia levels. https://www.ncbi.nlm.nih.gov/pubmed/15050973/ ",GLUD1,"Glutamate dehydrogenase, mitochondrial",1.4.1.3,,diazoxide,DB01119,ECO:0000352,,,,,Functional interaction (B),B,procedure to mitigate dominant effects of a genetically abnormal protein,,hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/23295286,https://www.ncbi.nlm.nih.gov/pubmed/20936362,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538,,,,,,,
1606,,,,,,,,,,,,,,,,,,,,epileptic seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096481/,https://www.ncbi.nlm.nih.gov/pubmed/28621098,,,,,,,,,
1607,,,,,,,,,,,,,,,,,,,,Hyperinsulinism,,HP:0000842,https://www.ncbi.nlm.nih.gov/pubmed/10969108,https://www.ncbi.nlm.nih.gov/pubmed/10453735/,,,,,,,,,
1608,,,,,,,,,Carglumic acid + diazoxide+ Glucose,DB06775+DB01119+DB01914,ECO:0000352,,,,,,,symptomatic treatment procedure+procedure to mitigate dominant effects of a genetically abnormal protein,,hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/26962538,,,,,,,,,,
1609,,,,,,,,,Levetiracetam,DB01202,ECO:0000352,,,,,,,symptomatic treatment procedure,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/26962538,,,,,,,,,,
1610,,,,,,,,,,,,,,,,,,,,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/10969108,,,,,,,,,,
1611,196,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,,diazoxide,DB01119,ECO:0000352,T65I,,GK-Y214C(De novo muttation),,Functional interaction (B),B,procedure to mitigate dominant effects of a genetically abnormal protein,,hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/15277402,https://www.ncbi.nlm.nih.gov/pubmed/19336674,,,,,,,,,
1612,,,,,,,,,,,,(Val455Met) at codon 455,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/15133749,https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448,,,,,,,,,
1613,,,,,,,,,,,,M197I,,Y214C,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,,,,,,,,,,
1614,,,,,,,,,,,,A456V,,ins454A ,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,,,,,,,,,,
1615,,,,,,,,,,,,W99R,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,,,,,,,,,,
1616,,,,,,,,,,,,S64Y,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,,,,,,,,,,
1617,,,,,,,,,,,,V452L,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,,,,,,,,,,
1618,,,,,,,,,,,,M197I,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,,,,,,,,,,
1619,,,,,,,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Octreotide ,,ECO:0007121,G68V,,,,Functional interaction (B),B,procedure to mitigate dominant effects of a genetically abnormal protein,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/8410522/,,,,,,,,,,
1620,,,,,,,,,Dextrose +Diazoxide,DB09341+DB01119,ECO:0000352,W99L,,,,Functional interaction (B),B,symptomatic treatment procedure+procedure to mitigate dominant effects of a genetically abnormal protein,,Hypoglycemia,,HP:0001943,,,,,,,,,,,
1621,197,307030,Hyperglycerolemia (Isolated glycerol kinase deficiency),,GK,Glycerol kinase ,2.7.1.30,,Rosuvastatin,DB01098,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542/,,,,,,,,,
1622,198,,Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency,,PIGM,GPI mannosyltransferase 1,2.4.1.-,,Antithrombotic agents,B01,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Thrombosis,,HP:0001977,https://www.ncbi.nlm.nih.gov/pubmed/16767100,,,,,,,,,,
1623,,,,,,,,,Sodium phenylbutyrate,DB06819,ECO:0000352,,,,,Functional interaction (B),B,activity modification of a genetically defective protein by transcriptional or translational modification,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/17442906,,,,,,,,,,
1624,199,237400,HYPER-BETA-ALANINEMIA,,,beta-alanine-alpha-ketoglutarate transaminase. ,,,Taurine,DB01956,ECO:0001565,,,,,Symptomatic (C),,symptomatic treatment procedure,, mitochondrial toxicity*,,HP:0012103,https://www.ncbi.nlm.nih.gov/pubmed/27023909,https://link.springer.com/article/10.1007%2Fs00726-017-2462-x,https://www.ncbi.nlm.nih.gov/pubmed/7936305,,,,,,,,
1625,,,,,,,,,Pyridoxine,DB00165,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,??,seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/7936305,https://www.ncbi.nlm.nih.gov/pubmed/6198500,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199,,,,,,,,
1626,,,,,,,,,,,,,,,,,,,,somnolence,,HP:0002360,https://www.ncbi.nlm.nih.gov/pubmed/7936305,,,,,,,,,,
1627,200,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase ,2.7.1.36,,anti-TNF-alpha (Adalimumab)+Etanercept,DB00051+DB00005 ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,periodic fever,,HP:0001954,https://www.ncbi.nlm.nih.gov/pubmed/24935455,,,,,,,,,,
1628,,,,,,,,,,,,,,,,Symptomatic (C),C,,,Abnormality of immune system physiology,,HP:0010978,https://www.ncbi.nlm.nih.gov/pubmed/24935455,,,,,,,,,,
1629,,,,,,,,,Anakinra,DB00026,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Arthralgia,,HP:0002829,https://www.ncbi.nlm.nih.gov/pubmed/20712835,https://www.ncbi.nlm.nih.gov/pubmed/25758134/,,,,,,,,,
1630,,,,,,,,,,,,,,,,,,,,joint swelling,,HP:0001386,,,,,,,,,,,
1631,,,,,,,,,Canakinumab,DB06168,ECO:0000352,,,,,,,symptomatic treatment procedure,,Fever,,HP:0001945,https://www.ncbi.nlm.nih.gov/pubmed/25758134/,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,,,,,,,,,
1632,,,,,,,,,,,,,,,,,,,,High serum amyloid A protein ,,NA,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,,,,,,,,,,
1633,,,,,,,,,,,,,,,,,,,,Elevated C-reactive protein,,HP:0011227,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,,,,,,,,,,
1634,,,,,,,,,prednisolone + azathioprine + immunoglobulins,DB00860+DB00993+DB00028,ECO:0000352,compound V377I and I126T mutations,,,,Symptomatic (C),C,symptomatic treatment procedure,,periodic fever,,HP:0001954,https://www.ncbi.nlm.nih.gov/pubmed/18839211?dopt=Abstract,,,,,,,,,,
1635,,,,,,,,,Thalidomide,DB01041,ECO:0007121,,,,,Symptomatic (C),C,,Drug withdrawn,Limited Efficacy of the drug.,,,https://www.ncbi.nlm.nih.gov/pubmed/11504824?dopt=Abstract,,,,,,,,,,
1636,,,,,,,,,steroids + simvastatin,DB00641,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Periodic fever,,HP:0001954,https://www.ncbi.nlm.nih.gov/pubmed/19011501?dopt=Abstract,,,,,,,,,,
1637,,,,,,,,,Infliximab,DB00065,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Nummular keratitis(keratitis)*,,HP:0000491,https://www.ncbi.nlm.nih.gov/pubmed/19656398?dopt=Abstract,,,,,,,,,,
1638,,,,,,,,,,,,,,,,,,,,Corneal scar,,HP:0000559,https://www.ncbi.nlm.nih.gov/pubmed/19656398?dopt=Abstract,,,,,,,,,,
1639,,,,,,,,,,,,,,,,,,,,Decreased visual acuity,,HP:0007663,,,,,,,,,,,
1640,,,,,,,,,tocilizumab,DB06273,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Fever,,HP:0001945,https://www.ncbi.nlm.nih.gov/pubmed/30225156,https://www.ncbi.nlm.nih.gov/pubmed/24561416,https://www.ncbi.nlm.nih.gov/pubmed/26516243,,,,,,,,
1641,,,,,,,,,,,,,,,,,,,,Fatigue,,HP:0012378,https://www.ncbi.nlm.nih.gov/pubmed/30225156,,,,,,,,,,
1642,,,,,,,,,,,,,,,,,,,,Pain,,HP:0012531,https://www.ncbi.nlm.nih.gov/pubmed/30225156,,,,,,,,,,
1643,,,,,,,,,,,,,,,,,,,,Oral ulceration,,HP:0000155,https://www.ncbi.nlm.nih.gov/pubmed/30225156,,,,,,,,,,
1644,,,,,,,,,Anakinra+ tocilizumab,,ECO:0001565/ECO:0000352,,,,,,,symptomatic treatment procedure,,Abnormal inflammatory response,,HP:0012647,https://www.ncbi.nlm.nih.gov/pubmed/25173351,,,,,,,,,,
1645,201,236800,hydroxykynureninuria,,KYNU,kynureninase,3.7.1.3,,Niacin,DB00627,ECO:0000352,,,,,Functional interaction (B),B,metabolite replacement,,dermatitis ,,HP:0011123,https://www.ncbi.nlm.nih.gov/pubmed/14169454,,,,,,,,,,
1646,,,,,,,,,,,,,,,,,,,,diarrhoea ,,HP:0002014,https://www.ncbi.nlm.nih.gov/pubmed/14169454,,,,,,,,,,
1647,,,,,,,,,,,,,,,,,,,,dementia ,,HP:0000726,https://www.ncbi.nlm.nih.gov/pubmed/17334708,,,,,,,,,,
1648,,,,,,,,,,,,,,,,,,,,sensitivity to sunlight,,HP:0000992,https://www.ncbi.nlm.nih.gov/pubmed/10540864,,,,,,,,,,
1649,,,,,,,,,Pyridoxal phosphate,DB00114,ECO:0000352,,,,,,,activity modification of a genetically defective protein,,Low enzyme activity,,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/5586569,,,,,,,,,,
1650,202,607015,Hurler-Scheie syndrome,,IDUA ,alpha-L-iduronidase,,,Laronidase,DB00090,ECO:0007121,,,,,Direct interaction (A) ,A,direct complementation of a genetically defective protein,,Low Forced Vital Capacity,,HP:0002111,https://clinicaltrials.gov/ct2/show/results/NCT00912925?cond=Hurler-Scheie+Syndrome&rank=1&sect=X8ca970156#outcome2,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,,,,,,
1651,,,,,,,,,,,,,,,,,,,,High Apnea/Hypopnea Index(sleep apnea)*,,HP:0010535*,,,,,,,,,,,
1652,,,,,,,,,,,,,,,,,,,,Decreased pulmonary function ,,HP:0005952 ,,,,,,,,,,,
1653,,,,,,,,,,,,,,,,,,,,Hepatomegaly,, HP:0002240,,,,,,,,,,,
1654,,,,,,,,,,,,,,,,,,,,Limitation of the Joint range of motion,,HP:0001376,,,,,,,,,,,
1655,,,,,,,,,,,,,,,,,,,,Six Minute Walk Test ,,NA,,,,,,,,,,,
1656,,,,,,,,,Nanotechnology-based gene therapy,NA,ECO:0001565,,,,,Direct interaction (A) ,A,direct complementation of a genetically defective protein by gene therapy,,Low IDUA activity(Abnormal enzyme activity)*,,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/29122734,,,,,,,,,,
1657,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1658,,,,,,,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",GNeo-IDUA,NA,ECO:0005542,,,,,Direct interaction (A) ,A,direct complementation of a genetically defective protein,,neurodegenerative astrogliosis,,HP:0002180*,https://www.ncbi.nlm.nih.gov/pubmed/28958576,,,,,,,,,,
1659,,,,,,,,,,,,,,,,,,,,glycosaminoglycan accumulation,,HP:0004371,,,,,,,,,,,
1660,203,607014,Hurler syndrome ,,IDUA,"iduronidase, alpha-L",,,Laronidase (IRT),DB00090,ECO:0000352,,,,,Direct interaction (A) ,A,direct complementation of a genetically defective protein,,Hepatosplenomegaly ,,HP:0001433,https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342,,,
1661,,,,,,,,,,,,,,,,,,,,Abnormality of joint mobility,,HP:0011729,,,,,,,,,,,
1662,,,,,,,,,,,,,,,,,,,,Sleep apnea,,HP:0010535,,,,,,,,,,,
1663,,,,,,,,,,,,,,,,,,,,Nocturnal hypopnea,,HP:0002877,,,,,,,,,,,
1664,,,,,,,,,,,,,,,,,,,,Abnormal apnea–hypopnea index,,NA,,,,,,,,,,,
1665,,,,,,,,,,,,,,,,,,,,Urinary glycosaminoglycan excretion ,,HP:0003541,,,,,,,,,,,
1666,,,,,,,,,,,,,,,,,,,,photophobia,,HP:0000613,,,,,,,,,,,
1667,,,,,,,,,,,,,,,,,,,,conjunctival irritation,,HP:0030953,,,,,,,,,,,
1668,,,,,,,,,,,,,,,,,,,,impaired Visual acuity,,HP:0007663,,,,,,,,,,,
1669,,,,,,,,,,,,,,,,,,,,low exercise endurance,,NA,,,,,,,,,,,
1670,,,,,,,,,,,,,,,,,,,,tricuspid regurgitation,,HP:0005180,,,,,,,,,,,
1671,,,,,,,,,,,,,,,,,,,,pulmonary regurgitation,,HP:0010444,,,,,,,,,,,
1672,,,,,,,,,,,,,,,,,,,,dyspnea at rest ,,HP:0012763,,,,,,,,,,,
1673,,,,,,,,,,,,,,,,,,,,pitting edema,,HP:0000969,,,,,,,,,,,
1674,,,,,,,,,,,,,,,,,,,,low quality of sleep,,HP:0002360,,,,,,,,,,,
1675,,,,,,,,,,,,,,,,,,,,Daytime somnolence,,HP:0002189,,,,,,,,,,,
1676,,,,,,,,,,,,,,,,,,,,white matter abnormalities,,HP:0002500,https://www.ncbi.nlm.nih.gov/pubmed/19748810,,,,,,,,,,
1677,,,,,,,,,,,,,,,,,,,,brain ventricular dilatation,,HP:0002119,,,,,,,,,,,
1678,,,,,,,,,,,,,,,,,,,, brain MRI abnormalities,,HP:0002500,,,,,,,,,,,
1679,,,,,,,,Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase,Gene therapy,NA,ECO:0001565,,,,,Direct interaction (A),A,direct complementation of a genetically defective protein by gene therapy,In Vitro Experiment ,Lysosomal storage abnormalities(Abnormality of lysosomal metabolism)*,,HP:0004356,https://www.ncbi.nlm.nih.gov/pubmed/8700879,https://www.ncbi.nlm.nih.gov/pubmed/30081189,,,,,,,,,
1680,,,,,,,,,Gene therapy,NA,ECO:0005542,,,,,Direct interaction (A),A,activity modification of a genetically defective protein by genome editing,in vivo (mice),ventricular hypertrophy,,HP:0001714,https://www.ncbi.nlm.nih.gov/pubmed/30170069,,,,,,,,,,
1681,,,,,,,,,,,,,,,,,,,,cardiac dilation/ Heart enlargment/ cardimegaly,,HP:0001640,,,,,,,,,,,
1682,,,,,,,,,,,,,,,,,,,,left ventricularc contractility abnormalities,,HP:0006670*,,,,,,,,,,,
1683,,,,,,,,,,,,,,,,,,,,Left ventricle dysfunction ,,HP:0030872,,,,,,,,,,,
1684,204,603174,Homocystinuria due to MTHFR deficiency,,MTHFR,methylenetetrahydrofolate reductase,1.5.1.20,,Methyltetrahydrofolic acid+Hydroxocobalamin+pyridoxine+ betaine,DB04789 + DB00200 +DB00165+ DB06756,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,, Abnormal Folate level,,HP:0040087,https://www.ncbi.nlm.nih.gov/pubmed/11916316,,,,,,,,,,
1685,,,,,,,,,,,,,,,,,,,, Abnormal serum Methylfolate Level,,NA,,,,,,,,,,,
1686,,,,,,,,"The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract
",Betaine+Folinic acid,DB06756+DB00650 ,ECO:0000352,,,,,Functional interaction (B)+Functional interaction (B),B+B,functional complementation of a genetically defective protein+metabolite replacement,,Abnormality of homocysteine metabolism,,HP:0010919,https://www.ncbi.nlm.nih.gov/pubmed/25024447,,,,,,,,,,
1687,,,,,,,,,,,,,,,,,,,,low muscle tone,,HP:0001290,,,,,,,,,,,
1688,,,,,,,,,Topiramate,DB00273,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,Symptomatic © + Mechanistic (B),seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/25024447,,,,,,,,,,
1689,,,,,,,,,"Betaine, Folic acid, Vitamin B6 , Vitamin B12",DB06756+DB00158+DB00165+DB00115,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,High plasma homocysteine level(Abnormal homocysteine level)*,,HP:0010919,https://www.ncbi.nlm.nih.gov/pubmed/29246599,,,,,,,,,,
1690,,,,,,,,"Due to prenatal diagnosis ofthe patient, early treatment with B vitamins and betaine had a favorable outcome. https://www.ncbi.nlm.nih.gov/pubmed/20356773",Vitamin B+Betaine,DB00165+DB6756,ECO:0000352,,,,,Functional interaction (B),B+B,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Developmental abnormality,,HP:0012759,https://www.ncbi.nlm.nih.gov/pubmed/20356773,,,,,,,,,,
1691,205,236200,Homocystinuria due to CBS deficiency,"  Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.",CBS,cystathionine beta-synthase,4.2.1.22, pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015). ,Pyridoxine,DB00165,ECO:0000352/ECO:0005542,"P49L, A114V, I278T, R266K, or R336H",,"R125Q, E176K, T191M, T262M, or G307S",,Functional interaction (B),B,activity modification of a genetically defective protein,Mehanistic(B),Misfolding of cystathionine β-synthase(Abnormal enzyme activity)*,,HP:0012379*,https://www.ncbi.nlm.nih.gov/pubmed/29119254,https://www.ncbi.nlm.nih.gov/pubmed/16619244?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,,,,,,,
1692,,,,,,,,,δ-aminolevulinate,DB00855,ECO:0001565,R125Q,"One of the mutations (R125Q) exhibited an outstanding heme sensitivity, and addition of heme arginate to a fibroblast culture obtained from a patient homozygous for this mutation rescued also the activity in these human cells and increased production of cystathionine",,,Symptomatic (C),C,,,Misfolding of cystathionine β-synthase(Abnormal enzyme activity)*,,HP:0012379*,https://www.ncbi.nlm.nih.gov/pubmed/20490928?dopt=Abstract,,,,,,,,,,
1693,,,,,,,,,,,,R266K,,,,,,,,Homocystinuria,,HP:0002156,,,,,,,,,,,
1694,,,,,,,,,,,,,,H65R,,,,,,,,,,,,,,,,,,,
1695,,,,,,,,,S-Adenosylmethionine, DB00118 ,ECO:0001565,,,,,Direct interaction (A),A,activity modification of a genetically defective protein,,"The approach is likely unsuccessful due to reactive properties, intrinsic instability, and charged character of SAM.",,,https://www.ncbi.nlm.nih.gov/pubmed/20506325?dopt=Abstract,,,,,,,,,,
1696,,,,,,,,"These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU",bortezomib,DB00188,ECO:0005542,I278T,,,,Direct interaction (A),A,activity modification of a genetically defective protein,Tried on Mice not human,Misfolding of cystathionine β-synthase(Abnormal enzyme activity)*,,,https://www.ncbi.nlm.nih.gov/pubmed/23592311?dopt=Abstract,,,,,,,,,,
1697,,,,,,,,,ONX-0912,DB11991,ECO:0005542,S466L /I278T ,"However, response rates varied, with 100% (8/8) of the p.S466L animals showing correction, but only 38% (10/26) of the p.I278T animals.https://www.ncbi.nlm.nih.gov/pubmed/23592311?dopt=Abstract",,,Direct interaction (A),A,activity modification of a genetically defective protein,Tried on Mice not human,Abnormal Hcy level,,HP:0010919*,https://www.ncbi.nlm.nih.gov/pubmed/23592311?dopt=Abstract,,,,,,,,,,
1698,,,,,,,,,,,,,,,,,,,,Homocystinuria,,HP:0002156,,,,,,,,,,,
1699,,,,,,,,"  Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.",pyridoxine/betaine,DB00165/DB06756,ECO:0000352,,,,,Functional interaction (B),B,activity modification of a genetically defective protein,, High total homocysteine levels,,HP:0002160,https://www.ncbi.nlm.nih.gov/pubmed/14739681,,,,,,,,,,
1700,,,,,,,,,,,,,,,,,,,,High total cysteine levels,,HP:0010918,,,,,,,,,,,
1701,,,,,,,,,,,,,,,,,,,, Low plasma serine levels,,HP:0012279,,,,,,,,,,,
1702,,,,,,,,,,,,,,,,,,,,high blood S -adenosylhomocysteine level ,,NA,,,,,,,,,,,
1703,,,,,,,,"There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.",serine,DB00133,ECO:0007764,,,,,Symptomatic (C),C,symptomatic treatment procedure,No trials / speculation,,,,,,,,,,,,,,
1704,206,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,creatine/Creatine phosphate,DB00148/DB13191,ECO:0000352,,,,,Functional interaction(Mechinistic B),B,metabolite replacement,,muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/22386973,https://www.ncbi.nlm.nih.gov/pubmed/20625172,,,,,,,,,
1705,,,,,,,,,,,,,,,,,,,,Low cerebral creatine content,,HP:0012113*,,,,,,,,,,,
1706,,,,,,,,,,,,,,,,,,,,Low developmental score,,HP:0012759*,,,,,,,,,,,
1707,,,,,,,,,,,,,,,,,,,,neurodevelopmental delay,,HP:0012758,,,,,,,,,,,
1708,,,,,,,,,,,,,,,,,,,,cognitive dysfunction,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/20682460,,,,,,,,,,
1709,,,,,,,,,,,,,,,,,,,,Low IQ score,,HP:0001249,,,,,,,,,,,
1710,,,,,,,,,,,,,,,,,,,,language impairment,,HP:0002463,https://www.ncbi.nlm.nih.gov/pubmed/23770102,,,,,,,,,,
1711,,,,,,,,,,,,,,,,,,,,behavior al abnormalities ,,HP:0000708,,,,,,,,,,,
1712,,,,,,,,,,,,,,,,,,,,communicative skills abnormalities ,,HP:0002474*,,,,,,,,,,,
1713,,,,,,,,,,,,,,,,,,,,psychomotor retardation ,,HP:0001263,,,,,,,,,,,
1714,,,,,,,,,,,,,,,,,,,,METABOLIC ENCEPHALOMYOPATHY,,NA,https://www.ncbi.nlm.nih.gov/pubmed/20625172,,,,,,,,,,
1715,207,# 612933,Lactate dehydrogenase A deficiency,,LDHA,"lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme",1.1.1.27,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1716,208,# 614128,Lactate dehydrogenase B deficiency,,LDHB,"lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme",1.1.1.27,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1717,209,607330,Lathosterolosis,,SC5D,3-beta-hydroxysteroid-delta-5-desaturase,,,cholesterol+Simvastatin,DB04540+DB00641,ECO:0000352,,,,,Functional interaction (B),B,metabolite replacement+functional complementation of a defective protein by inhibition,,Abnormal blood lathosterol level,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/30097991,,,,,,,,,,
1718,,,,,,,,The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991,Simvastatin,DB00641,ECO:0000352,p.K148E and p.D210E, A compound heterozygous missense mutation,,,Functional interaction (B),B,functional complementation of a defective protein by inhibition,,Abnormal neurodevelopmental profile,,HP:0012759,https://www.ncbi.nlm.nih.gov/pubmed/24142275,,,,,,,,,,
1719,,,,,,,,,,,,,,,,,,,,Developmental delay,,HP:0001263,,,,,,,,,,,
1720,,,,,,,,,,,,,,c.479C>G p.(Pro160Arg) and c.630C>A p.(Asp210Glu),,,,,,Abnormal blood lathosterol level,,HP:0001939*,,,,,,,,,,,
1721,210,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,heptanoate,CHEBI:32362,ECO:0000352,,,,,Symptomatic (C),C,dietary supplementation,,Elevation of creatine kinase,,HP:0003236,https://www.ncbi.nlm.nih.gov/pubmed/24997711/,,,,,,,,,,
1722,,,,,,,,,,,,,,,,,,,,Exercise-induced muscle cramps,,HP:0003710,,,,,,,,,,,
1723,,,,,,,,Dietry treatment supplementation,Docosahexaenoic acid (DHA),DB03756,ECO:0007121,,,,,Symptomatic (C),C,dietary supplementation,,Metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/16040264/,,,,,,,,,,
1724,,,,,,,,,,,,,,,,,,,,Disease progression(Retinopathy),,HP:0003676,,,,,,,,,,,
1725,,,,,,,,,,,,,,,,,,,,Reduced visual acuity,,HP:0007663,,,,,,,,,,,
1726,,,,,,,,,Triheptanoin,DB11677,ECO:0000352,,,,,,C,dietary supplementation,,Cardiomyopathy ,,HP:0001638,https://www.ncbi.nlm.nih.gov/pubmed/12122118/,,,,,,,,,,
1727,,,,,,,,,,,,,,,,,,,,Rhabdomyolysis,,HP:0003201,,,,,,,,,,,
1728,,,,,,,,,,,,,,,,,,,,Muscle weakness,,HP:0001324,,,,,,,,,,,
1729,,,,,,,,,,,,,,,,,,,,Low quality of life,,HP:0025142,https://www.ncbi.nlm.nih.gov/pubmed/16763896/,,,,,,,,,,
1730,,,,,,,,,bezafibrate,DB01393,ECO:0001565,c.1528G > C,,c.1528G > C,,Direct interaction (Mechanistic A) ,A,activity modification of a genetically defective protein,,Abnormal Fatty acid oxidation,,HP:0004359*,https://www.ncbi.nlm.nih.gov/pubmed/?term=bezafibrate+in+treating+LCHAD+deficiency+(long-chain+3-hydroxyacyl-CoA+dehydrogenase+deficiency),,,,,,,,,,
1731,,,,,,,,,,,,C2129-2A > C,,,,,,,,Low LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE activity,,NA,,,,,,,,,,,
1732,,,,,,,,,,,,c. 1393_1479del-Del exon,,,,,,,,,,,,,,,,,,,,,
1733,,,,,,,,,,,,c.180 + 3A > G,,,,,,,,,,,,,,,,,,,,,
1734,,,,,,,,,,,,c.914 T > A,,,,,,,,,,,,,,,,,,,,,
1735,,,,,,,,,,,,c.982G > A and c.1072C > A,,,,,,,,,,,,,,,,,,,,,
1736,211,535000,Leber hereditary optic neuropathy,,MT-ND1/MT-ND4L/MT-ND6,mitochondrially encoded NADH dehydrogenase 1/mitochondrially encoded NADH 4L dehydrogenase/ mitochondrially encoded NADH dehydrogenase 6,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1737,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,,,AAV-SOD2 (adeno-associated viral vector containing the human mitochondrial superoxide dismutase (SOD2) gene),NA,ECO:0001565,G11778A,,,,Functional interaction(Mechinistic B),B,functional complementation of a genetically defective protein,,Optic nerve damage,,HP:0001138,https://www.ncbi.nlm.nih.gov/pubmed/17296905,,,https://www.ncbi.nlm.nih.gov/pubmed/30107658,,,,,,,
1738,,,,,,,,,,,,,,,,,,,,Mitochondrial oxidative stress,,HP:0012103,,,,,,,,,,,
1739,,,,,,,,,"rAAV2-ND4 (recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4))",NA,ECO:0007121,G11778A,,,,Direct interaction (Mechanistic A) ,A,direct complementation of a genetically defective protein,,Abnormal visual acuity,,HP:0030532,https://clinicaltrials.gov/ct2/show/results/NCT01267422?cond=Leber+Hereditary+Optic+Neuropathy&rank=2&sect=X970156#outcome3,https://clinicaltrials.gov/ct2/show/NCT03153293?cond=Leber+Hereditary+Optic+Neuropathy&rank=1,,,,,,,,,
1740,,,,,,,,,MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus),NA,ECO:0007121,G11778A,,,,Direct interaction (Mechanistic A) ,A,direct complementation of a genetically defective protein by gene therapy,,Low ATP synthesis,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/30208599,,,,,,,,,,
1741,,,,,,,,,,,,,,,,,,,,Optic atrophy,,HP:0000648,,,,,,,,,,,
1742,,,,,,,,,,,,,,,,,,,,Abnormal visual acuity,,HP:0030534,,,,,,,,,,,
1743,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1744,,,,,,,,"Author: ""The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/",Idebenone,DB09081,ECO:0000352/ECO:0007121/ECO:0005542,"m.3460G>A, m.11778G>A, and m.14484T>C",,,,Symptomatic (C),C,functional complementation of a genetically defective protein,,Abnormal visual acuity,,HP:0030532,https://www.ncbi.nlm.nih.gov/pubmed/11723211,https://www.ncbi.nlm.nih.gov/pubmed/11001192,https://www.ncbi.nlm.nih.gov/pubmed/17573650,https://www.ncbi.nlm.nih.gov/pubmed/21788663,https://www.ncbi.nlm.nih.gov/pubmed/21810891/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/,https://www.ncbi.nlm.nih.gov/pubmed/27071925,https://www.ncbi.nlm.nih.gov/pubmed/28093355,https://www.ncbi.nlm.nih.gov/pubmed/23028832/
1745,,,,,,,,,,,,,,,,,,,,Abnormal retinal ganglion cell function ,,HP:0001112,https://clinicaltrials.gov/ct2/show/NCT00747487?cond=Leber+Hereditary+Optic+Neuropathy&rank=8,https://clinicaltrials.gov/ct2/show/NCT02771379?cond=Leber+Hereditary+Optic+Neuropathy&rank=16,https://clinicaltrials.gov/ct2/show/NCT01495715?cond=Leber+Hereditary+Optic+Neuropathy&rank=13,https://www.ncbi.nlm.nih.gov/pubmed/21788663/,,,,,,,
1746,,,,,,,,,,,,,,,,,,,,Retinal thickness,,HP:0000630,,,,,,,,,,,
1747,,,,,,,,,,,,,,,,,,,,Gliosis,,HP:0002171,,,,,,,,,,,
1748,,,,,,,,,,,,,,,,,,,,Functional loss of vision,,HP:0000572,,,,,,,,,,,
1749,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1750,,,,,,,,,Idebenone+Vitamin C+Vitamin B12,DB09081+DB00126+DB00115,ECO:0000352,,,,,,B,functional complementation of a genetically defective protein+symptomatic treatment procedure,,Slow recovery,,HP:0012823*,https://www.ncbi.nlm.nih.gov/pubmed/11001192/,,,,,,,,,,
1751,,,,,,,,,EPI-743(Vatiquinone),DB11917,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Disease progression (Rapidly progressive)*,,HP:0003678*,https://clinicaltrials.gov/ct2/show/NCT02300753?cond=Leber+Hereditary+Optic+Neuropathy&draw=2&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/22410442,https://www.ncbi.nlm.nih.gov/pubmed/26448041,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,,,,,,
1752,,,,,,,,,,,,,,,,,,,,Abnormal visual acuity,,HP:0030534,,,,,,,,,,,
1753,,,,,,,,,,,,,,,,,,,,Visual loss,,HP:0000572,,,,,,,,,,,
1754,,,,,,,,,,,,,,,,,,,,Retinal ganglion loss,,HP:0000479,,,,,,,,,,,
1755,,,,,,,,,Estrogens,DB00783,ECO:0001565,,,,,Functional interaction(Mechinistic B),B,functional complementation of a genetically defective protein,,Mitochondrial dysfunction,,HP:0003287,https://www.ncbi.nlm.nih.gov/pubmed/20943885,,,,,,,,,,
1756,,,,,,,,,elamipretide (MTP-131),DB11981,ECO:0007121,,,,,Symptomatic (C),A,activity modification of a genetically defective protein,,Increased reactive oxygen species production,,HP:0025464,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104515/,https://clinicaltrials.gov/ct2/show/NCT02693119?cond=Leber+Hereditary+Optic+Neuropathy&rank=3,https://clinicaltrials.gov/ct2/show/NCT02805790,,,,,,,,
1757,,,,,,,,,,,,,,,,,,,,Low ATP synthesis,,HP:0025464,,,,,,,,,,,
1758,,,,,,,,,Curcumin,DB11672,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Oxidative stress,,HP:0025464,https://clinicaltrials.gov/ct2/show/NCT00528151,,,,,,,,,,
1759,,,,,,,,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,Cyclosporine,DB00091,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Disease progression,,HP:0003678*,https://www.ncbi.nlm.nih.gov/pubmed/24161764,https://clinicaltrials.gov/ct2/show/NCT02176733?cond=Leber+Hereditary+Optic+Neuropathy&rank=12,,,,,,,,,
1760,,,,,,,,,Corticosteroid+Antiaggregates,H02+B01A,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Large central visual field defect,,HP:0001129,https://www.ncbi.nlm.nih.gov/pubmed/11723211,,,,,,,,,,
1761,212,220111,"Leigh syndrome, French Canadian type","Antioxidants (idebenone, N-acetyl cysteine, resveratrol) exacerbate palmitate plus lactate-induced cell death. Collectively, our results raise some concerns about the potential negative impact of a high-fat diet and of antioxidant treatments in LSFC patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383560/",LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,,,methylene blue,DB09241,ECO:0001565,A354V,,,,Functional interaction (B),B,metabolite replacement,, Low COX content and activity ,,NA,https://www.ncbi.nlm.nih.gov/pubmed/22202226,,,,,,,,,,
1762,,,,,,,,,,,,A354V and C12775STOP,,,,,,,,acidotic crises ,,HP:0001941*,,,,,,,,,,,
1763,,,,,,,,,propionate ,DB03766,ECO:0001565,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Palmitate plus lactate-induced cell death,,NA,https://www.ncbi.nlm.nih.gov/pubmed/25835550,,,,,,,,,,
1764,,,,,,,,,L-carnitine,DB00583,ECO:0001565,,,,,Symptomatic (C),C,symptomatic treatment procedure,,PL-induced cytotoxicity,,NA,https://www.ncbi.nlm.nih.gov/pubmed/25835550,,,,,,,,,,
1765,,,,,,,,,Trolox ornithylamide hydrochloride,NA,ECO:0001565,,,,,Symptomatic (C),,symptomatic treatment procedure,,Increased ROS production,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/25620325/,,,,,,,,,,
1766,,,,,,,,,,,,,,,,,,,,Decreased activity of mitochondrial complex I,,HP:0011923,,,,,,,,,,,
1767,,,,,,,,,,,,,,,,,,,,Decreased activity of mitochondrial complex IV,,HP:0008347,,,,,,,,,,,
1768,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1769,213,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,,,Ecopipam ((PSYRX 101),DB12273,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Self-injurious Behavior,,HP:0100716,https://clinicaltrials.gov/ct2/show/results/NCT01751802?cond=Lesch-Nyhan+Disease&rank=3&sect=X70156#outcome1,https://clinicaltrials.gov/ct2/show/results/NCT01065558?cond=Lesch-Nyhan+Disease&rank=2&sect=X01256#all,https://www.ncbi.nlm.nih.gov/pubmed/26922636/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,,,,,,,
1770,,,,,,,,,sapropterin,DB00360,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Behaviour abnormalities,,HP:0100851,https://clinicaltrials.gov/ct2/show/NCT00935753,,,,,,,,,,
1771,,,,,,,,,aminomidazole carboxamide riboside,NA,ECO:0007121,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,,No result was added,,,https://clinicaltrials.gov/ct2/show/NCT00004314?cond=Lesch-Nyhan+Disease&rank=4,,,,,,,,,,
1772,,,,,,,,,Hypoxanthine+ tetrahydrobiopterin,DB04076+DB00360,ECO:0000352,,,,,Functional interaction (B)+Symptomatic (C),B,functional complementation of a genetically defective protein+symptomatic treatment procedure,,No result was accessible,,,https://www.ncbi.nlm.nih.gov/pubmed/3728152,,,,,,,,,,
1773,,,,,,,,,SAM (S-adenosyl methionine ),DB00118,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Self-injurious behaviour,,HP:0100716,https://www.ncbi.nlm.nih.gov/pubmed/16906475/,https://www.ncbi.nlm.nih.gov/pubmed/24001191/,https://www.ncbi.nlm.nih.gov/pubmed/24055166/,,,,,,,,
1774,,,,,,,,,,,,,,,,,,,,Aggressive behavior,,HP:0000718,https://www.ncbi.nlm.nih.gov/pubmed/24055166/,,,,,,,,,,
1775,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1776,,,,,,,,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",Allopurinol,DB00437,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,hyperuricemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/17065067,https://www.ncbi.nlm.nih.gov/pubmed/22198833,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/,,,,,,,,
1777,,,,,,,,,,,,,,,,,,,,gouty arthritis,,HP:0001997,,,,,,,,,,,
1778,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1779,,,,,,,,,Baclofen ,DB00181,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Spasticity,,HP:0001257,https://www.ncbi.nlm.nih.gov/pubmed/16549399,,,,,,,,,,
1780,,,,,,,,,diazepam or alprazolam,DB00829 or DB00404,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,anxiety,,HP:0000739,https://www.ncbi.nlm.nih.gov/pubmed/21126241,,,,,,,,,,
1781,,,,,,,,,,,,Spa,,,,,,,,Abnormal muscle tone,,HP:0003808,https://www.ncbi.nlm.nih.gov/pubmed/21126241,,,,,,,,,,
1782,,,,,,,,,Risperidone,DB00734,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Self-mutilation,,HP:0000742,https://www.ncbi.nlm.nih.gov/pubmed/8870064/,,,,,,,,,,
1783,,,,,,,,,Tetrabenazin,DB04844,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Chorea,,HP:0002072,https://www.ncbi.nlm.nih.gov/pubmed/2455472/,https://www.ncbi.nlm.nih.gov/pubmed/12593632,,,,,,,,,
1784,,,,,,,,,,,,,,,,,,,,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/2455472/,,,,,,,,,,
1785,,,,,,,,,Carbidopa‐levodopa,DB00190+DB01235,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/2455472/,,,,,,,,,,
1786,,,,,,,,,,,,,,,,,,,,Chorea,,HP:0002072,https://www.ncbi.nlm.nih.gov/pubmed/2455472/,,,,,,,,,,
1787,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1788,214,240800,Leucine-sensitive hypoglycemia of infancy,,ABCC8,ATP binding cassette subfamily C member 8,,,diazoxide,DB01119,ECO:0000352,E1506K ,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,,hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/15356046,,,,,,,,,,
1789,,,,,,,,,,,,R1353H,,,,,,,,,,,,,,,,,,,,,
1790,,,,,,,,,,,,delSer1387,,,,,,,,,,,,,,,,,,,,,
1791,215,613724,Leukoencephalopathy-dystonia-motor neuropathy syndrome(STEROL CARRIER PROTEIN 2 DEFICIENCY),,SCP2,sterol carrier protein 2,,,No treatment is available in DDIEM,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16685654,,,,,,,,,,
1792,216,611105,Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation(LBSL),,DARS2,mitochondrial aspartyl-tRNA synthetase,,,acetazolamide,DB00819 ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,paroxysmal exercise-induced gait ataxia(exercise-induced episodic ataxia ),,HP:0002066*,https://www.ncbi.nlm.nih.gov/pubmed/21749991,,,,,,,,,,
1793,,,,,,,,,,,,,,,,,,,,Seizures ,,HP:0001250,,,,,,,,,,,
1794,,,,,,,,,glucocorticosteroid,DB00288 ,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,spastic bladder,,HP:0005340,https://www.ncbi.nlm.nih.gov/pubmed/23644316,,,,,,,,,,
1795,217,607155,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,fukutin-related protein (FKRP),,Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.,Prednisolone,DB00860,ECO:0000352/ECO:0007764,,,,,Symptomatic (C),C,symptomatic treatment procedure,Drug name: It has been mentioned that it might be beneficial in compound heterozygous mutations as patients have a milder phenotypes. https://www.ncbi.nlm.nih.gov/pubmed/28931339#,Myositis,,HP:0100614,https://www.ncbi.nlm.nih.gov/pubmed/28931339,https://www.ncbi.nlm.nih.gov/pubmed/17446099,,,,,,,,,
1796,,,,,,,,,,,,,,,,,,,,Muscle weakness,,HP:0001324,,,,,,,,,,,
1797,,,,,,,,,,,,,,,,,,,,Difficulty walking,,HP:0002355,,,,,,,,,,,
1798,,,,,,,,,,,,,,,,,,,,Rapid progression,,HP:0003678,,,,,,,,,,,
1799,,,,,,,,,rAAV-Fkrp,,ECO:0005542,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein by gene therapy,,Abnormal serum creatine kinase,,HP:0040081,https://www.ncbi.nlm.nih.gov/pubmed/25048216,https://www.ncbi.nlm.nih.gov/pubmed/23817215,https://www.ncbi.nlm.nih.gov/pubmed/28334834,https://www.ncbi.nlm.nih.gov/pubmed/28480302,,,,,,,
1800,,,,,,,,,,,,,,,,,,,,Muscle dystrophy,,HP:0006785,https://www.ncbi.nlm.nih.gov/pubmed/28107841,,,,,,,,,,
1801,,,,,,,,,,,,,,,,,,,,Abnormal muscle function,,HP:0011804,,,,,,,,,,,
1802,218,609308,LGMD2K,,POMT1,protein O-mannosyltransferase 1,2.4.1.109,,No treatment is available in DDIEM,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17339125,,,,,,,,,,
1803,219,611307,Limb-girdle muscular dystrophy type 2I (LGMD2I),,ANO5,anoctamin 5,Q75V66,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1804,220,253601,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2B; LGMD2B",,DYSF,dysferlin,O75923,,Resolaris (ATYR1940),NA,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Abnormal muscle function,,HP:0011804,https://clinicaltrials.gov/ct2/show/NCT02579239,https://musculardystrophynews.com/resolaris-atyr1940/,https://www.ncbi.nlm.nih.gov/pubmed/17339125,,,,,,,,
1805,221,253600,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A",,CAPN3,calpain 3,3.4.22.17,,AAV2 /1-mSeAP-propmyoD76A,NA,ECO:0005542,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Muscle atrophy,,HP:0003797,https://www.ncbi.nlm.nih.gov/pubmed/17330087,https://www.ncbi.nlm.nih.gov/pubmed/17339125,,,,,,,,,
1806,,,,,,,,,,,,,,,,,,,,abnormal muscle strenght,,HP:0001324,,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A,,,,,,,
1807,,,,,,,,,(r) AAV2/1-mediated calpain 3,NA,ECO:0005542,,,,,Direct interaction (Mechanistic A),,direct complementation of a genetically defective protein by gene therapy,,Low muscle mass,,,https://www.ncbi.nlm.nih.gov/pubmed/17330087,,,,,,,,,,
1808,222,608099,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2D; LGMD2D",,SGCA,sarcoglycan alpha,Q16586 ,,AAV2/1-MCK-Sgca,NA,ECO:0005542,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein by gene therapy,Drug name: Tried in mice not human,Decreased muscle mass,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=AAV-mediated+delivery+of+a+mutated+myostatin+propeptide+ameliorates+calpain+3+but+not+α-sarcoglycan+deficiency,https://www.ncbi.nlm.nih.gov/pubmed/17339125,,,,,,,,,
1809,223,608896,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2C; LGMD2C",,SGCG,sarcoglycan gamma,Q16586 ,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15252120,https://www.ncbi.nlm.nih.gov/pubmed/16635485,,,,,,,,,
1810,224,246650,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,lipase maturation factor 1,Q96S06,Poor compliance to the treatment was noticed,Fenofibrate+ω-3 fatty acids+EPA+DHA,DB01039+DB11133+DB00159 +DB03756,ECO:0000352,,,,,Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B),C,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,Drug name: Poor compliance to the treatment was noticed ,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/19820022,,,,,,,,,,
1811,,,,,,,,"Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil",gemfibrozil+ω-3 fatty acids,DB01241+DB11133,ECO:0000352,,,,,Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B),C,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,"Drug name: Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil (600 mg twice a day",Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/19820022,,,,,,,,,,
1812,,,,,,,,,Insulin aspart+Fibrate(gemfibrozil)+ ω-3 fatty acids,DB01306+DB01241+DB11133,ECO:0000352,W464X,,,,Symptomatic (C)+Functional interaction (Mechanistic B)+Functional interaction (Mechanistic B),C,symptomatic treatment procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,Drug name: Improvement in the triglycride level startrd Under insulin therapy with a good blood glucose control (glycosylated hemoglobin 5.6%) and an improved lipid profile with TG plasma levels as low as 195 mg/dl (2.2 mmol/liter),Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/19820022,,,,,,,,,,
1813,,,,,,,,,,,,,,,,,,,,Hyperglycemia,,HP:0003074,,,,,,,,,,,
1814,,,,,,,,A low fat regimen was added to metformin while treating the patient.,Metformin,DB00331,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/17994020/,,,,,,,,,,
1815,225,614462,Lipoic acid synthetase deficiency,,LIAS,lipoic acid synthetase,2.8.1.8,,Topiramate+lamotrigine,DB00273+DB00555,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure+symptomatic treatment procedure,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/24777537,,,,,,,,,,
1816,226,247100,Lipoid proteinosis of Urbach and Wiethe,,ECM1,extracellular matrix protein 1,Q16610,,Acitretin,DB00459,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Skin lesion,,HP:0011122,https://www.ncbi.nlm.nih.gov/pubmed/24748909,https://www.ncbi.nlm.nih.gov/pubmed/28720532,,,,,,,,,
1817,,,,,,,,,,,,,,,,,,,,Skin papules,,HP:0200034,,,,,,,,,,,
1818,,,,,,,,,,,,,,,,,,,,Mucosal lesions,,,,,,,,,,,,,
1819,,,,,,,,,,,,,,,,,,,,Hoarseness,,HP:0001609,https://www.ncbi.nlm.nih.gov/pubmed/23259080/,https://www.ncbi.nlm.nih.gov/pubmed/18808438/,,,,,,,,,
1820,,,,,,,,,,,,,,,,,,,,Elbow skin thickening,,HP:0001072,https://www.ncbi.nlm.nih.gov/pubmed/28681064,,,,,,,,,,
1821,,,,,,,,,,,,,,,,,,,,hyperkeratosis,,HP:0000962,,,,,,,,,,,
1822,,,,,,,,,,,,,,,,,,,,verrucous lesions,,HP:0012500,,,,,,,,,,,
1823,227,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",sodium bicarbonate,DB01390,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Proximal tubular dysfunction,,HP:0000114,https://www.ncbi.nlm.nih.gov/pubmed/12937245,https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33,,,,,,,,,
1824,,,,,,,,,potassium bicarbonate,DB11098,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Hypokalemia,,HP:0002900,https://www.ncbi.nlm.nih.gov/pubmed/20301653,https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33,,,,,,,,,
1825,,,,,,,,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",Potassium citrate,DB09125,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Metabolic acidosis (Hyperchloremic metabolic acidosis),,HP:0004918,https://www.ncbi.nlm.nih.gov/pubmed/20301653,,,,,,,,,,
1826,,,,,,,,,,,,,,,,,,,,Hypokalemia,,HP:0002900,,,,,,,,,,,
1827,,,,,,,,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",phosphate+calcitriol,DB14573+DB00136,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Renal rickets,,HP:0002748,https://www.ncbi.nlm.nih.gov/pubmed/20301653,,,,,,,,,,
1828,,,,,,,,,,,,,,,,Symptomatic (C),C,,,Hypophosphatemia,,HP:0002148,https://www.ncbi.nlm.nih.gov/pubmed/20301653,,,,,,,,,,
1829,,,,,,,,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",1-OH vitamin D,,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Hyperparathyrodism,,HP:0000867,https://www.ncbi.nlm.nih.gov/pubmed/2017228,https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33,,,,,,,,,
1830,,,,,,,,,pamidronate +growth hormone,DB00282+DB00052,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Hypophosphatasia,,HP:0002148,https://www.ncbi.nlm.nih.gov/pubmed/19773212/,,,,,,,,,,
1831,,,,,,,,,,,,,,,,,,,,Osteoporosis,,HP:0000939,,,,,,,,,,,
1832,,,,,,,,,Thiazide,DB01325,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,High calcium excretion,,HP:0002150,https://www.ncbi.nlm.nih.gov/pubmed/26251718,,,,,,,,,,
1833,,,,,,,,,L-carnitine,DB00583,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,secondary carnitine deficiency (Carnitine deficiency)*,,HP:0003234,https://pdfs.semanticscholar.org/3a8e/bd8dda73113f384215ca26d7df0fe61441a1.pdf,https://www.ncbi.nlm.nih.gov/books/NBK1480/,,,,,,,,,
1834,228,222700,Lysinuric protein intolerance,"General therapeutic management remains empirical with 3 major axes: prevention of hyperammonemia, nutritional supplementation and prevention of specific complications. There is a general consensus that a hypoproteinemic regimen should be initiated with an objective of 1 g/kg/d. associated with L-citrulline supplementation, L-carnitine 20-50 mg/kg/d., vitamins and other nutritional supplementation, if necessary. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217205/  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  https://www.ncbi.nlm.nih.gov/pubmed/22402328/",SLC7A7,Y+L amino acid transporter 1,Q9UM01,"Citrulline should be given in ""Low-dose"" as of 100 mg/kg/d.  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  
Adjusting l-citrulline dosage may be crucial, as excessive citrulline may worsen intracellular arginine accumulation  leading to harmful effects. https://www.ncbi.nlm.nih.gov/pubmed/22402328/ https://www.ncbi.nlm.nih.gov/pubmed/27567650",Citrulline,DB00155,ECO:0000352,,,,,Functional interaction (B),C,functional complementation of a genetically defective protein," Drug name: in ""Low-dose""",Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/22402328,https://www.ncbi.nlm.nih.gov/pubmed/6777479,https://www.ncbi.nlm.nih.gov/pubmed/25859380,,,,,,
1835,,,,,,,,"The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805",corticosteroids(Amcinonide),DB00288,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure," Drug namre: The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805",hemophagocytic-lymphohistiocytosis (Abnormality of immune system physiology)*,,HP:0010978,https://www.ncbi.nlm.nih.gov/pubmed/28057010,,,,,,,,,,
1836,,,,,,,,,cyclosporin,DB00091,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,,,,,,,,,,,,,
1837,,,,,,,,"THe drug is well known to be a putative therapy for severe osteopenia, but more reliable protocols are needed.",Alendronate,,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Osteopenia,,HP:0000938,https://www.ncbi.nlm.nih.gov/pubmed/16868861?dopt=Abstract,,,,,,,,,,
1838,,,,,,,,,ACEI (Benazepril),DB00542,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Kidney failure ,,HP:0000083,,,,,,,,,,,
1839,,,,,,,,,,,,,,,,,,,,proteinuria,,HP:0000093,,,,,,,,,,,
1840,,,,,,,,,,,,,,,,,,,,hypertension,,HP:0000822,,,,,,,,,,,
1841,,,,,,,,Drug has no difference in terms of prognosis.,sodium phenylbutyrate,DB06819,ECO:0000352,,,,,Functional interaction (B),C,functional complementation of a genetically defective protein,Drug has no difference in terms of prognosis.,hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/26865117,https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/20301535,,,,,,,
1842,,,,,,,,Drug has no difference in terms of prognosis.,sodium benzoate,DB03793,ECO:0000352,,,,,Functional interaction (B),C,functional complementation of a genetically defective protein,Drug has no difference in terms of prognosis.,hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/20301535,,,,,,,,,
1843,,,,,,,,,Lysine,DB00123,ECO:0000352,,,,,Functional interaction (B),,metabolite replacement,,hypolysinemia,,,,,,,,,,,,,
1844,,,,,,,,"Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650",Lysine/Arginine/carnitine/Citrulline,DB00123/DB00125/DB00583,ECO:0000352,,,,,Functional interaction (B),C,metabolite replacement,"No obvious benefit from oral supplementation with citrulline, lysine or arginine.",orotic aciduria,The drug works through preventing the aciduria and the hyperammonemia rather than treating it.  ,HP:0003218,https://www.ncbi.nlm.nih.gov/pubmed/25614305,,,,,,,,,,
1845,,,,,,,,,,,,,,,,Symptomatic (C),C,,"No obvious benefit from oral supplementation with citrulline, lysine or arginine.",hypolysinemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/20301535,,,,,,,,,
1846,,,,,,,,,,,,,,,,,,,,intracellular defect of arginine,,HP:0005961,,,,,,,,,,,
1847,,,,,,,,,,,,,,,,,,,The dosage of L-citrulline dosage was a subject of controversy because of the possibility that it could increase inflammatory damages through its conversion to arginine and NO. L-Citrulline supplementation is thus usually limited to 100 mg/kg/d,hyperproteinemia,,HP:0002152,,,,,,,,,,,
1848,,,,,,,,,Growth hormone,DB00052,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,"In order to get a favorable outcome in GH-treated children, Treatment with rhGH should be started early.",growth impairment,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/16775724/,https://www.ncbi.nlm.nih.gov/pubmed/25614305,https://www.ncbi.nlm.nih.gov/pubmed/23430827/,,,,,,,,
1849,,,,,,,,,,,,,,,,,,,,Short stature,,HP:0004322,,,,,,,,,,,
1850,,,,,,,,,carnitine,DB00583,ECO:0000352,,,,,Functional interaction (B),C,functional complementation of a genetically defective protein,,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/28057010,,,,,,,,,
1851,,,,,,,,The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650,Sodium benzoate+ L-carnitine+ low dose citrulline ,DB03793+DB00583+DB00155,ECO:0000352,,,,,Functional interaction (B)+Functional interaction (B)+Functional interaction (B),C,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,episodic behavioral abnormalities,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/27567650,,,,,,,,,,
1852,,,,,,,,,,,,,,,,,,,,social interaction defect,,HP:0000735,,,,,,,,,,,
1853,,,,,,,,,,,,,,,,,,,,lack eye-eye contact,,HP:0000817,,,,,,,,,,,
1854,,,,,,,,,,,,,,,,,,,,Hepatosplenomegaly,,HP:0001433,,,,,,,,,,,
1855,,,,,,,,,Azathioprine,DB00993,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,,,,,,,,,,,,,,
1856,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1857,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1858,,,,,,,,,Sargramostim,DB00020,ECO:0000352,,,,,Symptomatic (C),C,activity modification of a genetically defective protein,symptomatic treatment procedure,Pulmonary Alveolar Proteinosis,,HP:0006517,https://www.ncbi.nlm.nih.gov/pubmed/27783330,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/29058386,https://www.ncbi.nlm.nih.gov/pubmed/21110863/,,,,,,,
1859,,,,,,,,,,,,,,,,,,,,Low pulmonary function,,HP:0005952,,,,,,,,,,,
1860,,,,,,,,,Regramostim,DB05386,ECO:0007121,,,,,Symptomatic (C),C,activity modification of a genetically defective protein,,Pulmonary Alveolar Proteinosis,,HP:0006517,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/29058386,https://www.ncbi.nlm.nih.gov/pubmed/21110863/,https://www.ncbi.nlm.nih.gov/pubmed/28649527,,https://www.ncbi.nlm.nih.gov/pubmed/24886114,,,,,
1861,,,,,,,,,,,,,,,,,,,,Low pulmonary function,,HP:0005952,,,,,,,,,,,
1862,,,,,,,,,prednisolone+mycophenolate mofetil,DB00860+DB00688,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure+symptomatic treatment procedure,,membranoproliferative glomerulonephritis,,HP:0000793,https://www.ncbi.nlm.nih.gov/pubmed/28087478,,,,,,,,,,
1863,229,248360,Malonyl-CoA decarboxylase Deficiency,,MLYCD,malonyl-CoA decarboxylase,4.1.1.9,,Carnitine+Fat-limited diet+High carbohydrate diet,DB00583,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein+dietary regime modification,,High urinary malonic acid,,HP:0012120,https://www.ncbi.nlm.nih.gov/pubmed/26858006,https://www.ncbi.nlm.nih.gov/pubmed/24613099,https://www.ncbi.nlm.nih.gov/pubmed/28781843,,,,,,,,
1864,,,,,,,,MCT should be at least 70% of the total fat content of the diet.,Medium‐chain triglycerides,DB13959,ECO:0000352,,,,,Functional interaction (B),B,dietary regime modification,,High blood malonylcarnitine level,,HP:0031544,,,,,,,,,,,
1865,,,,,,,,,,,,,,,,,,,,Low endurance,,HP:0025142,,,,,,,,,,,
1866,,,,,,,,,,,,,,,,,,,,Failurre to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/28781843,,,,,,,,,,
1867,,,,,,,,,,,,,,,,,,,,Cardiomyopathy progrssion,,HP:0003679,,,,,,,,,,,
1868,230,614202,MAN1B1-CDG,,MAN1B1,mannosidase alpha class 1B member 1,,,No treatment is available in DDIEM,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/29908352,,,,,,,,,,
1869,231,611722,Krabbe disease atypical due to Saposin A deficiency,,PSAP,prosaposin,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1870,232,530000,Kearns-Sayre syndrome,,,,,,Folinic acid,DB00650,ECO:0000352,,,,,Functional interaction(m,C,metabolite replacement,"Drug has a controversial study regarding patients reponce to treatment. https://www.ncbi.nlm.nih.gov/pubmed/28318733
",Low 5‐MTHF level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/16365882,https://www.ncbi.nlm.nih.gov/pubmed/28318733,,,,,,,,,
1871,,,,,,,,,,,,,,,,,,,,White matter alteration,,HP:0002500,,,,,,,,,,,
1872,,,,,,,,,,,,,,,,,,,,deambulation,,HP:0100022,,,,,,,,,,,
1873,,,,,,,,,Growth Hormone,DB00052,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Short Stature,,HP:0004322,https://www.ncbi.nlm.nih.gov/pubmed/27718492,,,,,,,,,,
1874,,,,,,,,,coenzyme Q10,DB09270,ECO:0000352,,,,,Functional interaction(m,C,functional complementation of a genetically defective protein,,Corneal Oedema,,HP:0012040,https://www.ncbi.nlm.nih.gov/pubmed/27442316,https://www.ncbi.nlm.nih.gov/pubmed/27709644,https://www.ncbi.nlm.nih.gov/pubmed/26884075,,,,,,,,
1875,,,,,,,,,,,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/26118651,,,,,,,,,,
1876,,,,,,,,,l-carnitine,DB00583,ECO:0000352,,,,,Functional interaction(m,C,functional complementation of a genetically defective protein,,Mitochondrial respiratory chain defects,,HP:0200125,https://www.ncbi.nlm.nih.gov/pubmed/19891905,,,,,,,,,,
1877,,,,,,,,,,,,,,,,,,,,Myopathy,,HP:0003198,https://www.ncbi.nlm.nih.gov/pubmed/26884075,,,,,,,,,,
1878,,,,,,,,,"dopamine, dobutamine, thiazide and milrinone",DB00988+DB0084+DB00232+DB00235,ECO:0000352,,,,,Symptomatic(C),C,symptomatic treatment procedure,,acute congestive heart failure,,HP:0001635,https://www.ncbi.nlm.nih.gov/pubmed/26884075,,,,,,,,,,
1879,,,,,,,,,mitochonic acid 5,NA,ECO:0001565,,,,,Functional interaction(m,C,functional complementation of a defective protein by stimulation,,Mitochondrial dysfunction,,HP:0003287,https://www.ncbi.nlm.nih.gov/pubmed/26118651,,,,,,,,,,
1880,,,,,,,,,,,,,,,,,,,,Decreased cellular ATP level,,HP:0011925*,,,,,,,,,,,
1881,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1882,,,,,,,,,Insulin,DB00030,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Diabetes mellitus,,HP:0000819,https://www.ncbi.nlm.nih.gov/pubmed/25092642,,,,,,,,,,
1883,,,,,,,,,cysteamine bitartrate,DB00847,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,Terminated (Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001.),Terminated (Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001,,,https://clinicaltrials.gov/ct2/show/NCT02023866?cond=Kearns-Sayre+Syndrome&rank=4,https://clinicaltrials.gov/ct2/show/NCT02473445,,,,,,,,,
1884,,,,,,,,,Sodium Pyruvate,DB00119,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Elevated serum lactate level,,HP:0002151,https://www.ncbi.nlm.nih.gov/pubmed/30738201,,,,,,,,,,
1885,,,,,,,,,,,,,,,,,,,,High lactate /pyruvate ratio(Mitochondrial respiratory chain defects)*,,HP:0200125,,,,,,,,,,,
1886,,,,,,,,,,,,,,,,,,,,Increased lateral ventricular lactate level,,NA,,,,,,,,,,,
1887,,,,,,,,,,,,,,,,,,,,High serum GDF15 level,,NA,,,,,,,,,,,
1888,,,,,,,,,Phenobarbital+phenytoin,,ECO:0000352,,,,,Symptomatic (C)+Symptomatic (C),,symptomatic treatment procedure+symptomatic treatment procedure,,Generalized tonic-clonic seizures,,HP:0002069,,,,,,,,,,,
1889,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1890,233,609242,Kanzaki disease/schindler Disease type 2,,NAGA,alpha-N-acetylgalactosaminidase,," A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.","iminosugar DGJNAc( 2-acetamido-1,2-dideoxy-d-galactonojirimycin)",NA,EC0:0005542/ECO:0001565,,,,,Direct interaction (A),A,activity modification of a genetically defective protein,"clinical candidate , tested invitro and in cellular experiments ",Abnormal enzyme activity,,,https://www.ncbi.nlm.nih.gov/pubmed/23045655,,,,,,,,,,
1891,,,,,,,,,1-deoxygalactonojirimycin (DGJ,DB05018,EC0:0005542/ECO:0001565,,,,,Direct interaction (A),A,activity modification of a genetically defective protein,,,,,,,,,,,,,,,
1892,234,243500,Isovaleric acidemia,,IVD,isovaleryl-CoA dehydrogenase,,,carglumic acid,DB06775,ECO:0000352,,,,,Symptomatic (C),C,functional complementation of a defective protein by stimulation,,acute hyperammonemia,,HP:0008281,https://www.ncbi.nlm.nih.gov/pubmed/21207059,https://www.ncbi.nlm.nih.gov/pubmed/21403788,,,,,,,,,
1893,,,,,,,,"1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338",L-carnitine +L- glycine,DB00583+DB00145,ECO:0000352,,,,,Symptomatic (C),C,functional complementation of a defective protein by inhibition,,High toxic acyl-CoA level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/21290185,https://www.ncbi.nlm.nih.gov/pubmed/12069539/,https://www.ncbi.nlm.nih.gov/pubmed/20807522,https://www.ncbi.nlm.nih.gov/pubmed/19210957,,,,,,,
1894,,,,,,,,,,,,,,,,,,,,"abnormal Na+,K+-ATPase activity",,NA,https://www.ncbi.nlm.nih.gov/pubmed/15624372,,,,,,,,,,
1895,,,,,,,,,,,,,,,,,,,,Metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/16602101,,,,,,,,,,
1896,,,,,,,,,,,,,,,,,,,,High 3-hydroxyisovaleric acid level (C5),,NA,https://www.ncbi.nlm.nih.gov/pubmed/17299485,https://www.ncbi.nlm.nih.gov/pubmed/16602101/,,,,,,,,,
1897,,,,,,,,,,,,,,,,,,,,Metabolic stress,The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/8804338,,,,,,,,,,
1898,,,,,,,,,,,,,,,,,,,,Developmental delay,,,,,,,,,,,,,
1899,235,611283,Isobutyryl-CoA dehydrogenase deficiency,"It is as yet uncertain whether IBD deficiency may cause significant morbidity in affected children and whether treatment is necessary. In view of the limited experience worldwide, careful monitoring of the children is recommended. https://www.ncbi.nlm.nih.gov/pubmed/15505379",ACAD8,isobutyryl-CoA dehydrogenase,,,L-carnitine,DB00583,ECO:0000352,,,,,Symptomatic (C),C,metabolite replacement,,Carnitine deficiency,,HP:0003234,https://www.ncbi.nlm.nih.gov/pubmed/28053874,https://www.ncbi.nlm.nih.gov/pubmed/12359132?dopt=Abstract&holding=npg,https://www.ncbi.nlm.nih.gov/pubmed/9889013/,,,,,,,,
1900,,,,,,,,,,,,,,,,,,,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/12359132?dopt=Abstract&holding=npg,,,,,,,,,,
1901,,,,,,,,,L- carnitine+valine-restricted diet+riboflavin ,DB00583+DB00140,ECO:0000352,,,,,,,metabolite replacement+dietary exclusion+symptomatic treatment procedure,,Growth abnormality,,HP:0001507,https://www.ncbi.nlm.nih.gov/pubmed/16857760?dopt=Abstract&holding=npg,,,,,,,,,,
1902,236,261000,Intrinsic factor deficiency,,GIF,gastric intrinsic factor,,"The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/",Vitamin B12,DB00115,ECO:0000352,,,,,Functional interaction(m,B,metabolite replacement,,Low levels of serum vitamin B12,,HP:0100502,https://www.ncbi.nlm.nih.gov/pubmed/24424200,https://www.ncbi.nlm.nih.gov/pubmed/25308559,https://www.ncbi.nlm.nih.gov/pubmed/6823973,https://www.ncbi.nlm.nih.gov/pubmed/9694707,,,,,,,
1903,,,,,,,,,,,,,,,,,,,,High RBC's mean corpuscular volume ,,HP:0025548,,,,,,,,,,,
1904,,,,,,,,,,,,,,,,,,,,Low Hemoglobin concentration,,HP:0020062,,,,,,,,,,,
1905,,,,,,,,,,,,,,,,,,,,Abnormal reticulocyte count,,HP:0004312,,,,,,,,,,,
1906,,,,,,,,,Corticosteroid,DB00860,,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Gastric mucosal atrophy(Abnormality of gastric mucosa)*,,HP:0004295,https://www.ncbi.nlm.nih.gov/pubmed/24424200,https://www.ncbi.nlm.nih.gov/pubmed/921733,,,,,,,,,
1907,237,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,P05019,"The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of ""increlex "" supply.",Recombinant human IGF1(Mecasermin),DB01277,ECO:0007121/ECO:0000352,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein,,Low height velocity,,HP:0004322,https://www.ncbi.nlm.nih.gov/pubmed/10323388,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1,https://clinicaltrials.gov/ct2/show/NCT00747604?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=10,https://clinicaltrials.gov/ct2/show/NCT00125164?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=7,https://clinicaltrials.gov/ct2/show/NCT00330668?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=6
1908,,,,,,,,,,,,,,,,,,,,Low lean body mass,,HP:0045082,,,,,,,,,,,
1909,,,,,,,,,,,,,,,,,,,,Abnormal linear growth (Decreased linear growth /Abnormal body height)*,,HP:0000002,,,,,,,,,,,
1910,,,,,,,,,,,,,,,,,,,,low insulin senstivity,,HP:0008189,,,,,,,,,,,
1911,,,,,,,,,,,,,,,,,,,,Abnormal circulating GH level,,HP:0032367,,,,,,,,,,,
1912,,,,,,,,,,,,,,,,,,,,Abnormal circulating IGFBP level,,HP:0031034,,,,,,,,,,,
1913,,,,,,,,,,,,,,,,,,,,Abnormal circulating insulin level,,HP:0040215,,,,,,,,,,,
1914,,,,,,,,,,,,,,,,,,,,Decreased body mass index,,HP:0045082,https://www.ncbi.nlm.nih.gov/pubmed/10770174,,,,,,,,,,
1915,,,,,,,,,,,,,,,,,,,,Abnormal Body fat composition,,HP:0025521,,,,,,,,,,,
1916,,,,,,,,,,,,,,,,,,,,Insulin resistance,,HP:0000855,,,,,,,,,,,
1917,,,,,,,,The study is terminated (The study was prematurely terminated due to strategic reasons.),NutropinAq® (Somatropin [rDNA origin],DB00052,ECO:0007121,,,,,Functional interaction (B),,functional complementation of a genetically defective protein,,Short stature,,HP:0004322,https://clinicaltrials.gov/ct2/show/study/NCT00572156?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=4,,,,,,,,,,
1918,,,,,,,,The study is terminated (The study was prematurely terminated due to strategic reasons.),Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin]),DB01277+DB00052,ECO:0007121,,,,,Direct interaction (Mechanistic A)+Functional interaction (B),,direct complementation of a genetically defective protein+Functional complementation of a genetically defective protein,,Short stature,,HP:0004322,https://clinicaltrials.gov/ct2/show/study/NCT00572156?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=4,,,,,,,,,,
1919,,,,,,,,"Mecasermin rinfabate, however, is no longer available in the USA or Europe for treating conditions involving short stature, because of a legal requirement",Mecasermin rinfabate,DB14751,ECO:0000352,,,,,Direct interaction (Mechanistic A)+Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein,"Drug name: Mecasermin rinfabate, however, is no longer available in the USA or Europe for treating conditions involving short stature, because of a legal requirement",hypoglycemia,"The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect. ",HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/19627167,,,,,,,,,,
1920,,,,,,,,,,,,,,,,,,,,Low serum ICFBP level,,,,,,,,,,,,,
1921,238,271245,Infantile-onset spinocerebellar ataxia,Conventional antiepileptic drugs (phenytoin and phenobarbital) are ineffective in most affected individuals.,TWNK,twinkle mtDNA helicase,Q96RR1,The drug is occasionally effective especially when started early in status epilepticus.,Benzodiazepines,DB00252,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,"Drug nmae:However, phenytoin and phenobarbitates are ineffective in most affected individuals",Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/20301746,,,,,,,,,,
1922,,,,,,,,The drug has some effects but hyponatremia is a troublesome side effect.,Oxcarbazepine,DB00776,ECO:0000352,,,,,,,symptomatic treatment procedure,,Short nocturnal tonic seizures,,HP:0031951,https://www.ncbi.nlm.nih.gov/pubmed/19304794,https://www.ncbi.nlm.nih.gov/pubmed/20301746,,,,,,,,,
1923,,,,,,,,"Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.",valproate,DB00313,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure, Drug name: Should be avoided as it results in elevated liver enzymes only when treated with valproate,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/27551684,https://www.ncbi.nlm.nih.gov/pubmed/19304794/,,,,,,,,,
1924,,,,,,,,,Selective serotonin reuptake inhibitors+Antipsychotics,N06AB +N05A,ECO:0000352,,,,,,,symptomatic treatment procedure+symptomatic treatment procedure,,Agitation,,HP:0000713,https://www.ncbi.nlm.nih.gov/pubmed/19304794,,,,,,,,,,
1925,,,,,,,,,,,,,,,,,,,,Aggressive behavior,,HP:0000718,,,,,,,,,,,
1926,,,,,,,,,Carbamazepine,,ECO:0000352,,,,,,,symptomatic treatment procedure,,Complex partial seizure,,,,,,,,,,,,,
1927,,,,,,,,,,,,,,,,,,,,Generalized convulsion,,,,,,,,,,,,,
1928,,,,,,,,,Topiramate + pyridoxine,"DB00273+DB00165
",ECO:0000352,,,,,,,symptomatic treatment procedure+symptomatic treatment procedure,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/27551684,,,,,,,,,,
1929,,,,,,,,"The increased creatine/creatinine ratio in adult IOSCA patients, as well as in the IOSCA child patient who is motorically as active as her age‐mates, suggests an important role of creatine metabolism in the disease pathogenesis. Creatine synthesis is a major methyl group user, utilizing the same 1C/methyl pool as transsulfuration cycle, and thus, the creatine supplementation in IOSCA and IBM should be studied thus creatine is considered as a potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373890 ",creatine,DB00583,ECO:0007764,,,,,Functional interaction (B),C,functional complementation of a defective protein by stimulation,,Abnormal circulating creatinine level,,HP:0012100,https://www.ncbi.nlm.nih.gov/pubmed/30373890,,,,,,,,,,
1930,,,,,,,,"Glutathione depletion indicates decreased potential for antioxidant capacity in IOSCA. Additionally, we analysed a blood sample of an IOSCA child patient who showed high creatine/creatinine ratio and low taurine and kynurenate. The significant depletion of kynurenate and the significant depletion of niacinamide are both consistent with depletion of NAD+thus both Clutathione and Nicotinamide riboside are considered as potential drugs for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373891",Glutathione [N‐acetyl‐cysteine],DB00143,ECO:0007764,,,,,Functional interaction (B),C,functional complementation of a defective protein by stimulation,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/30373890,,,,,,,,,,
1931,,,,,,,,,,,,,,,,,,,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/30373890,,,,,,,,,,
1932,,,,,,,,A potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373892,NAD+ [nicotinamide riboside],DB14933,ECO:0007764,,,,,Functional interaction (B),C,functional complementation of a defective protein by stimulation,,Decreased niacinamide level ,,,https://www.ncbi.nlm.nih.gov/pubmed/30373890,,,,,,,,,,
1933,239,256600,Infantile neuroaxonal dystrophy,,PLA2G6,85/88 kDa calcium-independent phospholipase A2,3.1.1.4,"The clinicl trial status is active and not recruiting and no results have been yet posted.

The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (“fireproof”) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/","RT001 (11,11-di-deutero-linoleic acid ethyl ester)",NA,ECO:0007121/ECO:0000352,,,,,Functional interaction (B),B,metabolite replacement,,Chronic constipation,,HP:0012450,https://clinicaltrials.gov/ct2/show/NCT03570931?cond=infantile+neuroaxonal+dystrophy&rank=1,http://n.neurology.org/content/90/15_Supplement/P3.327,,,,,,,,,
1934,,,,,,,,,,,,,,,,,,,,Bulbar dysfunction,,HP:0001283,,,,,,,,,,,
1935,,,,,,,,,,,,,,,,,,,,Functional motoe deficit,,HP:0004302,,,,,,,,,,,
1936,,,,,,,,,,,,,,,,,,,,Defective eye motor function,,HP:0000496,,,,,,,,,,,
1937,,,,,,,,,,,,,,,,,,,,Poor head control ,,HP:0002421,,,,,,,,,,,
1938,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1939,,,,,,,,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",Desipramine,DB01151,ECO:0007121/ECO:0005542,,,,,Symptomatic (C),C,functional complementation of a defective protein by inhibition,,Lysosomal stress (Abnormality of lysosomal metabolism)*,In the mouse model syudy,HP:0004356,https://clinicaltrials.gov/ct2/show/NCT03726996,https://www.ncbi.nlm.nih.gov/pubmed/29909971,,,,,,,,,
1940,,,,,,,,,,,,,,,,,,,,Neurodegeneration,In the mouse model syudy,HP:0002180,,,,,,,,,,,
1941,240,269920,Free sialic acid storage disease,,SLC17A5,solute carrier family 17 member 5,Q9NRA2 ,,Treatment of manifestations:Management is symptomatic and supportive: rehabilitation to optimize mobility and communication; provision of adequate nutrition; standard treatment of seizures. Surveillance: Regular evaluation by a rehabilitation specialist to identify potentially helpful interventions.,,,,,,,Symptomatic (C),C,,Drug name: Treatment of manifestations: Management is symptomatic and supportive: rehabilitation to optimize mobility and communication; provision of adequate nutrition; standard treatment of seizures. Surveillance: Regular evaluation by a rehabilitation specialist to identify potentially helpful interventions.,,,,,https://www.ncbi.nlm.nih.gov/pubmed/20301643,,,,,,,,,
1942,241,604369,Salla Disease,,SLC17A5,solute carrier family 17 member 5,Q9NRA2 ,,Levetiracetam,DB01202,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,generalized tonic-clonic seizure,,HP:0002069,https://www.ncbi.nlm.nih.gov/pubmed/28662915,,,,,,,,,,
1943,,,,,,,,,Phenobarbital,DB01174,ECO:0000352,,,,,,,symptomatic treatment procedure,,Seizures,,,https://www.ncbi.nlm.nih.gov/pubmed/12794688,,,,,,,,,,
1944,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1945,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1946,242,605820,Inclusion body myopathy 2,,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,"3.2.1.183, 2.7.1.60",,ManNac (N-acetylmannosamine),DB12536,ECO:0007121,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,Decreased sialylation of muscle glycans,,HP:0012350,https://clinicaltrials.gov/ct2/show/NCT02346461?cond=Distal+Myopathy+with+Rimmed+Vacuoles&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/28641925,https://www.ncbi.nlm.nih.gov/pubmed/26546927,,,,,,,,
1947,,,,,,,,,,,,,,,,,,,,Low circulating levels of free sialic acids,,HP:0012363,,,,,,,,,,,
1948,,,,,,,,,,,,,,,,,,,,Rimmed vacuoles,,HP:0003805,https://www.ncbi.nlm.nih.gov/pubmed/21517694,,,,,,,,,,
1949,,,,,,,,,,,,,,,,,,,,Amyloid deposition,,HP:0003216*,https://www.ncbi.nlm.nih.gov/pubmed/21517694,,,,,,,,,,
1950,,,,,,,,,Sialic Acid Extended Release (SA-ER)+ManNac (N-acetylmannosamine),CHEBI:17012+DB12536,ECO:0007121,,,,,Functional interaction (Mechanistic B),B,metabolite replacement+metabolite replacment,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/28641925,https://clinicaltrials.gov/ct2/show/NCT01517880?cond=Inclusion+body+myopathy+2&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/26546927,https://www.ncbi.nlm.nih.gov/pubmed/20030229,,,,,,,
1951,,,,,,,,,,,,,,,,,,,,"Decreased sialylation of muscle glycans
",,HP:0012350,,,,,,,,,,,
1952,,,,,,,,,GNE gene lipoplex,NA,ECO:0007121,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein by gene therapy,,Decline of muscle strength (Muscle weakness),,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/21517694,,,,,,,,,,
1953,,,,,,,,,Sialic acid,CHEBI:17012,,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,Muscle weakness,,HP:0001324,,,,,,,,,,,
1954,243,252500,I cell disease,,GNPTAB,(α) &(β)GlcNAc-1-phosphotransferas,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1955,244,261100,Imerslund-Grasbeck syndrome,,CUBN/AMN,cubilin/amnion associated transmembrane protein,,,methylcobalamin,DB03614,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,Drug name :This study has been conducted in puppies but the treatment's results are the same for humans based on this sudy https://www.ncbi.nlm.nih.gov/pubmed/18768530,Megalobalstic anaemia,,HP:0001889,https://www.ncbi.nlm.nih.gov/pubmed/14593474,https://www.ncbi.nlm.nih.gov/pubmed/27942180,https://www.ncbi.nlm.nih.gov/pubmed/26958680,https://www.ncbi.nlm.nih.gov/pubmed/26040326,https://www.ncbi.nlm.nih.gov/pubmed/23364648,https://www.ncbi.nlm.nih.gov/pubmed/22219566,,,,,
1956,,,,,,,,,,,,,,,,,,,,Low level of serum B12,,HP:0040126,,,,,,,,,,,
1957,,,,,,,,,,,,,,,,,,,,Neurological abnormalities,,HP:0000707,,,,,,,,,,,
1958,,,,,,,,,,,,,,,,,,,,Normocytic anemia,,HP:0001897,https://www.ncbi.nlm.nih.gov/pubmed/29572946,https://www.ncbi.nlm.nih.gov/pubmed/18768530,,,,,,,,,
1959,,,,,,,,,,,,,,,,,,,,Hyperammonemia,,HP:0001987,,,,,,,,,,,
1960,,,,,,,,,,,,,,,,,,,,Increased liver enzyme activities,,HP:0002910,,,,,,,,,,,
1961,,,,,,,,,,,,,,,,,,,,Abnormal methylmalonic acid level.,,HP:0012120,,,,,,,,,,,
1962,,,,,,,,,,,,,,,,,,,,Hyperpigmentation,,HP:0000953,https://www.ncbi.nlm.nih.gov/pubmed/24222293,,,,,,,,,,
1963,245,242600,Iminoglycinuria,,SLC36A2 /SLC6A20/SLC6A19,solute carrier family 36 member 2 +solute carrier family 6 member 20 or solute carrier family 6 member 19,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1964,246,605637,Inclusion body myopathy type 3,,MYH2,myosin heavy chain 2,,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1965,247,246450,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,,HMGCL,HMG-CoA lyase,,,Carnitine+high-carbohydrate+low-protein and low-fat diet,DB00583,ECO:0000352,,,,,,,symptomatic treatment procedure+dietary regime modification,,Disease progression,,HP:0003678,https://www.ncbi.nlm.nih.gov/pubmed/28220407,https://www.ncbi.nlm.nih.gov/pubmed/29565174,https://www.ncbi.nlm.nih.gov/pubmed/26997609/,https://www.ncbi.nlm.nih.gov/pubmed/2443756,https://www.ncbi.nlm.nih.gov/pubmed/1886403,https://www.ncbi.nlm.nih.gov/pubmed/28220407,,,,,
1966,,,,,,,,,,,,,,,,,,,,Decreased plasma carnitine,,HP:0003234,,,,,,,,,,,
1967,,,,,,,,,leucine-restricted diet,NA,ECO:0000352,,,,,,,dietary exclusion,,White matter changes,,HP:0007103,https://www.ncbi.nlm.nih.gov/pubmed/17628222/,,,,,,,,,,
1968,,,,,,,,"The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690",Glucose+leucine-restricted diet,DB01914,ECO:0000352,,,,,,,symptomatic treatment procedure+dietary exclusion,,Nonketotic hypoglycemia,,HP:0001958,https://www.ncbi.nlm.nih.gov/pubmed/17628222/,https://www.ncbi.nlm.nih.gov/pubmed/28220407,,,,,,,,,
1969,,,,,,,,,,,,,,,,,,,,Acute decompensation,,,,,,,,,,,,,
1970,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1971,1,# 268200,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,Phosphatidate phosphatase,3.1.3.4,,Tauroursodeoxycholic acid,DB08834,ECO:0005542,,,,,Functional interaction (Mechanistic B),,functional complementation of a genetically defective protein,Drug name: Study was done on preclinical model of the disease.,ER (endoplasmic reticulum) stress,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30420558,,,,,,,,,,
1972,,,,,,,,,,,,,,,,,,,,High triglyceride levels,,HP:0002155,,,,,,,,,,,
1973,,,,,,,,,,,,,,,,,,,,Muscle weakness,,HP:0001324,,,,,,,,,,,
1974,,,,,,,,,bezafibrate,DB01393,ECO:0005542,,,,,Functional interaction (Mechanistic B),,functional complementation of a genetically defective protein,Drug name: Study was done on preclinical model of the disease.,Increased muscle lipid droplets,,HP:0012240,https://www.ncbi.nlm.nih.gov/pubmed/30420558,,,,,,,,,,
1975,,,,,,,,,,,,,,,,,,,,ER (endoplasmic reticulum) stress,,NA,,,,,,,,,,,
1976,,,,,,,,,,,,,,,,,,,,muscle weakness,,HP:0001324,,,,,,,,,,,
1977,,,,,,,,,,,,,,,,,,,,fiber necrosis,,HP:0003713,,,,,,,,,,,
1978,,,,,,,,,,,,,,,,,,,,Myopathy,,HP:0003198,,,,,,,,,,,
1979,2,# 550500,Myoglobinuria recurrent,,MT-CO1/MT-CYB/MT-CO3,Cytochrome c oxidase subunit 1/Cytochrome c oxidase subunit 2/Cytochrome c oxidase subunit 3,1.9.3.1/P00403/P00414,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
1980,3, # 545000,Myoclonic epilepsy with ragged red fibers ,"Mitochondrion-toxic agents, including mitochondrion-toxic AEDs, such as valproate, carbamazepine, phenytoin, and barbiturates, should be avoided as well as AEDs potentially enhancing the frequency of myoclonus, such as phenytoin, carbamazepine, lamotrigine, vigabatrin, tiagabine, gabapentin, pregabalin, and oxcarbazepine.",MT-TK,Mitochondrially encoded tRNA lysine,,"Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z",Levetiracetam/Clonazepam/Zonisamide,DB01202/DB01068/DB00909,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Myoclonic epliepsy,,HP:0002123,https://www.ncbi.nlm.nih.gov/pubmed/14981187,,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z,,,,,,
1981,,,,,,,,,Coenzyme Q10+L-carnitine+ lipoic acid,DB09270+DB00583+ DB00166,ECO:0000352,,,,,Functional interaction (Mechanistic B),,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Ankle weakness progression(Disease progression)*,,HP:0003287,https://www.ncbi.nlm.nih.gov/pubmed/17080429,,,,,,,,,,
1982,,,,,,,,,,,,,,,,,,,,High resting plasma lactate concentration ,,HP:0003288,https://www.ncbi.nlm.nih.gov/pubmed/17275787,,,,,,,,,,
1983,,,,,,,,,Levetiracetam+ l-carnitine +CoQ10 ,DB01202+DB00583+DB09270,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Myoclonus,,HP:0002123,,,,,,,,,,,
1984,,,,,,,,,,,,,,,,,,,,Low quality of life (Constitutional symptoms)*,,,https://www.ncbi.nlm.nih.gov/pubmed/28686997,https://link.springer.com/article/10.1007/s11940-011-0131-z,,,,,,,,,
1985,,,,,,,,,piracetam,DB09210,ECO:0000352,m.8344A > G,"Mutation improved:  In a 71yo female with MERRF syndrome due to the mutation m.8344A > G myoclonic, seizures did only respond to piracetam. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506757/",,,Symptomatic (C),,symptomatic treatment procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,"Mutation improved:  In a 71yo female with MERRF syndrome due to the mutation m.8344A > G myoclonic, seizures did only respond to piracetam. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506757/",Myoclonic seizures,,HP:0002123,https://www.ncbi.nlm.nih.gov/pubmed/28717435,,,,,,,,,,
1986,,,,,,,,,Clonazepam,DB01068,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Asterixis-like movement(Abnormality of movement),,HP:0100022,https://www.ncbi.nlm.nih.gov/pubmed/1490314,,,,,,,,,,
1987,4,# 601776,"EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1",,CHST14,Dermatan-4-sulfotransferase-1,2.8.2.35,,Magnesium,DB14513,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,constipation,,HP:0002019,https://www.ncbi.nlm.nih.gov/pubmed/21744491,,,,,,,,,,
1988,5,# 300559,"GSD IXd, MUSCLE PHOSPHORYLASE KINASE DEFICIENCY",,PHKA1,alpha subunit of muscle phosphorylase kinase,2.7.11.19,,cortisone,DB14681,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,Disease name: Most patients do not require any specific treatment.https://rarediseases.info.nih.gov/diseases/3858/muscular-phosphorylase-kinase-deficiency#,Muscular hypotonia,,HP:0001252,https://www.ncbi.nlm.nih.gov/pubmed/15637709,,,,,,,,,,
1989,,,,,,,,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410 ,Glucose,DB01914,ECO:0000352,,,,,Functional interaction (Mechanistic B),,metabolite replacement,,Exercise intolerance,,HP:0009020,https://www.ncbi.nlm.nih.gov/pubmed/18401027,,,,,,,,,,
1990,6,# 602541,Congenital megaconial myopathy,,CHKB,Choline/ethanolamine kinase,2.7.1.32/2.7.1.82,,L-carnitine,DB00583,ECO:0000352,,,,,Functional interaction (Mechanistic B),,functional complementation of a genetically defective protein,"Disease name: Cardiac involvement occurs relatively frequently in the patients with megaconial congenital muscular dystrophy, Heart transplanation is considered a successful therapeutic option in those patients not responding to medical treatment. https://www.ncbi.nlm.nih.gov/pubmed/26855408",Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*,,HP:0003287*,https://www.ncbi.nlm.nih.gov/pubmed/26006750,,,,,,,,,,
1991,,,,,,,,,Riboflavin,DB00140,ECO:0000352,,,,,Functional interaction (Mechanistic B),,functional complementation of a genetically defective protein,,Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*,,HP:0003287*,,,,,,,,,,,
1992,,,,,,,,,Thiamine,DB00152,ECO:0000352,,,,,Functional interaction (Mechanistic B),,functional complementation of a genetically defective protein,,Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*,,HP:0003287*,,,,,,,,,,,
1993,,,,,,,,,Corticosteroid,D07A,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Nummular eczema (Eczema)*,,HP:0000964*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830701/,,,,,,,,,,
1994,,,,,,,,,B-Blockers+Angiotensin-converting enzyme inhibitors,C07+C09,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Cardiomyopathy,,HP:0001638,https://www.ncbi.nlm.nih.gov/pubmed/26067811,,,,,,,,,,
1995,7,# 253280,Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3,,POMGNT1,"Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1",Q8WZA1,,botulinum toxin,DB00083,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,strabismus,,HP:0000486,https://www.ncbi.nlm.nih.gov/pubmed/29555514?dopt=Abstract,,,,,,,,,,
1996,,,,,,,,,,,,,,,,,,,,esotropia,,HP:0000565,,,,,,,,,,,
1997,,,,,,,,,Ad5-LARGE-eGFP,NA,ECO:0005542,,,,,Functional interaction (Mechanistic B),,functional complementation of a genetically defective protein,,Muscle dystrophy ,,HP:0003560,https://www.ncbi.nlm.nih.gov/pubmed/15184894,,,,,,,,,,
1998,8,# 236670,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1",,POMT1,protein O-mannosyltransferase 1,2.4.1.109,,Ad5-LARGE-eGFP,NA,ECO:0005542,,,,,Functional interaction (Mechanistic B),,functional complementation of a genetically defective protein,,Muscle dystrophy ,,HP:0003560,https://www.nature.com/articles/nm1059,,,,,,,,,,
1999,9,# 613150,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2",,POMT2,Protein O-mannosyl-transferase 2,2.4.1.109,,Diuretics,C03,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,congestive cardiac failure,,HP:0001635,https://www.ncbi.nlm.nih.gov/pubmed/28980384,,,,,,,,,,
2000,,,,,,,,,,,,,,,,,,,,tachypnea,,HP:0002789,,,,,,,,,,,
2001,10,# 253800,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4",,FKTN,Fukutin,O75072,,Antisense oligonucleotide,,ECO:0001565/ECO:0005542,,,,,Direct interaction (Mechanistic A) ,A,activity modification of a genetically defective protein by transcriptional or translational modification,,Abnormal Fukutin function,,NA,https://www.ncbi.nlm.nih.gov/pubmed/21979053,,,,,,,,,,
2002,11,# 613153,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5",,FKRP,Fukutin-related protein,Q9H9S5,,Adeno-associated Virus 9 Mediated FKRP Gene Therapy,NA,ECO:0005542,,,,,Direct intercation (Mechanistic A),,direct complementation of a genetically defective protein by gene therapy,,abnormal muscle function,,HP:0011804,https://www.sciencedirect.com/science/article/pii/S152500161632250X,,,,,,,,,,
2003,,,,,,,,,Ad5-LARGE-eGFP,NA,ECO:0005542,,,,,Functional interaction (Mechanistic B),,functional complementation of a genetically defective protein,,Muscle dystrophy ,,HP:0003560,https://www.nature.com/articles/nm1059,,,,,,,,,,
2004,12,# 613154,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6",,LARGE,LARGE xylosyl- and glucuronyltransferase 1,O95461,,Ad5-LARGE-eGFP,NA,ECO:0005542,,,,,Direct interaction (Mechanistic A),,direct complementation of a genetically defective protein by gene therapy,,Muscle dystrophy ,,HP:0003560,https://www.nature.com/articles/nm1059,,,,,,,,,,
2005,13,# 614643,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 7; MDDGA7",,ISPD,D-ribitol-5-phosphate cytidylyltransferase,2.7.7.40,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2006,14,# 614830,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 8; MDDGA8",,POMGNT2,"Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2",2.4.1.312,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2007,15,# 616538,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 9; MDDGA9",,DAG1,Dystroglycan,Q14118,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2008,16,# 615041,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 10; MDDGA10",,RXYLT1,Ribitol-5-phosphate xylosyltransferase 1,Q9Y2B1,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2009,17,# 615181,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 11; MDDGA11",,B3GALNT2,"UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2",2.4.1.313,,Phenobarbital,DB01174,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/29273094,,,,,,,,,,
2010,18,# 615249,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 12; MDDGA12",,POMK,Protein O-mannose kinase,2.7.1.183,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2011,19,# 615287,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 13; MDDGA13",,B4GAT1,"Beta-1,4-glucuronyltransferase 1",O43505,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2012,20,151800,Multiple symmetric lipomatosis,The surgical management  is the only effective treatment for the case. Patients are usually instructed to stop alcohol consumption. https://www.ncbi.nlm.nih.gov/pubmed/1696085/ https://www.ncbi.nlm.nih.gov/pubmed/8210195/,MT-TK,,,,salbutamol,DB01001,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,Drug name: A correlated gene mutation has not been discovered. https://www.ncbi.nlm.nih.gov/pubmed/8190288,Rapid progression in body fat mass( Abnormality of adipose tissue* ),,HP:0009124*,https://www.ncbi.nlm.nih.gov/pubmed/2897261?dopt=Abstract,,,,,,,,,,
2013,,,,,,,,,Fenofibrates,,,,,,,,,,,Disease progression,,,,,,,,,,,,,
2014,,,,,,,,,,,,,,,,,,,,Increased intraabdominal fat,,HP:0008993,,,,,,,,,,,
2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2016,21,# 272200,Multiple sulfatase deficiency,,SUMF1,Formylglycine-generating enzyme,1.8.3.7,,No treatment is available in DDIEM,,,,,,,,,,,Low metabolic rate ( Abnormality of fatty acid metabolism)*,,HP:0004359*,,,,,,,,,,,
2017,22,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,Dexamethasone,DB01234,ECO:0001565,,,,,Direct interaction( Mechanistic)>>>Activity modification,A,procedure to mitigate dominant effects of a genetically abnormal protein,Drug name: The trial was conducted on a cell line that is held to be an in vitro model for medullary carcinoma https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157381/ ,Abnormal cellular proliferation,,HP:0031377,https://www.ncbi.nlm.nih.gov/pubmed/10947080,https://www.ncbi.nlm.nih.gov/pubmed/3491070/,,,,,,,,,
2018,,,,,,,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",vandetanib,DB05294,ECO:0007121,M918T,,,,Direct interaction (Mechanistis A)>>>Activity modification,A,procedure to mitigate dominant effects of a genetically abnormal protein,"Mutation improved: If data from the ARMS assay are taken into account, patients with sporadic MTC received benefit from vandetanib whether their tumors were M918T positive or negative; however, the response rate was greater in those who had an M918T mutation. https://www.ncbi.nlm.nih.gov/pubmed/22025146/", low quality of life ( Constitutional symptom)*,,HP:0025142*,https://www.ncbi.nlm.nih.gov/pubmed/23766359,,,,,,,,,,
2019,,,,,,,,,,,,,,,,,,,,Pain,,HP:0012531,,,,,,,,,,,
2020,,,,,,,,,,,,,,,,,,,,Objective response rate (ORR),,NA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/,,,,,,,,,,
2021,,,,,,,,,,,,,,,,,,,,disease control rate(  Rapid disease progression),,HP:0003678,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/,,,,,,,,,,
2022,,,,,,,,,,,,,,,,,,,,Short Progression-free survival,,NA,https://www.ncbi.nlm.nih.gov/pubmed/22025146/,https://www.ncbi.nlm.nih.gov/pubmed/20371662/,https://www.ncbi.nlm.nih.gov/pubmed/27650489,https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract,,,,,,,
2023,,,,,,,,,,,,,,,,,,,,Elevated calcitonin ,,HP:0003528,https://www.ncbi.nlm.nih.gov/pubmed/23766359,https://clinicaltrials.gov/ct2/show/NCT00514046,,,,,,,,,
2024,,,,,,,,,,,,,,,,,,,,Increased plasma CEA,,HP:0031029,https://www.ncbi.nlm.nih.gov/pubmed/23766359,https://clinicaltrials.gov/ct2/show/NCT00514046,,,,,,,,,
2025,,,,,,,,,,,,,,,,,,,,Bone pain ,,HP:0002653,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307225/,https://clinicaltrials.gov/ct2/show/NCT00514046,,,,,,,,,
2026,,,,,,,,,,,,,,,,,,,,Low skeletal muscle mass,,HP:0003199,https://www.ncbi.nlm.nih.gov/pubmed/23543666?dopt=Abstract,,,,,,,,,,
2027,,,,,,,,,,,,,,,,,,,,Weight loss,,HP:0001824,https://www.ncbi.nlm.nih.gov/pubmed/23543666?dopt=Abstract,,,,,,,,,,
2028,,,,,,,,,,,,,,,,,,,,Decreased adipose tissue,,HP:0040063,https://www.ncbi.nlm.nih.gov/pubmed/23543666?dopt=Abstract,,,,,,,,,,
2029,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2030,,,,,,,,,bortezomib + vandetanib,DB00188+DB05294,ECO:0007121,,,,,,,procedure to mitigate dominant effects of a genetically abnormal protein+procedure to mitigate dominant effects of a genetically abnormal protein,Drug name: ,neoplastic growth,,HP:0002664,https://www.ncbi.nlm.nih.gov/pubmed/18381602/,https://www.ncbi.nlm.nih.gov/pubmed/26170630,https://clinicaltrials.gov/ct2/show/NCT00923247,https://www.ncbi.nlm.nih.gov/pubmed/30297385/,,,,,,,
2031,,,,,,,,,cabozantinib ( XL184),DB08875,ECO:0007121,,,,,Direct interaction (Mechanistis A),,procedure to mitigate dominant effects of a genetically abnormal protein,,phospholylation of RET,,NA,https://www.ncbi.nlm.nih.gov/pubmed/21606412/,https://clinicaltrials.gov/ct2/show/NCT00215605,,,,,,,,,
2032,,,,,,,,,,,,,,,,,,,,Elevated calcitonin,,HP:0003528,,,,,,,,,,,
2033,,,,,,,,,,,,,,,,,,,,Short Progression-free survival,,NA,https://www.ncbi.nlm.nih.gov/pubmed/24002501/,https://clinicaltrials.gov/ct2/show/NCT00704730,,,,,,,,,
2034,,,,,,,,,,,,,,,,,,,,Low tumor response rate ,"The estimated tumor response rate for cabozantinib and placebo is 28% and 0%, respectively, with results varying independently on RET-status, thus making it a promising treatment option. https://www.ncbi.nlm.nih.gov/pubmed/24002501",NA,,,,,,,,,,,
2035,,,,,,,,,,,,,,,,,,,,overall survival( premature death),"Overall survival (OS), was found to be statistically insignificant. Despite being insignificant, patients receiving cabozantinib had a median OS of 26.6 months vs. a median OS of just 21.1 months for placebo patients (HR 0.85; 95% CI 0.64 to1.12; p = 0.24), resulting in an actual difference of 5.5 months. This provides patients treated with cabozantinib a 20.68% longer survival period compared to the placebo group. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/", MP:    ....,,,,,,,,,,,
2036,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2037,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2038,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2039,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2040,23,# 614080,Multiple congenital anomalies-hypotonia-seizures syndrome  ,,PIGN,GPI ethanolamine phosphate transferase 1,O95427,"Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam",levetiracetam,DB01202,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552/,,,,,,,,,,
2041,,,,,,,,"Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam",topiramate,DB00273,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Seizures,,HP:0001250,,,,,,,,,,,
2042,,,,,,,,"Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam",oxcarbazepine,DB00776,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Seizures,,HP:0001250,,,,,,,,,,,
2043,24,# 300868,Multiple congenital anomalies-hypotonia-seizures syndrome type 2,Ketogenic diet - A novel treatment for early epileptic encephalopathy due to PIGA deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27126216,PIGA,Phosphatidylinositol N-acetylglucosaminyltransferase subunit A,2.4.1.198,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2044,25,# 300818,Paroxysmal nocturnal hemoglobinuria,PNH is caused by somatic mutations in PIGA https://www.ncbi.nlm.nih.gov/pubmed/28516949,PIGA,Phosphatidylinositol N-acetylglucosaminyltransferase subunit A,2.4.1.199,,Eculizumab,DB01257,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Paroxysmal nocturnal hemoglobinuria,,HP:0004818,https://www.ncbi.nlm.nih.gov/pubmed/28516949,,,,,,,,,,
2045,26,# 615398,Multiple congenital anomalies-hypotonia-seizures syndrome type 3,,PIGT,GPI transamidase component PIG-T,Q969N2,Drugs has decreased rhe frequency of the tonic seizuress,Phenobarbital,DB01174,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,tonic seizures ( Focal tonic seizures),,HP:0011167*,https://www.sciencedirect.com/science/article/pii/S0387760417301742?via%3Dihub,,,,,,,,,,
2046,,,,,,,,Drugs has decreased rhe frequency of the tonic seizuress,Clonzepam,DB01068,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,tonic seizures ( Focal tonic seizures),,HP:0011167*,https://www.sciencedirect.com/science/article/pii/S0387760417301742?via%3Dihub,,,,,,,,,,
2047,,,,,,,,Drugs has decreased rhe frequency of the tonic seizuress,Potassium bromide,CHEBI:32030,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,tonic seizures ( Focal tonic seizures),,HP:0011167*,https://www.sciencedirect.com/science/article/pii/S0387760417301742?via%3Dihub,,,,,,,,,,
2048,,,,,,,,,acetazolamide,DB00819,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,"Epileptic apnea(Apneic episodes precipitated by illness, fatigue, stress)",,HP:0002872*,,,,,,,,,,,
2049,28,# 248510,"MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB",,MANBA,Beta-mannosidase,3.2.1.25,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2050,29,# 248600,Maple syrup urine disease type Ia,"In vitro study in which a discussion about activation of MSUD E1 mutants by TMAO treatment was studied further by titrating the osmolyte concentration. The activation of E1 activity for the three type IA MSUD mutants Y368C- , F364C- , and Y393N- is insignificant below 0.4 M TMAO. Rapid rises in residual E1 activity were obtained at 0.5 M or higher TMAO concentrations. The highest degree of activation occurs at 1 M TMAO concentration for all three MSUD mutants, with Y368C- at 50%, F364C- at 39%, and Y393N- at 17% of the wild type specific activity. At higher than 1 M TMAO concentrations, elevated residual E1 activities decline precipitously.",BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",1.2.4.4,,Natural osmolyte trimethylamine N-oxide (TMAO),CHEBI:15724,ECO:0000352,F364C- alpha  ,Activity of F364C- mutant E1 was increased markedly from 1% of wild type without TMAO to 30% with 0.75 M TMAO. https://www.ncbi.nlm.nih.gov/pubmed/11507102?dopt=Abstract,A209D-alpha,"The S289L- beta and A209D- alpha mutants showed 0 and 40% residual activities, respectively, in the absence of TMAO, but these activities re- mained unchanged after incubation with the osmolyte",Direct interaction( Mechanistic A),A,activity modification of a genetically defective protein,,No phenotypes were mentioned in the study. In vitro Study. ,,,https://www.ncbi.nlm.nih.gov/pubmed/11507102?dopt=Abstract,,,,,,,,,,
2051,,,,,,,,,,,,Y368C- alpha,Y368C- E1 in that residue activity is 3% in the absence of TMAO and 27% in its presence.,,,,,,,,,,,,,,,,,,,,
2052,,,,,,,,,,,,Y393N- alpha,"TMAO also activated Y393N- E1 with activity increased from 0 to 9% of the wild type, in the absence and the presence of TMAO, respectively.",,,,,,,,,,,,,,,,,,,,
2053,,,,,,,,,Norleucine,NA,ECO:0000352,,,,,,,functional complementatin of a genetically defective protein,,Branched-chain amino acid accumulation,Study ws done in pups: Administering norleucine to heterozygous mothers of classic maple syrup urine disease pups reduced branched-chain amino acid accumulation in milk as well as blood and brain of these pups to enhance survival.,HP:0008344,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944/,,,,,,,,,,
2054,,,,,,,,,,,,,,,,,,,,Encephalopathy ,"The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.",HP:0001298,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944/,,,,,,,,,,
2055,,,,,,,,,,,,,,,,,,,,High α-ketoisocaproate level,,NA,,,,,,,,,,,
2056,30,# 248600,Maple syrup urine disease type Ib,,BCKDHB,"2-oxoisovalerate dehydrogenase subunit beta, mitochondrial",1.2.4.4,"There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.",Sodium phenylbutyrate,DB06819,ECO:0000352,,,,,Direct interaction ( Mechanistic  A),A,activity modification of a genetically defective protein,,High plasma branched chain keto acids,,NA,https://www.sciencedirect.com/science/article/pii/S0166432812001830?via%3Dihub#bib0070,https://www.ncbi.nlm.nih.gov/pubmed/28919799,,,,,,,,,
2057,,,,,,,,,,,,,,,,,,,,High plasma branched chain amino acids,,HP:0008344,,,,,,,,,,,
2058,31,# 248600,Maple syrup urine disease type II,,DBT,"Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial",2.3.1.168,,Thiamine,DB00152,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementatin of a genetically defective protein,,High plasma branched chain amino acids,,HP:0008344,https://www.ncbi.nlm.nih.gov/pubmed/?term=Thiamin-responsive+maple-syrup-urine+disease+chuang+2006,,,,,,,,,,
2059,32,# 246900,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",1.8.1.4,,N-acetylcysteine +deferoxamine,DB06151+ DB00746,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure+symptomatic treatment procedure,,Memory impairment,,HP:0002354,https://www.sciencedirect.com/science/article/pii/S0166432812001830?via%3Dihub#bib0070,,,,,,,,,,
2060,,,,,,,,,,,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/15938133,https://www.ncbi.nlm.nih.gov/pubmed/12927581,,,,,,,,,
2061,,,,,,,,,,,,,,,,,,,,Behavioural abnormalites,,HP:0000708,,,,,,,,,,,
2062,,,,,,,,,,,,,,,,,,,,cognitive imapirment,,HP:0100543,,,,,,,,,,,
2063,,,,,,,,,,,,,,,,,,,,Learning impairment,,HP:0001328,,,,,,,,,,,
2064,,,,,,,,,Riboflavin,DB00140,ECO:0000352,,, ,,Direct interaction (Mechanistic A),A,activity modification of a genetically defective protein,,Exercise intolerance,,HP:0003546,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,,,,,,,,,,
2065,,,,,,,,,,,,,,,,,,,,Mitochondrial proliferation in the muscle,,HP:0003200,,,,,,,,,,,
2066,,,,,,,,,,,,,,,,,,,,Myopathy,,HP:0003198,,,,,,,,,,,
2067,,,,,,,,,,,,,,,,,,,,Lactic acidosis,,HP:0003128,,,,,,,,,,,
2068,33,# 261600,PHENYLKETONURIA,"Dietary treatment has proved to be very effective in preventing the devastating consequences of PAH deficiency when started early in lifeDrug name: Tetrahydrobiopterin stimulates phenylalanine hydroxylase activity in about 20% of patients, and in those patients serves as a useful adjunct to the phenylalanine-restricted diet because it increases phenylalanine tolerance and allows some dietary freedom.. A striking normalisation (within 8 h) in phenylalanine concentrations after drug administartion indicates BH4 deficiency whereas very little or no reduction in phenylalanine indicates BH4-non-responsive phenylketonuria. https://www.sciencedirect.com/science/article/pii/S0140673610609610?via%3Dihub",PAH,PHENYLALANINE HYDROXYLASE,1.14.16.1,,Tetrahydrobiopterin (sapropterin),DB00360,ECO:0000352,"P407S
A373T
R241C","The serum Phe concentrations of patients have those mutaions never exceeded 20 mg/dL, even when they were not on a Phe-restricted diet, suggesting that mutant PAH molecules with P407S, A373T, and R241C have residual enzymatic activities. https://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihubhttps://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihub","Homozygotes of R252W 
Homozygotes of IVS4-1G→A 
Homozygotes of R413P","Homozygotes of R252W, IVS4-1G→A, and R413P presented with clinical symptoms typical of classical PKU. Therefore these mutations appear to abolish PAH function. https://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihub",Direct interaction (Mechanistic A)>>Functional interaction( functional complementation of a defective protein by stimulation),A,activity modification of a genetically defective protein,,Hyperphenylalaninemia,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/20971365,https://www.ncbi.nlm.nih.gov/pubmed/19323589,https://clinicaltrials.gov/ct2/show/results/NCT01977820?cond=sapropterin&rank=1,https://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihub,,,,,,,
2069,34,# 261600,"HYPERPHENYLALANINEMIA, NON-PKU MILD, INCLUDED",,PAH,PHENYLALANINE HYDROXYLASE,1.14.16.1,,Tetrahydrobiopterin,DB00360,ECO:0000352,,,,,Direct interaction (Mechanistic A),A,activity modification of a genetically defective protein,,Hyperphenylalaninemia,,HP:0004923,,,,,,,,,,,
2070,,,,,,,,,Pegvaliase,DB12839,ECO:0007121+ECO:0005542,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,Abnormal blood Phenylalanine levels,,HP:0004923,https://www.sciencedirect.com/science/article/pii/S1096719218300210,https://www.sciencedirect.com/science/article/pii/S1525001605000845,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short,,,,
2071,35,# 520000,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,Coenzyme Q10,DB09270,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/19323589,https://www.ncbi.nlm.nih.gov/pubmed/24746802,,,,,,,,,
2072,,,,,,,,"Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115",Vitamin B12+imipramine,DB00115+DB00458 ,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure+symptomatic treatment procedure,,Diabetic polyneuropathy,,HP:0001271,https://www.ncbi.nlm.nih.gov/pubmed/28766015,,,,,,,,,,
2073,,,,,,,,,Prokinetic agents,NA,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Epigastric pain ,,HP:0410019,https://www.ncbi.nlm.nih.gov/pubmed/28766015,,,,,,,,,,
2074,,,,,,,,,,,,,,,,,,,,Acid regurgitation,,HP:0002020,,,,,,,,,,,
2075,,,,,,,,,pregabalin,DB00230,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Neuropathic pain(Abnormality of pain sensation)*,,HP:0010832*,https://www.ncbi.nlm.nih.gov/pubmed/28766015,,,,,,,,,,
2076,,,,,,,,,insulin,DB00030,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Diabetes,"Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802",HP:0000819,https://www.ncbi.nlm.nih.gov/pubmed/28756474,,,,,,,,,,
2077,,,,,,,,,clonazepam,DB01068,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Involuntary movement,,HP:0004305,https://www.ncbi.nlm.nih.gov/pubmed/28756475,,,,,,,,,,
2078,,,,,,,,"The cystoid changes responed to treatment with systemic immunosuppression and a topical carbonic anhydrase inhibitor (CAI), recurred when treated with topical CAI monotherapy.",Immunosuppressent +Carbonic anhydrase inhibitors,L04+S01EC,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure+symptomatic treatment procedure,,Macular cystoid changes,,HP:0008028,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973/,,,,,,,,,,
2079,,,,,,,,The drug was administered through intravitreal injection.,Triamcinolone acetonide,DB00620,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Macular cystoid changes,,HP:0011505,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973/,,,,,,,,,,
2080,,,,,,,,,,,,,,,,,,,,Abnormal visual acuity,,HP:0030532,,,,,,,,,,,
2081,,,,,,,,,,,,,,,,,,,,Intraretinal cystoid spaces (Retinal disease)*,,HP:0000479*,,,,,,,,,,,
2082,,,,,,,,,Non-steroidal anti-inflammatory agents,M02AA,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Intraretinal cystoid spaces (Retinal disease)*,,HP:0000479*,https://www.ncbi.nlm.nih.gov/pubmed/23806424/,,,,,,,,,,
2083,,,,,,,,,Vitamins,A11,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Malnutrition,,HP:0004395,,,,,,,,,,,
2084,,,,,,,,,Coenzyme Q10+Vitamin C+Vitamin B+Vitamin K +Carnitine,DB09270+A11EB+B02BA+ DB00583,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure,,Mitochondrial dysfunction,,HP:0003287,,,,,,,,,,,
2085,36,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS","MELAS syndrome can be caused by mutation in several genes, including MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2. https://www.omim.org/entry/540000",MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,,,,Coenzyme Q10,DB09270,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Myopathy,,HP:0003198,https://www.ncbi.nlm.nih.gov/pubmed/26823911,https://www.ncbi.nlm.nih.gov/pubmed/10601810?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29596118,,,,,,,,
2086,,,,,,,,,,,,,,,,,,,,Reduced electron transport chain activity(Decreased activity of mitochondrial respiratory chain)*,,HP:0008972*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625994/,,,,,,,,,,
2087,,,,,,,,,arginine hydrochloride,DB00125,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Stroke-like episodes,,HP:0002401,https://www.ncbi.nlm.nih.gov/pubmed/26954033,https://www.ncbi.nlm.nih.gov/pubmed/15728297,https://www.ncbi.nlm.nih.gov/pubmed/26095523,,,,,,,,
2088,,,,,,,,,,,,,,,,,,,,Painful neuropathy(neuropathy)*,,HP:0009830*,,,,,,,,,,,
2089,,,,,,,,,,,,,,,,,,,,Congestive heart failure,,HP:0001635,,,,,,,,,,,
2090,,,,,,,,,,,,,,,,,,,,Pancreatic beta-cell dysfunction,,HP:0006279,,,,,,,,,,,
2091,,,,,,,,,Nicotinamide Riboside,DB03227,ECO:0007121,,,,,Symptomatic (C),,symptomatic treatment procedure,,Muscle abnormality related to mitochondrial dysfunction,,HP:0003800,https://clinicaltrials.gov/ct2/show/NCT03432871?cond=Chronic+progressive+external+ophthalmoplegia&rank=2,http://ichgcp.net/clinical-trials-registry/NCT03432871,,,,,,,,,
2092,,,,,,,,,Sodium Pyruvate,DB00119,ECO:0007121,,,,,,,symptomatic treatment procedure,,Elevated serum lactate level,,HP:0002151,https://www.ncbi.nlm.nih.gov/pubmed/30738201,,,,,,,,,,
2093,,,,,,,,,,,,,,,,,,,,High lactate /pyruvate ratio,,NA,,,,,,,,,,,
2094,,,,,,,,,,,,,,,,,,,,Increased lateral ventricular lactate level,,NA,,,,,,,,,,,
2095,,,,,,,,,,,,,,,,,,,,High serum GDF15 level,,NA,,,,,,,,,,,
2096,,,,,,,,,Duloxetine,DB00476,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Depression,,HP:0000716,https://www.ncbi.nlm.nih.gov/pubmed/29596118,,,,,,,,,,
2097,,,,,,,,,Taurine ,DB01956,ECO:0000352,,,,,,,symptomatic treatment procedure,,Oxidative stress,,HP:0025464,,,,,,,,,,,
2098,,,,,,,,,,,,,,,,,,,,Mitochondrial dysfunction,,HP:0003287,,,,,,,,,,,
2099,,,,,,,,,Idebenone,DB09081,ECO:0007121,,,,,Symptomatic (C),,symptomatic treatment procedure,,Decreased activity of mitochondrial ATP synthase complex,,HP:0011925,https://clinicaltrials.gov/ct2/show/NCT00887562,https://www.ncbi.nlm.nih.gov/pubmed/8757046,,,,,,,,,
2100,,,,,,,,,Idebenone+Riboflavin,DB09081+DB00140,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure+symptomatic treatment procedure,,Neurological abnormality,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/11382201,,,,,,,,,,
2101,,,,,,,,,,,,,,,,,,,,Abnormal EEG (focal epileptiform activity),,HP:0002353,,,,,,,,,,,
2102,,,,,,,,,,,,,,,,,,,,Hyperintensity of cerebral white matter on MRI,,HP:0030890,,,,,,,,,,,
2103,,,,,,,,,,,,,,,,,,,,Stroke-like attacks,,HP:0002401,,,,,,,,,,,
2104,,,,,,,,,Idebenone+Coenzyme Q10,DB09081+DB09270,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure+symptomatic treatment procedure,,Abnormal EEG,,HP:0002353,https://www.sciencedirect.com/science/article/pii/0022510X89901123,,,,,,,,,,
2105,37,# 610090,PNPO deficiency ,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,Pyridoxine,DB00165,ECO:0000352,R229W,,,,Direct interaction (Mechanistic A),,functional complementatin of a genetically defective protein,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Laboratory+Findings+in+Twins+with+Neonatal+Epileptic+Encephalopathy+Mimicking+Aromatic+L-Amino+Acid+Decarboxylase+Deficiency,,,,,,,,,,
2106,,,,,,,,,,,,,,,,,,,,Clonic contractions,There was partial improvement then patients died,,,,,,,,,,,,
2107,,,,,,,,,,,,,,,,,,,,Lip-smacking automatisms(Epilepsy)*,,HP:0001250,,,,,,,,,,,
2108,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2109,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2110,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2111,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2112,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2113,,,,,,,,,Pyridoxal phosphate,DB00114,ECO:0000352,,,,,Direct interaction (Mechanistic A),,metabolite replacement,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/12747882,,,,,,,,,,
2114,,,,,,,,,,,,,,,,,,,,Developmental delay,,HP:0001263,,,,,,,,,,,
2115,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2116,,,,,,,,,Phenobarbitone,DB01174,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/21310277,,,,,,,,,,
2117,38,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency ,,DHFR,Dihydrofolate reductase,1.5.1.3,,Folinic acid,DB00650,ECO:0000352,,,,,Functional interaction (Mechanistic B),,metabolite replacement,,Low total RBC folate level,,HP:0040087,https://www.ncbi.nlm.nih.gov/pubmed/21310277,,,,,,,,,,
2118,,,,,,,,,,,,,,,,,,,,Bone marrow megaloblastic changes,,HP:0001980,https://www.ncbi.nlm.nih.gov/pubmed/21310277,,,,,,,,,,
2119,,,,,,,,,,,,,,,,,,,,Low 5-MTHF level,,HP:0012446,https://www.ncbi.nlm.nih.gov/pubmed/21310277,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,,,,,,,,,
2120,,,,,,,,,,,,,,,,,,,,Abscent 5-MTHF(Abnormal CSF metabolite level)*,,HP:0025454*,https://www.ncbi.nlm.nih.gov/pubmed/21310277,,,,,,,,,,
2121,,,,,,,,,,,,,,,,,,,,Abnormal CSF folate level,,HP:0012446,https://www.ncbi.nlm.nih.gov/pubmed/21310277,,,,,,,,,,
2122,,,,,,,,,,,,,,,,,,,,Megaloblastic anemia,,HP:0001889,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,,,,,,,,,,
2123,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2124,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2125,,,,,,,,,Hydroxycobalamin + Folic acid,DB00200+DB00158,ECO:0000352,,,,,Functional interaction (Mechanistic B),,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Abnormal hemoglobin level,,HP:0025546,https://www.ncbi.nlm.nih.gov/pubmed/21310277,,,,,,,,,,
2126,,,,,,,,,,,,,,,,,,,,Abnormal MCV level,,HP:0025065,,,,,,,,,,,
2127,,,,,,,,,Phenobarbitone+levetiracetam,DB01174+DB01202 ,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,Phenotype improved: There was a partial control to seizures with phenobarbitone and levetiracetam.,seizure,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/21310277,,,,,,,,,,
2128,39,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,"The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011",Copper Histidine,NA,ECO:0000352/ECO:0007121,G666R,,2757delAG,"We found no evidence for residual copper transport in patients with ATP7A deletions that disrupt the translational reading frame, and the nine infants with Menkes disease who had these mutations did not achieve normal neurodevelopment, despite early treatment. However, these patients had better survival and a lower incidence of clinical seizures (two of nine infants, or 22%) than would be expected among those with untreated Menkes disease,4 perhaps as a result of their access to early diagnosis and treatment. The mechanisms underlying these improvements in patients with complete loss-of-function mutations remain unclear. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/",Functional interaction (Mechanistic B),,functional complementation of a genetically defective protein,"Drug name: The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/

Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472
They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/

A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub

Mutation that didn't get benefits out the treatment: We found no evidence for residual copper transport in patients with ATP7A deletions that disrupt the translational reading frame, and the nine infants with Menkes disease who had these mutations did not achieve normal neurodevelopment, despite early treatment. However, these patients had better survival and a lower incidence of clinical seizures (two of nine infants, or 22%) than would be expected among those with untreated Menkes disease,4 perhaps as a result of their access to early diagnosis and treatment. The mechanisms underlying these improvements in patients with complete loss-of-function mutations remain unclear. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/",Abnormal brain electrical activity,,HP:0002353,https://www.ncbi.nlm.nih.gov/pubmed/20652413/,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://clinicaltrials.gov/ct2/show/results/NCT00001262?cond=Menkes&rank=1,,,,,,,,
2129,,,,,,,,,,,,N1304S,,Del ex20–23,,,,,,Seizures,,HP:0001250,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/,,,,,,,,
2130,,,,,,,,,,,,"IVS9,DS,+6T→G",,Q1385X,,,,,,Neurological abnormalities.,,HP:0000707,,,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,,,,,,,
2131,,,,,,,,,,,,,,,,,,,,Neurologic burden,,HP:0002344,https://clinicaltrials.gov/ct2/show/results/NCT00001262,,,,,,,,,,
2132,,,,,,,,,,,,,,,,,,,,Rapid disease progression,,HP:0003678,https://www.ncbi.nlm.nih.gov/pubmed/30384011,,,,,,,,,,
2133,,,,,,,,,,,,,,,,,,,,Eplieptic discharge (Interictal EEG abnormality)*,,HP:0025373,https://www.ncbi.nlm.nih.gov/pubmed/8223785,,,,,,,,,,
2134,,,,,,,,,,,,,,,,,,,,Low muscular tone,,HP:0001290,,,,,,,,,,,
2135,,,,,,,,,,,,,,,,,,,,Appendicular hyoptonia,,HP:0012389,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272/,,,,,,,,,,
2136,,,,,,,,,,,,,,,,,,,,Socio-cognitive abnormality(Neurodevelopmental abnormality)*,,HP:0012759*,,,,,,,,,,,
2137,,,,,,,,,,,,,,,,,,,,Poor weight gain,,HP:0001508,,,,,,,,,,,
2138,,,,,,,,,,,,,,,,,,,,Woolly hair,,HP:0002224,,,,,,,,,,,
2139,,,,,,,,,,,,,,,,,,,,Hypopigmented skin,,HP:0001010,,,,,,,,,,,
2140,,,,,,,,"However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.",Thiuram + Copper Dimethyldithiocarbamate (Cu-DMDTC ),DB13245+DB09130+CHEBI:84293,ECO:0005542,,,,,Functional interaction (Mechanistic B),,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Low Brain Copper (Abnormal copper levels)*,,HP:0010836*,https://www.ncbi.nlm.nih.gov/pubmed/22815746,https://www.ncbi.nlm.nih.gov/pubmed/30384011,,,,,,,,,
2141,,,,,,,,,,,,,,,,,,,"Drug name: However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.",Copper accumulation in kidney(Abnormal copper levels)*,,HP:0010836*,,,,,,,,,,,
2142,,,,,,,,,Copper nitrilotriacetate (Cu-NTA),DB09130+CHEBI:25548,ECO:0005542,,,,,Functional interaction (Mechanistic B),,functional complementation of a genetically defective protein,,Low survival rate (Mortality)*,,HP:0040006*,https://www.ncbi.nlm.nih.gov/pubmed/?term=Copper+nitrilotriacetate%3A+A+potent+therapeutic+agent+in+the+treatment+of+a+genetic+disorder+of+copper+metabolism,,,,,,,,,,
2143,,,,,,,,"Due to its strong copper chelation capability, a copper salt should be added simultaneously",Alpha-lipoic acid,DB00166,ECO:0000352,,,,,symptomatic (C),,symptomatic treatment procedure,Drug name: Due to its strong copper chelation capability a copper salt should be added simultaneously,Copper storage abnormalities (Copper storage abnormalities)*,,HP:0010836*,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.sciencedirect.com/science/article/abs/pii/088789949190052M,,,,,,,,,
2144,,,,,,,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,Glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) CuGTSM,NA,ECO:0005542,,,,,Functional interaction (Mechanistic B),,functional complementation of a genetically defective protein,,Low life span (Mortality)*,,HP:0040006*,https://www.ncbi.nlm.nih.gov/pubmed/30127521,,,,,,,,,,
2145,,,,,,,,,Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine,NA,ECO:0005542,,,,,Direct interaction (Mechanistic A),,direct complementation of a genetically defective protein by gene therapy,,Low brain copper levels (Abnormal copper levels)*,,HP:0010836*,https://www.ncbi.nlm.nih.gov/pubmed/30090842,,,,,,,,,,
2146,,,,,,,,,,,,,,,,,,,,Abnormal brain neurochemical levels (Abnormality of neurotransmitter metabolism)*,,HP:0012535*,,,,,,,,,,,
2147,,,,,,,,,,,,,,,,,,,,Abnormal growth,,HP:0001507,,,,,,,,,,,
2148,,,,,,,,,,,,,,,,,,,,Brain mitochondrial abnormalities (Mitochondrial dysfunction),,HP:0003287*,,,,,,,,,,,
2149,,,,,,,,,,,,,,,,,,,,Behavioral abnormality,,HP:0000708,,,,,,,,,,,
2150,,,,,,,,,,,,,,,,,,,,Neurological abnormalties,,HP:0000707,,,,,,,,,,,
2151,40,# 249900,METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY,,PSAP,Prosaposin,P07602,,No medical treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2152,41,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",Recommendation and guidlines in treating this disease and other inherited methylation disorders can be found in this link: https://www.ncbi.nlm.nih.gov/pubmed/27671891,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,S-adenosylmethionine,DB00118,ECO:0000352,,,,,Functional interaction (Mechanistic B),,metabolite replacement,,Poor appetite,Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,HP:0004396,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,
2153,,,,,,,,,,,,,,,,,,,,Low IQ,,HP:0001249,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2154,,,,,,,,,,,,,,,,,,,,Behavioural abnormalities,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,
2155,,,,,,,,,,,,,,,,,,,,Abnormal Awake EEG ,,HP:0002353,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2156,,,,,,,,,,,,,,,,,,,,Delayed mylination,,HP:0012449,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,
2157,,,,,,,,,,,,,,,,,,,,Restricted diffusion in the corpus callosum in MRI (Abnormality of the nervous system)*,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,
2158,,,,,,,,,,,,,,,,,,,,Hyperreflexia,,HP:0001347,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2159,,,,,,,,,,,,,,,,,,,,Irritability,,HP:0000737,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2160,,,,,,,,,,,,,,,,,,,,Foot clouns,,HP:0011448,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2161,,,,,,,,,,,,,,,,,,,,Poor traction response,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2162,,,,,,,,,,,,,,,,,,,,Poor weight gain,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2163,,,,,,,,,,,,,,,,,,,,Delayed motor milestone,,HP:0001270,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2164,,,,,,,,,,,,,,,,,,,,Neurodevelopmental abnormalities,,HP:0012759,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2165,,,,,,,,,,,,,,,,,,,,Brain demylination,,HP:0007266,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/19585268,https://www.sciencedirect.com/science/article/pii/014067369192373A,,,,,,,,
2166,,,,,,,,,Valproic acid,DB00313,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Myoclonic epilepsy,,HP:0002123,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,,
2167,42,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,S-adenosylmethionine,DB00118,ECO:0000352,,,,,Functional interaction (Mechanistic B),,metabolite replacement,,Poor appetite,Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,HP:0004396,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,
2168,,,,,,,,,,,,,,,,,,,,Low IQ,,HP:0001249,https://www.ncbi.nlm.nih.gov/pubmed/27671892,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2169,,,,,,,,,,,,,,,,,,,,Behavioural abnormalities,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/27671893,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,
2170,,,,,,,,,,,,,,,,,,,,Abnormal Awake EEG ,,HP:0002353,https://www.ncbi.nlm.nih.gov/pubmed/27671894,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2171,,,,,,,,,,,,,,,,,,,,Delayed development,,HP:0001263,https://www.ncbi.nlm.nih.gov/pubmed/27671895,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,
2172,,,,,,,,,,,,,,,,,,,,Restricted diffusion in the corpus callosum in MRI(Abnormality of the nervous system)*,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/27671896,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,
2173,,,,,,,,,,,,,,,,,,,,Hyperreflexia,,HP:0001347,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2174,,,,,,,,,,,,,,,,,,,,Irritability,,HP:0000737,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2175,,,,,,,,,,,,,,,,,,,,Foot clouns,,HP:0011448,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2176,,,,,,,,,,,,,,,,,,,,Poor traction response (Poor muscle tone)*,,HP:0001290,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2177,,,,,,,,,,,,,,,,,,,,Poor weight gain,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2178,,,,,,,,,,,,,,,,,,,,Delayed motor milestone,,HP:0001270,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2179,,,,,,,,,,,,,,,,,,,,Neurodevelopmental abnormality,,HP:0012759,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2180,,,,,,,,,,,,,,,,,,,,Brain demylination,,HP:0007266,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/19585268,https://www.sciencedirect.com/science/article/pii/014067369192373A,,,,,,,,
2181,,,,,,,,,Valproic acid,DB00313,ECO:0000352,,,,,Symptomatic (C),,,,Myoclonic epilepsy,,HP:0002123,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,,
2182,43,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,"Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels",Hydroxicobalamin + betaine+ Folinic acid,DB00200+DB06756+DB00650,ECO:0000352,,,,,Functional interaction (Mechanistic B)+Symptomatic (c)+Symptomatic (c),,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Haemolysis,,HP:0001878,https://www.ncbi.nlm.nih.gov/pubmed/24210589,https://reader.elsevier.com/reader/sd/pii/S0140673615000768?token=4389B95C8EA9D0F160CF217C15E330D411BC795585FAED16D84C10BB5F2FDE929AA9811F76C4A655C40F1DB4ABEA64EA,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,,,,,,,,
2183,,,,,,,,,,,,,,,,,,,,Elevated total plasma homocysteine,,HP:0002160,https://www.ncbi.nlm.nih.gov/pubmed/24210590,https://reader.elsevier.com/reader/sd/pii/S0140673615000768?token=4389B95C8EA9D0F160CF217C15E330D411BC795585FAED16D84C10BB5F2FDE929AA9811F76C4A655C40F1DB4ABEA64EA,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,,https://www.ncbi.nlm.nih.gov/pubmed/19821145,,,,,
2184,,,,,,,,,,,,,,,,,,,,High urine methylmalonic acid level ,,HP:0012120,https://www.ncbi.nlm.nih.gov/pubmed/19821145,,,,,,,,,,
2185,,,,,,,,,,,,,,,,,,,,Impaired renal function,,HP:0012211,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/,,,,,,,,,,
2186,,,,,,,,,,,,,,,,,,,,decreased glomerular filtration rate,,HP:0012213,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/,,,,,,,,,,
2187,,,,,,,,,,,,,,,,,,,,Fatigue,,HP:0012378,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,,,,,,,,,,
2188,,,,,,,,,,,,,,,,,,,,Anorexia,,HP:0002039,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,,,,,,,,,,
2189,,,,,,,,,,,,,,,,,,,,Delirium ,,HP:0031258,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,,,,,,,,,,
2190,,,,,,,,,,,,,,,,,,,,Spasticity,,HP:0001257,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,,,,,,,,,,
2191,,,,,,,,,,,,,,,,,,,,Lower limb hyperreflexia,,HP:0002395,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,,,,,,,,,,
2192,,,,,,,,All patients received OHCbl (intramuscular injection; 0.5–1 mg/week) and betaine (oral administration; 1–3 g/day). Some patients also took oral administration of folic acid (10–30 mg/day) and compound vitamin B (20–60 mg/day),Hydroxicobalamin + betaine+ Folinic acid+Vitamin B complex,DB00200+DB06756+DB00650+A11EA,ECO:0000352,,,,,Functional interaction (Mechanistic B)+Symptomatic (c)+Symptomatic (c)+Symptomatic (c),,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Psychiatric disturbances,,HP:0000708,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119/,,,,,,,,,,
2193,,,,,,,,,,,,,,,,,,,,Lower extremity weakness,,HP:0007340,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119/,,,,,,,,,,
2194,,,,,,,,,,,,,,,,,,,,Gait instability,,HP:0002317,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119/,,,,,,,,,,
2195,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2196,,,,,,,,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Hydroxicobalamin + betaine+ carnitine,DB00200+DB06756+DB00583,ECO:0000352,,,,,Functional interaction (Mechanistic B)+Symptomatic (c)+Symptomatic (c),,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,High urine methylmalonic acid level ,,HP:0012120,https://link.springer.com/article/10.1023/A:1005353530303,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,
2197,,,,,,,,,,,,,,,,,,,,Elevated total plasma homocysteine,,HP:0002160,https://link.springer.com/article/10.1023/A:1005353530304,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,
2198,,,,,,,,,,,,,,,,,,,,High urine methylmalonic acid level ,,HP:0012120,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,,,,,,,,,,
2199,,,,,,,,,,,,,,,,,,,,Abnormal brain stem auditory evoked potentials,,HP:0006958,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,,,,,,,,,,
2200,,,,,,,,,,,,,,,,,,,,Abnormal visual evoked potentials,,HP:0000649,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,,,,,,,,,,
2201,,,,,,,,,,,,,,,,,,,,Mental impairment,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,,,,,,,,,,
2202,,,,,,,,,,,,,,,,,,,,Emotional lability,,HP:0000712,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,,,,,,,,,,
2203,,,,,,,,,,,,,,,,,,,,Psychiatric disturbances,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,,,,,,,,,,
2204,,,,,,,,,,,,,,,,,,,,Difficulty walking,,HP:0002355,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,,,,,,,,,,
2205,,,,,,,,,,,,,,,,,,,,Dementia,,HP:0000726,https://www.ncbi.nlm.nih.gov/pubmed/17431913,,,,,,,,,,
2206,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2207,,,,,,,,,Hydroxicobalamin,DB00200,ECO:0000352,,,,,Functional interaction (Mechanistic B),,functional complementation of a genetically defective protein,,Megaloblastic anemia,,HP:0001889,https://www.ncbi.nlm.nih.gov/pubmed/7357085/,https://www.ncbi.nlm.nih.gov/pubmed/17431913,,,,,,,,,
2208,,,,,,,,,,,,,,,,,,,,Methylmalonic aciduria,,HP:0012120,https://www.ncbi.nlm.nih.gov/pubmed/7357085/,https://www.ncbi.nlm.nih.gov/pubmed/17431913,,,,,,,,,
2209,,,,,,,,,,,,,,,,,,,,Elevated blood homocystine,,HP:0002160,https://www.ncbi.nlm.nih.gov/pubmed/19821145,,,,,,,,,,
2210,,,,,,,,,,,,,,,,,,,,Dementia,,HP:0000726,https://www.ncbi.nlm.nih.gov/pubmed/6749192/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,
2211,,,,,,,,,,,,,,,,,,,,Myelopathy,,HP:0002196,https://www.ncbi.nlm.nih.gov/pubmed/6749192/,,,,,,,,,,
2212,,,,,,,,,,,,,,,,,,,,Gait instability,,HP:0002317,https://www.ncbi.nlm.nih.gov/pubmed/17431913,,,,,,,,,,
2213,,,,,,,,,Coumadin,DB00682,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Deep venous thrombosis,,HP:0002625,https://www.ncbi.nlm.nih.gov/pubmed/11320193/,,,,,,,,,,
2214,,,,,,,,,Fluoxetine,DB00472,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Emotional lability,,HP:0000712,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,,
2215,,,,,,,,,,,,,,,,,,,,Poor eye contact,,HP:0000817,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,,
2216,,,,,,,,,lorazepam,DB00186,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Abnormal mental status,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,,
2217,,,,,,,,The drug has beeen weaned when patient developed visual hallucinatuion before his presentation with a status epilepticus attack. https://www.ncbi.nlm.nih.gov/pubmed/25511120,Zonisamide,DB00909,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,, sleep cycle disturbance,,HP:0002360,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,,
2218,,,,,,,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120","Methylprednisolone sodium succinate +
Immune Globulin ",DB14644+DB00028,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure+symptomatic treatment procedure,,Autoimmune encephalopathy(Encephalopathy)*/(Autoimmune disorder)*,"Doctors prescribed these drugs combination""""Methylprednisolone sodium succinate +
Immune Globulin """" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",HP:0001298*/HP:0002960*,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,,
2219,,,,,,,,,Risperidone,DB00734,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Psychiatric disturbance,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/17431913,,,,,,,,,,
2220,,,,,,,,,Hydroxicobalamin + betaine+Folinic acid+ carnitine,DB00200+DB06756+DB00650+DB00583,ECO:0000352,,,,,Functional interaction (Mechanistic B)+Symptomatic (c)+Symptomatic (c)+Symptomatic (c),,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,High urine methylmalonic acid level ,,HP:0012120,https://www.ncbi.nlm.nih.gov/pubmed/18848477,,,,,,,,,,
2221,,,,,,,,,,,,,,,,,,,,Elevated total plasma homocysteine,,HP:0002160,https://www.ncbi.nlm.nih.gov/pubmed/18848477,,,,,,,,,,
2222,,,,,,,,,Vatiquinone (Epi-743),DB11917,ECO:0007121,,,,,Symptomatic (C),,symptomatic treatment procedure,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027/,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,,,,,,,,,
2223,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2224,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2225,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2226,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2227,44,# 277410,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE;",,MMADHC,"Methylmalonic aciduria and homocystinuria type D protein, mitochondrial",Q9H3L0,,,,,,,,,,,,,,,,,,,,,,,,,,
2228,45,# 250940,Methylcobalamin deficiency cbl G type ,,MTR,Methionine synthase,2.1.1.13,,Eculizumab,DB01257,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,Microhematuria,,HP:0002907,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2229,,,,,,,,,,,,,,,,,,,,Microalbuminura,,HP:0012594,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2230,,,,,,,,,,,,,,,,,,,,Anemia,,HP:0001903,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2231,,,,,,,,,,,,,,,,,,,,Thrombocytopenia,,HP:0001873,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2232,,,,,,,,,,,,,,,,,,,,Thrombotic microangiopathy,,NA,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2233,,,,,,,,,Hydroxicobalamin,DB00200,ECO:0000352,,,,,Functional interaction (Mechanistic B),,activity modification of a genetically defective protein,,Elevated plasma homocysteine concentration,,HP:0002160,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2234,,,,,,,,,,,,,,,,,,,,Megaloblastic anemia,,HP:0001889,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2235,,,,,,,,,,,,,,,,,,,,Thrombocytopenia,,HP:0001873,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2236,,,,,,,,,,,,,,,,,,,,Granulocytopenia,,HP:0001913,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2237,,,,,,,,,,,,,,,,,,,,Microhematuria,,HP:0002907,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2238,,,,,,,,,,,,,,,,,,,,Neurological abnormality,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2239,,,,,,,,,,,,,,,,,,,,Developmental delay,,HP:0001263,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2240,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2241,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2242,46,# 236270,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE",,MTRR,Methionine synthase reductase,1.16.1.8,,Hydroxycobalamin,DB00200,ECO:0000352,,,,,,,functional complementation of a genetically defective protein,,,,,,,,,,,,,,,
2243,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2244,,# 157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,levodopa,DB01235,ECO:0000352,,,,,Symptomatic(c),,symptomatic treatment procedure,,Limb dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/30838265,,,,,,,,,,
2245,,,,,,,,,,,,,,,,,,,,Axial dystonia,,HP:0002530,https://www.ncbi.nlm.nih.gov/pubmed/30838265,,,,,,,,,,
2246,,,,,,,,,,,,,,,,,,,,Gait abnormality,,HP:0001288,https://www.ncbi.nlm.nih.gov/pubmed/30838265,,,,,,,,,,
2247,,,,,,,,,,,,,,,,,,,,Parkinsonism,,HP:0001300,https://www.ncbi.nlm.nih.gov/pubmed/24943079,,,,,,,,,,
2248,,,,,,,,,,,,,,,,,,,,Tremor,,HP:0001337,https://www.ncbi.nlm.nih.gov/pubmed/30941926,,,,,,,,,,
2249,,,,,,,,,,,,,,,,,,,,Rigidity,,HP:0002063,https://www.ncbi.nlm.nih.gov/pubmed/30941926,,,,,,,,,,
2250,,,,,,,,,,,,,,,,,,,,Bradykinesia,,HP:0002067,https://www.ncbi.nlm.nih.gov/pubmed/30941926,,,,,,,,,,
2251,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,"The combination of three antiepileptic drugs and LGIT""modified KD"" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract",Phenytoin+oxcarbazepine+levetiracetam,DB00252+DB00776+ DB01202  ,ECO:0000352,,,,,Symptomatic(c),,symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure,,Mitochondrial epilepsy(Epilepsy)*,,HP:0001250*,https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract,,,,,,,,,,
2252,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2253,,,,,,,,,coenzyme Q10,DB09270,,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Mitochondrial myopathy,,HP:0003737,https://www.ncbi.nlm.nih.gov/pubmed/27442316,,,,,,,,,,
2254,,,,,,,,,,,,,,,,,,,,Low energy level,,HP:0003473,,,,,,,,,,,
2255,,,,,,,,,prednisone,DB00635 ,,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Inflammatory myopathy,,HP:0009071,https://www.ncbi.nlm.nih.gov/pubmed/25674260,,,,,,,,,,
2256,,,,,,,,,,,,,,,,,,,,dysphagia,,HP:0002015,,,,,,,,,,,
2257,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2258,,,,,,,,,,,,,,,,,,,,neck muscle weakness,,HP:0000467,,,,,,,,,,,
2259,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2260,,,,,,,,,,,,,,,,,,,,dysarthria,,HP:0001260,,,,,,,,,,,
2261,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2262,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2263,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2264,,# 258450,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 1",,POLG,DNA polymerase subunit gamma-2,2.7.7.7,Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260,levodopa,DB01235,ECO:0000352,,,,,Symptomatic(c),,symptomatic treatment procedure,,Parkinsonism,,HP:0001300,https://www.ncbi.nlm.nih.gov/pubmed/12872260,,,,,,,,,,
2265,,# 609283,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 2",,SLC25A4,ADP/ATP translocase 1,P12235,,,,,,,,,,,,,,,,,,,,,,,,,,
2266,,# 616479,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 2",,RNASEH1,Ribonuclease H1,3.1.26.4,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,
2267,,# 609286,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 3",,TWNK,"Twinkle protein, mitochondrial",3.6.4.12,Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260,Levodopa,DB01235,ECO:0000352,,,,,Symptomatic(c),,symptomatic treatment procedure,,Parkinsonism,,HP:0001300,https://www.ncbi.nlm.nih.gov/pubmed/24076137,https://www.ncbi.nlm.nih.gov/pubmed/12872260,,,,,,,,,
2268,,# 617069,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 3",,TK2,"Thymidine kinase 2, mitochondrial",2.7.1.21,,,,,,,,,,,,,,,,,,,,,,,,,,
2269,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2270,,# 617070,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 4",,DGUOK,"Deoxyguanosine kinase, mitochondrial",2.7.1.113,,,,,,,,,,,,,,,,,,,,,,,,,,
2271,,# 613077,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 5",,RRM2B,Ribonucleoside-diphosphate reductase subunit M2 B,1.17.4.1,,,,,,,,,,,,,,,,,,,,,,,,,,
2272,,# 618098,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 5",,TOP3A,DNA topoisomerase 3-alpha,5.6.2.2,,,,,,,,,,,,,,,,,,,,,,,,,,
2273,,# 615156,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 6",,DNA2,DNA replication ATP-dependent helicase/nuclease DNA2,3.6.4.12/3.1.-.-,,Vitamin E+L-carnitine+Dichloroacetate+Creatine,DB00163+DB00583+DB08809+DB00148  ,ECO:0000352,,,,,Symptomatic(c),,symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure,,Difficulty walking,,HP:0002355,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728770/,,,,,,,,,,
2274,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044
",Idebenone,DB09081,ECO:0007121/ECO:0000352,,,,,,,symptomatic treatment procedure,,High left ventricular mass index ( Left ventricular hypertrophy)*,,HP:0001712*,https://www.ncbi.nlm.nih.gov/pubmed/11907009,https://www.ncbi.nlm.nih.gov/pubmed/12771264,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265,,,,,,,
2275,,,,,,,,,,,,,,,,,,,,Interventricular septal thickning (Ventricular septum abnormality)*,,HP:0010438*,https://www.ncbi.nlm.nih.gov/pubmed/12771264,,,,,,,,,,
2276,,,,,,,,,,,,,,,,,,,,Neurological abnormality,,Another study has an opposing results https://www.ncbi.nlm.nih.gov/pubmed/20697044,https://www.ncbi.nlm.nih.gov/pubmed/17826341,https://www.ncbi.nlm.nih.gov/pubmed/12368988,,,,,,,,,
2277,,,,,,,,,,,,,,,,,,,,Cerebellar dysfunction,,HP:0001317,https://www.ncbi.nlm.nih.gov/pubmed/12368988,,,,,,,,,,
2278,,,,,,,,,,,,,,,,,,,,"Saccadic ocular movement abnormality (Abnormality of saccadic eye movements)
",,HP:0000570,https://www.ncbi.nlm.nih.gov/pubmed/12368988,,,,,,,,,,
2279,,,,,,,,,,,,,,,,,,,,Nystagmus,,HP:0000639,https://www.ncbi.nlm.nih.gov/pubmed/12368988,,,,,,,,,,
2280,,,,,,,,,,,,,,,,,,,,Ataxia,,HP:0001251,,,,,,,,,,,
2281,,,,,,,,,,,,,,,,,,,,Disease progression (Rapid progression)* ,,HP:0003678,https://www.ncbi.nlm.nih.gov/pubmed/18234531,,,,,,,,,,
2282,,,,,,,,,recombinant human erythropoietin (rhuEPO),DB00016,ECO:0001565/ECO:0007121,,,,,Functional interaction (Mechanistic B),,compensatory complementation of a genetically defective protein,,Low Frataxin expression level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/16269021?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/17702040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,,,,,,,
2283,,,,,,,,,,,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/17702040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,,,,,,,,,
2284,,,,,,,,,,,,,,,,,,,,High urinary 8-hydroxydeoxyguanosine level(Abnormality of DNA repair)*,,HP:0003254,https://www.ncbi.nlm.nih.gov/pubmed/17702040?dopt=Abstract,,,,,,,,,,
2285,,,,,,,,,,,,,,,,,,,,Neurological impairment ,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,,,,,,,,,,
2286,,,,,,,,,,,,,,,,,,,,Tiredness,,HP:0012378,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,,,,,,,,,,
2287,,,,,,,,,,,,,,,,,,,,High ferritin level,,HP:0003281,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,,,,,,,,,,
2288,,,,,,,,,,,,,,,,,,,,Low NADH/NAD ratio(Mitochondrial dysfunction),,HP:0003287,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,,,,,,,,,,
2289,,,,,,,,,Rosuvastatin,DB01098,ECO:0007121,,,,,Symptomatic (C),,symptomatic treatment procedure,,,,,https://clinicaltrials.gov/ct2/show/NCT02705547,,,,,,,,,,
